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Type 1 diabetes (T1D) is a T cell mediated autoimmune disease that targets and destroys 
insulin-secreting pancreatic beta cells. Exercise induced lymphocytosis facilitates immune 
surveillance and regulation. This study aimed to explore whether exercise could modulate the 
T1D autoimmune process through regulation of lymphocyte mobilisation and trafficking. 
N=12 T1D (mean age 33.2yrs, predicted VO2 max 32.2 mL/(kg·min), BMI 25.3Kg/m2) and 
N=12 control (mean age 29.4yrs, predicted VO2 max 38.5mL(kg.min), BMI 23.7Kg/m2) male 
participants completed 30-minutes cycling at both 40% (moderate) and 80% predicted VO2 
max (vigorous) on separate days and in a fasting state. Peripheral blood was collected at 
baseline, immediately post-exercise, and 1 hour post-exercise. Intensity dependent 
lymphocytosis was observed in both groups; specifically, CD8+ effector memory CD45RA+ 
(EMRA) T cells and CD56dimCD16bright NK cells. However, the percentage increase of these 
subsets was blunted in T1D following vigorous intensity exercise. The reasons for this may 
include differences in blood glucose levels, adrenaline responses, and sequestration of these 
subsets in the pancreas of people with T1D. Lymphocyte trafficking was also regulated by 
vigorous exercise in T1D. Transmigration of lymphocytes was significantly suppressed during 
the recovery period together with a reduction in adhesion molecules on T cells following 
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aBM-MNC autologous Bone Marrow Mononuclear Cell  
ADH Adherence 
AIRE Autoimmune Regulator 
ANCOVA Analysis of Covariance 
APC Antigen Presenting Cell 
ATG Anti-thymocyte Globulin  
Bcl-2 B-cell lymphoma -2 
Bcl-x B-cell lymphoma x 
BMI Body Mass Index 
BP Blood Pressure 
BSA Bovine Serum Albumin 
CA2+ Calcium 
CCL Chemokine Ligand 
CCR Chemokine Receptor 
CD Cluster of Differentiation 
CD62L CD62 Ligand 
cDC conventional Dendritic Cell 
CDH-15 Cadherin 15 
CMV Cytomegalovirus 
CTL Cytotoxic T Lymphocyte 
CTLA-4 Cytotoxic T lymphocyte associated-4 
CVB4 Coxsackievirus B4  
CXCR C-X-C chemokine receptor 
DC Dendritic Cell 
ddH2O Double-distilled water 
DNA Deoxyribonucleic acid 
DPPIV Dipeptidyl peptidase IV  
ED Early Differentiated 
EDTA Ethylenediaminetetraacetic Acid  
ELD Early-like Differentiated 
EM Effector Memory 
EMRA Effector Memory  re-expressing CD45RA 
EXTOD Exercise for Type One Diabetes 
FBS Fetal Bovine Serum 
FcR Fc Receptor 
FCRL3 Fc receptor-like protein 3  
FCS Fetal Calf Serum 
Fgl2 Fibrinogen-like protein 2  
FlT3l FmS-like tyrosine kinase 3 ligand  
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FMO Fluorescence Minus One 
FoxP3 Forkhead winged helix transcription factor 
FSC-A Forward Scatter-Area 
FSC-H Forward Scatter-Height 
GAD Glutamic Acid Decarboxylase  
GADA GAD autoantibodies  
GCP Good Clinical Practice 
GLP-1 Glucose-dependent insulinotropic Peptide 1 
GLUT-2 Glucose transporter 2  
GWAS Genome Wide Association Studies 
HbA1c Haemoglobin A1c  
HDBEC Human Dermal Blood Endothelial Cells  
HELIOS Zinc finger protein encoded by the IKZF2 gene 
HLA Human Leukocyte Antigen 
HLA-DR Human Leukocyte Antigen – antigen D Related 
HR Heart Rate 
HSC Hematopoietic Stem Cells  
HSPC Hematopoietic Stem and Progenitor Cells  
IA-2 Protein tyrosine phosphatase-like protein  
IAA Inuslin autoantibodies 
ICAM-1 Intercellular Adhesion Molecule 1  
ID Intermediately Differentiated 
IDF Internation Diabetes Federaion 
IFN-γ Interferon gamma 
IL Interluekin 
IL-1RA IL-1R agonist 
IL2RA IL-2 Receptor alpha 
IL-6R IL-6 Receptor 
iNOS inducible Nitric Oxide 
IPAQ Internation Physical Activity Questionnaire 
KIR Killer cell Immunoglobulin-like Receptors  
KLRG1 Killer cell Lectin-like Receptor subfamily G member 1  
KO Knock-out 
L3T4 Mouse CD4 
LFA-1 Lymphocyte Function-associated Antigen 1  
LN Lymph Node 
mAb Monoclonal antibody 
Mac-1 Macrophage-1 antigen  
MadCAM-1 Mucosal vascular addressin Cell Adhesion Molecule 1  
MAPK Mitogen-Activated Protein Kinase  
MCHC Mean Corpuscular Haemoglobin Concentration  
MCV Mean Corpuscular Haemoglobin  
MDA malondialdehyde 
MFI Median Fluorescent Intensity 
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MHC Major Histocompatibility Complex 
MIN6 Mouse Insulinoma cell line 
MPV Mean Platelet Volume  
MS Multiple Sclerosis 
MSC mesenchymal stem cells  
mTEC medullary Thymic Epithelial Cells  
mTReg memory T-Regulatory 
NA Naïve 
naTReg Naïve T-Regulatory 
NFAT Nuclear Factor of Activated T cells  
NFκB Nuclear Factor-kappaB 
NHS National Health Service 
NIHR National Institute for Health Research 
NK Natural Killer 
NKG2D Natural-Killer Group 2-member D  
NO Nitric Oxide 
NOD Non-Obese Diabetic 
SCID Severe combined immunodeficiency 
NOR Non-Obese diabetes Resistant 
O2 Oxygen 
PBL Peripheral Blood Lymphocyte 
PBMC Peripheral Blood Mononuclear Cell 
PBS Phosphate Buffer Saline 
PCT plateletcrit 
PD-1 programmed cell death protein 1  
pDC plasmacytoid Dendritic Cell 
PDW Platelet Distribution Width  
PEPITEM Peptide Inhibitor of Trans-Endothelial Migration 
PGD2 Prostaglandin D2  
PIS Participant Information Sheet 
PLN Pancreatic Lymph Node 
PNAd Peripheral Lymph Node Addressins  
PolyIC Polyinosinic-polycytidylic acid  
pTReg periphery T-Regulatory cell 
RBC Red Blood Cell 
RDW Red Cell Distribution Width  
REC Research Ethics Committee 
RNA Ribonucleic acid 
ROS Reactive Oxygen Species 
RPE Rate of Perceived Exertion 
RPM Revolutions Per Minute 
RV Rotavirus 
S1PR Sphingosine-1-Phosphate Receptor  
SIP  Sphingosine-1-Phosphate 
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sIL2RA soluble IL2RA 
sIL-6R soluble IL-6R 
SNP Single Nucleotide Polymorphism 
SOCS Suppressor of cytokine signalling  
SSC-A Side Scatter- Area 
SSC-H Side Scatter- Height 
T1D Type 1 Diabetes 
T2D Type 2 Diabetes 
TCR T cell Receptor 
TEM Transendothelial Migration 
Tg Transgenic 
TGF-β Transforming growth factor beta 
Th1 Type 1 helper  
Th2 Type 2 helper  
Th17 Type 17 helper  
TIGIT T cell immunoreceptor with Ig and ITIM domains  
TLR Toll-like Receptor 
TReg T-Regulatory 
TReg17 regulatory T-helper type 17  
tTReg thymus T-Regulatory cell 
TSCM Stem cell like memory T cells 
UC-MSC Umbilical Cord blood Mesenchymal Stem Cells   
UHBFT University Hospitals Birmingham NHS Foundation Trust 
VCAM-1 Vascular cell adhesion protein 1 
VLA-4 Very Late Antigen-4  
VNTR Variable Number Tandem Repeat  
WBC White Blood Cell 
WHO World Health Organization 
WTCRF Wellcome Trust Clinical Research Facility 
ZnT8 Zinc Transporter 












CHAPTER 1. GENERAL 
INTRODUCTION   
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1.1 Type 1 Diabetes 
Type 1 Diabetes (T1D) is a chronic inflammatory disease characterised by autoimmune 
destruction of insulin secreting beta cells. This results in the loss of insulin production and 
subsequent hyperglycaemia [1].  
1.1.1 Epidemiology 
Diabetes mellitus has a worldwide prevalence of 451 million, and its incidence is rising. It is 
estimated to rise to 693 million by 2045 [2]. Ten percent of all National Health Service (NHS) 
costs go towards diabetes treatment, of which 10% accounts for T1D [3]. Scandinavia has the 
highest T1D prevalence in Europe [4]. The global incidence of T1D is rising by 2-5% annually 
[5]. The DIAMOND project (World Health Organization Multinational Project for Childhood 
Diabetes) reported that the average global incidence between 1990-1999 rose by 2.8% [6]. 
Similar observations were shown in Europe between 1989-1994 [7]. The EURODIAB study 
showed that incidence of juvenile T1D (under 15 years) in Europe increased annually by 3.9% 
from 1989-2003 [4]. Currently, the estimates of children and adolescents below the age of 20 
with T1D has risen to over a million (IDF Diabetes Atlas, 8th Edition). The incidence of adult-
onset T1D has also increased [8-10]. Some reports show that there is a higher incidence of T1D 
in males [11]. Others show that more cases of T1D are diagnosed in winter [12].  
1.1.2 Clinical presentation and diagnosis  
Polydipsia and polyuria, along with abnormally elevated glucose (above 11.1 mmol/L), are 
diagnostic features of T1D [1]. Further examination of people presenting with these classical 
symptoms can be carried out to confirm T1D diagnosis. People with T1D will often present 
with significant weight loss and complain of tiredness. A diagnosis of T1D can, if required, 
also be confirmed using antibodies (as described below) and C-peptide tests. People with T1D 
can also present with diabetic ketoacidosis [13]. Poorly managed T1D over the long-term 
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results in complications including retinopathy, nephropathy, and cardiovascular disease. The 
primary treatment for T1D is insulin replacement through multiple daily injections [1] or 
insulin pumps [14].  
Antibody testing allows for the prediction and diagnosis of T1D [15]. Antibodies against islet 
autoantigens can be detected before beta cell destruction occurs. The presence of more than 
one autoantigen indicates risk for T1D development [16]. Islet autoantigens are proteins within 
the beta cell and include insulin, proinsulin, protein tyrosine phosphatase-like protein (IA-2), 
glutamic acid decarboxylase (GAD), and the zinc transporter (ZnT8) [17-20]. Autoantibodies 
can be detected at diagnosis at any age [18]. The combined measurement of insulin 
autoantibodies (IAAs), GAD autoantibodies (GADA), and ZnT8 autoantibodies (ZnT8A) 
provides >90% detection rates of T1D disease onset [21, 22]. IAAs are believed to be the first 
to appear in early childhood [23, 24].  
1.1.3 Natural History of T1D 
Beta cell loss occurs in a step-wise fashion with periods of beta cell recovery (Figure 1) [25]. 
At least 10% of beta cells are believed to remain at the time of diagnosis [26, 27]. C-peptide, 
released at the same time as insulin, is a measure of beta cell function. Evidence of residual 
beta cell function, indicated by plasma C-peptide levels, has been shown within the first months 
of T1D diagnosis [26, 27]. Beta cell turnover and residual insulin production can be maintained 
at very low levels for up to 50 years post diagnosis [28].  
The existing beta cells following diagnosis contribute to controlling blood glucose levels. After 
beginning insulin therapy, insulin requirements often fall. This is referred to as the honeymoon 
phase, which occurs in both children [29] and adults [30, 31]. The length of the honeymoon 
phase is influenced by numerous factors. Higher blood glucose levels, incidence of diabetic 
ketoacidosis, and longer duration of symptoms prior to diagnosis inversely correlate with 
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honeymoon duration [29]. Conversely, C-peptide levels positively correlate with honeymoon 
duration [31].  
 
Figure 1 The Natural History of Type 1 Diabetes 
The natural history of T1D model adapted from the original model proposed by Eisenbarth (1986) to show that 
beta cell loss occurs in a step-wise fashion [1].  
1.1.4 Aetiology 
Many causes of T1D have been explored. Within these, links to both genetic and environmental 
factors have been identified.  
1.1.4.1 Genetic factors 
Genotype plays a role in the risk for T1D [32]. A study conducted in monozygotic and dizygotic 
twin pairs demonstrated that there was up to 50% concordance of T1D between monozygotic 
twins, but only 10% between dizygotic twins [33]. Another study reported that monozygotic 
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twin siblings had a higher risk of progression to T1D than dizygotic twins indicated by a 20% 
higher expression of autoantibodies [34].  
Genome wide associated studies (GWAS) have identified over 40 loci associated with T1D 
[35, 36]. The Human Leukocyte Antigen (HLA) loci, located on chromosome 6p21, makes up 
50% of this genetic susceptibility [36-38]. T1D risk is linked to an increase in HLA-DR3 and 
DR4, and a deficiency in HLA-DR2 haplotypes [39-41]. Certain HLA-DR3 (DRB1-0301, 
DQA1-0501, DQB1-0201) and HLA-DR4 (DRB1-04, DQA1-0301, DQB1-0302) haplotypes 
are positively associated with the disease and represent the key predisposing genetic 
determinants [40, 41]. HLA-DR2 haplotypes (DRB1-1501, DQA1-0102, DQB1-0602) are 
negatively associated with T1D [39, 40]. The above genotype is strongly associated with T1D 
onset in children under 5 years and the prevalence of carrying this genotype declines 
dramatically beyond this age [41]. 
The other loci associated with T1D risk are those related to insulin and immune regulation [36, 
42]. A variable number tandem repeat (VNTR) in the promoter of the insulin gene on 
chromosome 11p15 is linked to T1D risk [36]. Differential expression of the insulin protein in 
the thymus has been shown to lead to defective central tolerance towards insulin [43, 44]. 
Polymorphisms in genes relating to immune regulation have been identified in T1D [45-47]. 
Cytotoxic T lymphocyte associated-4 (CTLA-4) on chromosome 2q33 is involved in T cell 
regulation [48]. This was identified as a risk locus for T1D [45, 49]. The IL-2Rα gene (IL2RA) 
on chromosome 10p14 is involved in IL-2 signalling on T cells [50]. GWAS identified allelic 
heterogeneity at the IL2RA region to be associated with susceptibility to T1D [46]. This was 
caused by 2 single nucleotide polymorphisms (SNP) in IL2RA gene (the intron 1 and the 5' 
regions). This genetic variation correlated with lower circulating levels of soluble IL2RA 
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(sIL2RA) in T1D [47]. Furthermore, lower expression of IL-2RA on CD4+ naïve and memory 
T cells strongly correlates with the haplotypes in the IL2RA gene [51].  
1.1.4.2 Environmental factors 
Although genotype plays a major role in the predisposition to T1D, it does not account for all 
of the susceptibility. The risk of T1D is 50% between monozygotic twins [33], therefore 
environmental factors must also play a role [32, 52]. Environmental factors such as vitamin D 
deficiency [53, 54], diet [32, 55-57], gut dysfunction [58-60], and viral infections [61-63] have 
been implemented in the cause of T1D.  
The impact of diet at a young age has been associated with increased risk of T1D. Cow’s milk 
and gluten in the first few months of life is linked to islet autoantibody and T1D development 
[32]. In one study, spontaneous T1D development in rats was reduced by exclusion of cow’s 
milk [55]. It was also shown that increased antibodies (anti-beta-lactoglobulin and anti-bovine 
serum albumin) to milk proteins were higher in diabetic rats and children. These antibodies 
could cross react with beta cell membrane proteins, and had similar homology to HLA-DR and 
DQ [55]. Gluten and early infant feeding (before 3 months) is associated with increased islet 
autoantibody risk but not with coeliac disease [56]. Genetically pre-disposed children exposed 
to cereals before 3 months or after 7 months for the first time have increased hazard of islet 
autoimmunity compared to those who were exposed between 4-6 months therefore, there may 
be a window for gluten exposure [57].  
Gut dysfunction has also been associated with T1D [58]. Lower functional diversity of the gut 
microbiome in T1D was reported by Gut Microbiome Metagenomics Analysis [59]. Children 
with HLA conferred T1D (Finland – TRIGR and FINDIA pilot studies) had different fecal 
microbiota [60]. The abundance of several lactate- and butyrate-producing bacteria was 
inversely related to the number of islet autoantibodies in the T1D cohort. A low abundance 
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(<12%) of the two most common bifidobacteria, B. adolescentis and B. pseudocatenulatum, 
was associated with T1D in the aforementioned study [60]. Gut dysfunction is supported by 
studies in non-obese diabetic (NOD) mice lacking the MyD88 protein, necessary for 
recognition of microbial stimuli by toll like receptors (TLRs). Germ-free MyD88 knock-out 
(KO) NOD mice develop T1D. This was due to a lack of microbiota as colonization of these 
germ-free NOD mice with a microbial flora attenuated T1D [64]. 
Viral infections have been linked to the development of T1D. This may be caused by molecular 
mimicry of viral antigens with beta cell antigens. Enterovirus infections are associated with a 
higher risk of T1D. Enterovirus infections were higher in children with T1D and were more 
frequent in children during the 6-month period preceding the appearance of autoantibodies in 
the Finnish DIPP study [62]. Rotavirus (RV) contains peptide sequences highly similar to GAD 
and IA-2 T cell epitopes. A strong association between RV and increases in GAD and IA-2 
autoantibodies has been reported. Therefore, it is postulated that RV infection may trigger islet 
autoimmunity in genetically susceptible individuals [63]. Additionally, polyinosinic-
polycytidylic acid (PolyIC), a mimic of double-stranded viral RNA, can induce diabetes when 
administered to rats that have been previously immunized with the insulin (i.e. susceptible to 
T1D development) [61].  
1.2 Autoimmune Pathogenesis of T1D 
T1D is a complex autoimmune disorder with multiple components to its development. The 
pathogenesis of T1D involves a combination of a breakdown in immune tolerance, major 
immune cell cross-talk, and beta cell vulnerability. Ultimately, this leads to the infiltration of 
self-reactive T cells into the pancreas where beta cell destruction occurs.  
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1.2.1 Breakdown in Tolerance in T1D 
Immune tolerance is divided into central and peripheral tolerance. Both central and peripheral 
tolerance defects have been found in T1D.  
Central tolerance is mediated in part by the autoimmune regulator (AIRE) in the thymus. AIRE 
is primarily expressed by medullary thymic epithelial cells (mTECs). It functions to detect self-
reactive T cells by exposing thymocytes (pre-T cells) to a broad repertoire of self-antigens and 
facilitate the deletion of self-reactive thymocytes [65]. Differential expression of insulin in the 
thymus has previously been described for the insulin VNTR gene. This is linked to defects in 
central tolerance in T1D [43, 44]. AIRE presents self-insulin in the thymus to developing T 
cells [66-68]. This expression induces tolerance to insulin. Deletion of insulin from the thymus 
can cause T1D therefore, exposure of developing T cells to insulin is important for developing 
immune tolerance [69]. Diabetes is exacerbated in AIRE deficient NOD mice where there is 
also a lack of T-Regulatory cells (TRegs) [70]. This indicates that defects in both central and 
peripheral tolerance can be involved in the autoimmune pathogenesis of T1D.  
Self-reactive, or also referred to as autoreactive, T cells that escape central tolerance are 
subsequently controlled through peripheral tolerance. Peripheral tolerance aims to block 
activation of self-reactive effector T cells. It functions through mechanisms that include co-
inhibitory signals (programmed cell death protein 1 (PD-1), CTLA-4) as well as regulation by 
TRegs [71, 72]. 
Breakdown of peripheral tolerance is involved in the pathogenesis of T1D [73]. This is 
supported by a number of pieces of evidence. Firstly, polymorphisms in the co-inhibitory 
receptors PD-1 [74] and CTLA-4 [45] are associated with T1D. Secondly, TReg dysfunction 
has been reported in T1D [75-78]. TRegs from T1D donors co-cultured with effector T cells 
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failed to suppress IFN-γ production and the proliferation capacity of effector T cells [75, 77, 
79]. CTLA-4 polymorphisms are linked to this reduced TReg suppressive capacity [80, 81]. 
T1D onset can be delayed by TRegs. Whilst pre-diabetic and overtly diabetic NOD mice have 
similar numbers of autoreactive diabetogenic T cells, the difference in disease status relates to 
the number of TRegs in both models. [82]. However, diabetogenic T cells can also develop 
resistance to suppression by TRegs. Diabetogenic T cells show resistance to transforming 
growth factor beta (TGF-β) dependent mediated inhibition by TRegs [82, 83]. Furthermore, 
TRegs could not supress diabetogenic CD8+ T cells bearing a dominant negative TGF-β 
receptor type II [83]. This highlights a mechanism by which some diabetogenic CD8+ T cells 
develop resistance to peripheral tolerance i.e. regulation by TRegs.  
1.2.2 Immune cell involvement in T1D 
Part 1. Insulitis 
T1D beta cell destruction occurs following lymphocyte infiltration into the pancreas. This 
results in a hallmark inflammation within the pancreas referred to as insulitis [84]. In the initial 
stages of insulitis, a mixed leukocyte population including CD4+ T cells, CD8+ T cells, natural 
killer (NK) cells, Dendritic cells (DC), B cells, and macrophages infiltrates the pancreas [85-
88]. Lymphocytes expressing CD45 (the common leukocyte antigen) were identified at week 
4 of insulitis in NOD mice, and had expanded by week 14 [85]. CD4+ T cells, CD8+ T cells, B 
cells, and macrophages were also present by week 14 [85]. Trafficking of CD45+ cells from 
lymphoid organs to the pancreas, specifically to the region of insulitis, has been demonstrated 
by cell tracking in mice [85]. In the aforementioned study, the cells which migrated into the 
pancreas were identified as CD4+ T cells, CD8+ T cells, and B cells. The majority of the recent 
immigrant T cells exhibited a naïve phenotype which then became activated (CD69+) [85]. 
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Furthermore, there were no recent immigrants into the pancreas in the absence of insulitis [85]. 
Therefore, insulitis may drive lymphocyte infiltration in to the pancreas.  
CD3+ T cells are the dominant population in the pancreatic infiltrate [87]. High numbers of 
CD4+ and CD8+ T cells were found in the pancreas of diabetic donors, with CD8+ T cells 
dominating the infiltration [87]. Another study found that eighty percent of lymphocytes 
present in the pancreas were CD3+ T cells, and these were, again, mainly CD8+ T cells [86]. 
Pancreatic CD4+ and CD8+ T cells were comprised of central memory and effector memory T 
cell subsets which expressed CD69 and CD103, markers of activation and tissue resident 
memory subsets [86]. Additionally, intra-pancreatic T cells had increased proliferation 
compared to those isolated from peripheral lymph nodes and spleen of mice [85]. 
The remaining leukocyte subsets found within the pancreas include NK cells, B cells, DC, and 
macrophages. NK cells and B cells make up much lower proportions of pancreatic lymphocyte 
populations [86]. DC and macrophages can be detected within the pancreas during insulitis in 
diabetic donors [87, 89]. Macrophage infiltration is mediated by C-C Motif Chemokine Ligand 
2 (CCL2) expression on beta cells. CCL2 promotes recruitment of macrophages from the bone 
marrow to the islets. Furthermore, CCL2 receptor inactivation prevented macrophage 
recruitment in the aforementioned study [89].  
Although insulitis is a hallmark of T1D onset, and is key to the pathogenesis of T1D, it does 
not solely promote T1D autoimmunity. CD8+ T cell infiltration into the pancreas was also 
found in T1D in the absence of insulitis in other studies [87, 90]. T1D donors without insulin 
containing islets and those with long disease duration had elevated CD8+ T cell infiltration into 
the pancreas. CD4+ T cells and CD11c+ cells were also found at high levels [87]. Furthermore, 
adoptive transfer of insulin-specific CD8+ T cells into NOD and control mice induced diabetes 
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in both models indicating that pre-existing inflammation is not a necessity in T1D induction 
[90]. 
Part 2. Immune cells involved in T1D pathogenesis 
As demonstrated by the mixed immune populations infiltrating the pancreas in T1D, a range 
of immune cell subsets are involved in the pathogenesis of T1D [91]. Following insulitis, 
autoreactive T cells are primed in the circulation by beta cell antigens. DCs present 
autoantigens to beta cell specific T cells, which are in turn activated and migrate to the pancreas 
where they attack beta cells [92]. This process requires substantial coordination and cross-talk 
between innate and adaptive immune cell subsets (Figure 2) [91].  
Innate immunity 
Differentiation of islet-specific T cells depends on innate immune cells. Innate cells produce 
proinflammatory cytokines or suppressive cytokines which creates an environment that 
influences the islet-specific T cells [91]. In particular, macrophages secrete high levels of IL-
12 which promotes Th1 rather than Th2 differentiation.  
Dendritic cells 
Dendritic cells are present in the islets of diabetic donors [87, 88]. Depletion of DCs in 
transplanted pancreatic islets ensures graft survival in mice [93]. Total DC frequency is 
decreased in the peripheral blood of children with T1D [94]. However, there are mixed reports 
on the frequency of DC subpopulations in T1D. A lower proportion of circulating plasmacytoid 
DC (pDCs) was reported in people with T1D [95]. Conversely, the proportion of pDCs was 
reported to be elevated in another study [96]. In this study [96], pDCs were measured in early-
diagnosed T1D patients. pDCs were shown to present immune complexes to CD4+ T cells more 
efficiently than conventional DCs (cDCs), suggesting a possible pathogenic role of pDCs in 
T1D onset [96]. 
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Self-antigens released after beta cell death can be taken up by infiltrating DCs in the pancreatic 
islets and presented to T cells in the pancreatic lymph nodes (PLN). The infiltration of 
CD11c+CD11b+CD8a- DC into the pancreas at 2 weeks of age in NOD mice precedes insulitis 
[92]. In NOD mice, DCs are efficient antigen presenting cells (APC). DCs effectively 
stimulated GAD-reactive T cell proliferation in in vivo co-cultures [97].  
An imbalance favouring development of DC from myeloid-committed progenitors predisposes 
to autoimmune disease in NOD mice. Increased DC generation from myeloid cells in NOD 
mice compared to diabetes free Non-obese Diabetes-Resistant (NOR), Balb/C and C57BL/6 
mice has been shown [98]. NOD and NOR mice had increased numbers of DC in blood and 
thymus. However, NOD mice had an increased proportion of myeloid DC (CD11c+, CD11b+) 
subsets within the spleen. Prediabetic NOD mice exhibit a myeloid lineage-specific increase 
in DC generative capacity relative to diabetes-resistant NOR mice [98].  
cDCs play a crucial role in activating cells and driving lymphocyte infiltration into the 
pancreas. cDCs isolated from NOD mice had increased ability to activate T cells through higher 
IL-12 production and co-stimulatory molecule expression [99]. DCs from NOD mice had 
elevated nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) activation upon 
stimulation. Neutralisation of NFkB and IL-12 reduced the capacity of NOD DC to stimulate 
T cells [99]. Lymphocytic choriomeningitis virus (LCMV) glycoprotein under the rat insulin 
promoter (RIP) causes diabetes as a result of infiltrating CD8+ T cells, forming a transgenic 
(Tg) rodent model of T1D. Repeated injection of cDCs expressing the immunodominant 
LCMV epitope into LCMV-RIP mice resulted in severe lymphocyte infiltration into the 
pancreas and development of T1D [100].  
pDCs have also been shown to play a role in diabetes development. pDCs, which detect viral 
RNA or DNA, can also induce T1D via type I interferons (IFNs). Type 1 IFNs include IFN-α 
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and IFN-β. Blocking IFN-α prevented inflammation and T1D development in a Tg-mouse 
model [101]. There is elevated production of type I IFNs by pDCs and CD4+ T cells in the PLN 
[102]. Blockade of IFN-a decreased diabetes incidence and delayed onset, whilst 
simultaneously increased immature DC in pancreatic lymph node (PLN) and IL-10/IL-4 
producing CD4+ T cells in the spleen [98]. Furthermore, FmS-like tyrosine kinase 3 ligand 
(FlT3l) treatment, which expands both cDC and pDC populations, accelerated T1D in 15-
week-old NOD mice when islet antigen-specific cytotoxic T lymphocytes (CTLs) were 
detectable in blood [102]. Another study reported that FlT3l treatment expanded DC and 
delayed diabetes in NOD mice but antigen-specific CTLs were not measured [103]. Therefore, 
both the presence of diabetogenic T cells and DC is necessary for T1D development.  
Macrophages 
Another innate cell population, macrophages, have also been implemented in the pathogenesis 
of T1D. Macrophages are recruited to the pancreas by CD4+ T cells [104]. One week after 
adoptive transfer of CD4+ T cell into NOD.SCID mice, macrophages were detected in 
pancreatic infiltrates. Additionally, inflammatory cytokines from macrophages were increased 
in the pancreas. Recruited macrophages were activated by CD4+ T cells and subsequently 
secreted proinflammatory cytokines IL-1b, TNF-a, and nitric oxide (NO). When non-
pathogenic T cells were transferred, macrophages secreted less IL-1b [104]. Diabetogenic 
CD4+ T cells secrete CCL1 in the pancreas. This interacts with and recruits activated CCR8+ 
macrophages [104]. Furthermore, IL-1b secretion by activated macrophages induces NO by 
beta cells and subsequent beta cell death [105].  
Macrophages influence T cell differentiation in T1D. Blockade of macrophages in NOD mice 
(using a monoclonal antibody (mAb) for myelomonocytic adhesion-promoting type-3 
complement receptor specific for macrophages, but doesn’t bind T cells) prevents macrophage 
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and T cell infiltration into the islet, and subsequently inhibits T1D [106]. T cells in a 
macrophage deficient environment did not differentiate into diabetogenic T cells, therefore 
prevented T1D [107]. In this environment, Th1 immunity decreased, whereas Th2 immunity 
increased due to decreased IL-12 secretion by macrophages. T cell activation, denoted by Fas 
ligand and perforin expression, was also reduced. IL-12 administration caused T1D in NOD 
mice in the macrophage deficient environment, indicating that IL-12, predominantly secreted 
from macrophages, is necessary for T1D development [107]. In support of this, macrophages 
display dysregulated cytokine production in NOD mice; elevated IL-12 production combined 
with reduced IL-10 and TNF-α [108].  
Natural Killer cells 
NK cells can be found within the pancreas, even before T cell infiltration occurs [109-112]. 
NK cells were detected from day 1 in the pancreatic infiltrate, before established inflammatory 
conditions in NOD mice [109]. NK specific genes were also upregulated in the pancreatic 
infiltrate (Ly49A/P, Ly49C, Ly49D, Ly49I/F/H, NKG2A, and 2B4 changes on cell surface). 
NK cell frequency correlated with pancreatic infiltrate aggressivity in anti-CTLA-4 treated 
mice, with no change in splenic NK cell frequency [109]. Increased intra-pancreatic NK cells 
accelerated the onset of diabetes in NOD mice. Furthermore, NK cell associated cytokines were 
hyper-expressed in the pancreas from mice with accelerated diabetes onset [110]. Activated 
NK cells within the pancreas of NOD mice produced large amounts of IFN-γ , promoting 
effector function of diabetogenic CD4+ T cells [111]. A high percentage of NK cells were 
detected at weeks 4-5 in the NOD pancreas, i.e. the prediabetic stage. Both NK cells and T 
cells were then detected in the pancreas at weeks 9-10 in NOD mice [112]. Furthermore, NK 
cells were present in the pancreas of NOD-Rag (no B or T cells). Together this indicates that 
NK cells infiltrate the pancreas independent of T cells and established inflammation, and is 
believed to be the first event in insulitis [112]. 
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NK cells within the islet have a distinct phenotype that differs to splenic NK cells [113]. 
Pancreatic NK cells are in an activated state as indicted by increased expression of CD25, 
CD69, and PD-1, coupled with down-regulation of CD62 ligand (CD62L). Pancreatic NK cells 
also expressed higher killer cell lectin-like receptor subfamily G member 1 (KLRG1) than 
splenic NK cells, indicating their high proliferation state [113]. In the aforementioned study, 
natural-killer group 2-member D (NKG2D), a natural cytotoxicity receptor, was also reported 
to be down-regulated on pancreatic NK cells. Pancreatic NK cells were hyporesponsive in 
NOD mice but spontaneously produced high levels of IFN-γ and were highly cytotoxic i.e. 
CD107a+ , a marker of granule exocytosis [113].  
Depletion of NK cells has prevented T1D in animal models [109, 110, 114]. Depletion of NK 
cells using anti-Asialo GM1 polyclonal antibody and administration of anti-CTLA4 at the same 
time lead to a significant decrease in diabetes incidence and insulitis in treated NOD mice. 
Activated T cell infiltration was not affected, but more than 85% NK cells were eliminated 
[109]. NK cells depleted with anti-asialo GM1 antibodies in NOD mice with accelerated 
disease onset also abolished accelerated diabetes [110]. Suppressor of cytokine signalling 
(SOCS)-1-Tg NOD mice infected with coxsackievirus B4 (CVB4) are used as another T1D 
rodent model (develop early hyperglycaemia, acute diabetes, and show loss of insulin positive 
beta cell staining). In this model, NK cells but not CD8+ T cells were necessary for acute 
diabetes development. Again, depletion of NK cells in SOCS-1-Tg NOD mice prevented the 
loss of insulin staining beta cells [114].  
Adaptive immunity 
Adaptive immunity, or also known as acquired immunity, plays a significant role in T1D 
pathogenesis. Adaptive immune cells are highly specialized antigen specific cells, and 




B cells are another lymphocyte subset which play a role in the pathogenesis of T1D. It is 
believed that presentation of beta cell antigens by B cells to T cells is important for T1D 
development. B cell depletion in NOD mice significantly reduces T1D development. B cell 
deficient NOD mice (NOD.Ig mu null mice) had normal T cell frequencies but were insulitis 
resistant and did not develop T1D [115]. Anti-CD20 is used to deplete CD20+ B cells. Anti-
CD20 treatment in NOD mice expressing human CD20 on B cells delayed or reversed T1D 
[116]. Anti-CD20 treatment in 5 week old NOD mice reduced B cells by 95%, reduced 
insulitis, and prevented T1D in 60% NOD mice. T cell frequencies were not altered. However, 
impaired CD4+ and CD8+ T cell activation in lymph nodes was noted indicating a lack of 
antigen presentation by B cells to T cells [117]. Rituximab (anti-CD20 mAb) administration in 
people newly diagnosed with T1D preserved beta cell function as evidenced by preserved C-
peptide [118]. Again, this indicates a role for B cells in promoting autoreactive T cells and 
subsequent beta cell destruction.  
T cells 
Although many immune populations are involved the pathogenesis of T1D, it is considered to 
be a T cell mediated disorder. T cells are the predominant cell type found within the pancreas 
of T1D models and donors [85-88]. Disease can be transferred by splenic T cells from diabetic 
donors [119, 120]. Adoptive transfer of splenic T cells from diabetic donors into irradiated 
NOD mice, i.e. lacking immunity, induces T1D. Both T-helper and CTLs are involved; neither 
can induce diabetes independently [119]. T1D is prevented by T cell depletion. Depletion of 
T-helper cells (mAb for L3T4 determinant on surface of T-helper cells) in NOD mice prevented 
lymphocyte infiltration into the islet and mice became normoglycaemic [120]. Th1 transferred 
into NOD.SCID mice caused insulitis and T1D development, but not in those which received 
Th2 cells [121]. Islet-specific CD4+ T cell clones derived from overtly diabetic NOD mice 
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injected into young NOD mice accelerated disease progression. Control mice did not become 
diabetic and had no significant pancreatic infiltration [122]. CCR4+ T cells, mainly CD4+, were 
detected within islets of prediabetic NOD mice. Depletion of CCR4+ T cells inhibited the 
development of insulitis and diabetes [123]. Cytokine secretion (IFN-γ, IL-1β, TNF-α) and 
major histocompatibility complex (MHC) class I mediated cytotoxicity are mechanisms 
involved in T cell-meditated beta cell death [91, 124]. 
T cells migrate specifically to the pancreas in T1D. Transfer of diabetogenic T cells from T1D 
and nondiabetic control donors into NOD mice revealed that diabetogenic T cell from T1D 
donors only accumulated in the pancreas of NOD mice. This suggests that homing to the 
pancreas is dominant in T1D [125]. Autoreactive T cells express elevated levels of homing 
receptors. Lymphocytes found within the NOD pancreas expressed adhesion molecules 
Lymphocyte Function-associated Antigen 1 (LFA-1), Very Late Antigen-4 (VLA-4), CD11a, 
CD11b, and CCR7 [90, 126, 127]. CXCR3 on T cells also mediates their migration into 
pancreas [128]. 
Homing of diabetogenic T cells to the pancreas does not require pre-existing inflammation. 
Adoptive transfer of insulin-specific CD8+ T cells into NOD and control mice (BALB/c and 
DBA/2J) caused rapid diabetes in all strains. Tracking of insulin-specific CD8+ T cells showed 
that they accumulated in the islets 24 hours after transfer in all strains [90]. Transfer of labelled 
insulin-specific CD8+ T cells into NOD.Rag1-KO mice, which lack T and B cells, and are 
inflammation-free shows the accumulation of insulin-specific CD8+ T cells in the islets, 
therefore, pre-existing inflammation is not essential [90]. Furthermore, diabetogenic CD8+ T 
cells express a multitude of adhesion molecules including integrins and selectins. This allows 
them to engage with receptors constitutively expressed by the pancreatic endothelium in the 
absence of inflammation. This contributes to the initial stages of T cell infiltration and insulitis 
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[90]. Homing of diabetogenic T cells to the pancreas is MHC class I dependent. Diabetogenic 
T cells injected into NOD mice lacking MHC class I molecules (NOD.β2m-KO mice) do not 
accumulate in the pancreas [90]. Diabetogenic T cells can recognise islet endothelial cells. 
Islets co-cultured with diabetogenic CD8+ T cells were destroyed. Here, CD8+ T cells were 
specific for Glucose transporter 2 (GLUT-2) and CD105 (endothelial cell marker) on beta cells. 
Beta cells were intact in NOD.β2m-KO islet cultures [90].  
T1D displays ongoing islet autoimmunity and CD8+ T cell infiltration into the islet [28, 129, 
130]. Islet reactive CD8+ T cells have been found within insulin lesions of recent-onset and 
long-standing T1D, sustaining autoimmune destruction of beta cells post the initial presentation 
of T1D, and into the larger natural history of T1D [130]. This shows that T cells play a role in 





Figure 2 Immune cell cross-talk in T1D 
The coordination and cross-talk between innate and adaptive immune cell subsets involved in the pathogenesis 
of T1D [91]. 
 
1.2.3 Beta cell vulnerability in T1D 
Diabetogenic T cells can be found in the peripheral blood of healthy individuals, in which T1D 
does not progress [131]. Therefore, beta cell vulnerability may also be important in the natural 
history of T1D development.  
1.2.3i Co-stimulatory molecules  
Co-stimulatory molecules expressed by beta cells increase their vulnerability to inflammatory 
destruction. CD80 expression is increased by beta cells during inflammation and this is targeted 
40 
 
by CD8+ T cells [132]. Normally, the co-stimulatory molecule CD28 preferentially binds 
CTLA-4 on T-Regulatory cells, and therefore beta cell vulnerability is reduced through 
peripheral tolerance. However, in T1D CTLA-4 expression on T-Regulatory cells is reduced 
and therefore competition for binding is reduced [80, 81]. As a result, CD28 on memory CD8+ 
T cells binds effectively to CD80 on the beta cell. Additionally, reduced co-inhibitory molecule 
expression on beta cells, such as PD-L which binds to PD-1, also increases susceptibility to 
CD8+ T cell target [133].  
1.2.3ii Chemokines 
The expression of chemokines on beta cells increases beta cell vulnerability in T1D. The 
pancreatic endothelium in T1D is chronically activated [124]. During inflammation, high levels 
of IFN-γ are produced and this induces chemokine receptors on beta cells [91]. Adhesion 
molecules such as Intercellular Adhesion Molecule 1 (ICAM-1), VLA-4, CD44, peripheral 
lymph node addressins (PNAd), and mucosal vascular addressin cell adhesion molecule 1 
(MAdCAM-1) are upregulated by inflamed islets in T1D, therefore increasing lymphocyte 
homing to the islets [90, 126, 134, 135]. 
In addition to the expression of adhesion molecules, beta cells secrete chemokines in response 
to inflammatory stimuli in T1D [128, 136, 137]. Chemokine production by islets from 
NOD.SCID, NOR. and BALB/c mice is 50% lower than NOD mice [137]. In one study, beta 
cells were exposed to inflammatory cytokines IL-1β, IFN-γ, and TNF-α for 24 hours. Beta cells 
secreted the chemokines CXCL9 and CXCL10 in response to the inflammatory stimuli [128]. 
This specifically attracted CXCR3+ T cells. In CXCR3−/− NOD mice the onset of T1D is 
significantly delayed due to reduced T cell recruitment [128]. The chemokines CCL2, CCL3, 
CCL17, CCL21, and CCL22 are also produced by NOD beta cells, but to a lesser extent than 
CXCL10 [137-139]. CCL3 elevated in the pancreas of NOD mice correlated with insulitis. 
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Neutralisation of CCL3 following transfer of diabetogenic T cells into NOD mice with severe 
combined immunodeficiency (SCID) delayed onset of diabetes [139]. Furthermore, altered 
chemokine levels have been detected in individuals at risk of T1D development. CCL3 and 
CCL4 were increased while CCL2 was decreased in the serum of at risk individuals. This 
strongly correlated with auto-antibody status [140]. Increased CCL3 and CCL4 also correlated 
with proinsulin, a marker of beta-cell stress and negatively associated with C-peptide in T1D 
donors [141].  
1.2.3iii Toll-like receptors 
Expression of TLRs increases beta cell vulnerability in T1D. Pancreatic islets in mice and 
humans express TLR1-TLR9 [137, 142-144]. TLR3 is most strongly expressed in humans 
[144]. TLR expression renders beta cells susceptible to bacterial and viral derived molecules 
[142-144]. Stimulation of islets with specific TLR ligands (such as peptidoglycan for TLR2, 
poly(I:C) for TLR3, LPS for TLR4, flagellin for TLR5, R848 for TLR7, and CpG for TLR9) 
results in marked up-regulation of CXCL10, CCL5, CCL2, and CCL3 secretion which 
increases chemotaxis and trafficking of T cells to the islet [137]. Treatment of LCMV.RIP mice 
(T1D model) with the TLR3 ligand, poly(I:C), causes upregulation of MHC class I on beta 
cells. This does not occur in TLR3 -/- mice [143]. Injection of the TLR3 ligand poly(I:C), or 
the TLR7 ligand R-848 upregulated MHC I on beta cells and induced overt diabetes in 
LCMV.RIP mice [143]. In TLR-2 and TLR-4 deficient mice, diabetes development is 
attenuated [64].  
1.3 T1D treatment and Immunotherapies 
The primary treatment for T1D is insulin replacement [1, 14]. However, patients remain at risk 
of diabetic complications [145-147]. Therefore, there has been significant interest in 
approaches to prevent T1D, predominantly by modulating the immune system. These have 
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included cell depletion, peptide-based, anti-inflammatory, cell therapy, and stem cell strategies 
[148].  
1.3.1 Cell depleting strategies  
Given their role in T1D pathogenesis, a number of T cell depletion strategies have been tested. 
OKT3, a CD3 mAb, treatment in T1D maintained insulin production for 1 year [149]. In the 
DEFEND-1 study, OKT3 treatment in new onset T1D reduced C-peptide loss by up to 25% 
[150]. Teplizumab, another anti-CD3 mAb, preserved C-peptide and beta cell mass for 1-2 
years [149-153]. Teplizumab treatment resulted in maintained or improved beta cell function 
for at least 2 years post treatment in recent-onset T1D patients [149-152]. Evidence for beta 
cell preservation was also reported in long standing T1D patients for up to 1 year [154, 155]. 
Otelixizumab, also an anti-CD3 mAb, did not however prevent C-peptide decline as shown in 
the DEFEND-2 study [156]. Thymoglobulin, an anti-thymocyte globulin (ATG), 
administration showed no difference between the treated and placebo group in one study [157]. 
However, another study later found that intravenous ATG combined with subcutaneous 
pegylated granulocyte colony-stimulating factor (G-CSF) resulted in significantly reduced C-
peptide loss compared to the placebo group [158].  
B cell depletion has also been explored with some beneficial outcomes. Firstly, anti-CD22 
mAb treatment in NOD mice delayed disease and hyperglycaemia in two studies [116, 159]. 
Following this, Rituximab treatment, an anti-CD20 mAb, in people with T1D infused for 22 
days preserved the beta cell function as indicated by maintenance of C-peptide levels, but did 
not prevent T1D [118].  
1.3.2 Antigen specific strategies 
Strategies using insulin, GAD, and peptide islet antigens have also been explored. In the 
Diabetes Prevention Trial type-1 (DPT-1), insulin was administered to at risk individuals 
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containing islet autoantigens. Unfortunately, this was ineffective at preventing diabetes onset 
[160]. Some effect was however observed in a sub group of high IAAs [161]. A phase 3 study 
currently ongoing, aims to induce protective immunity in the sub group with high IAAs through 
administration of oral insulin (NCT00419562). GAD-based immunisation has also been 
explored. GAD-alum injections in recent onset T1D did not affect insulin secretion decay over 
1 year [162]. Another study employing lymph node injections of GAD-alum (Dynamid) once 
per month in combination with vitamin D supplementation is now underway (NCT02352974). 
A recent study administering a single proinsulin peptide in a newly diagnosed T1D cohort 
reported C-peptide preservation and increased regulation of immunity through IL-10 and 
TRegs (increased FoxP3 expression) [163]. Currently ongoing, MultiPepT1De, is a phase 1 
trial combining peptide islet autoantigens to induce beta cell tolerance in recent onset T1D. 
This involves 6 injections over 20 weeks at low, medium, and high dose, compared to a placebo 
group (NCT02620332). 
1.3.3 Anti-inflammatory strategies 
Inflammation plays a large role in T1D disease progression, therefore anti-inflammatory 
therapies have been explored. Nicotinamide alone or in combination with Vitamin E, both 
exhibiting anti-inflammatory and anti-oxidant properties, were shown to preserve basal C-
peptide secretion for up to 2 years i.e. preserved beta cell function [164]. However a follow up 
study, ENDIT, showed no difference [165]. Cyclosporin A associated with Methothrexate, 
immunosuppressant and anti-inflammatory drugs, reduced insulin requirements, lowered 
haemoglobin A1c (HbA1c), and induced remission of T1D [166]. Anakinra, IL-1R antagonist 
(IL-1RA), had no effect on C-peptide [167]. However, some improvement in glycaemic control 
was found in another study [168]. Canakimumab, an IL-1β mAb, had no effect on C-peptide 
[169]. Mycophenolate mofetil alone, an immunosuppressant drug, and associated with 
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Daclizumab, an anti-CD25 mAb, had no effect in T1D [170]. Golimumab (SIMPONI), an anti-
TNF-α mAb-based formulation, will be assessed in T1D (NCT02846545).  
1.3.4 Cell therapy strategies 
The dysregulation in regulatory cell types in T1D has led to efforts to boost immune regulation 
and tolerance in T1D. TRegs isolated and expanded from T1D patients maintained exhibited 
suppressive capacity equal to the control cohort [171]. Adoptive transfer of the expanded 
TRegs into a T1D maintained C-peptide levels for 2 years. Furthermore, up to 25% of TRegs 
were still detectable in the bloodstream after 1 year [172]. A new trial is exploring the effects 
of a single infusion of autologous TRegs combined with subcutaneous IL-2 for 5 days 
(NCT02772679). Administering a single infusion of CLBS03, a formulation containing 
autologous TRegs, in a low or high dose to T1D patients is also being explored 
(NCT02691247). A single infusion of umbilical cord blood TRegs combined with Liraglutide, 
an incretin-mimetic molecule, 3 days after the TRegs infusion and daily for 6 months is another 
TReg therapy currently ongoing (NCT03011021).  
Dendritic cell therapy strategies have also been explored. Autologous dendritic cells were 
administered every 2 weeks over 2 months to a T1D cohort. An increase in peripheral B220+ 
CD11c− B cells populations, a suppressive B cell population, was reported. However, no 
significant effect on glycaemia was shown [173].  
1.3.5 Stem cell strategies 
Further to cell based strategies, stem cells have also been examined. Autologous mesenchymal 
stem cells (MSCs) transplanted in T1D patients show a reduced decay in C-peptide levels after 
treatment [174]. Umbilical cord blood MSCs (UC-MSCs) were tested in association with 
autologous bone marrow mononuclear cells (aBM-MNC) infused through the pancreatic 
artery. Here, C-Peptide increased, coupled with reduced insulin requirements 1 year following 
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treatment [175]. In another trial, people with newly diagnosed T1D received ATG followed by 
autologous hematopoietic stem cells (HSCs). After treatment, all patients but 1 became insulin 
independent for at least 6 months, with increased C-peptide levels and decreased anti-GAD 
autoantibodies [176]. In another study, a combination of cyclophosphamide, ATG and G-CSF 
to induce immunosuppression was given to people with recent onset T1D, followed by the 
infusion of cryopreserved CD34+ HSCs as a single infusion. Among the treated patients, 59% 
reached insulin-independence and 32% remained insulin independent at the last follow-up (48 
months) [177].  
1.4 Exercise for beta cell preservation 
Previous research in the field of diabetes has revealed that exercise has beta cell preserving 
effects in type 2 diabetes (T2D) [178-183]. I have undertaken a systematic review detailing the 
effects of exercise on beta cell health parameters such as beta cell viability, proliferation, and 
insulin secretion, in which 56 relevant studies were found (manuscript in review). However, 
only 3 of these studies were in T1D animal models, and all were focused on regular exercise 
[184-186]. These studies showed that exercise training in diabetic rodents improved beta cell 
mass, beta cell viability, insulin content, insulin secretion, insulin signalling, and overall 
glucose homeostasis. 
In light of this lack of evidence for exercise in T1D, the exercise for type 1 diabetes (EXTOD) 
pilot study was set up to investigate exercise in people newly diagnosed with T1D (<3 months) 
[187]. In the EXTOD study, participants completed 12 months of unsupervised moderate 
intensity exercise (150-240 minutes per week). Clinical reviews took place at 3, 6, and 12 
months measuring blood glucose, meal stimulated C-peptide, and fitness levels. The EXTOD 
pilot trial showed that regular exercise was safe and maintained by T1D participants. 
Improvements in insulin sensitivity and reduced insulin requirements were reported. Beta cell 
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function, measured by C-peptide, did not change between groups but the increase in insulin 
sensitivity in the exercise group likely under-estimated beta cell function. Beta cell function 
corrected for insulin sensitivity, as done routinely for T2D but not for T1D yet, was however 
preserved by exercise compared to the non-exercise arm, where there was loss of beta cell 
function. This provides preliminary human data to support the role of exercise for beta cell 
preservation in T1D [187].  
Conducting an exercise trial in a T1D cohort may face difficulties due to the barriers to exercise 
for people with T1D [188]. In a qualitative analysis carried out by Lascar et al (2014), 
T1Dspecific barriers to exercise included low levels of knowledge about managing diabetes 
and its complications around exercise. Currently underway, the EXTOD education study aims 
to reduce barriers to exercise in T1D and support effective exercise in people with T1D. 
Two studies have examined exercise training in T1D mouse models. Huang et., al (2011) first 
showed that 6 weeks of exercise training in streptozotocin-induced T1D mice significantly 
improved insulin content and insulin secretion in islets compared to sedentary mice suggesting 
an increase in beta cell preservation [184]. A more recent study has examined the effects of 
exercise training on immune parameters in T1D [189]. Twenty weeks of training in NOD mice 
resulted in reduced immune cell infiltration into the pancreas and subsequently the insulitis 
index. This is the only exercise study in a model of T1D to demonstrate the modulatory effects 
of exercise on islet immunity [189]. 
The above studies have examined some effects of regular exercise in T1D only. One study has 
measured haematological changes in people with T1D during acute exercise. Here, they found 
that lymphocytes, monocytes, granulocytes, and platelets all increase following an exhaustive 
step test and endurance exercise in people with T1D [190]. However, only total blood counts 
were measured and not changes in specific immune cell subsets.  
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Whilst the effects of exercise on immunity has been characterised in healthy cohorts, there is a 
clear lack of research into the effects of acute exercise on immune parameters in people with 
T1D. Therefore, this study aimed to explore the effects of exercise on immune cells in T1D. 
Acute exercise has an abundance of beneficial effects on the immune system which could 
translate into diseases such as T1D. Firstly, exercise has the potential to modulate immune cells 
involved in the pathogenesis of T1D i.e. antigen experienced, memory T cells. Secondly, the 
aims of potential immunotherapies are to reduce aggressive memory phenotypes and 
inflammation, and promote the generation of new naïve cells. All of which have been shown 
during acute exercise and exercise training in healthy cohorts. The effects of exercise on 
immunity in T1D may be therefore used as an adjunct for other immunotherapeutic strategies. 
For example, agents that target CD8+ T cells may be more effective if administered following 
a bout of exercise when CD8+ T cells are mobilised into the peripheral circulation.  
1.5 Exercise Immunology 
A significant amount of evidence on the effects of exercise on immunity has been established 
outside T1D. Acute exercise causes immune cell mobilisation. The significant exercise 
intensity-dependant increase in the frequency of lymphocytes following acute exercise is one 
of the most replicated findings in exercise immunology. Lymphocytosis can then be followed 
by lymphopenia in healthy cohorts following vigorous intensity exercise [191-196].  
There is differential mobilisation within the lymphocyte subsets during acute exercise. Firstly, 
NK cells are the most responsive lymphocyte subset to acute exercise. Highly differentiated 
NK cells (CD56dimCD16brightCD57+KLRG1+) demonstrate the largest percentage increase 
following exercise [197, 198]. T cells show the next largest percentage increase during 
exercise, with fully differentiated CD8+ T cells (EMRA) being the most sensitive to 
mobilisation [199, 200]. Lastly, there is a small increase in CD4+ T cells and B cells [193, 199, 
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201]. Beta-adrenergic receptor expression is higher on NK and CD8+ T cells than other immune 
subsets, resulting in their preferential intensity-dependant mobilisation in response to 
adrenaline during acute exercise [202-205]. Further detail on the mobilisation of lymphocyte 
subsets during acute exercise is given in subsequent chapters.  
Other mononuclear cells also respond to exercise. Monocytes mobilise in an exercise intensity-
dependent manner, with mature monocytes (CD14low) increasing the most [206-208]. 
Granulocytes also increase, with the majority of these being neutrophils. Neutrophils increase 
immediately post exercise and fall below baseline during the 1 hour post exercise recovery 
period, this is followed by an increase 2 hours post exercise referred to as the “second wave” 
[209-211]. Vigorous acute exercise also increases hematopoietic stem and progenitor cells 
(HSPC) post exercise [212, 213].  
Dysregulated immunity underlies the pathogenesis and natural history of T1D. Acute exercise 
modulates immunity through the mobilisation of immune cells. Lymphocyte trafficking and 
tissue redistribution is essential for immunosurveillance and regulation [191]. The use of 
animal models demonstrates that T cells are released from the spleen and accumulate in the 
lungs, bone marrow, and Peyer's patches of mice following acute exercise [214]. The dramatic 
increase in the frequency of highly differentiated memory T cells following exercise is 
followed by a larger egress of these subsets from the peripheral blood during the recovery 
period [200, 215]. Lymphopenia following vigorous exercise is thought to partly occur from T 
cell apoptosis [216-218]. Vigorous intensity exercise (i.e. above 70% VO2 max) mobilises 
memory T cells expressing CD95, a marker of apoptosis [216, 219]. Therefore deletion of 
memory T cells following acute exercise may create “immunological space” [216-221]. 
Vigorous intensity exercise also increases hematopoietic stem and progenitor cells (HSPC) and 
stimulates haematopoiesis [212, 213]. Therefore, vacant immune space following exercise can 
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be taken up by newly generated immature cells, creating the opportunity to reprogram our 
immune memory. T1D and beta cell loss is sustained by aggressive memory T cell phenotypes. 
Acute exercise has the potential to reduce aggressive memory T cell phenotypes in T1D and 
thus reduce disease severity and beta cell loss. 
Amongst the abundance of cellular changes, acute exercise also causes other systemic changes. 
During acute exercise cytokines, adipokines, myokines, and various hormones are released into 
the bloodstream which reduce inflammation [222]. Muscle-derived IL-6 is a central myokine 
secreted by skeletal muscle during and after exercise. IL-6 peaks immediately following 
exercise [208, 211, 223, 224]. Conventionally, IL-6 is better known for its pro-inflammatory 
effects; released from pro-inflammatory immune cells and dependant on NFκB pathways. 
However, intramuscular IL-6 is regulated by pathways such as Ca2+/nuclear factor of activated 
T cells (NFAT) and glycogen/p38 mitogen-activated protein kinase (MAPK) pathways 
resulting in the release of IL-6 without the activation of pro-inflammatory pathways [225]. 
Furthermore, IL-6 release is followed by an increase in regulatory cytokines, IL-10 and IL-
1RA, during the recovery period (1-2 hours post-exercise) [223, 224, 226, 227]. This increase 
is greater than that with IL-1RA treatment used in trials for beta cell preservation in people 
with T1D. One week treatment with IL-1RA treatment in T1D caused a two-fold increase in 
adipose tissue IL-1RA. Whereas acute exercise can result in up to 128-fold increase in plasma 
IL-1RA [227]. However, as this was measured in different tissues, it is difficult to directly 
compare. IL-6 also stimulates glucose-dependent insulinotropic peptide 1 (GLP-1) secretion 
from intestinal cells. GLP-1 in turn potentiates insulin secretion [228].  
In addition to the above anti-inflammatory effects of exercise, pro-inflammatory adipokine, 
resistin is reduced [229] and anti-inflammatory adipokine, adiponectin is increased following 
acute exercise [230-232]. Acute exercise also reduces oxidative stress by lowering reactive 
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oxygen species (ROS), nitric oxide (NO), and inducible nitric oxide synthase (iNOS) 
production. It also reduces the markers of oxidative stress, malondialdehyde (MDA) and 
aggresome-like induced structures [233-235]. Chronic inflammation in T1D promotes beta cell 
loss of function and destruction; therefore exercise has the potential to preserve beta cell health 
through modulating beta cell function, reducing inflammation, and reducing oxidative stress. 
For this reason, it is important that residual beta cell function, measured by C-peptide, still 
exists in T1D patients in order to increase the initial honeymoon phase following diagnosis 
through exercise [236].  
The effects of acute exercise are well established in healthy and athletic cohorts. However, the 
effects of acute exercise on immune parameters in a disease state have only recently gained 
attention. Multiple sclerosis (MS), another T cell mediated autoimmune disorder, displayed 
normal cytokine responses to acute exercise. Plasma IL-6, TNF-α, and IFN-γ increased 
following exercise and decreased during the recovery period to a similar extent to control 
participants [237]. Other autoimmune disorders however, such as rheumatoid arthritis (RA) 
and systemic lupus (SLE), have abnormal responses to acute exercise. Here, CD8+ T cells are 
reduced following exercise, and CD4+ T cells are reduced at peak exercise but increased after 
cessation [238]. In a chronic disorder such as chronic kidney disease (CKD), normal 
leucocytosis and cytokine responses (IL-6, IL-10 increase) were found following acute exercise 
[226]. To date, no study has examined the effects of exercise on immune cell subset 




1.6 Hypothesis and Aims 
Here, I have set up an acute exercise trial in people with T1D in order to characterise the 
mobilisation of immune subsets following a moderate (40% VO2 max) and vigorous (80% VO2 
max) exercise bout. This will be compared to control participants and previous literature in the 
field of exercise immunology. Evidence from this study will provide insight for future exercise 
training studies and prospective immunotherapy targets in T1D.  
1.6.1 Overarching Hypothesis 
Acute exercise will induce intensity-dependent lymphocytosis thereby improving immune 
regulation in T1D 
1.6.2 Overarching Aims 
- Examine the safety and clinical effects of acute exercise in people with T1D. 
- Characterise the effects of acute exercise on lymphocyte trafficking in T1D.  











CHAPTER 2. GENERAL 
METHODS   
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2.1 EXTOD Mechanisms clinical trial set up 
2.1.1 Ethics 
Ethical approval was granted by the Preston Research Ethics Committee (REC) 
(supplementary). The study was sponsored by the University of Birmingham. The final 
protocol herein for the EXTOD Mechanisms study describes the design and organisation of the 
study. The protocol was maintained by the EXTOD Study team at the University Hospitals 
Birmingham NHS Foundation Trust (UHBFT) and the University of Birmingham 
(supplementary).  
2.1.2 Study Participants 
The study aimed to recruit 20 participants with T1D and 20 participants without T1D. No 
formal upper limit to participant recruitment was specified in this study. This was an 
exploratory study and formal power calculations were not possible. However, recruitment 
numbers were based on preliminary work which demonstrated that exercise serum improves 
proliferation and reduces apoptosis of a mouse insulinoma cell line (MIN6), and that 10 
samples were sufficient to demonstrate statistical significance. Screening and enrolment of 
participants with T1D was supported by medical and research staff, who had a Good Clinical 
Practice (GCP) certificate and experience in recruiting to studies. All patients with T1D who 
fulfilled the selection inclusion criteria were invited to participate in the research study, unless 
they were known to fulfil one of the exclusion criteria. Participants continued to receive their 
usual diabetes NHS care provided by their hospital consultant or GP during their participation 
in this study.  
2.1.3 Inclusion & Exclusion Criteria 
Members of the research team ensured that potential study participants fulfilled the inclusion 
and exclusion criteria prior to proceeding to obtaining full informed consent. 
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2.1.3i Inclusion Criteria 
1. Adult over 16 and below the age of 65 years of age at the start of the study. 
2. Male. 
3. Were not achieving the recommended physical exercise guidelines of 150mins 
moderate intensity exercise plus 2 days of strengthening exercise per week during the 
study. 
4. Both participant and physician felt that they were able to exercise safely. 
5. In addition if participants were in the T1D group, they were; 
1. given a clinical diagnosis of T1D 
2. on basal bolus insulin regime or insulin pump therapy 
3. ability to estimate carbohydrate content of meals 
4. willing to test glucose through capillary testing and adjust insulin and carbohydrate 
doses accordingly 
5. able to recognise hypoglycaemic symptoms before capillary blood glucose falls to 
3.9mmol/L 
2.1.3ii Exclusion Criteria 
1. Unable to provide fully informed consent. 
2. A history of cardiac disease. 
3. Significant illness or condition (including psychological, psychiatric, developmental or 
physical disease) that prevented attendance at a study site clinical centre. 
4. If it was felt by the principal investigator that participation in the study would not be in 




5. In addition, if subjects were in the T1D group: 
1. active proliferative diabetic retinopathy 
2. clinically evident autonomic neuropathy 
3. history of severe hypoglycaemia requiring third party assistance within the last 3 
months 
2.1.4 Consent 
All individuals who expressed an interest in participating in the study must have received the 
current version of the participant information sheet (PIS) (supplementary). At the point that 
consent was obtained the participant must have had enough time to have read the PIS and to 
discuss any concerns they may have with family, friends and medical staff. Also, participants 
were provided with the opportunity to discuss any remaining questions the participant may 
have had with a member of the research team prior to agreeing to provide their consent. Consent 
was taken by the approved members of the research team who had a certificate of GCP in line 
with current international research guidelines. All participants had the right to withdraw their 
consent at any time and without penalty. Once the form was signed, dated and counter-signed, 
the baseline assessment proceeded.  
2.1.5 Participant Withdrawal 
If at any time during the study, a participant fulfilled any of the withdrawal criteria stated 
below, his participation was discontinued. Wherever possible these reasons were discussed 
with the principal investigator prior to withdrawing the participant. All participants withdrawn 
due to an adverse effect were to be followed up until resolution of the event or until it was 
stable. Withdrawal from the trial did not affect the future provision of diabetes care provided 
by the primary or secondary care providers. All data collected up until the point the participant 
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withdrew from the study was kept as part of the study, unless the participant provided written 
instructions for it to be removed. 
Withdrawal Criteria:  
1. The participant was unwilling or unable to continue. 
2. The participant was lost during follow up or became uncontactable.  
3. Participant no longer fulfilled the eligibility criteria (see inclusion and exclusion)  
2.1.6 Study Plan for Investigation  
The study was divided into 3 phases: 
• Screening 
• Enrolment and baseline visit 
• Exercise study visits  
All visits occurred in the National Institute for Health Research (NIHR)/Wellcome Trust 
Clinical Research Facility (WTCRF) at UHBFT. 
2.1.6i Screening and Recruitment 
Screening and recruitment involved the identification of individuals who fulfilled the 
inclusion/exclusion criteria and who may be interested in participating in the study. For the 
T1D group, this involved approaching clinicians with responsibility of managing patients with 
T1D and fully informing them about the study. Then seeking a formal agreement for the 
research team to approach their patients with T1D, either directly in clinic or indirectly through 
a letter of invitation, to participate in the study. All letters of invitation whether posted or 
handed directly to the patient in clinic included a PIS. Patients were then asked to contact the 
research team should they be interested in participating in the study. A reminder follow-up 
phone call or SMS text message (“We are recruiting individuals who have diabetes to a clinical 
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research study at The University of Birmingham. To find out more call [insert name] on [insert 
contact number]”) was made to patients.  
2.1.6ii Enrolment & Baseline visit  
This involved the collection of informed consent and baseline information, including 
participant’s demographics and anthropometric assessment. For patients with T1D, HbA1c was 
checked if not done within the previous 6 weeks. 
Food diaries were provided for all participants to record all meals in the 24 hours prior to each 
exercise visit. Participants were required to disclose any medication (other than insulin for 
T1D) they were taking during the period of the exercise study. Participants were required to 
disclose other medical history (other than T1D). Participants were also required to disclose any 
symptoms of infection or illness in the last 7 days prior to each exercise visit. If infection or 
illness was present the visit was rescheduled. In addition, blood glucose diaries were provided 
for participants with T1D. T1D participants were asked to measure their glucose at least 4 times 
a day during the study (before each meal, before bed, and any time they were feeling unwell or 
it was appropriate to do so).  
All participants completed the Astrand-Rhyming predicted VO2 max test on the cycle 
ergometer [239]. This submaximal test was chosen as it is unknown if maximal tests are safe 
for T1D participants at risk of exercise-induced hypoglycaemia. This was undertaken in the 
exercise rooms of the NIHR/WTCRF. These values were used to guide the setting of the 
subsequent exercise study visits where the participant underwent moderate (40% VO2 max) 
and vigorous (80% VO2 max) exercise intensities. 
Participants were asked to complete an IPAQ [240] and perceived stress questionnaires; the 
life scale events questionnaire [241], perceived stress scale [242], the undergraduate stress 
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questionnaire [243], self-perceived health status [244], and the Pittsburgh sleep quality index 
[245]. 
2.1.6iii Exercise study visits 
Participants underwent two exercise study visits, each separated by between 7-21 days to allow 
for recovery (immune changes evident up to 72 hours following exercise [246]) and minimise 
variation between visits. Participants attended the study site at 8.30 am without having 
consumed food (water allowed) since midnight the night before. For all participants, any meals 
consumed within the previous 24 hours should have been repeated for the 24 hours preceding 
each of the other two study visits to control for variation in the effects of diet between exercise 
visits. These were recorded in a food diary by all participants. Participants were encouraged to 
undertake their usual levels of physical activity between study visits, but refrain from exercise 
for a 24-hour period before an exercise study visit. 
Participants with T1D were allowed and encouraged to take their basal insulin (with either pens 
or insulin pump) as usual in the morning, but not to take any bolus quick acting insulin prior 
to the visit.  
The exercise visits consisted of 30 minutes cycling at either moderate intensity exercise (40% 
VO2 max) or vigorous intensity exercise (80% VO2 max). Individuals cycled at pre-defined 
workload (wattage) and heart rate for each exercise intensity. Heart rate and RPE [247] were 
monitored throughout the exercise bout (measurements recovered at 5 minute intervals) and 
workload was adjusted to keep the heart rate within the pre-defined range (± 2bpm). All 
exercise was performed at the same speed (50 revolutions per minute (RPM)), with only 
workload adjusted to correct exercise intensity. The exercise intensity was blinded until the 
participant arrived at the WT CRF facility on the day of the visit. 
The procedure when they arrived at the WT CRF for each study visit involved: 
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1. If they had T1D, ensure they are safe to exercise according to EXTOD exercise 
guidelines.  
2. All participants completed a perceived stress questionnaire for the time between 
visits.  
3. Cannula was inserted into ante cubital fossa and secured by research nurses. 
4. Resting blood sample was taken once cannula was inserted. 
5. Heart Rate, blood glucose levels and blood pressure were recorded at each full 
blood sampling time point. 
6. Waited for 20 minutes whilst participant was resting. 
7. A full blood sample drawn immediately before 30-minute exercise intervention 
commenced.  
8. Participants completed a 5-minute warm up (50 RPM between 25-50 watts) on the 
cycle ergometer.  
9. Blood samples for glucose measurement was taken 10 mins and 20 mins post-
exercise commencement.  
10. A full blood sample was drawn immediately after exercise cessation.  
11. Heart rate and blood pressure was recorded every 15 minutes during the recovery 
period for 1 hour. If T1D, blood glucose levels were also checked*.  
12. A full blood sample was drawn 60 minutes after exercise cessation  
13. Breakfast was provided. If T1D, checked blood glucose was stable. 
If T1D, advise patient to test blood glucose 6-8 hours post exercise / consume 
carbohydrates to avoid post-exercise hypoglycaemia. 
14. For the control group, a 4-hour post exercise fasted blood sample was taken if 
participant agreed to do so.  
15. Arranged next visit and paid for travel. 
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*If a participant’s blood sugar dropped to 4mM before 60 minutes post exercise time-point, a 
blood sample was taken and the participants were fed immediately. 
2.1.6iv. Sample collection 
A full set of blood samples were taken immediately before exercise, immediately post-exercise, 
and 1 hour post-exercise. All blood samples were kept on a roller until all samples were ready 
for simultaneous processing (did not exceed 2 hours). Figure 3 displays the sample collection 
at each time point. Table 1 displays the outcome measures for the samples collected.  
Blood pressure, heart rate, and blood glucose was measured at each time point. A full set of 
blood samples included 5ml for serum separation, 5ml for plasma separation, 2 ml for plasma 
with DPPIV-inhibitor, and 20ml for immune based assays. All plasma samples were taken in 
Ethylenediaminetetraacetic Acid (EDTA) vacuette tubes (454087, Greiner Bio-one GmbH, 
Frickenhausen, Germany) and stored on ice until processing to prevent cytokine degradation. 
A separate 2ml blood sample was taken in EDTA tubes with Dipeptidyl Peptidase IV (DPPIV) 
inhibitor (DPP4, EMD Millipore Corporation, Billerica, MA, USA) added freshly prior to the 
visit and stored on ice until processing (20µl DPPIV inhibitor and 20µl of 100mM Pefabloc® 
SC (76307, Sigma-Aldrich, Dorset, UK) added to EDTA vacuette tubes). All serum samples 
were taken in clotted tubes (456048 VACUETTE® TUBE 6 ml Z Serum Clot Activator, 
Greiner Bio-one GmbH, Frickenhausen, Germany) and stored upright at room temperature 
until processing. Blood samples for immune function and phenotyping analysis were taken in 
lithium heparin vacuette tubes (95057-405, Greiner Bio-one GmbH, Frickenhausen, Germany) 
and placed on roller at room temperature to ensure constant mixing of the blood sample and 
















































Figure 3 Sample Collection during exercise visits 





Volume of blood sample Fresh samples Frozen samples 
Take 25µl from whole blood 
assigned for serum separation 






2mls (EDTA + DDP4 
inhibitor) 
Plasma and Serum Separation Cryopreserve plasma and 
serum for Metabolomics (2 x 
500µl aliquots), Luminex (5 x 
500µl aliquots) and CMV 
(200µl aliquot) testing 
20mls (Heparin) FACS (whole blood)- 5 mls 
Fresh PBMC separation for 
Transmigration assay (1x106 
lymphocytes) – 15mls 
 
 
Cryopreserve left over PBMC 
 
Table 1 Sample processing 
Sample volume, processing, and storage for moderate or vigorous intensity exercise visits. 
 
  
2.1.6v Storage and use of samples 
Participant samples were collected in the NIHR/WT CRF and transported at the required 
storage temperatures (heparin and lithium tubes at room temperature, EDTA tubes on ice) to 
the laboratories of the University of Birmingham where they were processed and analysed. 
Samples were stored in the laboratories of the University of Birmingham.  
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2.2. General haematological methods 
2.2.1 PBMC isolation 
 
Blood was collected in lithium heparin vacuette tubes (95057-405, Greiner Bio-one GmbH, 
Frickenhausen, Germany). A density gradient was formed using 5ml of Histopaque-1199 
(11191, Sigma-Aldrich, Dorset, UK) and 5ml of Histopaque-1077 (10771, Sigma-Aldrich, 
Dorset, UK). Ten ml of blood was layered onto the histopaque gradient and centrifuged at 
2500RPM for 25 minutes. The PBMC layer (i.e. the buffy coat) was removed carefully using 
a Pasteur pipette. PBMCs were washed with 12mls of media (M199-2%BSA) and centrifuged 
for 10 minutes at 1500RPM. Supernatant was removed and cells were washed a second time. 
Supernatant was removed and cells were be resuspended in 1 ml of media for counting.  
2.2.2 Haematological Measures 
Haematological measures were conducted on 25µl of whole blood using an automated coulter 
counter (ABX Micros ES 60, HORIBA Medical). Blood samples were kept on a roller at room 
temperature until cell counts were performed. An aliquot of 25µl of blood was transferred to a 
1.5ml micro-centrifuge tube. Once the coulter counter had warmed up, the micro-centrifuge 
tube was placed under the needle and the samples were extracted for analysis. This measures 
the following haematological parameters: total white blood cell (WBC) count, lymphocytes, 
monocytes, granulocytes, total red blood cell (RBC) count, haemoglobin (HBG), haematocrit 
(HCT), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean 
corpuscular haemoglobin concentration (MCHC), red cell distribution width (RDW) (variation 
and size of red blood cells), total platelet count, plateletcrit (PCT), mean platelet volume 




2.3 Designing an optimal multi-colour flow cytometry panel 
 
Five panels of 9-12 fluorophore-conjugated antibodies were designed to identify immune 
populations of interest (Table 2). The fluorophores for each marker were matched based on 
their level of expression or cell subset size i.e. dimly expressed/small cell subset surface 
markers were matched with bright fluorophores and highly expressed/large cell subset markers 
were matched with dim fluorophores. To minimise spectral overlap of the fluorophores they 
were spread across all possible filters, avoiding close emission wavelengths on the same laser 
where possible for surface markers expressed together on immune cell subsets (see Figure 4). 
This was approved by the BD biosciences technical support team (BD Biosciences Scientific 




Figure 4 BD LSR Fortessa X-20 Lasers and Filters 
Laser and filters available on the BD LSR Fortessa X-20 which fluorophores were spread across to clearly 
determine immune cell populations.  
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Panels Phenotyping markers 
 
Tube 1 - Lineage T 
cells subsets 
 
CD3, CD8, CD4, CCR7, CD45RA, CD95, CD127, CD11b, CD27, 
CD28, CD69, Viability 
 
Tube 2 - T-Regulatory 
and T-helper subsets  
 
CD3, CD4, CCR4, CD45RO, CD127, CXCR3, CCR6, CD25, IL-
6R, TIGIT, Viability 
Tube 3 - B cells  
 
CD19, CD3, CD10, CD34, CD62L, CD27, CD38, AdipoR1, 
AdipoR2, Viability 
 
Tube 4 - NK cells  CD56, CD16, CD57, CD3, NKG2A, KIR (CD158a), CD25, 
CD122, LFA-1 (CD18), Viability 
 
 
Table 2 Four panels developed for phenotyping immune populations of interest 
2.3.1 Antibody conjugation 
Lightning-link PerCP-Cy5.5 (763-0005, Innova Biosciences, Cambridge, UK) and Pe-Cy7 
tandem conjugation kits (762-0005, Innova Biosciences, Cambridge, UK) were used for anti-
AdipoR1 and R2 fluorochrome conjugation.  
2.3.2 Whole Blood Staining 
Blood was collected in 13 x 75 mm green cap-black ring vacuette heparin tubes (454087, 
Greiner Bio-one GmbH, Frickenhausen, Germany). Red blood cells were lysed by preparing 
whole blood in 4ml aliquots and washed with 16mls Ammonium Chloride lysis buffer (16g 
Ammonium Chloride (326372, Sigma-Aldrich, Dorset, UK), 2g sodium hydrogen carbonate 
(S/4240/60, Fisher scientific Ltd, Loughborough, UK ), 0.2g EDTA (E5134, Sigma-Aldrich, 
Dorset, UK), and 2L ddH2O) by centrifuging at 1000g for 5 minutes. Pelleted cells were 
resuspended in 10mls RPMI-1640 (R0833, Sigma-Aldrich, Dorset, UK) (supplemented with 
2% FBS) and washed again. Cells were then counted and resuspended to a concentration of 
1x106 cells/ml. Cells were stained with appropriate antibodies according to the panels shown 
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in Table 1 (antibodies shown in Table 2) and incubated in dark at 4°C for 15-20 mins. Stained 
cells were lysed and fixed with 500µl 1X BD FACS lysing solution (containing 14% 
formaldehyde) (349202, BD Biosciences, Wokingham, UK) and incubated in dark at 4°C for 
15minutes. Fixed cells were washed in 2mls phosphate-buffered saline (PBS). Pelleted cells 
were resuspended in 500µl PBS and stored at 4°C until analysis. The stability of fixed stains 
was assessed and confirmed that cells could be stored up to 24hours at 4°C during the 
optimisation of the staining conditions. All samples were analysed using flow cytometry (BD 
LSR Fortessa X-20). Parent populations (i.e. lymphocytes) were gated on based on their size 
on FSC/SSC. Doublets were omitted by gating on the linear population shown on FSC-A/FSC-
H prior to recording. Events to record were set to 100,000 within the parent population gate. 
Newest compensation set up (see Section 2.3.4) was linked to each experiment. A negative 
control (unstained whole blood) was run for each experiment.  
Notes: all flow cytometry antibodies used were from BD Biosciences (Wokingham, UK) 
excluding NKG2A (RNDSystems, Oxford, UK), AdipoR1 and AdipoR2 (Phoenix Europe 
GmbH, Viktoriastraße, Karlsruhe, Germany).  
Cat. # Description Clone Reaction Format  
563423 CD3 UCHT1 Hu PE-Cy7 
560179 CD8 SK1 Hu APC-H7 
564975 CD4 RPA-T4 Hu APC-R700 
552176 CD197 (CCR7) 3D12 Hu PE 
563870 CD45RA HI100 Hu BV786 
562616 CD95  DX2 Hu BV421 
558598 CD127 (IL-7 Receptor 
α chain) 
HIL-7R-M21 Hu Alexa Fluor 647 
562399 CD11b/Mac-1 (CR3) ICRF44 Hu PE-CF594 
564642 CD27 M-T271 Hu BB515 
563075 CD28 (TLR2) CD28.2 Hu BV510 
563835 CD69 (Very Early 
Activation Antigen) 
FN50 (also known as 
FN 50) 
Bab, Cyno, Hu, 
Rhe 
BV650 
563041 CD56 (N-CAM) NCAM16.2 Hu BV510 
562293 CD16  3G8 Hu PE-CF594 
565285 CD57 NK-1 Hu BB515 
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563183 CD158a HP-3E4 Hu BV711 
560989 CD25 (IL-2 Receptor α 
chain) 
M-A251 Hu PE 
562887   CD122 (IL-2 Receptor 
β chain)    
Mik-β3 Hu BV421 
551060 CD18 (Integrin b2 
chain, CR3/CR4) 
6.7 Cyno, Hu, Pig, 
Rab, Rhe 
APC 
562579 CD194 (CCR4) 1G1 Hu BV421 
564290 CD45RO UCHL1 Hu BV786 
562451 CD183 (CXCR3) 1C6/CXCR3 Hu PE-CF594 
563923 CD196 (CCR6) 11A9 Bab, Cyno, Hu, 
Rhe 
BV711 
340526 IL-6R AS12 Hu FITC 
46-9500-41 TIGIT MBSA43 Hu PerCP-eFluor710 
565388 FVS780 - - APC-Cy7 
643397 Lineage cocktail 2 (lin 






563362 CD123 (IL-3 Receptor 
α chain) 
7G3 Hu BV421 
563026 CD11c (Integrin αX 
chain) 
B-ly6 Hu BV510 
563883 CD103 (Integrin αE 
chain) 
Ber-ACT8 Hu APC 
563372 CD14 MPhiP9 Hu BV711 
564041 HLA-DR G46-6 Hu BV786 
564727 CD207 (Langerin) 2G3 Hu PE 
562294 CD19 HIB19 Hu PE-CF594 
563219 CD3 (Leu4) SK7 (also known as 
Leu-4) 
Hu BV605 
562902 CD10  HI10a Hu BV421 
555822 CD34 (gp 105-120) 581 Hu PE 
559772 CD62L (L-selectin) DREG-56 Hu APC 
563965 CD38 HIT2 Hu BV711 
FAB1059C NKG2A 131411 Hu PerCP 
G-001-44 Adipo R1 (357-375)  Hu *unconjugated 
G-001-23 Adipo R2 (374-386)  Hu *unconjugated 
 
Table 3 List of fluorophore conjugated antibodies used in immunophenotyping panels (Table 2) 
2.3.3 Antibody Titrations 
All antibodies were titrated using single stained lysed whole blood (1x106 cells per stain). The 
optimal titre of each antibody was chosen where there were distinct negative and positive 
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peaks. Examples antibody titrations for CD8, CD45RA, CCR6, and CD11b are shown below 
(Figure 5). In Figure 5 (a), all stains show a separate positive peak, therefore the lower titration 
i.e 1'l was chose. In Figure 5 (b), 2 'l and 5 'l show a separate positive peak, but the 2'l 
titration is closer to the negative peak. Here, 5 'l was chosen to ensure the best positive 
staining.  
 
Figure 5 Antibody titration for flow cytometry optimisation 
Antibody titrations shown for (a) CD8 (b) CD45RA (c) CCR6 and (d) CD11b.  
2.3.4 Compensation 
Compensation beads (BD CompBead Set Anti-Ms Ig k, 552843, BD Biosciences, Wokingham, 
UK) were used to calculate automatic compensation. A negative bead control was used to gate
on the bead population using the same FSC/SSC voltages applied for whole blood samples. 
Voltages for each filter were adjusted on the unstained whole blood and negative beads to 
ensure all filters were set to negative. Positive beads were stained with an antibody 
representative of each filter (antibodies for highly expressed markers were chosen for this). 
Once compensation was calculated, single stained whole blood for each filter were used to 
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manually test compensation. Spectral overlap and median fluorescence intensity (MFI) were 
adjusted to correct for under or over e-compensation. The MFI for each fluorophore (excluding 
the single stain) must be equal to its corresponding MFI for the unstained cells. Adjusting the 
spectral overlap will increase or decrease the percentage of the fluorophore being taken away 
from overlapping spectrums to equalise the MFI to that of the unstained. Compensation was 
performed at least monthly to accommodate for changes in filter excitation and emission.  
2.3.5 Fluorescence Minus One controls 
Florescence minus one (FMO) controls were used to define gating strategies for the absent 
antibody population, indicating where the negative and positive populations for this marker 
should be found. For each panel, one antibody was omitted from the staining procedure, whilst 
the rest of the antibodies were still included in the panel. This was done for all the antibodies 
apart from distinct surface markers such as CD3, CD4, CD8, CD19, and CD56. This is because 
these markers always have a strong positive signal due to their high cell surface expression. 
Examples for CD95, CD127, CD28, and CD27 are shown in Figure 6. Doublets were omitted 
by gating on the linear population shown on FSC-A/FSC-H prior to recording. In Figure 6 (d), 
the unstained peak (red) and the negative peak for the CD27 are different due to the presence 
of other stains in the CD27 FMO tube. This indicates how an FMO can be used to define gating 
strategies by knowing where the true negative populations are located. Isotype controls can 
also be used for the same purpose as FMO controls. 
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Figure 6 Fluorescent Minus One controls 
Florescent minus one controls shown for (a) CD95 (b) CD127 (c) CD28 and (d) CD27.  
2.3.6 Whole blood counts 
Whole blood counts (cells/'l) to calculate the total cell frequency of subsets measured by flow 
cytometry were performed as described in Section 2.2.2. 
2.3.7 Data analysis 
All analysis was performed using FlowJo version 10.2 (FlowJo LLC, Oregon. Gating strategies 
were optimised through the use of unstained controls and FMO controls (Section 2.3.5). Gating 
strategies for all populations of interest are represented in subsequent results chapters. Further 
compensation could be applied on FlowJo to acquire the cleanest data. Population proportions 
(%) given in flowjo were exported to excel where the relative cell frequencies were calculated 
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for each sample using coulter counter cell count data. This was done by multiplying the 
percentage proportions (found through specific population gating) by the total cell count for 
each main population (e.g. lymphocytes, monocytes etc.). Once total cell frequencies (cells/µl) 
for each main population were calculated, these were used as the parent population to calculate 
frequencies of daughter cell subsets.  
2.4 Statistical analysis 
Statistical analysis was performed using SPSS version 24 (IBM, Chicago) and GraphPad Prism 
version 7 (GraphPad Software, California). Firstly, normality tests were performed on all data 
using Q-Q plots in SPSS. Multiple regression analysis was used to analyse within subjects 
effect (time) and between subjects effects overtime (time*group). Changes over time compared 
to baseline were also reported in tables for each group under the heading “contrast”. P values 
were reported as sphericity assumed however where mauchly’s test of sphericity was violated 
i.e. p £0.05, Greenhouse-Geisser corrected value was used. The p values, F values and degrees 
of freedom (df) are reported in tables as [F = (df, df error) value, p-value]. Variation in n 
frequencies is a result of a participant having no data for one time-point or no data for the 
second visit. Baseline data compared between groups was analysed using parametric students 
T-test. All results are presented as means and SD unless otherwise stated. P values £0.05 were 

















CHAPTER 3. THE EFFECTS OF 
ACUTE EXERCISE ON CLINICAL 
AND HAEMATOLOGICAL 
OUTCOMES IN TYPE 1 





3.1.1 Clinical and physiological outcomes 
Clinical and physiological outcomes such as VO2 max, cytomegalovirus (CMV) status, 
physical activity levels, and psychological stress levels were measured in the EXTOD 
Mechanisms study. This was conducted in order to validate and stratify our findings during the 
acute exercise intervention. 
VO2 max, a measurement of individual fitness, is the maximum amount of oxygen that an 
individual can use during maximal exercise [248-250]. VO2 max can be measured in a number 
of ways including treadmill tests, step tests, and the Astrand-Rhyming sub-maximal predicted 
VO2 max test [239]. In this study herein, the Astrand-Rhyming sub-maximal cycling 
performance test was used to predict VO2 max. A sub-maximal test was chosen as this was 
deemed safer for T1D participants who were at risk of exercise-induced hypoglycaemia. The 
Astrand-Rhyming test is consistent and significantly correlates with VO2 max [251-253]. In 
comparison to a maximal treadmill test and a step test, the Astrand- Rhyming method was 
reported as reliable, deviating only by 6% from the maximal treadmill test [253]. 
CMV infection is highly prevalent amongst the general population [254-256] and affects the 
mobilisation of lymphocyte subsets during acute exercise [200, 257, 258]. The prevalence of 
CMV is approximately 60% in the US and up to 80% in the UK, increasing with age [254-
256]. CMV prevalence measured between 1991 to 2002 in England and Wales was 15% in 
those aged 1-4 and 80% in those aged 65 and above [255]. Prior CMV infection increases the 
mobilisation of lymphocyte subsets and therefore it is important to measure the prevalence 
amongst participants when comparing between independent groups [258]. Specifically, CMV+ 
CD8+ memory T cells are preferentially mobilised during acute exercise, with a two-fold 
greater increase compared to CMV- CD8+ memory T cells [200]. Because memory T cell 
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populations are analysed in the EXTOD Mechanisms study it is important to control for CMV 
status between the groups. In addition to CMV infection, other underlying infections will 
increase white blood cell counts at rest and therefore skew the baseline lymphocyte numbers. 
It is important to record recent infection history before conducting the exercise intervention so 
that this can be considered for data and statistical analysis.   
Other factors affecting lymphocyte frequencies include physical activity levels and 
psychological stress. Physical activity levels can be measured using the International Physical 
Activity Questionnaire (IPAQ) [240]. Higher baseline lymphocyte frequencies are reported 
during stress, predominantly in memory CD4+ and CD8+ T cell subsets [259, 260]. As is 
standard practice in exercise immunology studies and in order to have a true baseline sample, 
pre-existing life stress can be accounted for using a combination of validated stress 
questionnaires; the life scale events questionnaire [241], perceived stress scale [242], the 
undergraduate stress questionnaire [243], self-perceived health status [244], and the Pittsburgh 
sleep quality index [245]. These questionnaires can be used to compare stress levels between 
groups, and to enable interpretation of any potential differences in lymphocyte mobilisation. 
In addition to lifestyle stress, other lifestyle factors such as dietary habits and intolerances may 
affect immunity. Dietary components can also affect the proportion of lymphocytes at rest. In 
one study, mice fed carbohydrate-rich and fat-rich diets had higher CD3+ lymphocytes than 
those mice fed a standard diet [261]. In this study, higher systemic adiponectin in mice fed a 
fat-rich diet compared to carbohydrate-rich diet was also observed [261]. Adiponectin has anti-
inflammatory and anti-diabetic properties, and this further supports the impact of dietary 
components on immunity. Furthermore, increasing probiotic intake and improving gut health 
impacts immunity through boosting TReg function [262]. Although dietary habits can be 
difficult to control in an intervention, food diaries can be supplied to record this information 
and used for future data and statistical analysis.  
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3.1.3 Haematological parameters in T1D  
Some differences in haematological parameters compared to healthy cohorts have been 
reported in T1D. Whilst there are no differences in RBC between T1D and healthy cohorts, 
differences in white blood cells have been described [263-271]. Perturbations in WBC 
potentially reflect chronic inflammation and disease pathogenesis in T1D. Some studies have 
reported a decrease in lymphocytes in T1D [264, 265]. Whereas, others have reported no 
change in lymphocytes in T1D [263]. Differences in monocytes and granulocytes have also 
been found in T1D. Increased frequency and activation of monocytes has been shown in people 
with T1D [266-268]. Additionally, peripheral neutropenia has been reported to precede and 
accompany the onset of T1D [263]. However, increased neutrophil frequencies and neutrophil 
activity have also been found [269-271]. This increase in neutrophils correlated with risk of 
vascular disease in T1D [270].  
Studies of platelet count in T1D have also been inconsistent [263, 272-274]. Platelet counts 
were found to be marginally lower in T1D [263]. However, in another study platelets were 
found to be increased in T1D with poor metabolic controls and this is linked to the risk of 
cardiovascular events [272]. Platelets from children with T1D show morphological evidence 
of hyper-reactivity, particularly, higher MPV [272-274]. Therefore, platelet parameters can 
vary in T1D depending on age, duration of disease, and metabolic control.  
3.1.4 Haematological parameters during exercise 
The frequency of WBC, lymphocytes, monocytes, and granulocytes all increase during acute 
exercise in healthy cohorts [275, 276]. Acute exercise causes a significant increase in the 
frequency of lymphocytes in the peripheral blood, and can be followed by lymphopenia, in 
healthy cohorts. This increase is intensity-dependent and can double in response to vigorous 
intensity exercise [191-196]. Monocytes also respond to acute exercise in an intensity-
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dependent manner [206, 207]. Mature monocytes (CD14low) increased more than regular 
monocytes (CD14bright) during exercise [206, 207]. Monocytes fall below baseline during the 
recovery period measured at up to 3 hours after exercise cessation [206]. Granulocytes, 
predominantly neutrophils, increase post exercise. A decrease in neutrophils immediately post 
exercise followed by a “second wave” increase 2 hours post exercise has been found [209, 
210]. 
Blood flow and RBC measures change during exercise. [277-279]. Physical exercise is 
characterized by an increase in oxygen consumption by the whole body. During acute exercise, 
blood is circulated to supply oxygen to the working muscles. RBC carry O2, bound to 
haemoglobin, from lungs to tissues, and transport CO2 back to the lungs for expiration [277, 
278]. Haematocrit, the ratio of RBC to total blood volume, increases during exercise as a result 
of fluid loss from sweating and accumulation of metabolites during exercise, all leading to a 
decrease in plasma volume [279].  
Platelets also mobilise during acute exercise [280-284]. All platelet parameters increased 
following short exhaustive running exercise (PCT, MPV, Pct, PDW) [280]. The transient 
increase in platelets is due to platelets released into circulation predominantly from the spleen, 
and some from the liver and lungs [281-283]. Splenic platelets have a larger MPV and 
contribute to the increased MPV noted following exercise [281, 283]. Platelets express α2-
adrenergic receptors, therefore mobilise in response to adrenaline during exercise [283, 284].  
Only one study has measured haematological outcomes in T1D during acute exercise [190]. In 
the aforementioned study, 16 T1D and 16 control male participants performed two exercise 
tests; an exhaustive incremental VO2 max test on a cycle ergometer and an endurance test at 
90% of VO2 max lasting for 45 minutes. It was found that lymphocytes, monocytes, 
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granulocytes, and platelets all increased following both the exhaustive and the endurance 
exercise.  
Acute exercise causes alterations in haematological measures in healthy individuals, with some 
evidence of haematological alterations in people with T1D. This study explores changes in 
clinical and haematological parameters during moderate and vigorous intensity acute exercise 





The overarching aim of the EXTOD Mechanisms study was to explore physiological and 
immune changes arising in response to acute exercise in people with T1D. 
3.1.6 Specific Aims 
 
In this Chapter, the specific aims were to explore: 
 
1. Explore the feasibility of an acute exercise intervention in T1D.  
2. Differences in clinical and haematological parameters at rest in T1D and control 
participants. 
3. Changes in clinical and haematological parameters during and in response to acute 





3.2.1 Experimental design 
Twelve controls and twelve T1D male participants were recruited into the study (as described 
in Chapter 3). Briefly, participants had one enrolment visit, where an incremental sub-maximal 
cycle ergometer test was performed to calculate their predicted VO2 max. This was used to 
calculate workload and heart rate for subsequent exercise visits adjusted to individual fitness 
[285]. These two visits consisted of a thirty-minute bout of cycling at either 40% VO2 max 
(moderate) or 80% VO2 max (vigorous). Blood was collected intravenously at baseline, 
immediately post exercise, and 1 hour post exercise in vacuette heparin tubes (95057-405, 
Greiner Bio-one GmbH, Frickenhausen, Germany).  
3.2.2 Cytomegalovirus ELISA 
Anti-CMV IgG was measured in baseline serum (serum separation, section 2.2.1) samples 
using the Cytomegalovirus (CMV) IgG Enzyme Immunoassay Test Kit (GWB-892399, 
Genway, 2BScientific, Upper Heyford, UK).  
3.2.3 Haematological Measurements 
As described in Chapter 2 (Section 2.3.2). Briefly, this measures WBC parameters 
(lymphocytes, monocytes, granulocytes), RBC parameters (RBC count, HBG, HCT, MCV, 







The EXTOD Mechanisms study aimed to recruit 20 Caucasian male participants into both the 
T1D and control group. However, due to time constraints recruitment was limited to 12 
participants in each group. Control participants were identified and recruited directly through 
work relations which may have led to a bias in the control cohort as those most likely to 
participate were interested in exercise and therefore likely to be fitter than the T1D group. 
Although a high number of people with T1D were contacted through clinics, there was a low 
rate of agreement to enter the study. A total of 63 potential T1D participants were contacted at 
UHB, of these 48 were contacted through clinics at the Diabetes Research Unit and a further 
15 of these were participants original participants in the original EXTOD study in Birmingham. 
Diabetes clinics at Heartlands and Dudley Trusts were also contacted, however no participants 
were referred to the study from these sites. To boost recruitment in future it may be worth 
offering a monetary incentive to cover the cost of time off work which participants needed to 
attend the study visits.  
Efforts were made to increase recruitment. This included requesting contacts through clinical 
lists at Heartlands and Dudley to recruit T1D participants. To recruit control participants, other 
departments within the University of Birmingham were approached. Amendments to the 
inclusion/exclusion criteria were also made to boost recruitment. For example, the age range 
was increased from 20-40 years to 16-65 years. The ethnicity was changed from white 
Caucasian only to include all ethnicities. An increase in the recruitment, particularly for T1D 
participants, is noted following these amendments from January 2017 indicated by the green 
box in Figure 7 (Figure 7b). Completion of study visits also took longer than predicted as a 
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result of delayed recruitment. The study was due to finish in April 2017 but was completed in 
June 2017 with 12 participants in each group (Figure 7c).  
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Figure 7 EXTOD mechanisms participant recruitment and visit timeline 
(a) CONSORT flow diagram of participant recruitment, enrolment, and analysis (b) Predicted (blue) and actual 
(red) participant recruitment timeline (c) Predicted (blue) and actual (red) participant visit timeline. Increase in 
participant recruitment and visits in January 2017 indicated by the green box. 
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3.3.2 Baseline Characteristics for T1D and control cohorts 
Baseline characteristics for both groups are displayed in Table 4. There were no statistically 
significant differences in demographics or clinical characteristics (age, weight, height, BMI, 
waist circumference, hip circumference, chest circumference, waist-hip ratio, body fat, and 
VO2 max) between T1D and control participants. However, there was a trend for VO2 max to 
be lower in the T1D group (p=0.059). Although there were no statistically significant 
differences between groups for age, weight, height, BMI and body fat percentage, the 
differences observed between groups are clinically significant and this may impact differences 
in response to exercise between groups. 
Within the T1D group there was evident variation in HbA1c levels amongst the participants 
(65±12.4mmol). There was also evident variation in the disease duration (13.5±8.9 years) 
(Table 4). These are important factors which may impact on the disparity of responses observed 
during exercise in the T1D participants and should be taken into account for statistical analysis 
where possible. 
There was no significant difference in CMV index between groups. Both T1D and control 
groups had an equal proportion of participants that were CMV seropositive (Table 4). 
The average number of cigarettes and alcohol units per week for each group was recorded. 
There was no significant difference between groups (Table 4). 
Physical activity (min/wk) was recorded for each participant according to the International 
Physical Activity Questionnaire (IPAQ) [240]. Job related physical activity was higher in the 
T1D group (this is mainly due to one participant who cycled as part of his work role). Physical 
activity which was undertaken by participants as part of transportation was higher in the control 
group than the T1D group. Physical activity which was undertaken by participants as part of 
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house maintenance was similar between the two groups. The sport and leisure physical activity 
was divided into light, moderate, and vigorous physical activity. The T1D group participated 
in more light and moderate physical activity than the control group. The control group 
participated in more vigorous physical activity than the T1D group. Overall, the total physical 
activity was higher in the T1D group. This was driven by one participant who cycled to and 
from work, as well as during working hours. Furthermore, the time spent sitting (hours/wk) 
was marginally lower in the T1D group compared to the control group.  
Psychological stress scores were recorded for the past year, the past month and for the time 
passed in between each visit for each participant [241-244]. There were no differences in the 
stress scores in the past year or the past month between T1D and control groups. There were 
no differences in the stress scores recorded for the time that passed before each visit between 
T1D and control groups (Table 4).  
Sleep quality was recorded for each participant using the Pittsburgh sleep quality index [245]. 
No participants from the control group reported abnormal sleeping patterns. However, two 
participants from the T1D reported an average of less than 4-5 hours sleep per night. 
Dietary preferences were recorded for each participant. One participant from the T1D group 
and one participant from the control group followed a vegetarian diet. One participant from the 
control group reported lactose and soya intolerance.  
Influenza vaccine history was recorded for each participant. Eight participants from the T1D 







1Control  2T1D  
mean± SD mean± SD 
Age (years) 28.8±4.6 33.2±9.7 
Weight (kg) 74.5±8.7 80.8±15.6 
Height (cm) 156±55 178±7 
BMI (kg/m2) 24±2 25±4 
Waist circumference (cm) 86±7 90±12 
Hip circumference (cm) 90±7 95±8.6 
Chest Circumference (cm) 94±4 99±12 
Waist-hip ratio  0.95±0.03 0.94±0.06 
Body fat (%) 16.6±4.8 21.1±6.2 
VO2 max (mL/(kg·min)) 38.5±5.4 32.2±9.3 
CMV index 0.42±0.47 0.51±0.5 
Glucose (mmol) 5.24±0.48 8.91±3.15 
HbA1c (mmol)*  65±12.4 
Disease duration (years)*  13.5±8.9 
Heart Rate (bpm) 68±8 74±14 
Systolic BP (mmHg) 123±8 129±19 
Dystolic BP (mmHg) 72±11 79±11 
Number of cigarettes (per wk)#   
0 10 11 
1-5 2 1 
Alcohol intake (units per wk)#   
0 2 3 
1-5 3 4 
6-10 4 1 
11-20 1 3 
21-40 2 0 
Job related PA (min/wk) 325±470 557±1221 
Transportation PA (min/wk) 313±237 240±190 
House Maintenance (min/wk) 129±122 136±129 
Sport and Leisure PA (min/wk) 140±86 286±282 
Light PA (min/wk) 43±45 81±91 
Moderate PA (min/wk) 7.5±19 65±132 
Vigorous PA (min/wk) 90±97 140±12 
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Time sitting (hrs/wk) 48±18 40±12 
   
Stress score (1 year) 4±3 5±4 
Stress score (1 month) 10±8 12±10 
Stress score (visit 1) 7±10 6±9 
Stress score (visit 2) 4±3 4±5 
 
Table 4 Baseline Characteristics of T1D and control participants 
Mean and standard deviation values for baseline characteristics in control and T1D participants. 





3.3.3 Clinical parameters in T1D and control participants  
3.3.3.1 Clinical parameters in T1D and control participants at rest 
Clinical parameters including heart rate, blood pressure, fasting blood glucose, and VO2 max 
were measured at rest in T1D and control participants. The mean and standard deviation are 
displayed in Table 4. Fasting blood glucose was significantly higher in the T1D group 
compared to the control group (p=0.001). There was no significant difference in heart rate and 
blood pressure between groups. 
3.3.3.2 Clinical measures in T1D and control participants during a submaximal fitness 
test 
Clinical measures including heart rate and rate of perceived exertion (RPE) [247] were 
measured during a submaximal fitness test in T1D and control participants. The mean and 
standard deviation are displayed in Table 5. There was no significant difference in heart rate 
(bpm), RPE (Borg), or time (minutes) to reach sub maximal target heart rate between groups 









2T1D	 15.5±2.6	 159±8	 15.6±2.5	
  
Table 5 Measurements taken during a sub-maximal fitness test in T1D and control participants 




3.3.3.3 Clinical parameters in T1D and control participants in response to acute exercise 
Clinical parameters including heart rate, blood pressure, fasting blood glucose, and RPE were 
measured during moderate (40% VO2) and vigorous (80% VO2) intensity exercise in T1D and 
control participants. Clinical measures were recorded pre, post, and 1 hour post-exercise; this 
is described as the change overtime. The change over time was analysed in groups combined 
under the heading “time (overall)” and in each group independently (time) displayed in all 
results tables. The interaction over time between groups was compared and results are 
displayed under the heading “time*group”. Post and 1 hour post-exercise measurements were 
compared to baseline levels as shown under the heading “contrasts” in the results tables. The 
mean, standard deviation, and statistical analyses are displayed in Table 6. 
As expected, heart rate significantly changed over time during moderate intensity exercise 
overall (p<0.001), and in both the T1D (p<0.001) and control group (p=0.011) independently. 
Heart rate was significantly increased post moderate exercise in both the T1D and control group 
(p=0.0001, p<0.001 respectively). Heart rate returned to resting levels 1 hour post exercise, 
with no significant difference compared to baseline in heart rate in either group. Heart rate 
significantly changed over time during vigorous intensity exercise overall (p<0.001), and in 
both the T1D (p<0.001) and control group (p<0.001). Heart rate was significantly increased 
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post vigorous exercise in both the T1D and control group (p<0.001, p<0.001 respectively). 
Heart rate returned to baseline 1 hour post vigorous intensity exercise in the T1D with no 
significant differences compared to baseline in heart rate. However, heart rate in the control 
group remained above resting levels 1 hour post vigorous intensity exercise (p=0.005) (Table 
6).  
Systolic blood pressure significantly changed over time during moderate intensity exercise 
overall (p<0.001), and in both the T1D (p=0.007) and control group (p=0.038) independently. 
Systolic blood pressure was significantly increased post moderate exercise in the T1D 
(p=0.029) but not in the control group. Systolic blood pressure levels returned to baseline 1 
hour post moderate intensity exercise, with no significant differences compared to baseline 
measurements in either group. Systolic blood pressure also significantly changed over time 
during vigorous intensity exercise overall (p<0.001), and in the control group (p=0.001), but 
only a trend to change was seen in the T1D group (p=0.052). Systolic blood pressure was 
significantly increased post vigorous exercise in the control group (p=0.033) but not in the T1D 
group (Table 6). 
There was an overall change in diastolic blood pressure during moderate intensity exercise 
(p=0.043), but not in either the T1D or control group independently. No changes in diastolic 
blood pressure were found during vigorous intensity exercise in either group. This is considered 
a normal response during acute exercise; systolic BP increases post exercise and decreases 
following recovery, with no significant changes in diastolic BP [286-288]. Systolic and 
diastolic blood pressure changes from pre-exercise (0 minutes) to 1 hour post exercise (+60 
minutes) in T1D and control participants during moderate and vigorous intensity exercise are 
shown in Figure 8a (Table 6). 
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Glucose significantly changed over time in the control group (p=0.002) but not the T1D group 
during moderate intensity exercise. There was no significant change immediately post 
moderate exercise, however there was a significant decrease 1 hour post moderate exercise 
(p=0.009) in the control group only. There was also a significant change over time during 
vigorous intensity exercise in the control group, but not the T1D group. The response 
immediately post vigorous exercise was significantly different between groups (p=0.037) 
(Table 6). 
Glucose was also measured during exercise at 10 and 20 minutes after the exercise commenced 
(Table 7). There was a change in glucose during moderate intensity exercise overall (p=0.045), 
but this was not seen in the T1D or control group independently. Glucose showed a trend to 
change at 10 minutes in the T1D group (p=0.052) compared to pre-exercise measurements. No 
changes were seen at this time point in the control group. Glucose had significantly reduced at 
20 minutes into the moderate exercise in both T1D and control groups (p=0.046, p=0.034 
respectively). There was a change in glucose during vigorous intensity exercise overall 
(p=0.046), and in both the T1D (p=0.017) and control group (p=0.004) independently. Glucose 
was significantly lower at 20 mins into the vigorous exercise in the T1D only (p=0.027). The 
glucose changes over time were significantly different between groups (time*group) 
(p=0.002). This is due to the fact that glucose continued to fall in the T1D group throughout 
the exercise and was lower post exercise compared to pre-exercise levels. However, glucose 
levels began to rise above baseline in the control group post exercise. Glucose changes from 
baseline (-20 minutes) to 1 hour post exercise (+60 minutes) in T1D and control participants 
during moderate and vigorous intensity exercise are shown in Figure 8b.  
As expected, the rate of perceived exertion (RPE) significantly changed during moderate 
intensity exercise overall (p<0.001), and in both the T1D (p<0.001) and control groups 
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(p<0.001) independently. RPE was significantly increased immediately post moderate intensity 
exercise in both T1D and control groups (p=0.001, p<0.001 respectively). RPE significantly 
changed during vigorous intensity exercise overall (p<0.001), and in both the T1D (p<0.001) 
and control groups (p<0.001) independently. RPE was significantly increased immediately 
post vigorous intensity exercise in both T1D and control groups (p<0.001, p<0.001 
respectively). The above changes in RPE validate that both exercise protocols were completed 
at the correct intensity. A higher RPE is seen following both moderate and vigorous intensity 
exercise compared to pre-exercise, with a higher RPE recorded following vigorous intensity 
exercise. There was no difference in the changes in RPE between groups indicating that both 




Figure 8 Clinical parameters during moderate and vigorous intensity exercise in T1D and control 
participants.  
Clinical parameters for T1D (blue) and control (red) participants during moderate and vigorous intensity exercise 






 Table 6 Clinical parameters during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of clinical parameters for control and T1D participants during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1controls n= 11-12 
2T1D n= 10-11 
  
dTime (overall) dTime*Group
Parameter Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
Glucose (mmol) moderate 5.21 0.38 5.09 0.26 4.86 0.29 F(2, 12)= 10.774, p=0.002 T2 F(1, 6)= 1.235, p=0.309 2.27 8.82 2.83 8.62 3.62 9.13 3.56 F(2, 12)= 0.192, p=0.828 T2 F(1, 6)= 0.267, p=0.624 2.24 F(2, 24)= 0.429, p=0.656 F(2, 24)= 0.656, p=0.528
T3 F(1, 6)= 14.580, p=0.009 6.64 T3 F(1, 6)= 0.001, p=0.980 3.46
vigorous 5.32 0.64 5.54 0.36 5.05 0.45 F(2, 18)= 5.271, p=0.016 T2 F(1, 9)= 1.923 p=0.199 4.13 9.36 3.43 8.36 2.36 8.30 2.94 F(2, 18)= 2.818, p=0.086 T2 F(1, 9)= 3.599, p=0.090 10.68 F(1.5, 27.1)= 3.543, p=0.055 F(1.5, 27.1)= 2.470, p=0.116
T3 F(1, 9)= 3.243, p=0.105 5.10 T3 F(1, 9)= 3.220, p=0.106 11.36
Heart Rate (bpm) moderate 68.45 9.57 90.58 11.98 70.90 11.23 F(1.2, 9.5)= 9.260, p=0.011 T2 F(1, 8)= 33.208, p<0.001 32.33 74.00 12.83 94.10 14.26 74.38 15.29 F(2, 14)= 21.737, p<0.001 T2 F(1, 7)= 36.458, p=0.001 27.16 F(1.3, 19)= 26.945, p<0.001 F(1.3, 19)= 0.269, p=0.766
T3 F(1, 8)= 0.157, p=0.703 3.57 T3 F(1, 7)= 0.206, p=0.664 0.51
vigorous 68.08 8.65 123.00 21.99 73.58 9.02 F(1.1, 11.9)= 64.206, p<0.001 T2 F(1, 11)= 79.508 p<0.001 80.66 78.45 12.21 126.00 16.78 79.60 12.19 F(2, 18)= 70.657, p<0.001 T2 F(1, 9)= 125.187, p<0.001 60.60 F(1.2, 23.8)= 126.532, p<0.001 F(1.2, 23.8)= 0.697, p=0.436
T3 F(1, 11)= 12.137, p=0.005 8.08 T3 F(1, 9)= 0.085, p=0.777 1.46
Systolic BP (mmHg) moderate 120.55 7.74 125.50 6.95 118.00 9.54 F(2, 16)= 4.025, p=0.038 T2 F(1, 8)= 2.830, p=0.131 4.11 127.30 16.79 133.10 15.33 122.63 15.19 F(2, 14)= 7.188, p=0.007 T2 F(1, 7)= 7.461, p=0.029 4.56 F(2, 30)= 11.466, p<0.001 F(2, 30)= 0.790, p=0.463
T3 F(1, 8)= 1.827, p=0.213 2.11 T3 F(1, 7)= 2.224, p=0.179 3.67
vigorous 118.33 6.30 128.50 15.07 113.25 8.63 F(2, 22)= 9.143, p=0.001 T2 F(1, 11)= 5.907 p=0.033 8.59 126.18 15.87 136.82 15.56 121.40 14.55 F(2, 18)= 3.504 p=0.052 T2 F(1, 9)= 1.748, p=0.219 8.43 F(2, 40)= 11.230, p<0.001 F(2, 40)= 0.070, p=0.932
T3 F(1, 11)= 4.448, p=0.059 4.30 T3 F(1, 9)= 1.510, p=0.250 3.79
Dystolic BP (mmHg) moderate 75.09 9.80 72.73 7.02 64.27 45.56 F(2, 16)= 3.188, p=0.068 T2 F(1, 8)= 0.124, p=0.734 3.15 76.90 7.11 77.80 5.00 75.00 10.56 F(2, 14)= 0.962, p=0.406 T2 F(1, 7)= 0.285, p=0.610 1.17 F(2, 30)= 3.492, p=0.043 F(2, 30)= 0.332, p=0.720
T3 F(1, 8)= 4.059, p=0.079 14.41 T3 F(1, 7)= 1.306, p=0.291 2.47
vigorous 72.25 8.30 68.42 11.54 67.92 7.68 F(2, 22)= 0.710, p=0.502 T2 F(1, 11)= 0.685, p=0.425 5.31 74.82 9.44 74.27 9.44 71.70 8.12 F(2, 18)= 0.890 p=0.428 T2 F(1, 9)= 0.080, p=0.783 0.73 F(2, 40)= 1.261, p=0.294 F(2, 40)= 0.171, p=0.844
T3 F(1, 11)= 1.641, p=0.227 6.00 T3 F(1, 9)= 1.641, p=0.227 4.17
RPE (Borg) moderate 8.00 1.91 12.17 2.44 F(2, 22)= 51.780, p<0.001 T2 F(1, 11)= 123.809, p<0.001 47.92 7.60 1.56 11.40 2.20 F(1.3, 11.8)= 22.974, p<0.001 T2 F(1, 9)= 27.563, p=0.001 36.84 F(1.4, 28.1)= 68.810, p<0.001 F(1.4, 28.1)= 1.037, p=0.364
T3 F(1, 11)= 52.481, p<0.001 52.08 T3 F(1, 9)= 25.186, p=0.001 50.00










Table 7 Blood glucose levels during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of blood glucose levels for control and T1D participants during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1controls n= 11-12 
2T1D n= 10-11 
dTime (overall) dTime*Group
Parameter Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
Glucose (mmol) moderate 5.21 0.38 4.97 0.53 4.88 0.35 5.09 0.26 F(3, 27)= 2.347 p=0.095 10 F(1, 9)= 2.022, p=0.189 4.64 8.82 2.83 8.33 2.86 8.12 2.92 8.62 3.62 F(3, 24)= 1.718, p=0.190 10 F(1, 8)= 5.192, p=0.052 5.56 F(1.9, 33.1)= 3.441, p=0.045 F(1.9, 33.1)= 0.460, p=0.630
30 F(1, 9)= 6.279, p=0.034 6.40 30 F(1, 8)= 5.547, p=0.046 7.94
T2 F(1, 9)= 5.063, p=0.051 2.27 T2 F(1, 8)= 0.695, p=0.429 2.24
vigorous 5.32 0.64 4.94 0.30 4.91 0.54 5.54 0.36 F(3, 30)= 5.428, p=0.004 10 F(1, 10)= 2.596, p=0.138 7.05 9.36 3.43 9.37 3.07 8.53 2.73 8.36 2.36 F(1.7, 17.3)= 5.549, p=0.017 10 F(1, 10)= 0.001, p=0.977 0.10 F(1.9, 39.4)= 3.360, p=0.046 F(1.9, 39.4)= 7.682, p=0.002
30 F(1, 10)= 1.313, p=0.278 7.68 30 F(1, 10)= 6.688, p=0.027 8.93
T2 F(1, 10)= 3.350, p=0.097 4.13 T2 F(1, 10)= 4.572, p=0.058 10.68
ccontrastT1+20mins T1+20mins
1Controls 2T1D
T1 T1+10mins T2 ccontrast T1 T1+10mins T2
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3.3.3.4 Clinical parameters in T1D and control participants during recovery from acute 
exercise 
Clinical parameters including heart rate and blood pressure were measured during the recovery 
period in T1D and control participants. The recovery period was defined as the time between 
the end of the acute exercise bout and 1 hour post cessation of exercise. Measurements were 
taken every 15 minutes within this period. The mean, standard deviation, and statistical 
analyses are displayed in Table 8. 
As anticipated, heart rate significantly changed during the recovery period following moderate 
intensity exercise overall (p<0.001), and in both the T1D (p<0.001) and control group 
(p<0.001) independently. Heart rate was significantly lower compared to post moderate 
exercise at 15, 30, and 45 minutes post moderate exercise in the T1D (p=0.011, p=0.001, 
p=0.002 respectively) and control group (p<0.001, p<0.001, p<0.001 respectively). Heart rate 
significantly changed during the recovery period following vigorous intensity exercise overall 
(p<0.001), and in both the T1D (p<0.001) and control group (p<0.001) independently. Heart 
rate was significantly lower compared to immediately post vigorous exercise at 15, 30, and 45 
minutes post vigorous exercise in the T1D (p=0.000, p<0.001, p<0.001 respectively) and 
control group (p=0.001, p<0.001, p<0.001 respectively) (Table 8). 
Systolic blood pressure significantly changed during the recovery period following moderate 
intensity exercise overall (p=0.001), and in both the T1D (p=0.005) and control group 
(p=0.001) independently. Systolic blood pressure was significantly lower compared to 
immediately post moderate exercise at 15, 30, and 45 minutes post moderate exercise in the 
T1D group (p=0.000, p=0.032, p=0.002 respectively). Systolic blood pressure was 
significantly lower compared to immediately post moderate exercise at 30 and 45 minutes post 
moderate exercise the control group (p=0.002, p=0.003 respectively). The change in systolic 
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blood pressure during the recovery period was significantly different between groups 
(time*group) (p=0.042). Systolic blood pressure is lower in the control group than the T1D 
group throughout the recovery period. Systolic blood pressure significantly changed during the 
recovery period following vigorous intensity exercise overall (p=0.003), and in the T1D group 
(p=0.002), but this was only seen as a trend to change in the control group (p=0.070). Systolic 
blood pressure was significantly lower compared to immeidately post vigorous exercise at 15 
and 30 post vigorous exercise in the T1D group (p=0.000, p=0.032 respectively) and a trend to 
be lower at 45 minutes post vigorous exercise (p=0.059). Systolic blood pressure was 
significantly lower compared to immediately post moderate exercise at 15, 30, and 45 minutes 
post moderate exercise the control group (p=0.015, p=0.033, p=0.003 respectively) (Table 8).  
No changes in diastolic blood pressure were seen during the recovery period following either 
exercise intensity, in either group (Table 8).  
Both T1D and control groups recovered similarly during the recovery period. The above results 
suggest that T1D and control participants were fully recovered following moderate and 
vigorous intensity exercise; heart rate and blood pressure returned to resting levels (shown in 





Table 8 Heart rate and blood pressure during the recovery period following moderate and vigorous intensity exercise in control and T1D groups  
Mean, standard deviation, and statistical analysis of heart rate, systolic blood pressure, and diastolic blood pressure for control and T1D participants during moderate and 
vigorous intensity exercise. Significant results highlighted in bold where p values <0.05 were considered significant. 
Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1controls n= 11-12 
2T1D n= 10-11 
dTime (overall) dTime*Group
Parameter Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
Heart Rate (bpm) moderate 90.58 11.98 66.40 8.14 64.40 5.75 64.10 5.97 F(1.3, 12.1)= 35.250, p<0.001 15 F(1, 9)= 55.917, p<0.001 26.70 94.10 14.26 77.38 18.54 72.38 13.36 73.50 14.77 F(3, 21)= 15.396, p<0.001 15 F(1, 7)= 11.542, p=0.011 17.77 F(1.8, 28.5)= 46.672, p<0.001 F(1.8, 28.5)= 0.351, p=0.682
30 F(1, 9)= 36.241, p<0.001 28.91 30 F(1, 7)= 32.591, p=0.001 23.09
45 F(1, 9)= 39.777, p<0.001 29.24 45 F(1, 7)= 22.495, p=0.002 21.89
vigorous 123.00 21.99 82.00 13.57 78.00 8.76 74.40 10.72 F(1.7, 13.3)= 19.721, p<0.001 15 F(1, 8)= 28.952, p=0.001 33.33 126.00 16.78 98.27 17.83 86.70 11.38 82.10 12.79 F(1.9, 17.1)= 51.308, p<0.001 15 F(1, 9)= 46.451, p<0.001 22.01 F(2.2, 37.4)= 77.078, p<0.001 F(2.2, 37.4)= 1.282, p=0.291
30 F(1, 8)= 33.309, p<0.001 36.59 30 F(1, 9)= 104.343, p<0.001 31.19
45 F(1, 8)= 49.082, p<0.001 39.51 45 F(1, 9)= 164.406, p<0.001 34.84
Systolic BP (mmHg) moderate 125.50 6.95 121.64 10.89 113.64 12.48 116.64 9.65 F(1.5, 15.1)= 14.565, p=0.001 15 F(1, 10)= 3.835, p=0.079 3.08 133.10 15.33 124.75 13.87 127.25 14.28 124.88 15.81 F(3, 21)= 5.847, p=0.005 15 F(1, 7)= 7.177, p=0.032 6.27 F(3, 51)= 15.544, p<0.001 F(3, 51)= 2.945, p=0.042
30 F(1, 10)= 17.950, p=0.002 9.45 30 F(1, 7)= 22.389, p=0.002 4.40
45 F(1, 10)= 14.581, p=0.003 7.06 45 F(1, 7)= 8.741, p=0.021 6.18
vigorous 128.50 15.07 115.50 11.03 107.75 23.90 113.42 10.19 F(1.5, 16.1)= 3.408, p=0.070 15 F(1, 11)= 8.281, p=0.015 10.12 136.82 15.56 120.64 12.87 120.00 10.73 122.30 13.29 F(3, 27)= 6.171, p=0.002 15 F(1, 9)= 10.519, p=0.010 11.83 F(1.9, 37.1)= 7.135, p=0.003 F(1.9, 37.1)= 0.229, p=0.780
30 F(1, 11)= 5.900, p=0.033 16.15 30 F(1, 9)= 11.901, p=0.007 12.29
45 F(1, 11)= 13.897, p=0.003 11.74 45 F(1, 9)= 4.687, p=0.059 10.61
Dystolic BP (mmHg) moderate 72.73 7.02 70.00 8.82 69.45 10.69 72.27 9.28 F(3, 27)= 0.888, p=0.460 15 F(1, 9)= 2.484, p=0.149 3.75 77.80 5.00 76.38 10.42 73.13 8.84 76.38 11.69 F(3, 21)= 1.086, p=0.377 15 F(1, 7)= 0.608, p=0.461 1.83 F(3, 48)= 1.772, p=0.165 F(3, 48)= 0.352, p=0.788
30 F(1, 9)= 0.919, p=0.363 4.50 30 F(1, 7)= 0.919, p=0.363 6.01
45 F(1, 9)= 0.134, p=0.722 0.63 45 F(1, 7)= 0.134, p=0.722 1.83
vigorous 68.42 11.54 69.67 9.37 67.00 8.07 68.92 8.22 F(1.9, 20.6)= 0.352, p=0.694 15 F(1, 11)= 0.158, p=0.698 1.83 74.27 9.44 72.18 10.72 71.70 8.23 71.60 8.20 F(3, 27)= 0.755, p=0.529 15 F(1, 9)= 0.986, p=0.347 2.82 F(2.1, 41.9)= 0.561, p=0.583 F(2.1, 41.9)= 0.392, p=0.688
30 F(1, 11)= 0.191, p=0.671 2.07 30 F(1, 9)= 1.119, p=0.318 3.46
45 F(1, 11)= 0.021, p=0.886 0.73 45 F(1, 9)= 1.256, p=0.291 3.60
1Controls 2T1D
T2 T2+15mins T2+45mins ccontrast T2 T2+15mins T2+45minsT2+30mins T2+30mins ccontrast
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3.3.4 Haematological measures in T1D and control participants  
3.3.4.1 Haematological parameters in T1D and control participants at rest 
Haematological parameters including white blood cell parameters, red blood cell parameters, 
and platelet parameters were measured at rest in T1D and control participants. The mean and 
standard deviation are displayed in Table 9. 
3.3.4.1i White blood cells 
There was a significantly higher WBC count in the T1D group compared to the control group 
(p=0.008) (Figure 9a). Within WBC, differences in lymphocytes, monocytes, and granulocytes 
were noted (Table 9). The percentage of lymphocytes was significantly lower in T1D 
participants (p=0.002) compared to control participants, with no difference in the frequency 
observed. The frequency, but not the percentage, of monocytes was significantly higher in the 
T1D group (p=0.007) compared to control participants. However, the percentage and 
frequency of granulocytes were significantly higher in the T1D group (p=0.017, p=0.004 
respectively) compared to control participants. Therefore, the elevation in WBC and altered 
WBC proportions in people in our study with T1D was driven by an increase in granulocytes.  
3.3.4.1ii Red blood cells 
As expected. there was no difference in red blood cell count between groups (Figure 9b). There 
was no difference in any red blood cell parameters between groups; HGB, HCT, MCV, MCH, 
MCHC, or RDW (Table 9).  
3.3.4.1iii Platelets 
There was a significantly higher platelet count in the T1D group (p=0.004) (Figure 9c). The 
PCT was also significantly higher in the T1D group (p=0.0011). There was no difference in 
MPV or PDW between groups (Table 9). 
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Figure 9 Haematological measures at rest in T1D and control participants 
Baseline haematological counts in control and T1D participants (a) frequency of white blood cells (b) frequency 





Table 9 Haematological parameters at rest in T1D and control participants 







White Blood Cells mean SD mean SD
WBC count (cells/μl) 3650 922 4844 1156
Lymphocyte (%) 39.22 5.93 30.09 8.11
Monocyte (%) 6.29 1.44 7.13 2.06
Granulocyte (%) 54.49 6.69 62.80 8.90
Lymphocyte (cells/μl) 1354.17 381.86 1333.33 249.44
Monocyte (cells/μl) 175.00 59.51 294.44 139.33
Granulocyte (cells/μl) 2120.83 611.68 3216.67 1168.21
Red Blood Cells mean SD mean SD
RBC count (cells/μl) 4793750 407081 4807222 376664
HGB (g/dL) 15.48 1.48 15.15 1.13
HCT (%) 41.85 3.78 41.70 3.34
MCV (L/cell) 87.88 4.38 86.41 3.22
MCH (g/cell) 32.48 1.93 31.65 1.73
MCHC (g/L) 36.99 1.28 36.31 0.71
RDW (%) 13.23 0.72 13.31 0.49
Platelets mean SD mean SD
PLT count (cells/μl) 167042 38261 229765 61562
MPV (fL) 8.61 0.90 8.12 0.62
PCT (%) 0.14 0.03 0.18 0.04




3.3.4.2 Haematological measures in T1D and control participants in response to acute 
exercise 
Haematological parameters including WBC, RBC, and platelets were measured during 
moderate (40% VO2 max) and vigorous (80% VO2 max) intensity exercise in T1D and control 
participants.  
3.3.4.2i White blood cells 
The mean, standard deviation, and statistical analyses for white blood cell parameters are 
displayed in Table 10. 
The WBC count significantly changed over time during vigorous intensity exercise overall 
(p<0.001), and in both the T1D and control group (p<0.001, p<0.001 respectively). There was 
a significant increase immediately post vigorous exercise in both T1D and control groups 
(p<0.001, p<0.001 respectively). No significant changes were observed 1 hour post vigorous 
exercise in either group. Moderate intensity exercise also caused a significant change overtime 
overall (p<0.001), and in both the T1D and control groups independently (p=0.026, p=0.023 
respectively). There was a significant increase post moderate exercise in both T1D and control 
groups (p=0.019, p=0.013 respectively), and remained significantly elevated above baseline 1 
hour post moderate exercise in the control group only (p=0.007) (Table 10). 
Lymphocytes significantly mobilised during vigorous intensity exercise overall (p<0.001), and 
in both T1D and control groups independently (p=0.003, p=0.000 respectively). There was a 
significant increase post vigorous exercise in both T1D and control groups (p=0.004, p<0.001 
respectively), and a significant decrease below baseline 1 hour post exercise in the control 
group only (p=0.020). However, the percentage increase post vigorous exercise was larger in 
the control group (T1D: 55.5%, control: 71.4%). Moderate intensity exercise caused a 
significant change over time overall (p=0.013) and in the control group (p=0.019), but only a 
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trend to mobilise was seen in the T1D group (p=0.068). There was a significant increase post 
moderate exercise in the control group only (p=0.034). This is supported by a larger percentage 
increase post moderate exercise in the controls (T1D: 25.62%, control: 43.9%). No significant 
changes were found 1 hour post moderate exercise in either group (Table 10).  
Monocytes significantly mobilised during vigorous intensity exercise overall (p<0.001), and in 
both T1D and control groups independently (p=0.004, p<0.001 respectively). There was a 
significant increase post vigorous exercise in both T1D and control groups (p=0.038, p=0.002 
respectively). However, the percentage increase post vigorous exercise was larger in the control 
group (T1D: 41.38%, control: 63.6%). No significant changes were found 1 hour post vigorous 
exercise in either group. Moderate intensity exercise caused a significant change over time 
overall (p=0.005), but this was only seen as a trend to mobilise in the T1D group (p=0.063). 
No trends to significantly mobilise were seen in the control group. There was a significant 
increase post moderate exercise in the T1D group (p=0.030), but this was only seen as a trend 
to increase in the control group (p=0.054). The percentage increase post moderate exercise was 
similar between groups (T1D: 41.7%, control: 40.9%). No significant changes were found 1 
hour post exercise in either group (Table 10). 
Granulocytes significantly mobilised during vigorous intensity exercise overall (p<0.001), and 
in both T1D and control groups independently (p<0.001, p<0.001 respectively). There was a 
significant increase post vigorous exercise in both T1D and control groups (p<0.001, p<0.001 
respectively). However, the percentage increase post vigorous exercise was larger in the control 
group (T1D: 33.2%, control: 51.6%). Granulocytes remained significantly elevated 1 hour post 
vigorous exercise in the control group only (p=0.012), returning to baseline in the T1D group. 
This change overtime during vigorous exercise was significantly different between groups 
(time*group) (p=0.046). Moderate intensity exercise caused a significant change over time 
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overall (p<0.001) and in the control group (p=0.009), but only a trend to mobilise was seen in 
the T1D group (p=0.079). There was a significant increase post moderate exercise in both T1D 
and control groups (p=0.013, p=0.005 respectively). The percentage increase post moderate 
exercise was similar between groups (T1D: 24.4%, control: 32%). The frequency of 
granulocytes remained significantly elevated 1 hour post moderate exercise in the control group 
(p=0.003). They also remained significantly elevated in the T1D group, but this did not reach 







Table 10 White blood cells mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of white blood cell populations for control and T1D participants during moderate and vigorous intensity exercise. 
Significant results highlighted in bold where p values <0.05 were considered significant. 
Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1controls n= 11-12 
2T1D n= 8-10 
dTime (overall) dTime*Group
Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
WBC moderate 3725.00 967.92 5091.67 1849.98 3890.91 1058.69 F(1, 10.3)= 7.076, p=0.023 T2 F(1, 10)= 9.086, p=0.013 36.69 4566.67 991.07 5744.44 1726.34 5228.57 1890.36 F(2, 12)= 5.035, p=0.026 T2 F(1, 6)= 10.045, p=0.019 25.79 F(1.4, 23.1)= 10.803, p<0.001 F(1.4, 23.1)= 0.471, p=0.628
T3 F(1, 10)= 11.489, p=0.007 4.45 T3 F(1, 6)= 2.849, p=0.142 14.49
vigorous 3575.00 868.07 5718.18 1054.70 3941.67 946.45 F(2, 20)= 65.274, p<0.001 T2 F(1, 10)= 91.528, p<0.001 59.95 5122.22 1238.98 7144.44 1529.06 5125.00 1186.12 F(2, 14)= 36.449, p<0.001 T2 F(1, 7)= 39.947, p<0.001 39.48 F(1.5, 25.5)= 97.397, p<0.001 F(1.5, 25.5)= 0.675, p=0.477
T3 F(1, 10)= 4.011, p=0.073 10.26 T3 F(1, 7)= 0.036, p=0.855 0.05
Lymphocytes moderate 1308.33 325.21 1883.33 814.28 1336.36 393.75 F(1.2, 11.2)= 4.845, p=0.019 T2 F(1, 10)= 6.029, p=0.034 43.95 1344.44 275.32 1688.89 766.59 1314.29 203.04 F(1.1, 6.3)= 3.390, p=0.068 T2 F(1, 6)= 2.777, p=0.147 25.62 F(1.1, 17.6)= 7.228, p=0.013 F(1.1, 17.6)= 0.195, p=0.824
T3 F(1, 10)= 0.124, p=0.732 2.14 T3 F(1, 6)= 5.170, p=0.063 2.24
vigorous 1400.00 426.22 2400.00 453.27 1233.33 322.32 F(2, 20)= 70.685, p<0.001 T2 F(1, 10)= 83.814, p<0.001 71.43 1322.22 219.99 2055.56 643.10 1262.50 172.75 F(1.1, 7.4)= 17.502, p=0.003 T2 F(1, 7)= 18.584, p=0.004 55.46 F(1.2, 20.1)= 71.426, p<0.001 F(1.2, 20.1)= 1.359, p=0.265
T3 F(1, 10)= 7.577, p=0.020 11.90 T3 F(1, 7)= 2.739, p=0.142 4.52
Monocytes moderate 183.33 55.28 258.33 118.73 218.18 93.60 F(2, 20)= 2.692, p=0.092 T2 F(1, 10)= 4.776, p=0.054 40.91 266.67 141.42 377.78 209.64 328.57 148.46 F(2, 12)= 3.500, p=0.063 T2 F(1, 6)= 8.000, p=0.030 41.67 F(2, 32)= 6.420, p=0.005 F(2, 32)= 0.317, p=0.731
T3 F(1, 10)= 1.000, p=0.341 19.01 T3 F(1, 6)= 2.077, p=0.200 23.21
vigorous 166.67 62.36 272.73 86.24 158.33 49.30 F(2, 20)= 20.137, p<0.001 T2 F(1, 10)= 18.333, p=0.002 63.64 322.22 131.47 455.56 149.90 300.00 122.47 F(2, 14)= 8.680, p=0.004 T2 F(1, 7)= 6.481, p=0.038 41.38 F(1.4, 23.8)= 25.595, p<0.001 F(1.4, 23.8)= 0.346, p=0.635
T3 F(1, 10)= 2.222, p=0.167 5.00 T3 F(1, 7)= 1.000, p=0.351 6.90
Granulocytes moderate 2233.33 720.34 2950.00 1035.62 2336.36 673.22 F(1.1, 11.1)= 9.631, p=0.009 T2 F(1, 10)= 12.982, p=0.005 32.09 2955.56 878.27 3677.78 1168.83 3585.71 1703.30 F(1.2, 7)= 4.091, p=0.079 T2 F(1, 6)= 12.294, p=0.013 24.44 F(2, 32)= 10.909, p<0.001 F(2, 32)= 1.906, p=0.165
T3 F(1, 10)= 14.613, p=0.003 4.61 T3 F(1, 6)= 3.284, p=0.120 21.32
vigorous 2008.33 451.77 3045.45 678.72 2550.00 720.53 F(2, 20)= 21.282, p<0.001 T2 F(1, 10)= 58.573, p<0.001 51.64 3477.78 1349.71 4633.33 1534.06 3562.50 1186.32 F(2, 14)= 26.387, p<0.001 T2 F(1, 7)= 61.606, p<0.001 33.23 F(2, 34)= 44.692, p<0.001 F(2, 34)= 3.372, p=0.046
T3 F(1, 10)= 9.434, p=0.012 26.97 T3 F(1, 7)= 0.229, p=0.647 2.44
ccontrast
1Controls 2T1D
T1 T2 T3 ccontrast T1 T2 T3
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3.3.4.2ii Red blood cells 
The mean, standard deviation, and statistical analyses for red blood cell parameters are 
displayed in Table 11. 
The RBC count significantly changed over time during vigorous intensity exercise overall 
(p=0.001), and in the control group (p=0.004). There was a small significant increase post 
vigorous exercise (11.9%) in the control group (p=0.014). No mobilisation was seen in the T1D 
group. There were no significant changes during moderate intensity exercise in either the T1D 
or control group (Table 11).  
HGB significantly changed over time during vigorous intensity exercise overall (p=0.001), and 
in the control group (p=0.012). There was a small significant increase post vigorous exercise 
(10.2%) in the control group (p=0.016). There were no changes during vigorous intensity 
exercise in the T1D group. There were no significant changes during moderate intensity 
exercise in either the T1D or control group (Table 11). 
HCT significantly changed over time during vigorous intensity exercise overall (p=0.002), and 
in the control group (p=0.010). There was a small significant increase post vigorous exercise 
(12.17%) in the control group (p=0.013). There were no changes during vigorous intensity 
exercise in the T1D group. During moderate intensity exercise, HCT significantly increased in 
the T1D group only post moderate exercise (p=0.008). No changes over time or 1 hour post 
moderate exercise were seen in either group (Table 11). 
MCH significantly changed over time during vigorous intensity exercise in the control group 
(p=0.034), with a small significant decrease (0.55%) post exercise (p=0.007). There were no 
significant changes in the T1D group. MCH significantly changed over time during moderate 
intensity exercise in the control group (p=0.019), with a small significant increase immediately 
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post moderate exercise and 1 hour post moderate exercise (0.74%, 0.99% respectively) 
(p=0.033, p=0.007 respectively). No changes were seen in the T1D group. This difference in 
response was significant between groups overall (time*group) (p=0.014), and at both the post-
exercise and 1 hour post-exercise time points (p=0.013, p=0.025 respectively) (Table 11). 
MCHC significantly changed over time during vigorous intensity exercise overall (p=0.002) 
and in the control group (p=0.034), but only a trend to change was seen in the T1D group 
(p=0.062). A small significant decrease (1.07%) post vigorous exercise was seen in the control 
group (p=0.014). However, small significant increase (1.05%) post vigorous exercise was seen 
in the T1D group (p=0.046). This difference in response post vigorous exercise was significant 
between groups (time*group) (p=0.002). There were no significant changes during moderate 
intensity exercise in either the T1D or control group (Table 11). 
RDW significantly changed over time during vigorous intensity exercise in the control group 
(p=0.010), but only a trend to change was seen overall (p=0.061) and no changes in the T1D 
group. A small significant increase (2.06%) post vigorous exercise (p=0.004), and a trend to 
remain elevated 1 hour post vigorous exercise was seen in the control group (p=0.057). There 
were no changes in RDW in the T1D group during vigorous intensity exercise. There were no 








Table 11 Red blood cells mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of red blood cell measures for control and T1D participants during moderate and vigorous intensity exercise. Significant 
results highlighted in bold where p values <0.05 were considered significant. 
Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1controls n= 11-12 












mean SD mean SD mean SD mean SD mean SD mean SD
RBC (cells/μl) moderate 4935000 309771 4671500 1324942 4887273 487183 F(1.1, 10.9)= 0.425, p=0.545 T2 F(1, 10)= 0.553, p=0.474 5.34 4745556 335596 3481000 2153043 4985714 538539 F(1.1, 6.5)= 1.875, p=0.218 T2 F(1, 6)= 1.540, p=0.261 26.65 F(1.1, 17.4)= 2.736, p=0.114 F(1.1, 17.4)= 1.092, p=0.317
T3 F(1, 10)= 0.573, p=0.467 0.97 T3 F(1, 6)= 0.752, p=0.419 5.06
vigorous 4652500 442232 5209091 744757 4667500 504631 F(2, 20)= 7.577, p=0.004 T2 F(1, 10)= 8.956, p=0.014 11.96 4868889 404377 4997778 358136 4578750 421113 F(1.1, 7.9)= 3.242, p=0.108 T2 F(1, 7)= 0.407, p=0.544 2.65 F(2, 34)= 8.342, p=0.001 F(2, 34)=1.983, p=0.153
T3 F(1, 10)= 0.037, p=0.851 0.32 T3 F(1, 7)= 1.905, p=0.210 5.96
HGB (g/dL) moderate 15.85 1.65 16.31 1.59 16.00 2.36 F(1.3, 13.2)= 0.413, p=0.587 T2 F(1, 10)= 0.729, p=0.413 2.89 14.99 0.94 15.43 1.02 15.42 1.45 F(1.1, 5.2)= 0.496, p=0.519 T2 F(1, 6)= 19.612, p=0.007 2.92 F(2, 30)= 0.684, p=0.474 F(2, 30)= 0.103, p=0.847
T3 F(1, 10)= 0.038, p=0.849 0.95 T3 F(1, 6)= 0.366, p=0.572 2.86
vigorous 15.11 1.18 16.73 1.69 15.07 1.32 F(1.3, 13.4)= 7.390, p=0.012 T2 F(1, 10)= 8.325, p=0.016 10.72 15.29 1.26 15.76 0.79 14.48 1.17 F(1, 7.3)= 3.401, p=0.105 T2 F(1, 7)= 0.593, p=0.466 3.05 F(2, 34)= 8.792, p=0.001 F(2, 34)= 1.427, p=0.254
T3 F(1, 10)= 0.032, p=0.863 0.28 T3 F(1, 7)= 1.715, p=0.232 5.32
HCT (%) moderate 42.90 4.13 43.96 3.01 43.04 5.92 F(1.3, 13.9)= 0.231, p=0.699 T2 F(1, 10)= 0.364, p=0.560 2.47 41.00 2.53 42.50 2.94 42.57 4.12 F(1.1, 5.3)= 0.747, p=0.433 T2 F(1, 5)= 17.868, p=0.008 3.66 F(1.5, 21.9)= 0.644, p=0.488 F(1.5, 21.9)= 0.209, p=0.744
T3 F(1, 10)= 0.001, p=0.970 0.32 T3 F(1, 5)= 0.549, p=0.492 3.82
vigorous 40.79 3.05 45.75 5.41 40.79 3.75 F(1.3, 13.1)= 8.038, p=0.010 T2 F(1, 10)= 9.125, p=0.013 12.17 42.32 3.82 43.19 2.66 39.86 3.53 F(1.1, 7.6)= 2.618, p=0.146 T2 F(1, 7)= 0.173, p=0.690 2.05 F(2, 34)= 7.901, p=0.002 F(2, 34)= 2.178, p=0.129
T3 F(1, 10)= 0.003, p=0.961 0.00 T3 F(1, 7)= 1.725, p=0.230 5.81
MCV  (L/cell) moderate 88.00 4.60 88.25 4.30 88.27 4.59 F(2, 20)= 1.681, p=0.211 T2 F(1, 10)= 1.000, p=0.341 0.28 86.00 3.24 86.25 3.23 84.67 2.49 F(2, 10)= 0.294, p=0.687 T2 F(1, 5)= 0.294, p=0.611 0.29 F(2, 30)= 0.888, p=0.422 F(2, 30)= 0.754, p=0.479
T3 F(1, 10)= 3.378, p=0.096 0.31 T3 F(1, 5)= 0.000, p=1.000 1.55
vigorous 87.75 4.15 88.27 4.47 87.67 4.23 F(2, 20)= 1.957, p=0.167 T2 F(1, 10)= 1.957, p=0.192 0.60 86.78 3.15 86.44 3.34 87.13 3.22 F(2, 14)= 1.145, p=0.346 T2 F(1, 7)= 2.032, p=0.197 0.38 F(2, 34)= 0.074, p=0.928 F(2, 34)= 2.988, p=0.064
T3 F(1, 10)= 0.000, p=1.000 0.09 T3 F(1, 7)= 0.000, p=1.000 0.40
MCH (g/cell) moderate 32.44 1.98 32.68 2.07 32.76 1.93 F(2, 20)= 4.889, p=0.019 T2 F(1, 10)= 8.692, p=0.015 0.74 31.39 1.17 31.30 1.33 30.65 0.83 F(2, 10)= 1.486, p=0.272 T2 F(1, 5)= 1.839, p=0.233 0.28 F(2, 30)= 0.362, p=0.699 F(2, 30)= 4.950, p=0.014
T3 F(1, 10)= 6.131, p=0.033 0.99 T3 F(1, 5)= 1.984, p=0.218 2.35
vigorous 32.53 1.88 32.35 1.95 32.35 1.72 F(2, 20)= 4.014, p=0.034 T2 F(1, 10)= 11.645, p=0.007 0.55 31.89 2.08 31.59 1.31 31.65 1.04 F(2, 14)= 0.587, p=0.569 T2 F(1, 7)= 0.374, p=0.560 0.94 F(1.3, 22.3)= 1.762, p=0.199 F(1.3, 22.3)= 0.366, p=0.608
T3 F(1, 10)= 3.159, p=0.106 0.54 T3 F(1, 7)= 0.744, p=0.417 0.75
MCHC (g/L) moderate 36.93 1.50 37.03 1.42 37.14 1.33 F(2, 20)= 0.611, p=0.553 T2 F(1, 10)= 1.006, p=0.340 0.27 36.50 0.86 36.31 0.64 36.27 0.59 F(2, 10)= 0.760, p=0.493 T2 F(1, 5)= 1.106, p=0.341 0.51 F(2, 30)= 0.030, p=0.970 F(2, 30)= 1.271, p=0.295
T3 F(1, 10)= 0.564, p=0.470 0.55 T3 F(1, 5)= 0.455, p=0.530 0.64
vigorous 37.04 1.01 36.65 1.23 36.93 1.09 F(2, 20)= 4.886, p=0.019 T2 F(1, 10)= 8.878, p=0.014 1.07 36.13 0.48 36.51 0.55 36.35 0.43 F(2, 14)= 3.404, p=0.062 T2 F(1, 7)= 5.898, p=0.046 1.05 F(2, 34)= 0.035, p=0.963 F(2, 34)= 7.889, p=0.002
T3 F(1, 10)= 1.171, p=0.305 0.29 T3 F(1, 7)= 0.697, p=0.431 0.60
RDW (%) moderate 13.28 0.76 13.43 0.61 13.44 0.59 F(2, 20)= 0.385, p=0.685 T2 F(1, 10)= 0.636, p=0.444 1.13 13.25 0.46 13.43 0.65 13.35 0.48 F(1.1, 5.4)= 0.412, p=0.561 T2 F(1, 5)= 0.558, p=0.489 1.32 F(2, 30)= 0.777, p=0.469 F(2, 30)= 0.021, p=0.979
T3 F(1, 10)= 0.728, p=0.414 1.22 T3 F(1, 5)= 0.251, p=0.638 0.75
vigorous 13.19 0.68 13.46 0.66 13.41 0.61 F(2, 20)= 5.916, p=0.010 T2 F(1, 10)= 14.157, p=0.004 2.06 13.37 0.51 13.38 0.48 13.25 0.32 F(2, 14)= 0.185, p=0.833 T2 F(1, 7)= 0.121, p=0.738 0.08 F(2, 34)= 3.051, p=0.061 F(2, 34)= 1.940, p=0.159











The mean, standard deviation, and statistical analyses for platelet parameters are displayed in 
Table 12. 
Vigorous intensity exercise caused a significant change over time overall (p<0.001), and in 
both the control and T1D groups independently (p=0.000, p=0.001 respectively). There was a 
small significant increase post vigorous exercise in both T1D and control groups (p=0.008, 
p=0.016 respectively). Both groups showed a similar percentage increase post vigorous 
exercise (T1D: 16.4%, control: 20.8%). No significant changes were seen 1 hour post vigorous 
exercise in either group. The platelet count significantly changed over time during moderate 
intensity exercise overall (p<0.001), and in both the control and T1D groups independently 
(p=0.006, p=0.009 respectively). There was a small significant increase post moderate exercise 
in both the T1D and control groups (p=0.016, p=0.039 respectively). Both groups showed a 
similar percentage increase post moderate exercise (T1D: 11.2%, control: 13.6%). No 
significant changes were seen 1 hour post exercise in either group (Table 12).  
MPV significantly changed over time during vigorous intensity exercise overall (p<0.001), and 
in both the control and T1D groups independently (p=0.004, p=0.048 respectively). There was 
no significant increase post vigorous exercise in either the T1D or control group, however there 
was a significant drop below baseline 1 hour post vigorous exercise in the T1D group 
(p=0.009). Moderate intensity exercise caused a significant change over time overall 
(p=0.017), and in the control group (p=0.013), but not the T1D group. MPV fell (by 2%) 
significantly below baseline post moderate exercise in the T1D group (p=0.033), no changes 
immediately post moderate exercise were seen in the control group. This difference in response 
post moderate exercise showed a trend to be different between groups (time*group) (p=0.059). 
However, MPV fell (by 2.38%) significantly below baseline 1 hour post moderate exercise in 
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the control group only (p=0.002). No significant changes 1 hour post moderate intensity 
exercise were seen in the T1D group (Table 12). 
PCT significantly changed over time during vigorous intensity exercise overall (p<0.001), and 
in both the control and T1D groups independently (p<0.001, p<0.001 respectively). There was 
a significant increase post vigorous exercise in both T1D and control groups (p=0.003, p=0.009 
respectively). The percentage increase post vigorous exercise was similar between groups 
(T1D: 18.5%, control: 23.2%). There was a significant fall below baseline in both the T1D 
group (p=0.049) and a trend to decrease in the control group 1 hour post vigorous exercise 
(p=0.068). Moderate intensity exercise caused a significant change over time overall 
(p<0.001), and in both the control and T1D groups independently (p=0.009, p=0.004 
respectively). There was a significant increase post moderate exercise in both T1D and control 
groups (p=0.043, p=0.034 respectively). The percentage increase post moderate exercise was 
similar between groups (T1D: 9.3%, control: 14%). PCT significantly fell below baseline 1 
hour post moderate exercise in the T1D group (p=0.037), but not in the control group (Table 
12). 
PDW significantly changed over time during vigorous intensity exercise overall (p=0.012), but 
this was not seen in either group independently. There was a significant increase (2.94%) post 
vigorous exercise in the control group (p=0.027), but not in the T1D group. No significant 
changes were seen 1 hour post vigorous exercise in either group. There were no significant 






Table 12 Platelets mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of platelet measures for control and T1D participants during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1controls n= 11-12 
2T1D n= 8-10 
dTime (overall) dTime*Group
Parameter Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
Platelet count (cells/μl) moderate 162667 39942 184833 39057 150364 35405 F(2, 20)= 6.087, p=0.009 T2 F(1, 10)= 5.630, p=0.039 13.63 229250 44654 255000 47671 202333 18776 F(2, 10)= 8.724, p=0.006 T2 F(1, 5)= 12.945, p=0.016 11.23 F(2, 30)= 13.788, p<0.001 F(2, 30)= 0.555, p=0.580
T3 F(1, 10)= 0.963, p=0.350 7.56 T3 F(1, 5)= 3.693, p=0.113 11.74
vigorous 171417 35973 207091 39223 158917 29652 F(2, 20)= 10.526, p=0.001 T2 F(1, 10)= 8.369, p=0.016 20.81 230222 73388 267889 83479 221125 73062 F(2, 14)= 15.338, p<0.001 T2 F(1, 7)= 13.489, p=0.008 16.36 F(2, 34)= 22.073, p<0.001 F(2, 34)= 0.137, p=0.872
T3 F(1, 10)= 2.543, p=0.142 7.29 T3 F(1, 7)= 0.882, p=0.379 3.95
MPV (fL) moderate 8.64 0.84 8.69 0.97 8.44 0.97 F(1.3, 12.8)= 7.493, p=0.013 T2 F(1, 10)= 0.427, p=0.528 0.58 8.13 0.60 7.96 0.57 7.92 0.71 F(1.1, 5.5)= 1.361, p=0.298 T2 F(1, 5)= 8.571, p=0.033 2.00 F(2, 30)= 4.696, p=0.017 F(2, 30)= 1.507, p=0.238
T3 F(1, 10)= 18.519, p=0.002 2.38 T3 F(1, 5)= 2.238, p=0.195 2.56
vigorous 8.58 0.95 8.63 0.88 8.43 0.93 F(2, 20)= 3.551, p=0.048 T2 F(1, 10)= 1.202, p=0.299 0.51 8.12 0.64 8.23 0.69 7.88 0.73 F(2, 14)= 8.171, p=0.004 T2 F(1, 7)= 1.579, p=0.249 1.37 F(2, 34)= 11.270, p<0.001 F(2, 34)= 0.867, p=0.429
T3 F(1, 10)= 2.608, p=0.137 1.84 T3 F(1, 7)= 13.000, p=0.009 3.04
PCT (%) moderate 0.14 0.04 0.16 0.04 0.13 0.04 F(2, 20)= 7.225, p=0.004 T2 F(1, 10)= 6.067, p=0.034 14.03 0.18 0.02 0.20 0.02 0.16 0.01 F(2, 10)= 10.866, p=0.009 T2 F(1, 5)= 7.225, p=0.043 9.25 F(2, 30)= 15.892, p<0.001 F(2, 30)= 0.873, p=0.428
T3 F(1, 10)= 1.361, p=0.270 9.06 T3 F(1, 5)= 7.982, p=0.037 15.10
vigorous 0.15 0.03 0.18 0.04 0.13 0.02 F(2, 20)= 13.922, p<0.001 T2 F(1, 10)= 10.250, p=0.009 23.22 0.18 0.05 0.22 0.06 0.17 0.05 F(2, 14)= 24.594, p<0.001 T2 F(1, 7)= 19.842, p=0.003 18.49 F(2, 34)= 31.271, p<0.001 F(2, 34)= 0.009, p=0.991
T3 F(1, 10)= 4.186, p=0.068 8.77 T3 F(1, 7)= 5.631, p=0.049 7.37
PDW (%) moderate 16.13 1.27 15.53 1.32 15.01 1.94 F(2, 20)= 2.584, p=0.100 T2 F(1, 10)= 3.899, p=0.077 3.72 15.79 0.92 16.13 1.57 16.15 1.25 F(2, 10)= 0.728, p=0.507 T2 F(1, 5)= 0.953, p=0.374 2.14 F(2, 30)= 0.340, p=0.714 F(2, 30)= 2.421, p=0.106
T3 F(1, 10)= 4.564, p=0.058 6.97 T3 F(1, 5)= 0.821, p=0.406 2.30
vigorous 15.82 1.61 16.28 1.76 15.55 1.52 F(2, 20)= 2.521, p=0.106 T2 F(1, 10)= 6.702, p=0.027 2.94 15.48 1.18 15.56 0.88 14.81 1.10 F(2, 14)= 3.190, p=0.072 T2 F(1, 7)= 0.014, p=0.910 0.50 F(2, 34)= 5.021, p=0.012 F(2, 34)= 0.776, p=0.468
T3 F(1, 10)= 0.274, p=0.612 1.69 T3 F(1, 7)= 3.127, p=0.120 4.30
1Controls 2T1D





The first aim of this study was to measure clinical and haematological parameters at rest in 
T1D and control participants. Participants in each group were closely matched for gender, age, 
and BMI to minimise differences in these parameters. The clinical measures showed that 
fasting blood glucose levels were significantly higher in the T1D group compared to the control 
group. There was also a trend for VO2 max to be lower in the T1D group even though their 
total physical activity levels were higher. The haematological measurements showed a higher 
WBC count in the T1D group compared to the control group. Within the WBC, the proportions 
were skewed by a substantial increase in the proportion and frequency of granulocytes in the 
T1D group. A higher platelet count was also found in the T1D group.  
This study also aimed to investigate the effects of moderate and vigorous intensity exercise on 
clinical and haematological parameters in T1D and control participants. During exercise, heart 
rate and RPE increased with exercise intensity as expected. Higher heart rates and RPE were 
detected in the vigorous compared to the moderate intensity exercise bout as anticipated. These 
observations validate the intensity of both acute exercise protocols. Systolic BP increases 
during exercise as expected however it is only significant in the control group. During the 
recovery period, all parameters returned to basal levels by 1 hour post exercise. This indicates 
that participants from both the T1D and control group fully recovered to a similar degree by 
the 1 hour time point. Glucose responses were different in T1D and control participants. 
Glucose levels decreased initially in the control group, but then began to increase before 
exercise cessation. However in the T1D group, glucose levels continued to fall during the 
exercise. This provides insight into the clinical factors such as heart rate, blood pressure, and 




with T1D. These observations indicate that acute vigorous intensity exercise is safe in people 
with T1D as recorded for the first few hours following the exercise bout.  
There were a number of limitations in this study. Although data was collected for lifestyle 
factors by providing glucose and food diaries, these only covered a short time period of 24 
hours prior to the exercise visits and did not provide data for these factors in between visits. 
Additionally, due to time constraints, the data collected was not analysed and therefore was not 
used to account for any differences between participants or groups. Measuring glucose in the 
24 hours following the exercise visit would provide insight into the safety of vigorous exercise 
in T1D participants.  
A number of haematological changes occurred during exercise. Firstly, during vigorous 
intensity exercise all WBC populations increased in frequency immediately following exercise 
in both groups. However, the percentage increase of lymphocytes following vigorous exercise 
was lower in the T1D group. Yet, monocytes and granulocytes increased following exercise to 
a similar degree in both groups. Therefore, this blunted response is specific to lymphocytes in 
T1D participants. Secondly, all RBC parameters were affected by vigorous exercise in the 
control group, but not in the T1D group. However, the percentage increases for all RBC 
parameters are small and unlikely to contribute to a difference in effects of exercise between 
groups. Lastly, there was an increase in platelet count during moderate and vigorous exercise 
in both groups. Altogether, the WBC response during exercise was much higher than that of 
RBC and platelet measures.  
Previous studies have also demonstrated elevated granulocytes and platelets in T1D. Elevated 
neutrophils in T1D have been reported, and this is linked to an increased risk of vascular disease 




in the risk of cardiovascular events [272]. Higher MPV has also been found in children with 
T1D [273, 274].  
During acute exercise, a number of cellular changes occur within WBC, RBC, and platelet 
subsets in healthy cohorts. It is established that the frequency of WBC, lymphocytes, 
monocytes, and granulocytes all increase during acute exercise in healthy cohorts [206, 207, 
209, 210, 275, 276]. In this study, leucocytosis was demonstrated in both the T1D and control 
group. Specifically, acute exercise caused a significant intensity-dependent increase in the 
frequency lymphocytes in the peripheral blood, followed by lymphopenia, in healthy cohorts 
[191-196]. Here, lymphocytosis following vigorous intensity exercise occured in both the T1D 
and control group. However lymphocytosis was marginally blunted in the T1D group. One 
other study has measured haematological outcomes in T1D during acute exercise [190]. An 
increase in lymphocytes, monocytes, and granulocytes was found following exhaustive and 
endurance exercise. In the aforementioned study, lymphocytosis was found to a similar extent 
in both groups (T1D: 120%, controls: 133%). However, the exercise bout was performed at a 
higher intensity than the exercise conducted in the EXTOD Mechanisms study and therefore 
cannot be directly compared. 
Increases in RBC parameters during exercise in healthy cohorts have also been previously 
demonstrated [277-279, 289]. Likewise, platelets increase following exercise in heathy cohorts. 
All platelet parameters increase (PCT, MPV, Pct, PDW), mainly accounted for by platelets 
released from the spleen during exercise [280-284]. One other study has shown increased 
platelets following acute exercise in T1D [190]. 
The findings from this analysis provide evidence of a typical immune response to acute 
exercise in people with T1D. The data from this chapter also provides validation of the exercise 




during both moderate and vigorous intensity exercise bouts. A detailed analysis of the effects 










CHAPTER 4. THE EFFECTS OF 
ACUTE EXERCISE ON 
LYMPHOCYTE MOBILISATION 
AND TRAFFICKING IN TYPE 1 






Lymphocyte trafficking and mobilisation is involved in immune surveillance and regulation. 
Acute exercise induces changes in lymphocyte trafficking and mobilisation. Lymphocyte 
subsets, NK cells, and CD8+ T cells exhibit the largest mobilisation during acute exercise in 
healthy individuals. However, the effects of moderate or vigorous acute exercise on the 
mobilisation of lymphocyte subsets in T1D is not fully known.  
4.1.1 Lymphocytes 
 
Human lymphocytes are comprised of T cells, B cells, and NK cells. T cells are formed and 
mature in the thymus. Phenotypically identified by co-expression of T cell receptor (TCR) and 
CD3, T cells are the most abundant lymphocyte population [290, 291]. CD3+ T cells are made 
up of highly heterogeneous CD4+ and CD8+ populations. Through their diverse TCR they 
recognise foreign antigen. B cells, derived from pluripotent haematopoietic stems cells, are 
formed and mature in the bone marrow. They are the smallest lymphocyte population and are 
phenotypically defined as CD3-CD19+ [291]. B cells mediate humoral immunity through the 
secretion of antigen specific antibodies [292].  
NK cells, making up 15% of lymphocytes, are derived from common lymphoid progenitor 
populations and are formed in the bone marrow [293, 294]. NK cells act as a first line of defence 
and are critical for immune surveillance. Unlike, T and B cells, they rapidly respond to foreign 
antigen without the need for priming. NK cells are phenotypically identified as CD3-CD56+ 
[291, 295]. NK cells can be further divided based on their CD16 expression into functionally 
different subsets; CD56dimCD16bright, CD56brightCD16dim, CD56dimCD16dim CD56brightCD16-, 
and CD56-CD16+ [296]. CD56dimCD16bright are the most abundant NK cell subset in the 
peripheral blood, making up to 90% of the NK population [294]. CD56dimCD16bright NK cells 




CD56dimCD16bright NK cells express high levels of killer cell immunoglobulin-like receptors 
(KIR) and perforin granules, rendering them the superior cytotoxic subset [296, 297]. In 
contrast, CD56brightCD16dim are predominantly found in secondary lymphoid tissues and do not 
express KIR [294]. CD56brightCD16dim NK cells express higher CD62L for migration to 
secondary lymph nodes [197]. CD56brightCD16dim NK cells secrete a diverse repertoire of 
proinflammatory cytokines such as TNF-α and IFN-γ	 to counteract their poor cytotoxic 
capabilities [297]. More recently identified, CD56dimCD16dim represent a high percentage of 
immature cells denoted by lack of CD57 expression and are NKG2A+ [298]. Less is known 
about the other two minor NK cells subsets: CD56brightCD16- and CD56-CD16+. 
CD56brightCD16- NK cells have been found in psoriasis and express high levels of chemokine 
receptors [299]. However, another study suggested a regulatory role for this subset [300]. Very 
little is known about the function of the CD56-CD16+ NK cell subset. However, it has been 
found to be expanded in human immunodeficiency virus (HIV) infection with lower cytotoxic 
activity and cytokine secretion compared to CD56+ NK cell subsets [301].  
4.1.2 Lymphocyte Trafficking 
Lymphocyte trafficking is essential for immunosurveillance and efficient immune responses. 
Peripheral blood lymphocytes are recruited to sites of inflammation during an immune 
response by chemoattraction [302, 303]. During lymphocyte recruitment, also described as 
lymphocyte homing, inflamed tissues also release cytokines and chemokines which guide 
lymphocytes to the target site [304, 305]. Lymphocytes express homing receptors that mediate 
lymphocyte trafficking such as LFA-1, CXCR3, members of the integrin family (CD11a, 
CD11b, CD11c), and an array of chemokine receptors such as CCR4, CCR6, CCR7 [305-307]. 
Expression of homing receptors allows lymphocytes to respond to cytokines and chemokines 
in circulation [308, 309]. Whereas blocking of homing receptors blunts lymphocyte recruitment 




coordinated steps; rolling, activation, arrest and diapedesis (Figure 10) [313, 314]. Endothelial 
cells (EC)  on the inflamed tissue, also referred to as the target tissue, upregulate cellular 
adhesion receptors such as MAdCAM-1, ICAM-1, vascular cell adhesion protein 1 (VCAM-
1), P-Selectin, and E-Selectin [304, 315, 316]. Lymphocytes slow down and roll while 
lymphocyte adhesion molecules bind to the above corresponding receptors on endothelial cells. 
P-selectin mediates initial contact and rolling of lymphocytes. Beta-2 integrins on lymphocytes 
interact with VCAM-1 on the EC which results in rolling and tethering of the lymphocyte 
[317]. Sphingosine-1-phosphate receptor 1/4 (S1PR1/4), necessary for tissue retention, is now 
upregulated on the lymphocyte surface [318-320]. Together, this results in stable lymphocyte 
arrest, allowing for lymphocyte cytoskeleton rearrangement and spreading across the 
endothelium mediated by prostaglandin D2 (PGD2) [310, 314, 321]. Diapedesis, also referred 
to as extravasion or TEM, into the target tissue can then occur. Preferentially memory T cells 
are recruited through endothelium [310, 315, 322, 323]. It is predominantly the chemokine 
receptor CXCR3 on memory T cells that mediates TEM [322]. This is supported by evidence 
of blockade of CXCR3, which results in reduced TEM of total CD3+ T cells [324]. CD18, 
which can form complexes with CD11a and CD11b to form LFA-1 and Macrophage-1 antigen 
(Mac-1) respectively, also mediates transmigration [325, 326]. 
Lymphocyte migration can be studied using static TEM assays. This is done by layering 
peripheral blood lymphocytes (PBL) over activated endothelium monolayers [327-329]. PBLs 
can migrate across endothelium monolayers in minutes, migrating back and forward 
continuously [330]. Activation of human endothelium monolayers with inflammatory stimuli 
induces upregulation of ICAM-1, VCAM-1, P-selectin, and E-selectin, as well as chemokines 
CXCL9, CXCL10, and CXCL11 [315, 316, 331, 332]. P-selectin and E-selectin are essential 
for the initial lymphocyte arrest, evidenced by inhibited adhesion through blocking of these 




bind to CXCL9, CXCL10, and CXCL11 on endothelial cells in these static TEM models [322, 
325, 326]. 
Using the static TEM assay, a novel adiponectin-dependent mechanism of TEM regulation was 
identified by Myriam Chimen et al., (2015) (Figure 10). Adiponectin is an adipokine with anti-
inflammatory, anti-diabetic, and insulin sensitizing properties [333, 334]. It signals through its 
receptors, adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2) [335, 336]. 
AdipoR1 and AdipoR2 are expressed by monocytes, B cells, and NK cells, but not T cells 
[337]. B cells respond to adiponectin in circulation through these receptors resulting in 
secretion of a homeostatic molecule, PEPITEM (peptide inhibitor of trans-endothelial 
migration). PEPITEM binds to cadherin-15 (CDH15) expressed on stimulated endothelium 
resulting in the release of sphingosine-1-phosphate (SIP) from endothelial cells. SIP binds to 
its receptors, S1PR1/4, on lymphocytes to down-regulate LFA-1 expression, preventing 
lymphocyte binding to endothelial adhesion molecules and therefore preventing TEM. 
Lymphocyte homing to the endothelial is however unaffected as chemotactic responses to 







Figure 10 Transendothelial migration and regulation via PEPITEM 
Transendothelial migration and regulation by the B cell-adiponectin-PEPITEM axis as shown by Myriam Chimen 
et al., (2015) [315].  
4.1.3 Lymphocyte trafficking in T1D  
 
The pancreatic endothelium in T1D is chronically activated due to ongoing beta cell damage 
and inflammation. Adhesion molecules ICAM-1, VLA-4, CD44, PNAd, and MAdCAM-1 are 
upregulated by inflamed islets in T1D, increasing pancreatic lymphocyte trafficking [126, 134, 
338]. Beta cells also secrete the chemokine ligands CXCL9, CXCL10, CCL2, CCL3, CCL17, 
CCL21, and CCL22 in NOD mice [128, 137-139]. Corresponding adhesion molecules and 
homing receptors expressed by T cells allow for tissue homing and TEM to the islet. 
Lymphocytes found within NOD pancreas were CD69+ and CD103+, markers of tissue resident 
memory subsets, and they expressed markers of adhesion; LFA-1, VLA-4, CD11b, and CCR7 
[86, 126, 127, 191]. CD11b+ CD4+ and CD8+ T cells have also been found within the NOD islet 
[127, 134]. Beta cell specific T cells display a stem cell like memory (TSCM) phenotype [339]. 
TSCM express CCR7 and may contribute to the CCR7+ islet population [340].  
Alterations in NK cell frequency in the peripheral blood has not been well characterised in 




recent-onset and long-standing T1D in one study [341]. There have however been a number of 
studies showing a high frequency of NK cells infiltrating the pancreas and contributing to the 
onset and pathogenesis of T1D [109-112]. NK cells have been found to surround and infiltrate 
the pancreas of NOD mice [111, 112]. NK cells within the islet have a distinct phenotype, 
differing from splenic NK cells. Pancreatic NK cells demonstrated an increased expression of 
CD25, CD69 and PD-1, and a down-regulation of CD62L. Pancreatic NK cells also expressed 
higher KLRG1 than splenic NK cells, indicating a high proliferation state. In this study, 
NKG2D was also shown to be down-regulated on pancreatic NK cells [111, 112]. This is due 
to the expression of the rae-1 ligand. Rae-1 normally binds NK cells to stimulate their 
activation, however, as rae-1 ligand is increased this preferentially binds to rae-1 over NKG2D. 
This also indicates that NK cells are not activated readily in T1D [342, 343]. On the other hand, 
beta cells express rae-1 which may be involved in the initial homing of NK cells into the 
pancreas prior to established insulitis. Other homing mechanisms include the binding of NK 
cells to CXCL10 through CXCR3 and LFA-1 expression [113].  
As discussed, the B cell-adiponectin-PEPITEM axis has been shown to regulate TEM in 
healthy individuals. This TEM regulation is perturbed in inflammatory disorders such as T1D 
[315]. Although, adiponectin levels are unchanged in T1D [344] the expression of AdipoR1 
and AdipoR2 by monocytes and B cells is reduced compared to healthy individuals [315, 344]. 
Therefore, adiponectin signalling is disrupted and consequently, so is PEPITEM release. This 
results in a “leaky” endothelium allowing autoreactive T cells into the islet and causing further 
beta cell destruction [315, 344]. 
4.1.4 Lymphocyte trafficking and mobilisation during exercise 
 
Acute exercise causes a significant intensity-dependent increase in the number of lymphocytes 




NK cells are the most responsive lymphocyte subset to acute exercise [345-347]. Of these, 
CD56dimCD16bright and those with a highly differentiated phenotype (CD57+) are preferentially 
redeployed, demonstrating the largest increase following exercise [197, 198]. This is followed 
by a larger decrease below baseline during the recovery period. Following exercise, CD56bright 
subsets return to baseline levels, whereas CD56dim decrease below baseline levels [197]. 
Preferentially mobilised NK cell subsets are highly differentiated, CD57+ KIR+ NKG2A- [198]. 
Furthermore, IL-2Rβ (CD122+) and IL-2Rα (CD25+) NK cells increase following exercise. 
CD25 is expressed on CD56bright NK cells in comparison to CD122 which is constitutively 
expressed on all naïve NK cells [346, 347]. Secondary to NK cells, fully differentiated CD8+ 
T cells are significantly mobilised in an exercise intensity-dependant manner [199, 200], with 
lower levels of mobilisation amongst CD4+ T cells and B cells [193, 199, 201]. 
Lymphocyte trafficking and mobilisation is regulated by adrenergic responses [214, 348]. Beta-
adrenergic receptor expression is highest on NK and CD8+ T cells therefore are preferentially 
mobilised in an intensity-dependant manner during acute exercise [202-205]. Adrenergic 
stimulation causes detachment of NK cells from endothelium, releasing NK cells for 
mobilisation [349]. Blocking of the adrenaline response prevents an increase in NK cells, 
reiterating that lymphocytosis is controlled by adrenergic mechanisms [350]. 
Lymphopenia following exercise may be explained by changes in lymphocyte trafficking due 
to altered adhesion molecule expression and TEM [191, 348]. Studies have shown that 
lymphocytes expressing adhesion molecules are mobilised during exercise. Increases in 
CD11b+, CD11c+, and LFA-1+ lymphocytes are reported following exercise [195, 351-353]. 
CD11b+ and CD11c+ lymphocytes increased following exercise are largely due to CD16+ cells, 




not shown to mobilise with exercise [354]. However, another study showed that CD11a+ and 
CD62L+ T cells increased post exercise, and this increase was blunted in fit  
individuals [355].  
TEM is increased with shear force, suggesting that acute exercise would increase TEM [331]. 
However, increased adrenaline reduces CD11b/CD18 expression on PBMC [356, 357]. This 
means that during an acute exercise bout, whilst adrenaline levels are elevated, lymphocyte 
TEM would be impaired until exercise cessation, when adrenaline levels drop again. 
Furthermore, exercise training may reduce TEM. One study found that fit individuals show 
reduced PMBC adhesion to endothelial cells following acute exercise compared to a non-fit 
cohort which showed no change [358]. This may be explained by a reduction in adhesion 
molecules on lymphocytes in fit individuals. Furthermore, in vitro migration of CD4+ and CD8+ 
T cells decreased following exercise [359]. Therefore, exercise may inhibit TEM of 
lymphocytes. Clarification of the effects of acute exercise on lymphocyte TEM is needed.  
Acute exercise may modulate TEM through the adiponectin-PEPITEM axis. Acute exercise 
increased circulating adiponectin following low and vigorous intensity, and remained above 
baseline levels 30 minutes following exercise [360]. In a separate study, when lymphocytes 
were treated with adiponectin, a positive correlation was seen between the expression of 
AdipoR1 and AdipoR2 on B cells with the quantity of PEPITEM released [315]. Therefore, 
the effects of exercise on B cells expressing AdipoR1 and AdipoR2, and subsequent PEPITEM 
release, needs to be explored.  
Lymphocyte trafficking and TEM is essential for homeostasis of immune function. However, 
immune function is dysregulated in T1D [73]. Constant recruitment and TEM of autoreactive 
T cells and cytotoxic NK cells to the pancreas sustains this chronic inflammatory state [28, 




immunosurveillance and regulation [199, 214, 220, 345, 361, 362]. It is not known if acute 
exercise elicits the same response in T1D. Immunomodulation by exercise has the potential to 
resolve perturbations to immune regulation and lymphocyte trafficking in T1D, thus reducing 







Acute exercise will improve lymphocyte trafficking and transmigration in T1D.  
4.1.5 Aims 
 
To characterise adhesion molecule expression by lymphocytes using multi-parameter flow 
cytometry: 
1. In T1D and control participants at rest. 
2. In T1D and control participants following an acute bout of moderate intensity exercise. 
3. In T1D and control participants following an acute bout of vigorous intensity exercise. 
 
To measure transendothelial migration of lymphocytes: 
1. In T1D and control participants at rest. 
2. In T1D and control participants following an acute bout of moderate intensity exercise. 






4.2.1 Experimental design 
Twelve controls and twelve T1D male participants were recruited into the study (as described 
in Chapter 3). Briefly, participants had one enrolment visit, where an incremental sub-maximal 
cycle ergometer test was performed to calculate their predicted VO2 max. This was used to 
calculate workload and heart rate for subsequent exercise visits adjusted to individual fitness 
[285]. These two visits consisted of a thirty-minute bout of cycling at either 40% VO2 max 
(moderate) or 80% VO2 max (vigorous). Blood was collected intravenously at baseline, 
immediately post exercise, and 1 hour post exercise in vacuette heparin tubes (95057-405, 
Greiner Bio-one GmbH, Frickenhausen, Germany).  
4.2.2 Endothelial cell culture 
 
Human Dermal Blood Endothelial Cells (HDBEC) were cultured for 4 passages before 
aliquoting and storing in liquid nitrogen (500,000 cryopreserved: Female Caucasian, aged 22, 
tissue origin: Labia) (C-12225, Lot#398Z028.2, Promocell, Heidelberg, Germany).  
4.2.2.1 Passaging HDBEC 
 
All reagents were pre-warmed to 37oC prior to use. Cells were detached using 2mls of 0.25% 
trypsin-EDTA (C-41000, Promocell, Heidelberg, Germany) per T25 flask, or 3mls for T75 
flasks. Cells became phase-bright once they had detached after approximately 2 minutes. Then, 
3ml M199 (M4530, Sigma-Aldrich, Dorset, UK) supplemented with 2% bovine serum albumin 
(BSA) (A2153, Sigma-Aldrich, Dorset, UK) (referred to as M199-2%BSA from here on) (6ml 
for T75) was added to detached cells and centrifuged for 5 minutes at 1500 RPM. Supernatant 
was removed and cells were split accordingly. HDBEC were cultured in endothelial cell growth 
medium (C-22020, Promocell, Heidelberg, Germany) (including supplement mix 2% Fetal 




Factor (recombinant human), 1 ng/ml Basic Fibroblast Growth Factor (recombinant human), 
90 µg/ml Heparin, 1 µg/ml Hydrocortisone) supplemented with 350µl gentamycin (50mg/ml) 
(SLBJ8029V, Sigma-Aldrich, Dorset, UK) (referred to as BEC media from here on). For the 
first passage (P1), cells were split 1 in 2, into T25 flasks. Passages P2-P4 were split 1 in 3 into 
T75 flasks. Cells were then frozen at P4 for cryo-storage (see section 4.2.2.2).  
4.2.2.2 Freezing HDBEC 
 
Cryovials were pre-labelled and pre-chilled on ice. One T75 flask of HDBEC was aliquoted 
into 3 cryovials. Cells were detached (trypsin-EDTA) and pelleted as previously described for 
passaging (Section 2.3.1). Pelleted cells were resuspended in 1500µl of cryoSFM freezing 
media (C-29910, Promocell, Heidelberg, Germany, Heidelberg, Germany) and 500 µl of this 
was transferred to each cryovial. All cryovials were placed in a Mr Frosty freezing chamber 
and left -80 oC overnight. Cryovials were then transferred to liquid nitrogen for long-term 
storage. 
4.2.3 Preparation of HDBEC layer  
 
4.2.3.1 Defrosting HDBEC 
 
Firstly, 14ml of BEC media (C-22020, Promocell, Heidelberg, Germany) was incubated at 
37oC in a T25 flask. One cryovial of HDBEC was collected from liquid nitrogen on ice in the 
meantime. To defrost, HDBEC cells were warmed in a water bath for up to 2 minutes, until 
there was only a small ice pellet left in the vial. HDBEC were collected using a 5ml pipette and 
transferred to the pre-warmed BEC media. To ensure a monolayer is formed, the flask was 
circulated in a side to side motion, avoiding the lid to prevent contamination, to spread the 





4.2.3.2 Plating cells 
 
Following 2 days of culture, HDBEC were detached (trypsin-EDTA) and pelleted as previously 
described in passaging protocol (Section 2.3.1). Pelleted cells were resuspended in 15mls of 
pre-warmed BEC media (C-22020, Promocell, Heidelberg, Germany). One vial of HDBEC 
was enough for 10 wells of a 12 well plate, 1.5ml was added to each well. The plate was 
circulated in a side to side motion to spread HDBEC in the well. They were incubated at 37°C 
for 24hours. 
4.2.3.3 Stimulation of HDBEC 
 
HDBEC were activated with inflammatory cytokines; 100 U/ml TNF-α (210-TA-010, 
RNDsystems, Abingdon, UK) and 10ng/ml recombinant human IFN-γ (300-02, Peprotech, 
London, UK) was added to 5ml of pre-warmed BEC media. Media was removed from each 
well and replaced with 1ml of stimulation media. Cells were incubated at 37°C for 24hours.  
4.2.4 PBL isolation and adiponectin treatment  
 
Freshly isolated PBMCs (>5 million) (see Section 2.2.3) were placed into a T25 with 5mls of 
M199-2%BSA. Cells were incubated at 37°C for 30 minutes. PBLs were collected by intense 
washing of the flasks. Monocytes will stick to the bottom of the flask whilst PBLs will come 
off into solution [363]. Collected PBLs were transferred to a 15ml falcon and centrifuged for 
7 minutes at 1500RPM. Pelleted cells were resuspended in 1ml of MI99-2%BSA. PBLs were 
resuspended to a concentration of 1x106/ml. One million of these cells were taken for 
adiponectin treatment; PBLs were centrifuged at 1500RPM for 7 minutes and resuspended in 
100µl of sterile PBS. Adiponectin (10 µg/ml) (ALX-522-063-C050, Enzo Life Sciences, 




treatment, cells were centrifuged for 7minutes at 1500RPM, then resuspended in 1ml M199-
2%BSA. 
4.2.5 Transmigration Assay  
 
Media was removed from HDBEC wells. Cells were washed twice with 1.5ml M199-2%BSA. 
One condition was added to each well (i.e adiponectin treated PBL, pre-exercise PBL, post-
exercise PBL, 1 hour post exercise PBL). The plate was incubated for 6.5 minutes at 37°C. 
Media was removed from wells. Cells were washed twice with 0.5ml M199-2%BSA. Cells 
were fixed with 1 ml of 2% paraformaldehyde and incubated for 10minutes at 37°C. 
Supernatant was removed from wells and cells were washed twice with 0.5ml M199-2%BSA. 
To analyse wells, 1ml of M199-2%BSA was added to each well. Using Image ProPlus 6.0 
software, 7 random images were taken for each well. Phase bright and phase dark cells were 
counted for each image (Figure 11b). Percentage transmigration was the calculated for each 





Figure 11 Transendothelial migration of lymphocytes shown by representative phase contrast images 
Representative phase contrast images showing (a) unstimulated HDBEC control (b) Stimulated HDBEC; adherent 




4.2.6 Lymphocyte subset analysis 
Four multicolour flow cytometry panels were designed to enable phenotypic analysis of 
lymphocyte subsets. The following mAbs (see Table 3, Section 2.3.2 for mAb details); T cells 
tube 1: anti-CD3 PE-Cy7, anti-CD4 APC-R700, anti-CD8 APC-H7, anti-CD11b PE-CF594, 
anti-7-AAD PerCP-Cy5.5. T cells tube 2: anti-CD3 PE-Cy7, anti-CD4 APC-R700 ,anti-
CXCR3 PE-CF594, anti-CCR4 BV421, anti-CCR6 BV711, Live/Dead fixable viability stain 
780. B cells: anti-CD3 BV605, anti-CD19 PE-CF594, anti-CD62L APC, anti-AdipoR1 PerCP-
Cy5.5, anti-AdipoR2 Pe-Cy7, Live/Dead fixable viability stain 780. NK cells: anti-CD3 Pe-
Cy7, anti-CD16 PE-CF594, anti-CD18 (LFA-1) APC, anti-CD56 BV510, Live/Dead fixable 
viability stain 780. Whole blood was stained as per Chapter 2 (Section 2.3.2). Whole blood 
counts were completed using a coulter haematology analyser (Section 2.2.2) to calculate 
relative cell frequency (cells/μl) of lymphocyte subsets.  
4.2.7 Data analysis 
Flowjo v.10 was used to analyse flow cytometry data. Doublets were removed using FSC-A 
against FSH-H. Dead cells positive for viability stain were removed, and lymphocytes were 
gated based on size on SSC-A versus FSC-A dot plot (Figure 12). T cells were selected as 
CD3+, and further selected on CD4+ and CD8+ expression (Figure 13.2). NK cells were selected 
as CD3- and further selected on CD56+/CD16+/- expression as follows: CD56dimCD16bright, 
CD56brightCD16dim, CD56brightCD16-, CD56dimCD16dim, and CD56-CD16+ (Figure 13.3). B 
cells were selected as CD3-CD19+ (Figure 13.4). Adhesion molecules and chemokine receptors 
CD11b, LFA-1, CXCR3, CCR6, CCR4, and CD62L expression were selected on CD3+ and 
CD3- in their corresponding panels (Figure 14). Adiponectin receptor expression, AdipoR1 and 
AdipoR2, was selected on CD3-CD19+ B cells (Figure 15).  
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Figure 12 Selection of live lymphocytes shown by representative flow plots 
Representative flow cytometry plots showing (1) Lymphocyte selection based on size (SSC-A vs FSC-A) (2) 




Figure 13 Lymphocyte subset selection; T cells, NK cells, and B cells gating strategy shown by 
representative flow plots.
Representative flow cytometry plots following parent gate for lymphocytes (shown in figure 3) (1) CD3 histogram 
(2) CD3+ gate showing CD4+ vs CD8+ T cells gates (3) NK cell subsets following CD3- population selection; 
A. CD56dimCD16bright, B. CD56brightCD16dim, C.CD56brightCD16-, D. CD56dimCD16dim, E. CD56-
CD16+ (4) B cell selection from CD3-CD19+ gate. 
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Figure 14 Adhesion molecule and chemokine receptor gating shown by representative flow plots. 
Representative flow cytometry plots showing following parent gate for CD3+/- populations; (a) CD11b+ (b) LFA-
1+ (c) CXCR3+ (d) CCR6+ (e) CCR4+ (f) CD62L+.  
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Figure 15 Adiponectin receptor gating strategy shown by representative flow plots. 
Representative flow cytometry plots showing adiponectin receptors following parent gate for CD3-CD19+ B cells 





4.3.1 Peripheral blood lymphocyte populations in T1D and control 
participants 
	
4.3.1.1 Lymphocyte populations at rest 
 
The proportion (%) and frequency (cells/μl) of peripheral blood lymphocytes, CD3+ T cells, 
CD4+ T cells, CD8+ T cells, NK cells, and B cells were measured at rest in T1D and control 
participants.  
The proportion and frequency of NK cells were significantly higher in T1D than control 
participants (p=0.041, p=0.011 respectively) (Figure 16a and b). The proportion of 
CD56brightCD16- NK cells were significantly increased in T1D (p=0.025), but this was not seen 
in the frequency of this subset. There were no significant differences between groups in the 
other NK cell subsets; CD56dimCD16bright, CD56brightCD16dim, CD56dimCD16dim (Table 16) 
(Figure 16c and d).  
There were no significant differences in the proportion or frequency of total peripheral 
lymphocytes, CD3+, CD4+, CD8+, CD3-, and B cell populations between groups at baseline 
(Table 13) (Figure 16).  
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Figure 16 The proportion and frequency of lymphocyte subsets at baseline in T1D and control groups. 
Flow cytometry and whole blood cell counts were used to determine the frequency of CD4+T cells, CD8+ T cells, 
NK cell and B cell lymphocyte subsets in control and T1D participants at baseline. (a) Proportion of lymphocyte 
populations in control and T1D groups (b) Frequency of lymphocyte populations in control and T1D groups (c) 
Proportion of NK cell subsets in control and T1D groups (d) Frequency of NK cell subsets in control and T1D 








Table 13 Lymphocyte populations at baseline in T1D and controls. 
Mean and standard deviation values for the proportion and frequency of lymphocytes populations in controls 
and T1D participants. 
Note: % of total lymphocytes 
1controls CD3+/- n=76, CD4+ n=40, CD8+ n=22, NK cells n=20, B cells n=8. 
2T1D CD3+/- n=51, CD4+ n= 2, CD8+ n=15, NK cells n=14, B cells n=7  
Subset
mean SD mean SD
Lymphocytes         (cells/μl) 1348 398 1375 262
CD3+                     (%) 61.75 19.61 55.57 25.64
                               (cells/μl) 833.8 414.4 776.3 350.2
CD4+  T cells        (%) 48.56 11.01 51.17 11.57
                               (cells/μl) 430.0 222.9 400.2 236.5
CD8+  T cells        (%) 38.70 7.32 42.31 10.50
                               (cells/μl) 364.0 150.2 352.9 188.4
CD3-                      (%) 38.34 19.69 44.11 25.59
                               (cells/μl) 554.7 337.7 585.9 392.9
NK cells (CD56+)  (%) 33.11 17.06 46.17 19.04
                               (cells/μl) 143.4 91.8 244.6 127.3
B cells (CD19+)     (%) 30.45 21.91 33.27 19.31







Table 14 NK cell subsets at baseline in T1D and controls. 
Mean and standard deviation values for the proportion and frequency of NK cell subsets in controls and T1D 
participants. 
Note: % of total NK cells 
1controls n=20, 2T1D n=14 
 
 
4.3.1.2 Lymphocyte subsets in response to acute exercise in T1D and control 
participants 
 
The effects of moderate (40% VO2 max) and vigorous (80% VO2 max) intensity exercise were 
investigated in T1D and control participants on CD3+ lymphocyte populations (CD4+ and CD8+ 
T cells) and CD3- lymphocyte populations (NK cells and B cells). Lymphocyte subpopulations 
were measured pre, post, and 1 hour post exercise. The change over time was analysed in 
groups combined under the heading “time (overall)” and in each group independently under 
the heading “time” displayed in all results tables. The interaction over time between groups 
was compared and results are displayed under the heading “time*group” displayed in all results 
tables. Post and 1 hour post exercise measurements were compared to baseline levels as shown 
under the heading “contrasts” in the results tables. The mean, standard deviation, and statistical 
analyses are displayed in Table 15.  
Subset
mean SD mean SD
CD56dimCD16bright (%) 18.76 11.35 21.63 14.05
                               (cells/μl) 74.58 55.41 107.64 73.07
CD56brightCD16dim  (%) 0.63 0.46 0.92 0.73
                               (cells/μl) 2.23 1.56 4.05 2.48
CD56dimCD16dim    (%) 3.12 1.83 4.44 3.52
                               (cells/μl) 11.98 9.46 24.36 25.11
CD56+CD16-        (%) 10.60 10.40 19.17 10.98
                               (cells/μl) 54.66 52.33 108.49 75.12
CD56-CD16+        (%) 5.21 6.14 3.10 6.57





As described in Chapter 3, lymphocytes mobilise during moderate and vigorous intensity 
exercise. There was an overall change over time in total lymphocytes during moderate intensity 
exercise (p=0.021), a trend was seen in controls (p=0.058) but not in T1D (Figure 6a). 
Lymphocytes were significantly increased post moderate exercise in the control group 
(p=0.046). Lymphocytes were significantly mobilised by vigorous intensity exercise in T1D 
(p=0.002) and control (p<0.001) groups, with an overall significant change over time (groups 
combined) (p<0.001). Lymphocytes were significantly increased immediately post vigorous 
exercise in T1D (p=0.003) and controls (p<0.001), followed by a significant fall below baseline 
in controls only (p=0.032) 1 hour post vigorous exercise, with a trend seen in the T1D group 
at this time point (p=0.067) (Figure 17a).  
4.3.1.3 CD3+ subsets in response to acute exercise in T1D and control participants 
 
There was an overall change over time in total CD3+ lymphocytes during moderate intensity 
exercise (p<0.001), and this was seen in control (p=0.003) and T1D (p=0.025) groups 
independently. Total CD3+ lymphocytes were significantly increased post moderate exercise 
overall (p<0.001) (groups combined) and in the control group (p=0.003), but not in the T1D 
group. However, there was a significant decrease below baseline at 1 hour post moderate 
exercise in the T1D group (p=0.026). The observed change in response 1 hour post moderate 
exercise was significantly different between groups (p=0.005) (time*group) because the 
frequency of CD3+ lymphocytes remained above (7.1%) baseline in the control group at this 
time point, but dropped below baseline (14.13%) in the T1D group. Total CD3+ lymphocytes 
significantly changed during vigorous intensity exercise overall (p<0.001) and in both the T1D 
(p<0.001) and control (p<0.001) groups independently. There was an overall significant 
increase post vigorous exercise (p<0.001) and significant decrease below baseline 1 hour post 
vigorous exercise (p<0.001). There was a significant increase post vigorous exercise (T1D: 




(T1D: p=0.007, control: p<0.001) in both groups. However, the difference in response 1 hour 
post exercise was significantly different between groups (p=0.013) (time*group) because there 
was a larger decline below baseline in the control group (T1D: 0.14%, control: 15.95%) (Table 
15).  
There was a significant overall change in CD4+ T cells during vigorous intensity exercise 
(p<0.001), this was seen in the control (p=0.001), but a only trend was seen in the T1D 
(p=0.052) group. CD4+ T cells significantly increased post exercise overall (p=0.011), with a 
trend to increase in T1D (p=0.060), and then CD4+ T cells significantly decreased 1 hour post 
exercise overall (p=0.005) and in the control group (p=0.008). The observed contrast in 
response 1 hour post exercise between groups showed a trend to be different (p=0.052) 
(time*group) because there was a decline below baseline in the control and not the T1D group 
(control: 18.74%, T1D: 0%). CD4+ T cells did not significantly mobilise during moderate 
intensity exercise in either group, but a trend to mobilise was seen overall (p=0.051) (Figure 
17b) (Table 15). 
There was a significant overall change in CD8+ T cells during vigorous intensity exercise 
(p<0.001), and this was seen in the T1D (p=0.016) and control (p=0.001) groups independently. 
CD8+ T cells significantly increased post vigorous exercise in T1D (p=0.040) and control 
(p=0.033) groups. This was followed by a significant decrease 1 hour post vigorous exercise 
overall and in the control group (p=0.021), but only a trend to decrease in the T1D group 
(p=0.057). CD8+ T cells did not significantly mobilise during moderate intensity exercise in 






4.3.1.4 CD3- subsets in response to acute exercise in T1D and control participants 
 
There was an overall change over time in total CD3- lymphocytes during moderate intensity 
exercise (p=0.002), and this was seen in the control group only (p=0.013). Total CD3- 
lymphocytes significantly increased post exercise overall (p=0.003) and in the control group 
(p=0.13). Total CD3- lymphocytes significantly changed during vigorous intensity exercise 
overall (p<0.001), and in both the control (p<0.001) and T1D (p<0.001) groups. There was an 
overall significant increase post exercise (p<0.001), and this was seen in T1D (p<0.001) and 
control (p<0.001) groups independently. However, the magnitude of the response post exercise 
showed a trend to be different between groups (p=0.066) (time*group) as there is a larger 
increase post exercise in the control group (T1D: 66.7%, control: 114.4%). A trend in 
difference between groups (time*group) was also seen in the change overtime (p=0.061) (Table 
15). 
There was an overall change over time in NK cells during moderate intensity exercise 
(p=0.002), and this was seen in the T1D group only (p=0.010). There was a significant increase 
post moderate exercise overall (p=0.001), and in the T1D group (p=0.035) with a trend to 
increase post moderate exercise in the control group (p=0.052). The observed contrast in 
response to moderate exercise was significantly different between groups (p=0.036) 
(time*group). The magnitude of the response post moderate exercise was significantly different 
between groups (p=0.032) because there was a larger increase in NK cells in T1D participants 
at this time point (T1D: 125.4%, control: 96.65%). NK cells significantly mobilised during 
vigorous intensity exercise overall (p=0.002), and this was seen in control (p=0.021) and T1D 
(p=0.005) groups independently. NK cells were significantly increased post vigorous exercise 
overall (p=0.003) and in both groups independently (T1D: p=0.044, control: p=0.021). The 




control: 174.13%) but this was not significantly different between groups. There was a 
significant fall below baseline overall (p=0.010), and a trend to decrease in the control 
(p=0.051) at this time point but not the T1D group (Figure 17d) (Table 15).  
There was an overall change in B cells during vigorous intensity exercise (p=0.045), but this 
was only seen in the control group (p=0.008). B cells did not significantly increase post 
vigorous exercise in either group. However, there was a significant decrease 1 hour post 
exercise in the control group only (p=0.012). There was no significant mobilisation of B cells 
during moderate intensity exercise, however an overall trend to mobilise was seen (p=0.063). 
The mobilisation of B cells also showed a trend to be different between groups (p=0.063) 




Figure 17 Lymphocyte populations during moderate and vigorous exercise in control and T1D groups 
Flow cytometry and whole blood cell counts were used to determine the frequency of lymphocyte populations in 
control and T1D participants during moderate and vigorous intensity exercise. (a) Frequency of lymphocytes (b) 
frequency of CD4+ T cells (c) frequency of CD8+ T cells (d) frequency of NK cells and (e) the frequency of B 
cells during moderate and vigorous intensity exercise. Error bars represent SEM. Statistical significance 






Table 15 Lymphocytes populations mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of lymphocytes populations for control and T1D participants during moderate and vigorous intensity exercise Significant 
results highlighted in bold where p values <0.05 were considered significant. 
Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1controls CD3+/- n=38, CD4+ n=18-22, CD8+ n=10-12, NK cells n=10, B cells n=4. 
2T1D CD3+/- n=20-30, CD4+ n= 8-17, CD8+ n=6-9, NK cells n=6-8, B cells n=2. 
dTime (overall) dTime*Group
Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
Lymphocytes moderate 1290.91 350.58 1754.55 759.43 1340.00 435.12 F(1.2, 12.1)= 4.177, p=0.058 T2 F(1, 10)= 5.202, p=0.046 35.92 1400.00 310.91 1814.29 893.36 1350.00 216.79 F(1.05, 5.3)= 3.405, p=0.074 T2 F(1, 5)= 2.925, p=0.148 29.59 F(1.2, 15.8)= 6.209, p=0.021 F(1.2, 15.8)= 0.230, p=0.667
T3 F(1, 10)= 0.013, p=0.912 3.80 T3 F(1, 5)= 4.000, p=0.102 3.57
vigorous 1400.00 445.18 2400.00 475.39 1233.33 336.65 F(1.26, 13.9)= 46.127, p<0.001 T2 F(1, 11)= 55.113, p<0.001 71.43 1355.56 235.11 2088.89 658.49 1255.56 174.01 F(1.1, 8.8)= 319.030, p=0.002 T2 F(1, 8)= 18.615, p=0.003 54.10 F(1.24, 22.4)= 74.637, p<0.001 F(1.24, 22.4)= 1.867, p=0.185
T3 F(1, 11)= 6.044, p=0.032 11.90 T3 F(1, 8)= 4.500, p=0.067 7.38
CD3+ moderate 739.78 337.59 1000.60 452.79 792.22 364.65 F(1.5, 46.4)= 7.594, p=0.003 T2 F(1, 31)= 10.426, p=0.003 35.26 886.87 326.51 1112.88 466.55 752.82 238.49 F(1.4, 18.1)= 5.206, p=0.025 T2 F(1, 13)= 2.211, p=0.161 25.48 F(1.5, 63.9)= 12.194, p<0.001 F(1.5, 63.9)= 2.235, p=0.129
T3 F(1, 31)= 1.211, p=0.280 7.09 T3 F(1, 13)= 6.277, p=0.026 15.12
vigorous 922.91 453.67 1311.97 483.18 775.68 343.18 F(1.6, 48.2)= 37.853, p<0.001 T2 F(1, 31)= 25.158, p<0.001 42.16 698.97 339.38 1051.24 440.65 600.20 332.16 F(1.1, 28.6)= 17.892, p<0.001 T2 F(1, 26)= 15.612, p=0.001 50.40 F(1.3, 74.4)= 51.340, p<0.001 F(1.3, 74.4)= 0.950, p=0.357
T3 F(1, 31)= 22.832, p<0.001 15.95 T3 F(1, 26)= 8.609, p=0.007 14.13
 -- CD4+ moderate 417.47 145.29 488.44 229.49 432.59 157.11 F(2, 30)= 0.873, p=0.428 T2 F(1, 15)= 1.484, p=0.242 14.53 525.02 168.51 636.07 213.75 410.10 114.35 F(1.1, 6.6)= 3.276, p=0.114 T2 F(1, 6)= 4.168, p=0.087 21.19 F(2, 42)= 3.201, p=0.051 F(2, 42)= 0.861, p=0.413
T3 F(1, 15)= 0.169, p=0.687 3.62 T3 F(1,6)= 1.696, p=0.241 21.89
vigorous 440.21 265.70 569.00 306.55 357.71 204.76 F(2, 34)= 9.354, p=0.001 T2 F(1, 17)= 3.019, p=0.100 29.26 341.50 234.21 481.75 284.29 341.14 209.30 F(1.8, 16.6)= 4.267, p=0.052 T2 F(1, 15)= 4.149, p=0.060 41.07 F(1.4, 45)= 11.752, p<0.001 F(1.4, 45)= 0.763, p=0.429
T3 F(1, 17)= 8.877, p=0.008 18.74 T3 F(1,15)= 1.216, p=0.287 0.10
 -- CD8+ moderate 448.95 149.11 626.88 335.59 480.60 162.84 F(2, 20)= 3.224, p=0.061 T2 F(1, 10)= 3.357, p=0.097 39.63 478.30 157.11 677.33 430.18 491.82 80.48 F(2,10)= 2.186, p=0.163 T2 F(1, 5)= 1.317, p=0.303 41.61 F (1, 17.1)= 0.315, p=0.597 F (1, 17.1)= 0.474, p=0.513
T3 F(1, 10)= 0.352, p=0.566 7.05 T3 F(1, 5)= 3.020, p=0.143 2.83
vigorous 329.85 165.90 460.90 178.81 229.11 98.35 F(2, 22)= 10.326, p=0.001 T2 F(1, 11)= 5.961, p=0.033 39.73 248.34 158.17 354.41 225.31 192.54 122.80 F(1.2, 9.7)= 7.791, p=0.016 T2 F(1, 8)= 6.021, p=0.040 42.71 F (2, 42)= 3.295, p=0.047 F (2, 42)= 0.126, p=0.882
T3 F(1, 11)= 7.253, p=0.021 30.54 T3 F(1, 8)= 4.942, p=0.057 22.47
CD3- moderate 616.22 416.03 799.23 535.95 599.74 408.74 F(1.6, 51.4)= 5.170, p=0.013 T2 F(1, 31)= 6.898, p=0.013 29.70 544.10 346.54 751.03 631.26 617.57 339.57 F(1.1, 14.9)= 3.269, p=0.087 T2 F(1, 13)= 3.354, p=0.090 38.03 F(1.6, 69.6)= 7.963, p=0.002 F(1.6, 69.6)= 0.383, p=0.634
T3 F(1, 31)= 0.172, p=0.681 2.68 T3 F(1, 13)= 1.022, p=0.330 13.50
vigorous 496.38 219.47 1064.24 519.78 453.08 272.30 F(1.4, 41.8)= 43.458, p<0.001 T2 F(1, 30)= 55.897, p<0.001 114.40 614.27 413.10 1023.82 531.45 645.71 451.19 F(1.6, 44.2)= 41.125, p<0.001 T2 F(1, 28)= 61.552, p<0.001 66.67 F(1.5, 83.9)= 79.996, p<0.001 F(1.5, 83.9)= 3.215, p=0.061
T3 F(1, 30)= 0.457, p=0.504 8.72 T3 F(1, 28)= 0.054, p=0.819 5.12
 -- NK cells (CD56+) moderate 122.67 69.29 241.24 187.31 103.63 59.06 F(1.1, 9)= 4.917, p=0.051 T2 F(1, 8)= 5.195, p=0.052 96.65 326.23 135.16 735.27 388.70 251.50 162.63 F(1.1, 5.1)= 7.441, p=0.010 T2 F(1, 5)= 8.185, p=0.035 125.38 F(1, 13.4)= 14.777, p=0.002 F(1, 13.4)= 5.366, p=0.036
T3 F(1, 8)= 0.225, p=0.648 15.53 T3 F(1, 5)= 1.965, p=0.220 22.91
vigorous 164.22 101.76 450.18 345.08 119.25 72.19 F(1.1, 7.1)= 8.584, p=0.021 T2 F(1, 7)= 8.710, p=0.021 174.13 183.29 62.26 367.47 173.00 154.55 40.17 F(2, 8)= 11.212, p=0.005 T2 F(1, 4)= 8.402, p=0.044 100.49 F(1, 11.4)= 14.696, p=0.002 F(1, 11.4)= 0.118, p=0.748
T3 F(1, 7)= 5.549, p=0.051 27.38 T3 F(1, 4)= 5.026, p=0.088 15.68
 -- B cells (CD19+) moderate 114.38 51.46 153.51 65.02 109.92 76.97 F(2, 12)= 3.634, p=0.058 T2 F(1, 6)= 7.323, p=0.035 34.21 105.60 56.64 97.22 68.90 87.72 87.80 F(2, 2)= 2.950, p=0.253 T2 F(1, 1)= 1.305, p=0.458 7.94 F(2, 14)= 1.458, p=0.266 F(2, 14)= 1.010, p=0.389
T3 F(1, 6)= 1.047, p=0.346 3.90 T3 F(1, 1)= 6.643, p=0.236 16.94
vigorous 147.66 93.61 236.23 68.43 112.99 73.44 F(2, 10)= 7.468, p=0.010 T2 F(1, 5)= 2.992, p=0.144 59.98 80.36 36.61 180.64 153.89 68.38 3.68 F(1, 2)= 1.219, p=0.469 T2 F(1, 1)= 1.462, p=0.440 124.78 F(1.2, 7.1)= 6.398, p=0.036 F(1.2, 7.1)= 0.139, p=0.760
T3 F(1, 5)= 7.662, p=0.039 23.48 T3 F(1, 1)= 0.265, p=0.698 14.91
ccontrast
1Controls 2T1D




4.3.1.5 NK cell subsets in response to acute exercise in T1D and control participants 
 
NK cell subsets were defined using the markers CD56 and CD16; CD56dimCD16bright, 
CD56brightCD16dim, CD56dimCD16dim, CD56brightCD16-, and CD56-CD16+. The mean, standard 
deviation, and statistical analyses are displayed in Table 16.  
There was an overall change over time in CD56dimCD16bright NK cells during moderate 
intensity exercise (p=0.030), and this was seen in the T1D (p=0.009) group only. There was a 
significant increase post moderate exercise overall (p=0.028) and in the T1D group (p=0.041). 
CD56dimCD16bright NK cells mobilised significantly during vigorous intensity exercise overall 
(p<0.001) and in both groups independently (T1D: p=0.049, controls: p=0.001). 
CD56dimCD16bright NK cells were significantly increased post vigorous exercise overall 
(p<0.001) and in the control group only (p=0.001). The magnitude of response post exercise 
was much larger in control participants (T1D: 97.06%, control: 185.12%) but this difference 
was not significant between groups (time*group) (Figure 18a) (Table 16).  
There was an overall change over time in CD56brightCD16dim during moderate intensity exercise 
(p=0.030), and this was seen in the T1D (p=0.008) group only. There was a significant increase 
post moderate exercise in the T1D group (p=0.043). CD56brightCD16dim NK cells mobilised 
significantly during vigorous intensity exercise overall (p=0.001) and in the control group 
(p=0.002), but only a trend to change over time was seen in the T1D group (p=0.07). There 
was a significant increase post vigorous exercise overall (p=0.002) and in the control group 
(p=0.006) (Figure 18b) (Table 16). 
There was an overall change over time in CD56dimCD16dim NK cells during moderate intensity 
exercise (p<0.001) and in the T1D group (p=0.018), with a trend to mobilise seen in control 
group (p=0.055). There was a significant increase post moderate exercise overall (p=0.001), 




was much larger in T1D participants (T1D: 168.5%, control: 22.74%) and this was significantly 
different group at this time point (p=0.025) (time*group) and overall (p=0.024). 
CD56dimCD16dim NK cells significantly mobilised during vigorous intensity exercise overall 
(p=0.009), but this was seen only in the control group (p=0.015). CD56dimCD16dim NK cells 
were significantly increased post vigorous exercise overall (p=0.007) and in the control group 
(p=0.025), but not the T1D group (Figure 18c) (Table 16). 
There was an overall change over time in CD56brightCD16- NK cells during moderate intensity 
exercise (p=0.005) and in the T1D group (p=0.037), with a trend to mobilise seen in control 
group (p=0.059). There was a significant increase post moderate exercise in the T1D group 
only (p=0.032). However, there was a significant decrease below baseline 1 hour post exercise 
in the control group only (p=0.038). CD56brightCD16- NK cells significantly mobilised during 
vigorous intensity exercise overall (p<0.001) and in both groups independently (T1D: p=0.012, 
control: p=0.001). There was a significant increase post vigorous exercise overall (p<0.001) 
and in both groups (T1D: p=0.029, control: p=0.004) (Figure 18d) (Table 16). 
There was an overall change over time in CD56-CD16+ cells during moderate intensity exercise 
(p=0.005) but this was seen in the control group only (p=0.047). There was a significant 
increase post exercise overall (p=0.006) and in the control group only (p=0.026). CD56-CD16+ 
NK cells significantly mobilised during vigorous intensity exercise overall (p=0.020), but this 
was seen in the control group only (p=0.005). There was a significant increase post exercise 
overall (p=0.001) and in the control group only (p=0.004) (Table 16). 
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Figure 18 NK cell subsets during moderate and vigorous exercise in control and T1D groups 
Flow cytometry and whole blood cell counts were used to determine the frequency of NK cell subsets in control 
and T1D participants during moderate and vigorous intensity exercise. (a) Frequency of CD56dimCD16bright (b) 
frequency of CD56brightCD16dim (c) frequency of CD56dimCD16dim (d) frequency of CD56brightCD16- NK 
cells during moderate and vigorous intensity exercise. Error bars represent SEM. Statistical significance 






Table 16 NK cell subsets mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of NK cell subsets for control and T1D participants during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 





Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%





moderate 94.88 100.01 396.61 449.08 75.54 96.61 F(1, 7)= 3.807, p=0.092 T2 F(1, 7)= 4.003, p=0.086 318.01 70.91 36.01 286.25 178.41 39.87 33.71 F(2, 6 )= 11.175, p=0.009 T2 F(1, 3)= 11.909, p=0.041 303.66 F(1, 10.1)= 6.379, p=0.030 F(1, 10.1)= 0.008, p=0.992
T3 F(1, 7)= 1.279, p=0.295 20.38 T3 F(1, 3)= 2.501, p=0.212 43.77
vigorous 72.85 34.95 207.70 106.46 53.35 43.13 F(1.1, 7.5)= 27.545, p=0.001 T2 F(1, 7)= 29.471, p=0.001 185.12 104.38 47.47 205.69 120.49 78.18 51.31 F(2, 12 )= 3.929, p=0.049 T2 F(1, 6)= 3.345, p=0.117 97.06 F(1.4, 18.2)= 22.237, p<0.001 F(1.4, 18.2)= 2.113, p=0.159





moderate 2.69 1.38 4.93 4.79 2.54 1.45 F(1, 7.2)= 2.798, p=0.137 T2 F(1, 7)= 2.391, p=0.166 83.14 1.72 1.14 2.99 1.84 1.63 1.42 F(2, 6 )= 12.130, p=0.008 T2 F(1, 3)= 11.372, p=0.043 74.34 F(2, 20)= 4.184, p=0.030 F(2, 20)= 0.062, p=0.940
T3 F(1, 7)= 1.810, p=0.220 5.51 T3 F(1, 3)= 0.013, p=0.916 5.00
vigorous 3.63 3.14 5.62 4.52 3.28 2.55 F(2, 14)= 10.682, p=0.002 T2 F(1, 7)= 15.235, p=0.006 54.79 3.35 1.32 5.31 2.83 2.45 0.82 F(2, 12 )= 3.340, p=0.070 T2 F(1, 6)= 2.911, p=0.139 58.34 F(1.4, 17.9)= 12.477, p=0.001 F(1.4, 17.9)= 0.662, p=0.473





moderate 27.60 29.14 33.87 31.24 22.15 25.28 F(2, 14)= 3.602, p=0.055 T2 F(1, 7)= 2.676, p=0.146 22.74 9.42 4.33 25.30 18.80 7.50 5.32 F(2, 6 )= 8.413, p=0.018 T2 F(1, 3)= 17.656, p=0.025 168.50 F(2, 20)= 15.736, p<0.001 F(2, 20)= 4.502, p=0.024
T3 F(1, 7)= 1.321, p=0.288 19.72 T3 F(1, 3)= 2.169, p=0.237 20.36
vigorous 14.17 12.58 30.29 26.43 11.93 9.88 F(1.2, 8.2)= 8.822, p=0.015 T2 F(1, 7)= 8.095, p=0.025 113.78 14.81 6.47 20.51 12.72 20.60 22.54 F(1.1, 6.3 )= 0.385, p=0.689 T2 F(1, 6)= 3.877, p=0.096 38.54 F(2, 26)= 5.679, p=0.009 F(2, 26)= 2.657, p=0.089





moderate 78.39 74.13 93.73 87.71 64.55 69.07 F(2, 14)= 3.484, p=0.059 T2 F(1, 7)= 0.075, p=0.792 19.57 116.46 88.20 166.46 104.64 93.67 50.05 F(2, 6 )= 5.976, p=0.037 T2 F(1, 3)= 14.489, p=0.032 42.93 F(2, 20)= 7.083, p=0.005 F(2, 20)= 2.565, p=0.102
T3 F(1, 7)= 6.548, p=0.038 17.65 T3 F(1, 3)= 0.232, p=0.663 19.57
vigorous 59.03 52.93 93.16 109.78 40.12 41.74 F(2, 14)= 13.011, p=0.001 T2 F(1, 7)= 17.043, p=0.004 57.81 71.46 48.75 162.20 201.27 84.84 86.38 F(2, 12 )= 6.493, p=0.012 T2 F(1, 6)= 8.078, p=0.029 126.98 F(2, 26)= 17.607, p<0.001 F(2, 26)= 0.471, p=0.630





moderate 16.35 20.51 25.15 30.78 23.47 30.95 F(2, 12)= 4.004, p=0.047 T2 F(1, 6)= 8.607, p=0.026 53.82 10.52 18.13 15.71 25.65 12.10 20.93 F(2, 6 )= 2.974, p=0.127 T2 F(1, 3)= 4.344, p=0.128 49.42 F(2, 18)= 7.362, p=0.005 F(2, 18)= 1.875, p=0.182
T3 F(1, 6)= 0.808, p=0.403 43.51 T3 F(1, 3)= 0.941, p=0.404 15.02
vigorous 22.29 27.52 36.13 43.37 28.28 28.36 F(2, 14)= 7.781, p=0.005 T2 F(1, 7)= 18.022, p=0.004 62.10 8.35 8.58 12.80 13.36 11.98 16.08 F(2, 12 )= 2.076, p=0.168 T2 F(1, 6)= 4.559, p=0.077 53.38 F(1.4, 18.4)= 5.590, p=0.020 F(1.4, 18.4)= 0.778, p=0.432











4.3.2 Migratory capacity of peripheral blood lymphocyte populations in 
T1D and control participants 
 
3.2.1 Lymphocyte transendothelial migration and migratory capacity at rest 
 
Transendothelial migration (TEM) of lymphocytes was measured at rest in T1D and control 
participants. The percentage TEM of lymphocytes showed a trend to be higher in the T1D 
group than control group (p=0.061) (Figure 19a). The total adherence of lymphocytes was not 
significantly different between groups (Figure 19b) (Table 17).  
 
  
Table 17 Transendothelial migration of lymphocytes at baseline in T1D and controls. 
Mean and standard deviation values for the percentage behaviour of transendothelial migration and total 
adherence of lymphocytes in controls and T1D participants. 
1controls n=16, 2T1D n=16 
 
The homing propensity and migratory capacity of total CD3+ and CD3- lymphocyte 
subpopulations were measured using the expression of the following adhesion molecules and 
chemokine receptors; CD11b, LFA-1, CXCR3, CCR6, CCR4, and CD62L. The mean and 
standard deviations values are displayed in Table 18. 
The frequency of CD3+CXCR3+ cells was significantly lower in T1D (p=0.033), but there was 
no significant difference in the proportion of this subset between groups (Figure 19a and b). 
However, the proportion of CD3-CXCR3+ cells were significantly higher in T1D (p=0.043), 
but there was no significant difference in the frequencies of this subset between groups (Figure 
19c and d). The frequency of CD3-LFA-1+ cells showed a trend to decrease in the T1D group 
(p=0.064). However, the frequency of CD3+LFA-1+ cells showed a trend to increase in the T1D 
group (p=0.064), and a small trend in the proportion of this subset (p=0.085). There were no 
Subset
mean SD mean SD
Percentage TEM 26.77 11.36 33.70 7.83
Total adherence 300.29 194.23 245.63 100.30
1Controls 2T1D
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differences between groups in CD11b, CCR6, CCR4 or CD62L expression by CD3+ and CD3- 
lymphocytes (Table 18). This data provides evidence of an imbalance in adhesion molecules 
on lymphocyte subpopulations in T1D.  
 
Figure 19 The proportion and frequency adhesion molecules expressed by lymphocyte subsets at baseline 
in T1D and control groups. 
Flow cytometry and whole blood cell counts were used to determine the frequency of CD11b, LFA-1, CXCR3, 
CCR6, CCR4, and CD62L expression by lymphocyte subsets in control and T1D participants at baseline. (a) 
Proportion of adhesion molecules expressed by CD3+ cells (b) Frequency of adhesion molecules expressed by 
CD3+ cells (c) Proportion of adhesion molecules expressed by CD3- cells (d) Frequency of adhesion molecules 
expressed by CD3- cells. (e) Proportion of LFA-1 expressed by NK cell subsets (f) Frequency of LFA-1 expressed 
by NK cell subsets. Error bars represent SEM. Statistical significance represented by * p<0.05, ** p<0.01, 







Table 18 Adhesion molecule and chemokine receptor expression by CD3+ and CD3- lymphocytes at baseline in T1D and control participants 
Mean and standard deviation values for the proportion and frequency of adhesion molecules expressed by CD3+ and CD3- lymphocytes populations in control and T1D 
participants. 
1controls CD11b n=22, LFA-1 n=20, CXCR3 n=18, CCR6 n= 20, CCR4 n=19, CD62L n= 9. 
2T1D CD11b n=13, LFA-1 n=14, CXCR3 n=10, CCR6 n=14, CCR4 n=9, CD62L n= 3. 
CD11b LFA-1 CXCR3 CCR6 CCR4 CD62L
mean SD mean SD mean SD mean SD mean SD mean SD
CD3+ (%) 8.02 7.97 35.04 27.16 50.01 17.11 16.88 8.49 17.96 17.38 66.68 9.42
           (cells/μl) 65.76 54.58 283.38 278.45 421.36 284.61 141.56 110.29 158.02 195.07 431.35 347.67
CD3- (%) 25.11 16.41 28.51 27.01 10.04 7.72 30.11 19.88 12.89 19.18 39.43 22.59
           (cells/μl) 100.44 68.26 105.17 83.56 53.09 43.91 140.40 87.95 82.45 151.32 307.84 308.50
CD3+ (%) 16.01 19.27 55.19 40.08 41.65 27.32 21.98 12.34 16.83 9.59 64.53 23.08
           (cells/μl) 170.81 204.96 486.01 435.55 203.26 147.23 137.96 104.70 74.41 48.02 535.51 360.50
CD3-  (%) 31.76 17.10 36.48 27.18 17.59 12.36 37.85 27.69 21.98 24.53 38.93 23.71






The homing propensity and migratory capacity of NK cell subpopulations was measured using 
the surface expression of the LFA-1 on NK cell subsets; CD56brightCD16dim, CD56dimCD16dim, 
CD56dimCD16dim, CD56brightCD16-, and CD56-CD16+ (Table 19) (Figure 19e and f).  
The proportion of CD56dimCD16dim NK cells expressing LFA-1 was significantly elevated in 
the T1D group (p=0.006), but no significant difference in the frequencies of this subset were 
observed between groups (Figure 19a). There were no differences in LFA-1 expression 
between groups on CD56brightCD56dim, CD56dimCD16dim, CD56brightCD16-, and CD56-CD16+ 
NK cell subsets (Figure 19e and f). The mean and standard deviations values are displayed in 
Table 19.  
 
  
Table 19 LFA-1 expression by NK cell subsets at baseline in T1D and controls. 
Mean and standard deviation values for the proportion and frequency of LFA-1+ NK cell subsets in control and 
T1D participants. 
1controls n=20, 2T1D n=14 
  
Subset
mean SD mean SD
CD56dimCD16bright (%) 18.76 11.35 21.63 14.05
                               (cells/μl) 74.58 55.41 107.64 73.07
CD56brightCD16dim  (%) 28.33 36.72 42.24 37.78
                               (cells/μl) 0.51 0.67 2.06 2.63
CD56dimCD16dim    (%) 34.31 26.63 61.04 26.06
                               (cells/μl) 3.51 2.94 15.50 17.37
CD56+CD16-        (%) 18.89 25.36 34.60 29.92
                               (cells/μl) 9.37 10.54 28.53 29.58
CD56-CD16+        (%) 22.13 27.19 38.51 30.35





4.3.2.2 Lymphocyte transendothelial migration in response to acute exercise in T1D and 
control participants 
 
Transendothelial migration (TEM) and total adherence (ADH) of lymphocytes was measured 
during moderate (40% VO2 max) and vigorous (80% VO2 max) acute exercise in T1D and 
control participants.  
There was a significant change over time in the TEM of lymphocytes during vigorous intensity 
exercise overall (p=0.001), but this was observed for the T1D group only (p=0.001) (Figure 
20e). TEM was significantly reduced 1 hour post vigorous exercise overall (p=0.007) and in 
the T1D group (p=0.018). There was a significant decrease with adiponectin treatment overall 
(p=0.035), but this was seen only as a trend to decrease in the T1D group (p=0.060). There was 
no change in TEM during moderate intensity exercise for either group (Table 20) (Figure 20c).  
There was a significant change over time in the total ADH of lymphocytes to endothelial cells 
during vigorous intensity exercise overall (p=0.020), but this was seen in the T1D group only 
(p=0.027). There was a significant decrease in total ADH with adiponectin treatment overall 
(p=0.004), but this was seen only in the T1D group (p=0.003) (Figure 20f). There was no 
change in TEM during moderate intensity exercise. There was a significant decrease in total 
ADH with adiponectin treatment overall (p=0.001), but this was seen only in the control group 
(p=0.004) (Table 20) (Figure 20d). 
In summary, TEM and total ADH of lymphocytes is affected by vigorous intensity exercise in 
the T1D group only.  
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Figure 20 The percentage transmigration and total adherence by lymphocytes at baseline, and during moderate and vigorous intensity exercise in T1D and control 
participants. 
Transendothelial migration of lymphocytes was in control and T1D participants at baseline, and during moderate and vigorous intensity exercise. (a) Percentage transmigration 
of lymphocytes at baseline (b) Total adherence of lymphocytes at baseline (c) Percentage transmigration of lymphocytes at during moderate intensity (d) Total adherence of 
lymphocytes at during moderate intensity (e) Percentage transmigration of lymphocytes at during vigorous intensity (f) Total adherence of lymphocytes at during vigorous 







Table 20 Transendothelial migration and total adherence of lymphocytes during moderate and vigorous intensity exercise in control and T1D participants 
Mean, standard deviation, and statistical analysis of NK cell subsets for control and T1D participants during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 




Intensity Adipo bTime aΔ% Adipo bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD mean SD mean SD
Percentage TEM moderate 26.48 7.059 28.84 10.98 24.72 9.2202 24.67 11.12 F(2, 14)= 0.778, p=0.478 T2 F(1, 7)= 0.384, p=0.555 8.91 33.22 7.11 33.20 7.85 30.25 9.28 29.30 12.77 F(2, 10)= 0.635, p=0.550 T2 F(1, 5)= 0.361, p=0.574 0.08 F(2, 24)= 0.932, p=0.408 F(2, 24)= 0.412, p=0.667
T3 F(1, 7)= 0.593, p=0.467 6.63 T3 F(1, 5)= 0.847, p=0.400 8.95
adipo F(1, 7)= 0.775, p=0.408 6.83 adipo F(1, 5)= 0.948, p=0.375 11.81
vigorous 27.07 14.42 27.65 14.29 20.89 10.56 17.91 4.887 F(2, 14)= 3.004, p=0.082 T2 F(1, 6)= 0.056, p=0.821 2.15 34.18 8.46 36.93 7.97 28.92 10.41 25.86 10.45 F(2, 14)= 6.826, p=0.009 T2 F(1, 7)= 1.706, p=0.233 8.06 F(2, 28)= 8.452, p=0.001 F(2, 28)= 0.167, p=0.847
T3 F(1, 6)= 2.833, p=0.143 22.83 T3 F(1, 7)= 9.493, p=0.018 15.38
adipo F(1, 6)= 1.401, p=0.281 33.83 adipo F(1, 7)= 5.019, p=0.060 24.34
Total adherence moderate 340.75 213.15 357.63 153.23 325.13 156.46 195.13 138.16 F(2, 14)= 0.310, p=0.738 T2 F(1, 7)= 0.139, p=0.721 4.95 222.75 64.36 235.00 94.00 198.00 67.12 154.25 44.22 F(2, 10)= 0.434, p=0.660 T2 F(1, 5)= 0.144, p=0.720 5.50 F(2, 24)= 0.760, p=0.479 F(2, 24)= 0.031, p=0.970
T3 F(1, 7)= 0.104, p=0.757 4.59 T3 F(1, 5)= 0.298, p=0.609 11.11
adipo F(1, 7)= 17.902, p=0.004 42.74 adipo F(1, 5)= 4.272, p=0.094 30.75
vigorous 264.33 167.72 303.22 148.68 246.78 187.88 160.11 101.06 F(2, 14)= 0.534, p=0.598 T2 F(1, 7)= 0.767, p=0.410 14.71 268.50 122 347.88 103.6 206.00 80.1 163.25 83.5 F(2, 10)= 4.705, p=0.027 T2 F(1, 7)= 2.391, p=0.166 29.56 F(2, 28)= 4.494, p=0.020 F(2, 28)= 1.623, p=0.215
T3 F(1, 7)= 0.005, p=0.946 6.64 T3 F(1, 7)= 2.489, p=0.159 23.28
adipo F(1, 7)= 3.460, p=0.105 39.43 adipo F(1, 7)= 19.807, p=0.003 39.20
ccontrast
1Controls 2T1D




4.3.2.3 CD3+ subsets migratory capacity in response to acute exercise in T1D and 
control participants 
 
The homing propensity and migratory capacity of total CD3+ lymphocytes was measured 
during moderate (40% VO2 max) and vigorous (80% VO2 max) acute exercise using the 
expression of the following adhesion molecules and chemokine receptors; CD11b, LFA-1, 
CXCR3, CCR6, CCR4, and CD62L. The mean, standard deviation and statistical analysis are 
displayed in Table 21.  
CD11b 
CD3+CD11b+ cells significantly mobilised during vigorous intensity exercise overall 
(p=0.002), and in both groups independently (T1D: p=0.046, control: p<0.001). There was a 
significant increase post vigorous exercise in the control group only (p<0.001). A significant 
decrease below baseline 1 hour post vigorous exercise was seen overall (p=0.001), but this was 
seen in the T1D only (p=0.011). This response 1 hour post vigorous exercise was significantly 
different between groups (p=0.009) (time*group) because there was a much larger decrease 
below baseline in the T1D group at this time point (T1D: 42.3%, control: 9.09%) (Figure 21a). 
There was no significant mobilisation of CD3+CD11b+ cells during moderate intensity 
exercise.  
LFA-1 
There was no significant mobilisation of CD3+LFA-1+ cells during moderate or vigorous 
intensity exercise in either group (Table 21).  
CXCR3 
CD3+CXCR3+ cells significantly mobilised during vigorous intensity exercise overall 
(p=0.003), but this was seen in the control group only (p=0.006). There was a significant 




group (p=0.058). This was followed by a significant decrease below baseline 1 hour post 
vigorous exercise (p=0.035) overall, with a trend to decrease seen in the control group 
(p=0.071) (Figure 21b). There was no significant mobilisation of CD3+CXCR3+ cells during 
moderate intensity exercise.  
CCR6 
CD3+CCR6+ cells significantly mobilised during moderate intensity exercise overall 
(p=0.032), and in both groups (T1D: p=0.023, control: p=0.049). There was a significant 
increase post moderate exercise in the T1D group only (p=0.008), with a small trend to increase 
seen in the control group (p=0.075). There was a significant decrease below baseline 1 hour 
post moderate exercise overall (p=0.023), but this was only seen in the control group (p=0.038) 
(Table 21). CD3+CCR6+ cells significantly changed over time during vigorous intensity 
exercise overall (p<0.001), and in the control group (p<0.001), with a trend to mobilise seen in 
the T1D group (p=0.056). There was a significant increase post vigorous exercise overall 
(p<0.001), and in the control group (p= 0.000), with a trend to increase observed in the T1D 
group (p=0.056). This was followed by a significant decrease below baseline 1 hour post 
exercise overall (p<0.001), and in the control (p=0.002) and T1D (p=0.044) groups 
independently (Figure 21c).  
CCR4 
CD3+CCR4+ cells significantly mobilised during vigorous intensity exercise overall (p=0.002), 
and in the T1D (p=0.004) and control (p=0.014) groups independently. There was a significant 
increase post vigorous exercise overall (p=0.002), and in both the T1D (p=0.003) and control 
(p=0.014) groups. There was a significant decrease below baseline 1 hour post vigorous 
exercise overall (p=0.002), and in the T1D (p=0.004) and control (p=0.014) groups (Figure 
21d). There was no significant mobilisation of CD3+CCR4+ cells during moderate intensity 
exercise (Table 21).  
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CD62L
Data for CD3+CD62L+ cells is shown for the control group only due to missing data for the 
T1D group (Table 21). There was no significant change over time during vigorous intensity 
exercise. A decrease below baseline 1 hour post vigorous exercise was observed (p=0.046). 
There was no significant mobilisation of CD3+CD62L+ cells during moderate intensity 
exercise.  
 
Figure 21 Adhesion molecules expressed by CD3+ cells mobilised during vigorous exercise in control and 
T1D participants 
Flow cytometry and whole blood cell counts were used to determine the frequency of CD11b, CXCR3, CCR6, 
and CCR4 expression on CD3+ cells in control and T1D participants during vigorous intensity exercise. (a) 
Frequency of CD3+CD11b+ cells (b) frequency of CD3+CXCR3+ cells (c) frequency of CD3+CCR6+ cells (d) 
frequency of CD3+CCR4+ cells during vigorous intensity exercise. Error bars represent SEM. Statistical 








Table 21 CD3+ lymphocytes mobilised during moderate and vigorous intensity exercise in control and T1D participants 
Mean, standard deviation, and statistical analysis of CD3+ lymphocytes for control and T1D participants during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1controls CD11b n=11, LFA-1 n=10, CXCR3 n=7-11, CCR6 n= 9-11, CCR4 n=19, CD62L n= 4-5. 
2T1D CD11b n= 4-8, LFA-1 n=5-9, CXCR3 n=4-7, CCR6 n=7, CCR4 n=7, CD62L n= 1-2. 
dTime (overall) dTime*Group
Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
CD3+CD11b+ moderate 69.74 62.58 95.77 100.50 62.14 77.36 F(1.3, 11.153)= 3.301, p=0.090 T2 F(1, 9)= 0.013, p=0.911 37.32 274.97 144.10 335.53 147.25 249.91 149.96 F(2, 6 )= 1.373, p=0.323 T2 F(1, 3)= 3.190, p=0.172 22.03 F(1.3, 16)= 2.132, p=0.161 F(1.3, 16)= 0.933, p=0.377
T3 F(1, 9)= 3.466, p=0.096 10.90 T3 F(1, 3)= 0.000, p=0.985 9.11
vigorous 59.80 42.10 117.95 80.44 54.36 37.35 F(2, 18)= 17.796, p<0.001 T2 F(1, 9)= 29.527, p<0.001 97.23 135.33 208.68 82.47 46.41 78.08 129.36 F(2, 12 )= 4.007, p=0.046 T2 F(1, 6)= 0.183, p=0.684 39.06 F(1.3, 19.3)= 22.464, p=0.002 F(1.3, 19.3)= 2.096, p=0.161
T3 F(1, 9)= 2.153, p=0.176 9.09 T3 F(1, 6)= 13.373, p=0.011 42.30
CD3+LFA1+ moderate 252.37 221.36 375.33 333.87 240.18 220.35 F(1.1, 7.8)= 2.983, p=0.122 T2 F(1, 7)= 0.694, p=0.432 48.72 370.77 354.31 404.64 280.41 387.61 361.16 F(1, 3)= 3.014, p=0.181 T2 F(1, 3)= 8.561, p=0.061 9.14 F(2, 20)= 6.781, p=0.006 F(2, 20)= 0.715, p=0.501
T3 F(1, 7)= 1.382, p=0.278 4.83 T3 F(1, 3)= 1.732, p=0.280 4.54
vigorous 293.66 329.12 474.92 426.27 294.71 215.22 F(2, 14)= 1.739, p=0.212 T2 F(1, 7)= 2.796, p=0.138 61.73 580.84 409.29 565.19 338.03 529.31 465.31 F(2, 12 )= 2.564, p=0.118 T2 F(1, 6)= 0.001, p=0.974 2.69 F(2, 26)= 2.877, p=0.074 F(2, 26)= 1.181, p=0.323
T3 F(1, 7)= 0.43, p=0.841 0.36 T3 F(1, 6)= 2.151, p=0.193 8.87
CD3+CXCR3+ moderate 468.22 239.25 509.08 279.29 464.01 221.56 F(2, 10)= 0.082, p=0.922 T2 F(1, 5)= 0.052, p=0.829 8.73 112.03 57.99 174.07 118.37 98.61 21.42 F(2, 4 )= 1.077, p=0.422 T2 F(1, 2)= 2.082, p=0.286 55.38 F(2, 14)= 0.583, p=0.571 F(2, 14)= 0.171, p=0.845
T3 F(1, 5)= 0.690, p=0.804 0.90 T3 F(1, 2)= 0.150, p=0.736 11.98
vigorous 391.54 294.07 621.30 351.46 319.44 222.92 F(2, 16)= 7.304, p=0.006 T2 F(1, 8)= 4.880, p=0.058 58.68 242.35 146.07 409.65 290.22 204.96 127.25 F(1.1, 6.6 )= 3.420, p=0.108 T2 F(1, 6)= 2.667, p=0.154 69.03 F(1.3, 18)= 10.007, p=0.003 F(1.3, 18)= 0.234, p=0.695
T3 F(1, 8)= 4.325, p=0.071 18.42 T3 F(1, 6)= 2.185, p=0.190 15.43
CD3+CCR6+ moderate 101.31 76.47 161.51 174.84 112.88 103.57 F(2, 12)= 3.921, p=0.049 T2 F(1, 6)= 4.609, p=0.075 59.42 131.50 42.33 262.98 296.39 128.82 60.01 F(2, 4 )= 11.065, p=0.023 T2 F(1, 2)= 125.133, p=0.008 99.98 F(2, 16)= 4.306, p=0.032 F(2, 16)= 0.164, p=0.850
T3 F(1, 6)= 6.986, p=0.038 11.41 T3 F(1, 2)= 10.489, p=0.084 2.04
vigorous 174.49 117.55 296.13 136.97 146.22 98.07 F(2, 16)= 25.744, p<0.001 T2 F(1, 8)= 32.771, p<0.001 69.71 144.42 135.95 275.09 281.24 122.45 115.29 F(1.1, 6.4 )= 5.364, p=0.056 T2 F(1, 6)= 5.616, p=0.056 90.49 F(1.2, 16.6)= 21.344, p<0.001 F(1.2, 16.6)= 0.090, p=0.809
T3 F(1, 8)= 22.150, p=0.002 16.20 T3 F(1, 6)= 6.491, p=0.044 15.21
CD3+CCR4+ moderate 171.51 229.00 191.77 233.51 215.74 258.05 F(1, 7)= 3.765, p=0.093 T2 F(1, 7)= 3.795, p=0.092 11.81 45.05 44.20 26.82 36.47 27.73 37.09 F(2, 2 )= 1.041, p=0.490 T2 F(1, 1)= 1.049, p=0.492 40.47 F(1, 8)= 1.347, p=0.288 F(1, 8)= 0.472, p=0.632
T3 F(1, 7)= 3.736, p=0.095 25.79 T3 F(1, 1)= 1.033, p=0.495 38.44
vigorous 148.20 154.59 273.48 289.59 102.11 109.62 F(1, 9)= 9.249, p=0.014 T2 F(1, 9)= 9.294, p=0.014 84.53 82.80 41.96 160.21 120.61 67.30 38.76 F(1, 6 )= 21.571, p=0.004 T2 F(1, 6)= 21.876, p=0.003 93.49 F(1, 15)= 13.590, p=0.002 F(1, 15)= 1.516, p=0.237
T3 F(1, 9)= 9.204, p=0.014 31.10 T3 F(1, 6)= 21.281, p=0.004 18.72
CD3+CD62L+ moderate 274.11 130.57 491.99 241.95 262.02 151.61 F(2, 6)= 1.120, p=0.528 T2 F(1, 3)= 1.409, p=0.321 79.49 F(2, 6)= 2.952, p=0.128
T3 F(1, 3)=  0.035, p=0.861 4.41
vigorous 627.92 388.45 912.97 492.10 478.26 347.20 F(2, 4)= 2.311, p=0.215 T2 F(1, 2)= 1.013, p=0.420 45.40 F(2, 4)= 2.949, p=0.163
T3 F(1, 2)=  20.076, p=0.046 23.83
ccontrast
1Controls 2T1D




4.3.2.4 CD3- subsets migratory capacity in response to acute exercise in T1D and control 
participants 
 
The homing propensity and migratory capacity of total CD3- lymphocytes was measured 
during moderate (40% VO2 max) and vigorous (80% VO2 max) acute exercise using the 
expression of the following adhesion molecules and chemokine receptors; CD11b, LFA-1, 
CXCR3, CCR6, CCR4, and CD62L. The mean, standard deviation and statistical analysis are 
displayed in Table 22. 
CD11b 
CD3-CD11b+ cells significantly mobilised during moderate intensity exercise overall 
(p=0.013), and in the T1D group (p=0.034), with a trend to mobilise seen in the control group 
(p=0.060). There was a significant increase post moderate exercise overall (p=0.016), with a 
trend to increase seen in the T1D (p=0.064) and control group (p=0.071). CD3-CD11b+ 
significantly changed over time during vigorous intensity exercise overall (p=0.012), but this 
was only significant in the control group (p=0.038). CD3-CD11b+ cells significantly increased 
post vigorous exercise overall (p=0.015), and in the control group (p=0.040). This was 
followed by a significant decrease below baseline 1 hour post vigorous exercise overall 
(p<0.001), and in the T1D (p<0.001) and control (p=0.030) groups (Figure 22a).  
LFA-1 
CD3-LFA-1+ cells significantly mobilised during moderate intensity exercise overall 
(p=0.014), but this was only significant in the control group (p=0.026). There was a trend to 
increase post moderate exercise in the control group (p=0.053). There was a significant 
difference 1 hour post moderate exercise overall (p=0.007), and this response was significantly 
different between groups (p=0.002) (time*group) because there was a decrease below baseline 




control group. CD3+LFA-1+ cells significantly mobilised during moderate intensity exercise 
overall (p=0.002), and in both groups independently (T1D: p=0.001, control: p=0.048). There 
was a significant increase post moderate exercise overall (p=0.002), and in both groups (T1D: 
p=0.016, control: p=0.035) (Figure 22b). 
CXCR3 
CD3-CXCR3+ cells significantly mobilised during vigorous intensity exercise overall 
(p=0.001), and in the control group only (p=0.008), with a trend to mobilise in the T1D group 
(p=0.061). There was a significant increase post vigorous exercise overall (p=0.003), and in 
the control group (p=0.012), with a trend to increase observed in the T1D group (p=0.076). 
This was followed by a significant decrease below baseline 1 hour post vigorous exercise in 
the control group only (p=0.041). There was no significant mobilisation of CD3-CXCR3+ cells 
during moderate intensity exercise (Table 22).  
CCR6 
There was a significant change over time in CD3-CCR6+ cells during vigorous intensity 
exercise overall (p=0.001), and in the control group (p<0.001), with a trend to mobilise seen in 
the T1D group (p=0.058). CD3-CCR6+ cells significantly increased post vigorous exercise 
overall (p=0.003), and in the control group (p= 0.003). This was followed by a significant fall 
below baseline 1 hour post vigorous exercise overall (p=0.0016), and in the control (p=0.030) 
group. CD3-CCR6+ cells significantly mobilised during moderate intensity exercise overall 
(p=0.014), but this was not seen in either the T1D or control group independently. A trend to 
mobilise was seen in the T1D group (p=0.071) (Figure 22c).  
CCR4 
Data for CD3-CCR4+ cells during moderate intensity exercise is shown for the control group 




exercise in the control group. During vigorous intensity exercise, there was significant 
mobilisation of CD3-CCR4+ cells overall (p<0.001), but this was only significant in the control 
group (p=0.002). There was a significant increase post vigorous exercise overall (p=0.001), 
and in the control (p=0.005) group. This response post exercise was significantly different 
between groups (p=0.047) (time*group) because there was a much larger increase at this time 
point in the control group (T1D: 94.16%, control: 162.48%). This was supported by a trend in 
difference between groups overall (p=0.060) (time*group) (Table 22).  
CD62L 
Data for CD3-CD62L+ cells is shown for the control group only during moderate intensity 
exercise due to missing data for the T1D group (Table 22). There was no significant change 
over time during moderate intensity exercise in the control group.  
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Figure 22 Adhesion molecules expressed by CD3- cells mobilised during moderate and vigorous exercise in 
control and T1D participants 
Flow cytometry and whole blood cell counts were used to determine the frequency of CD11b, LFA-1, and CCR6 
expression on CD3- cells in control and T1D participants during moderate and vigorous intensity exercise. (a) 
Frequency of CD3-CD11b+ cells (b) frequency of CD3-LFA-1+ cells (c) frequency of CD3-CCR6+ cells during 
moderate and vigorous intensity exercise. Error bars represent SEM. Statistical significance represented by * 






Table 22 CD3- lymphocytes mobilised during moderate and vigorous intensity exercise in control and T1D participants 
Mean, standard deviation, and statistical analysis of CD3- lymphocytes for control and T1D participants during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1controls CD11b n=11, LFA-1 n=10, CXCR3 n=7-11, CCR6 n= 9-11, CCR4 n=19, CD62L n= 4-5. 





Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%




+ moderate 98.12 73.31 204.36 186.41 79.77 59.02 F(1.03, 9.3)= 4.541, p=0.060 T2 F(1, 9)= 4.184, p=0.071 108.28 138.94 64.27 268.95 138.87 124.08 56.64 F(2, 6 )= 6.226, p=0.034 T2 F(1, 3)= 8.257, p=0.064 93.57 F(1.1, 12.7)= 8.249, p=0.013 F(1.1, 12.7)= 0.211, p=0.667
T3 F(1, 9)= 0.853, p=0.380 18.70 T3 F(1, 3)= 0.608, p=0.492 10.70
vigorous 106.13 57.23 513.04 521.27 74.95 37.86 F(1, 9.1)= 5.864, p=0.038 T2 F(1, 9)= 5.741, p=0.040 383.42 133.10 70.95 363.47 327.03 92.90 78.02 F(1, 6 )= 3.526, p=0.109 T2 F(1, 6 )= 2.862, p=0.142 173.09 F(1, 15.1)= 8.193, p=0.012 F(1, 15.1)= 0.412, p=0.532




+ moderate 102.07 90.47 204.10 185.10 123.13 125.55 F(1.2, 9.7)= 4.636, p=0.026 T2 F(1, 8)= 5.147, p=0.053 99.95 221.96 111.37 274.31 172.80 159.45 71.13 F(2, 4 )= 4.309, p=0.100 T2 F(1, 2)= 0.297, p=0.641 23.58 F(1.3, 12.6)= 7.339, p=0.014 F(1.3, 12.6)= 2.350, p=0.147
T3 F(1, 8)= 0.640, p=0.447 20.63 T3 F(1, 2)= 8.430, p=0.101 28.16
vigorous 108.27 71.14 289.79 248.39 68.94 30.45 F(1, 7)= 5.730, p=0.048 T2 F(1, 7)= 6.756, p=0.035 167.67 139.50 91.53 253.87 154.86 108.02 133.45 F(2, 14 )= 11.840, p=0.001 T2 F(1, 7)= 9.886, p=0.016 81.99 F(1.2, 16.3)= 13.283, p=0.002 F(1.2, 16.3)= 0.454, p=0.539




+ moderate 52.94 30.96 89.94 69.39 62.63 41.20 F(1.1, 5.3)= 1.424, p=0.287 T2 F(1, 5)= 1.404, p=0.289 69.90 75.08 25.71 135.13 62.82 48.49 7.09 F(2, 2 )= 2.027, p=0.330 T2 F(1, 1)= 2.054, p=0.388 80.00 F(2, 12)= 3.193, p=0.077 F(2, 12)= 0.660, p=0.534
T3 F(1, 5)= 0.604, p=0.472 18.31 T3 F(1, 1)= 1.931, p=0.397 35.41
vigorous 53.18 48.68 183.44 148.15 30.11 28.30 F(1, 8.2)= 11.968, p=0.008 T2 F(1, 8)= 10.369, p=0.012 244.92 74.58 30.59 199.05 159.60 72.86 49.12 F(1.1, 6.4 )= 5.133, p=0.061 T2 F(1, 6)= 4.603, p=0.076 166.89 F(1.1, 14.7)= 15.177, p=0.001 F(1.1, 14.7)= 0.076, p=0.799




+ moderate 128.32 68.29 174.27 91.36 133.56 83.73 F(2, 14)= 1.045, p=0.377 T2 F(1, 7)= 1.933, p=0.207 35.81 144.90 72.69 251.16 90.93 117.30 55.07 F(2, 6 )= 4.255, p=0.071 T2 F(1, 3)= 4.621, p=0.121 73.33 F(2, 20)= 5.351, p=0.014 F(2, 20)= 1.866, p=0.181
T3 F(1, 7)= 0.989, p=0.353 4.08 T3 F(1, 3)= 0.262, p=0.644 19.05
vigorous 150.28 96.58 322.72 196.77 94.58 72.80 F(2, 16)= 18.688, p<0.001 T2 F(1, 8)= 17.205, p=0.003 114.75 201.52 53.72 368.38 189.37 161.09 15.89 F(1.1, 6.7 )= 5.085, p=0.058 T2 F(1, 6)= 4.212, p=0.086 82.80 F(1.2, 16.5)= 16.631, p=0.001 F(1.2, 16.5)= 0.250, p=0.663




+ moderate 125.75 202.78 208.03 228.19 98.28 113.06 F(1.2, 6.95)= 3.073, p=0.122 T2 F(1, 6)= 3.235, p=0.122 65.43 F(1.2, 6.95)= 3.073, p=0.122
T3 F(1, 6)= 0.003, p=0.958 21.84
vigorous 50.96 72.18 133.77 114.85 30.09 48.24 F(2, 14)= 10.337, p=0.002 T2 F(1, 7)= 16.644, p=0.005 162.48 76.19 72.93 147.92 158.28 56.48 41.57 F(2, 12 )= 3.215, p=0.076 T2 F(1, 6)= 2.855, p=0.142 94.16 F(2, 26)= 12.547, p<0.001 F(2, 26)= 3.150, p=0.060
T3 F(1, 7)= 0.810, p=0.398 40.95 T3 F(1, 6)= 1.899, p=0.217 25.86
CD3-CD62L+ moderate 259.25 325.30 387.20 354.01 271.48 380.72 F(2, 6)= 1.002, p=0.421 T2 F(1, 3)= 0.246, p=0.654 49.36 F(2, 6)= 0.845, p=0.475












4.3.2.5 NK cell subsets migratory capacity in response to acute exercise in T1D and 
control participants 
 
The homing propensity and migratory capacity of NK cell subsets was measured during 
moderate (40% VO2 max) and vigorous (80% VO2 max) acute exercise using cell surface 
expression of the adhesion molecule LFA-1 on NK cell subsets; CD56brightCD16dim, 
CD56dimCD16dim, CD56dimCD16dim, CD56brightCD16-, and CD56-CD16+. The mean, standard 
deviation and statistical analysis are displayed in Table 23. 
CD56dimCD16bright 
There was an overall change over time in LFA-1+ CD56dimCD16bright NK cells during moderate 
intensity exercise (p<0.001), and in both T1D (p=0.009) and control (p=0.007) groups 
independently. There was an increase post moderate exercise overall (p=0.001), and in both 
T1D (p=0.041) and control (p=0.034) groups. However, there was an overall trend to respond 
differently between groups (p=0.062) (time*group) because there was a much larger increase 
post moderate exercise in the T1D group (T1D: 243.55%, control: 139.35%). 
CD56dimCD16bright NK cells significantly mobilised during vigorous intensity exercise overall 
(p<0.001), and in control group (p=0.007), but not in the T1D group. There was an overall 
trend between groups to respond differently to vigorous intensity exercise (p=0.074). An 
increase post vigorous exercise was seen overall (p=0.003) and in the control group only 
(p=0.006) (Figure 23a).  
CD56brightCD16dim  
There was an overall change over time in LFA-1+ CD56brightCD16dim NK cells during moderate 
intensity exercise (p=0.028), but this was not seen in either group independently. There was an 
increase post moderate exercise in the control group only (p=0.016). LFA-1+ 




(p=0.035), but no effect over time was seen. This response was significantly different between 
groups at this time point (p=0.046) (time*group) (Table 23).  
CD56dimCD16dim  
There was an overall change over time in LFA-1+ CD56dimCD16dim NK cells during moderate 
intensity exercise overall (p=0.023) and in the T1D group (p=0.029), but this was not seen in 
the control group. There was a trend to increase post moderate exercise in the T1D group only 
(p=0.069). No mobilisation of LFA-1+ CD56dimCD16dim NK cells was seen during vigorous 
intensity exercise (Figure 23b).  
CD56brightCD16-  
There was an overall change over time in LFA-1+ CD56brightCD16- NK cells during moderate 
intensity exercise overall (p=0.002), with a trend to mobilise in both T1D (p=0.068) and control 
(p=0.061) groups. There was an overall decrease below baseline 1 hour post moderate exercise 
(p=0.041), but this was not seen in either T1D or control groups independently. LFA-1+ 
CD56dimCD16- NK cells significantly mobilised during vigorous intensity exercise overall 
(p=0.001), and in both T1D (p=0.039) and control (p=0.01) groups. There was an increase post 
vigorous exercise overall (p=0.018) and in the control group (p=0.025), but this was not 
significant in the T1D group (Table 23).  
CD56-CD16+  
There was an overall change over time in LFA-1+ CD56-CD16+ NK cells during moderate 
intensity exercise (p=0.012) and in the control group (p=0.006), but this was not seen in the 
T1D group. There was a significant increase post moderate exercise overall (p=0.011) and in 
the control group only (p=0.005). LFA-1+ CD56-CD16+ NK cells significantly mobilised 
during vigorous intensity exercise overall (p=0.009) and in the control group (p=0.015), but 
this was not seen in the T1D group. There was a significant increase post vigorous exercise 
168 
overall (p=0.013) and in the control group only (p=0.008). No mobilisation of LFA-1+ CD56-
CD16+ NK cells was seen during either exercise intensity in the T1D group (Figure 23c).  
 
Figure 23 LFA-1 expressed by CD56+ and CD56- cells mobilised during moderate and vigorous exercise in 
control and T1D participants 
Flow cytometry and whole blood cell counts were used to determine the frequency of LFA-1 expression on NK 
cells in control and T1D participants during moderate and vigorous intensity exercise. (a) Frequency of LFA-1+ 
CD56dimCD16bright NK cells (b) frequency of LFA-1+ CD56brightCD16dim (c) frequency of LFA-1+ CD56-
CD16+ cells during moderate and vigorous intensity exercise. Error bars represent SEM. Statistical significance 







Table 23 LFA-1+ NK cell subsets during moderate and vigorous intensity exercise in control and T1D participants 
Mean, standard deviation, and statistical analysis of LFA-1+ NK cell subsets for control and T1D subjects during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1Controls n=9-10, 2T1D n =5-9 
dTime (overall) dTime*Group
Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
CD56dimCD16bright LFA-1+ moderate 48.81 51.80 116.82 105.40 47.80 72.75 F(2, 14)= 7.156, p=0.007 T2 F(1, 7)= 6.909, p=0.034 139.35 47.95 28.63 164.73 100.77 30.23 29.75 F(2, 6 )= 11.236, p=0.009 T2 F(1, 3)= 11.921, p=0.041 243.55 F(1.3, 12.9)= 22.201, p<0.001 F(1.3, 12.9)= 3.887, p=0.062
T3 F(1, 7)= 0.009, p=0.928 2.06 T3 F(1, 3)= 1.151, p=0.362 36.96
vigorous 48.56 35.22 141.14 114.30 41.14 33.83 F(1, 7.3)= 13.541, p=0.007 T2 F(1, 7)= 13.633, p=0.008 190.63 70.92 49.46 118.81 73.34 56.46 52.87 F(2, 12 )= 2.674, p=0.110 T2 F(1, 6)= 2.081, p=0.199 67.53 F(1.5, 20.1)= 14.133, p<0.001 F(1.5, 20.1)= 2.880, p=0.074
T3 F(1, 7)= 3.680, p=0.097 15.29 T3 F(1, 6)= 0.551, p=0.486 20.39
CD56brightCD16dim LFA-1+ moderate 0.44 0.63 0.70 0.90 0.41 0.63 F(1, 4.2)= 5.239, p=0.081 T2 F(1, 4)= 15.867, p=0.016 59.40 0.64 0.71 0.66 0.68 0.50 0.49 F(2, 2 )= 4.688, p=0.275 T2 F(1, 1)= 0.207, p=0.728 3.80 F(1.1, 5.3)= 8.888, p=0.028 F(1.1, 5.3)= 3.937, p=0.100
T3 F(1, 4)= 0.167, p=0.703 5.88 T3 F(1, 1)= 3.115, p=0.328 22.17
vigorous 1.88 2.83 2.88 3.92 1.30 1.49 F(2, 12)= 2.383, p=0.134 T2 F(1, 6)= 7.342, p=0.035 52.99 1.73 1.88 1.97 2.74 1.23 1.16 F(2, 10 )= 0.616, p=0.559 T2 F(1, 5)= 0.643, p=0.459 13.80 F(2, 22)= 1.110, p=0.347 F(2, 22)= 1.850, p=0.181
T3 F(1, 6)= 0.000, p=0.987 31.00 T3 F(1, 5)= 1.586, p=0.264 29.01
CD56dimCD16dim  LFA-1+ moderate 12.96 18.56 13.41 21.48 10.32 20.57 F(2, 12)= 0.674, p=0.528 T2 F(1, 6)= 0.075, p=0.793 3.44 5.06 5.04 9.72 5.23 4.57 4.76 F(2, 6 )= 6.745, p=0.029 T2 F(1, 3)= 7.700, p=0.069 91.88 F(2, 18)= 4.684, p=0.023 F(2, 18)= 1.444, p=0.262
T3 F(1, 6)= 0.500, p=0.506 20.36 T3 F(1, 3)= 2.407, p=0.219 9.72
vigorous 8.41 12.84 14.47 19.42 6.81 9.12 F(2, 14)= 1.381, p=0.284 T2 F(1, 7)= 0.922, p=0.369 72.04 6.28 3.25 8.15 4.20 9.34 8.62 F(1.4, 7 )= 0.671, p=0.463 T2 F(1, 6)= 2.188, p=0.190 29.85 F(2, 26)= 1.589, p=0.223 F(2, 26)= 0.514, p=0.604
T3 F(1, 7)= 0.762, p=0.412 19.04 T3 F(1, 6)= 0.266, p=0.624 48.74
CD56brightCD16-  LFA-1+ moderate 15.13 18.83 18.50 26.63 12.50 24.55 F(1.2, 8.1)= 4.541, p=0.061 T2 F(1, 7)= 0.160, p=0.701 22.24 6.96 6.71 16.46 14.61 6.69 7.72 F(2, 6 )= 4.338, p=0.068 T2 F(1, 3)= 5.559, p=0.100 136.56 F(2, 20)= 8.761, p=0.002 F(2, 20)= 1.644, p=0.218
T3 F(1, 7)= 4.298, p=0.077 17.38 T3 F(1, 3)= 2.017, p=0.251 3.92
vigorous 13.58 11.85 25.58 31.93 12.13 14.23 F(2, 12)= 6.959, p=0.010 T2 F(1, 6)= 3.032, p=0.025 88.34 29.04 32.95 37.62 47.60 21.68 18.94 F(2, 10 )= 4.542, p=0.039 T2 F(1, 5)= 0.826, p=0.405 29.57 F(2, 22)= 9.611, p=0.001 F(2, 22)= 1.696, p=0.207
T3 F(1, 6)= 0.001, p=0.972 10.71 T3 F(1, 5)= 3.052, p=0.141 25.34
CD56-CD16+  LFA-1+ moderate 2.32 3.42 5.46 8.00 3.33 5.64 F(2, 6)= 12.145, p=0.006 T2 F(1, 3)= 55.173, p=0.005 134.69 6.27 11.94 6.01 11.23 5.97 11.35 F(2, 2 )= 1.040, p=0.490 T2 F(1, 1)= 1.051, p=0.492 4.10 F(2, 8)= 8.047, p=0.012 F(2, 8)= 1.496, p=0.281
T3 F(1, 3)=4.180, p=0.133 43.42 T3 F(1, 1)= 1.297, p=0.459 4.75
vigorous 8.32 12.89 16.24 25.08 6.57 7.77 F(2, 12)= 6.135, p=0.015 T2 F(1, 6)= 15.628, p=0.008 95.13 3.13 4.63 4.23 6.94 3.94 7.82 F(2, 12 )= 1.843, p=0.200 T2 F(1, 6)= 1.387, p=0.283 35.36 F(2, 24)= 5.825, p=0.009 F(2, 24)= 0.190, p=0.829
T3 F(1, 6)= 0.630, p=0.457 21.13 T3 F(1, 6)= 0.636, p=0.455 26.02
ccontrast
1Controls 2T1D
T1 T2 T3 ccontrast T1 T2 T3
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4.3.2.6 AdipoR1 and AdipoR2 B cell expression in T1D and control participants 
AdipoR1+ and AdipoR2+ B cells were measured at rest in T1D and control participants. The 
frequency of AdipoR1+ and AdipoR2+ B cells showed a trend to be reduced in T1D compared 
to control participants (Figure 24c and d). However, there was no significant difference was 
observed in the proportion of thee subsets between groups (Figure 24a and b) (Table 24).  
 
Figure 24 The proportion and frequency adiponectin receptors expressed by B cells at baseline in T1D and 
control groups.
Flow cytometry and whole blood cell counts were used to determine the frequency of AdipoR1 and AdipoR2 
expression by B cells in control and T1D participants at baseline. (a) Proportion AdipoR1+ B cells (b) Proportion 
of AdipoR2+ B cells (c) Frequency AdipoR1+ B cells (d) Frequency of AdipoR2+ B cells. Error bars represent 






Table 24 Adiponectin receptor expression on B cells at baseline in T1D and control groups. 
Mean and standard deviation values for the proportion and frequency of AdipoR1+ and AdipoR2+ B cells in 
controls and T1D participants. 
1controls n=5, 2T1D n=5 
 
The frequency of AdipoR1+ and AdipoR2+ B cells were measured in response to moderate 
(40% VO2 max) and vigorous (80% VO2 max) acute exercise. Data is missing for AdipoR1 
during vigorous intensity exercise in the T1D group. Data is missing for AdipoR2 during 
vigorous intensity exercise in both the T1D and control group due to missing time-points for 
each group. The mean, standard deviation and statistical analysis are displayed in Table 25. 
However, no changes were observed in the frequency of AdipoR1+ and AdipoR2+ B cells in 
either group during moderate or vigorous intensity exercise.  
Subset
mean SD mean SD
AdipoR1+   (%) 7.07 3.09 8.71 3.59
                  (cells/μl) 17.10 9.44 9.26 4.69
AdipoR2+   (%) 15.03 8.71 14.24 4.38







Table 25 B cells expressing adiponectin receptors mobilised during moderate and vigorous intensity exercise in control and T1D participants 
Mean, standard deviation, and statistical analysis AdipoR1+ and AdipoR2+ B cells for control and T1D subjects during moderate and vigorous intensity exercise. Significant 
results highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1Controls n=2-3, 2T1D n =4-1 
dTime (overall) dTime*Group
Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
B cells AdipoR1+ moderate 32.06 13.31 39.89 12.75 11.59 13.82 F(1, 2)= 4.651, p=0.276 T2 F(1, 1)= 1.371, p=0.450 24.42 53.78 58.01 53.70 76.83 48.54 58.89 F(1, 2)= 1.281, p=0.461 T2 F(1, 1)= 0.010, p=0.450 0.16 F(2, 4)= 4.463, p=0.096 F(2, 4)= 0.056, p=0.946
T3 F(1, 1)= 6.255, p=0.242 63.85 T3 F(1, 1)= 23.037, p=0.131 9.75
vigorous 63.10 56.92 57.68 48.83 35.19 32.61 F(1, 2)= 2.858, p=0.340 T2 F(1, 1)= 0.896, p=0.517 8.59 T2 F(1, 2)= 1.000, p=0.500 F(1, 2)= 1.101, p=0.485
T3 F(1, 1)= 2.635, p=0.351 44.24 T3
B cells AdipoR2+ moderate 23.12 30.12 49.99 54.77 4.68 0.10 F(1, 2)= 21.465, p=0.135 T2 F(1, 1)= 15.804, p=0.157 116.21 86.11 71.55 74.75 86.70 51.49 58.52 F(1, 2)= 3.131, p=0.327 T2 F(1, 1)= 1.123, p=0.482 13.19 F(2, 14)= 1.458, p=0.266
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4.4 Discussion  
The first aim of this study was to measure peripheral blood lymphocyte populations and their 
migratory capacity in T1D and control participants at rest. NK cells were elevated in T1D, but 
no other baseline differences in lymphocyte populations were found. Lymphocytes from T1D 
participants showed a trend to have higher proportion of subsets expressing adhesion 
molecules. Although lymphocyte adherence to endothelial cells was not higher in T1D, TEM 
of lymphocytes showed a trend to increase in T1D at rest indicating an increased migratory 
capacity of the present lymphocytes. Additionally, the mean frequency of AdipoR1+ and 
AdipoR2+ B cells show a trend to be higher in control participants compared to T1D 
contributing to TEM regulation in control participants. However, the numbers in this analysis 
were low, and therefore it is difficult to conclude these findings.  
This study also aimed to investigate the effects of moderate and vigorous intensity exercise on 
peripheral blood lymphocyte populations and their migratory capacity in T1D and control 
participants. In summary, vigorous intensity exercise elicited a strong increase in lymphocytes 
in both T1D and control participants. This increase in lymphocytes was mainly comprised of 
CD8+ T cells and NK cells. Minimal mobilisation of CD4+ T cells and B cells was observed in 
controls, with no significant mobilisation of these lymphocyte subsets observed in T1D. 
Exercise-induced mobilisation of particular lymphocyte subsets appeared to be blunted in T1D 
compared to control participants. In T1D, there was a reduced percentage increase of 
lymphocytes following vigorous exercise. This was driven by a blunted increase in total NK 
cells during vigorous exercise in T1D. Both of the CD56dim NK cells subsets, 
CD56dimCD16bright and CD56dimCD16dim, were blunted following vigorous exercise in the T1D 
group. However, moderate exercise mobilised NK cells dramatically in the T1D group, which 
was not observed in control group. Further phenotyping showed that all NK cell subsets were 




mobilised in the T1D cohort during moderate exercise. Amongst these subsets 
CD56dimCD16bright displayed the largest increase post exercise.  
Vigorous intensity exercise only affected total lymphocyte adherence and TEM, and this was 
seen only in the T1D group. No change in TEM immediately following vigorous exercise was 
found, however TEM was significantly suppressed 1 hour following vigorous exercise 
cessation in the T1D group. This is supported by minimal changes in adhesion molecules on 
lymphocytes immediately following vigorous exercise and a larger significant decrease in 
lymphocytes expressing adhesion molecules 1 hour following vigorous exercise in T1D 
participants. In the TEM model used in this study, LFA-1+ NK cells have the potential to adhere 
and transmigrate. However, no changes in LFA-1+ NK cell subsets were found during exercise. 
Therefore, it can be postulated that changes in TEM are likely due to alterations in peripheral 
blood CD3+ T cells. The adhesion molecules CD11b, CCR4, and CCR6 on CD3+ T cells were 
significantly reduced in T1D participants 1 hour following vigorous exercise.  
In the TEM model used in this study, activated endothelial cells express ICAM-1 and 
chemokines CXCL9, CXCL10, and CXCL11 [315, 316, 331, 332]. This facilitates the 
migration of LFA-1+ (ICAM-1) and CXCR3+ (CXCL9, CXCL10, and CXCL11) lymphocytes 
across HDBEC [322, 325]. It is possible that CD11b+ lymphocytes may also transmigrate 
because when bound to CD18 this forms Mac-1 which can also bind to ICAM-1 [326]. 
However, this model does not express the chemokine receptors for CCR4 (CCL2, 4, 5, 17, and 
22) or CCR6 (CCL20) [305, 307]. Therefore, the changes in adhesion molecules during 
exercise in this study herein cannot be directly linked to TEM in the model used. They can 
however be used to understand physiological changes in TEM that may occur during acute 
exercise in humans. In the context of T1D, islets express numerous adhesion molecules and 
chemokine ligands to which the homing markers on lymphocytes used in this study can respond 




to. CD3+ T cells expressing CD11b, CCR4, and CCR6 can respond to ICAM-1 and the 
chemokine ligands CXCL9, CXCL10, CCL2, CCL3, CCL17, CCL21, and CCL22 expressed 
by islets in T1D [126, 128, 134, 137-139, 338].Therefore, TEM into the pancreas may be 
suppressed during the recovery period following exercise.  
The strengths of this study are that it is the first study of the effects of steady-state acute exercise 
on lymphocyte subpopulations in T1D. This study gives an in-depth analysis of lymphocyte 
subsets mobilised by two different exercise intensities, in two cohorts. This is also the first 
study looking at lymphocyte trafficking and TEM during exercise in T1D. However, the 
number of recruited participants were low therefore comparisons between groups are difficult. 
In particular, missing data for AdipoR1 and AdipoR2 makes it difficult to elucidate the 
mechanisms involved in TEM changes during vigorous exercise in T1D. As discussed, one 
disadvantage is that the model used to measure TEM cannot be directly related to the changes 
in adhesion molecules observed following vigorous exercise in T1D participants. Furthermore, 
it is not defined if exercise directly affects diabetogenic T cell migration. In order to preserve 
beta cell health, it is imperative that migration of diabetogenic T cells to the pancreas is 
impaired by exercise. In future work, the migrated lymphocytes could be collected from the 
bottom of the well and characterised by flow cytometry. It would be useful to include a tetramer 
for diabetogenic T cells and quantify the number of diabetogenic T cells adhered and migrating 
across the endothelium at each time point. This would clarify whether diabetogenic T cells 
specifically migrate during vigorous exercise and if this is reduced 1 hour following exercise 
cessation as observed for total lymphocytes in this study. Furthermore, soluble chemokine 
receptors and ligands could be measured in cryo-preserved plasma samples taken for the 
purpose of this study. This would elucidate trafficking signals during and after vigorous 
exercise.  




In agreement with previous findings, this study demonstrates that vigorous exercise causes a 
significant increase in peripheral blood lymphocytes, followed by lymphopenia, in healthy 
cohorts [191-195]. This is the first time this has been shown during steady-state acute exercise 
in T1D. More specifically, the majority of redeployed lymphocytes were NK cells and CD8+ 
T cell, with minimal mobilisation of CD4+ T cells and B cells in healthy cohorts [191, 197-
200, 215, 257, 364, 365]. Furthermore, the effects of exercise on CD56dimCD16bright and 
CD56brightCD16dim NK subsets are well established [197, 198]. However, the effects of exercise 
on CD56dimCD16dim, CD56brightCD16-, and CD56-CD16+ NK cells have not been explored. 
This study also provides evidence of exercise-induced mobilisation of the less characterised 
NK cell subsets; CD56dimCD16dim, CD56brightCD16-, and CD56-CD16+.  
Although adhesion molecules on lymphocytes increase following vigorous exercise in control 
participants, no changes in TEM behaviour occurred, suggesting a mechanistic regulation of 
lymphocyte trafficking during exercise in control participants. Reduced migration of CD4+ and 
CD8+ T cells following exercise has been previously observed [359]. Firstly, this may be due 
to the regulation of TEM by the adiponectin-PEPITEM axis reported at rest previously in 
healthy individuals [315]. However, PEPITEM has not yet been measured following acute 
exercise. Secondly, crosstalk between stem cells and endothelial cells has been reported to 
reduce the activation of endothelium [366]. IL-6 produced by stem cells down-regulated 
adhesion of lymphocytes to endothelial cells. Both IL-6 and HSPC are increased during acute 
exercise, therefore could modulate TEM regulation following exercise [212, 213, 367].  
The effects of acute exercise on lymphocyte trafficking have important implications in T1D. 
The mobilisation of NK cells and T cells increases immune surveillance through tissue 
redistribution [191, 214]. This may be important to decrease the high susceptibility to infection 
observed in people with T1D [368, 369].  Furthermore, suppression of TEM in the recovery 




period may inhibit ongoing islet infiltration seen in long-standing T1D [28, 129, 339, 359, 370-
372]. This is imperative for beta cell preservation thereby reducing insulin requirements, 
disease severity, and T1D associated complications.  
Preliminary data presented here provides evidence to investigate exercise training in T1D. 
Exercise-induced improvements in T1D following exercise training has been shown in NOD 
mice [189]. NOD mice that were trained for 20 weeks demonstrated reduced immune cell 
infiltration into the pancreas and therefore a reduction in insulitis [189]. Exercise training also 
acts as a preventative measure for atherosclerosis in people at risk [373, 374]. Exercise training 
in people with T2D has been shown to improve atherosclerosis risk through reduction in 
endothelial activation parameters. These studies reported that decreased HbA1c following 
exercise training correlated with reduced ICAM-1 and endothelial activation [375, 376]. 
Furthermore, exercise training in cancer models reduced tumour growth and increased immune 
surveillance [362]. NK cell infiltration into tumours was increased in trained mice. It was 
reported that epinephrine and IL-6 were imperative for NK cell mobilisation, redistribution, 
and activation to control tumour growth [362].  
In conclusion, exercise-induced lymphocytosis of particular subsets during vigorous intensity 
vigorous exercise is blunted in T1D compared to control participants. However, the increase in 
lymphocytes following exercise may still contribute to increased immune surveillance in T1D. 
Furthermore, suppression of TEM in the recovery period following vigorous exercise may offer 
protection from T cell infiltration into the islet in T1D. 
  












CHAPTER 5. THE EFFECTS OF 
ACUTE EXERCISE ON T CELL 
LINEAGE SUBSETS IN THE 
PERIPHERAL BLOOD OF TYPE 1 
DIABETES   






T cells are mobilised by acute exercise in healthy individuals. In particular, memory T cell 
subsets which are highly differentiated are the most responsive to acute exercise [199, 200, 
215, 257, 364, 365]. However, the effects of acute exercise on T cell subsets, including those 
implicated in the pathogenesis of T1D is not yet known.  
5.1.1 T cell differentiation stages 
 
The linear differentiation pathway that gives rise to a range of phenotypically and functionally 
diverse T cell subsets is described below (Figure 25). T cells are characterised by their co-
expression of CD3 and the T cell receptor (TCR) [290]. T cells mature in the thymus into two 
distinct subsets; CD4+ and CD8+ T cells. Both CD4+ and CD8+ T cells are released into the 
circulation as naïve T cells which are characterised by their cell surface co-expression of 
CD45RA, CCR7, CD27 and CD28 [291, 377-381]. CD45, the leukocyte common antigen, has 
multiple isoforms which are differentially expressed based on maturation status [382]. Naïve 
T cells express the high molecular weight CD45RA isoform [383, 384]. CCR7 is a chemokine 
which mediates lymph node (LN) homing, and as a result CCR7+ cells are continuously 
redeployed into the blood stream [380, 385, 386]. CD27 and CD28 are costimulatory molecules 
involved in T cell activation and formation of antigen-primed cells [387-389].  
Central memory (CM) cells are formed (CD45RA-CCR7+) following antigen experience and 
loss of CD45RA [378, 381]. Memory cells lose the expression of the high molecular weight 
CD45RA isoform and gain expression of the low molecular CD45RO isoform following 
activation [383]. CD45RA- memory T cells can respond to recall antigens whereas CD45RA+ 
naïve T cells cannot [383]. Both naïve and CM T cells are typically CD27+CD28+ [390]. This 
is because co-stimulation from antigen presenting cells is required for the activation of these 
early stage T cells during antigen presentation and TCR engagement [391-393].  




Following antigen presentation, CM T cells can rapidly differentiate into T cells with effector 
functions [380]. CCR7 is down-regulated as CM T cells become specialised, antigen specific 
T cells or now known as effector memory (EM) T cells. Subsequently, EM T cells upregulate 
adhesion molecules to facilitate their migration to peripheral non-lymphoid tissues [380, 394]. 
EM T cells acquire increased cytolytic activity and capacity for cytokine release to exert their 
effector functions [395-397]. EM T cells can be divided into four subsets based on their 
expression of CD27 and CD28: early (ED) (CD27+CD28+), early-like (ELD) (CD27-CD28+), 
intermediate (ID) (CD27+CD28-), and fully differentiated EM T cells (CD27-CD28-) [398, 
399]. CD27+CD28+ EM exhibit limited cytotoxic functions whereas CD27+CD28- and CD27-
CD28- EM display higher cytotoxic killing and cytokine secretion capabilities [399]. CD27 and 
CD28 diminish in a stepwise fashion following successive rounds of differentiation in response 
to antigen stimulus [399-401]. CD27 expression is lost after prolonged antigen exposure such 
as that received by EM T cells [402]. Downregulation of CD28 on EM T cells is associated 
with loss of proliferative capacity and telomere length [403, 404], but increased cytolytic 
activity and susceptibility to apoptosis following an immune response [401, 405]. Therefore, 
loss of CD27 and CD28 expression by late differentiated EM T cells indicates progression 
towards senescence.  
Re-expression of CD45RA on fully differentiated EM T cells (EMRA) is the final stage of T 
cell differentiation [384]. EMRA express both CD45RA and CD45RO isoforms 
(CD45RA+CCR7-) [406]. This leads to a more stable resting memory T cell pool that responds 
to recall antigen [407]. EMRA express lower levels of apoptotic proteins B-cell lymphoma -2 
(Bcl-2) and B-cell lymphoma x (Bcl-x), in comparison to EM T cells which express higher 
levels because they undergo programmed cell death after resolution of infection [407]. EMRA 
exhibit high migratory capacity, cytotoxic functions and cytokine secretion in response to 
stimulus, analogous to EM T cells [407]. Conventionally EMRA are CD27-CD28- as they have 




undergone successive rounds of differentiation [400, 401]. However there is evidence of further 
subdivisions of differentiation based on the differential expression of these markers [408]. 
Pedro Romero et al., (2007) identified small subpopulations of CD27-CD28+ and CD27+CD28- 
EMRA [408]. Nonetheless, CD27+CD28+ and CD27-CD28- EMRA make up the larger 
proportion of EMRA subpopulations [408, 409].  
The phenotypic outline of T cell differentiation (Figure 25) is well defined in CD8+ T cells, 
with evidence of similar heterogeneity in CD4+ T cells [390, 410]. Naïve and early 
differentiated subsets are the most abundant CD4+ and CD8+ T cells in peripheral blood in the 
steady state. Naïve and CM cells are the most abundant within the LN, with EM and EMRA 
residing in peripheral tissues [411, 412]. CD4+ T cells comprise the major part of CM cells, 
whereas CD8+ T cells comprise the major part of EM and EMRA [291].  
More recently, a memory T cell population has been identified with hematopoietic stem cell-
like properties, stem-cell like memory T cells (TSCM) [340, 413-415]. TSCM express naïve 
markers such as CD45RA, CCR7, CD27, and CD28 and co-localise in the lymph nodes [415, 
416]. TSCM are the least differentiated memory subset, following naïve T cells in the linear 
differentiation pathway [416]. However, TSCM have the ability to rapidly acquire effector 
functions upon stimulation and respond to recall antigens, analogous to memory subsets [416]. 
TSCM express CD95 which is also found on conventional memory subsets [416]. TSCM have 
shortened telomeres compared to naïve T cells, indicative of their sustained proliferation cycles 
[416, 417]. TSCM are capable of extensive proliferation and self-renewal, similar to 
hematopoietic stem cells [340, 416, 417]. Wnt signalling, which is involved in the self-renewal 
capacity of hematopoietic stem cells, was found to inhibit T cell differentiation and promote 
generation of TSCM [414]. TSCM were first identified in the CD8+ compartment [340] and 




Figure 25 Linear T cell differentiation pathway 
The progressive linear differentiation pathway of CD4+ and CD8+ T cell subsets; naïve T cells --> Stem cell like 
memory T cells (TSCM) --> Central Memory (CM) --> Effector Memory (EM) --> Early Differentiated (ED) --> 
Early-like Differentiated (ELD) --> Intermediately differentiated (ID) --> Effector Memory Re-expressing 
CD45RA (EMRA).  
5.1.2 T cells in T1D 
A few studies have reported differences in peripheral blood CD4+ T cell subsets in T1D 
compared to healthy cohorts. One study showed increased CD4+ T cell proportions, which was 
comprised of increased CD4+ CD45RA+ T cells in T1D donors [419]. Another study found no 
differences in CD4+ T cell proportions or absolute numbers, but did report a lower absolute 
count of CD4+ CM T cells [420]. A more comprehensive phenotyping study reported that 
antigen exposed memory T cell subsets were elevated in T1D [339, 371, 421]. Absolute 
numbers of naïve and CM T cells in both the CD4+ and CD8+ compartment were reported to 
be lower in T1D, whereas both CD4+ and CD8+ EMRA were dramatically higher [371]. 
Elevated EMRA subsets in T1D were highly differentiated as denoted by CD26 expression 
[371]. CD26 is a costimulatory molecule expressed late in the differentiation of T cells, 
therefore indicating a mature phenotypic state [371].  




No differences in total peripheral blood CD8+ T cell counts have been described in T1D. 
Furthermore, circulating islet specific CD8+ T cells have been found at similar frequencies in 
both T1D and non-diabetic cohorts [131]. In the aforementioned study, circulating islet specific 
CD8+ T cells displayed a naïve phenotype (CD45RO+CD45RA–CD62Lhi) and equal 
functionality in both cohorts [131]. The antigen-experienced islet reactive CD8+ T cells 
(ZnT8186–194 multimer+) were found sequestered in the pancreas of T1D donors, but not non-
diabetic donors [131]. A decrease in peripheral CD8+CD11b+ subsets in T1D compared to 
healthy donors has been described [419]. This is likely due to sequestration of pan 
CD8+CD11b+ T cells within the islets of T1D donors, similar to that seen for islet reactive 
CD8+ T cells [131]. This is supported by evidence of CD8+CD11b+ T cells within NOD islets 
[127, 134]. Islet resident CD8+ T cells in the human pancreas also express CD69 and CD103 
which are markers of activated tissue resident memory cells [86].  
Antigen exposed memory T cell subsets elevated in the peripheral blood of T1D such as that 
found by Matteucci et al [371], and more recently identified populations by Skowera et al [339], 
are thought to sustain autoimmune destruction throughout T1D lifetime. Skowera et al also 
showed that beta cell specific CD8+ T cells exhibit a highly differentiated memory phenotype 
that reflects chronic antigen exposure [339]. These cells express CD57, a marker of 
differentiation, and have shorter telomeres, indicative of their successive rounds of cell division 
[339, 422]. Furthermore, it was also demonstrated that a population of beta cell specific CD8+ 
T cells exhibit a TSCM-like phenotype (CD27+CD45RO-CD95+CCR7+) [339]. A recent study 
detected beta cell specific autoreactive CD8+ TSCM in people with T1D, indicating a role for 
TSCM in the pathogenesis of T1D [421]. 
 




5.1.3 T cells and acute exercise 
 
Acute exercise causes a significant increase in lymphocyte frequency, proportional to exercise 
intensity, in the peripheral blood immediately following exercise. This rise can be followed by 
intensity-dependent lymphopenia during the recovery period. [192, 193, 195, 196]. The 
observed lymphopenia is primarily due to the redistribution of cells to peripheral tissues [191, 
214] and T cells constitute a large proportion of these redeployed lymphocytes [193, 201].  
The largest mobilisation within T cells is seen by CD8+ T cells, with minimal CD4+ T cell 
mobilisation. Increases in both CD4+ and CD8+ T cells following 120 minutes cycle ergometer 
test at 65% VO2 max is described in one study [201]. CD4+ T cells increased by only 30% 
compared to CD8+ T cells which increased by 105%. [201]. Another study reported increases 
in both CD4+ and CD8+ T cells following a 120 minutes treadmill test at 65% VO2 max. Again, 
a smaller increase in CD4+ T cells was found and this resulted in a decrease in the CD4/CD8 
ratio [193]. CD3+ T cells fell below baseline during the recovery period measured at 2 hours 
post exercise, with an increase in the CD4/CD8 ratio due to decreased CD8+ T cells at this time 
point [193]. The CD4/CD8 ratio was also significantly reduced following 60 minutes running 
at 70% VO2 max [196] and 30 minute steady state cycling at 15% above participant’s blood 
lactate threshold [257]. 
There has been a greater focus on CD8+ T cells than CD4+ T cells due to their preferential 
mobilisation. CD8+ T cells with a highly differentiated memory phenotype demonstrate the 
largest percentage increase following exercise [199, 200, 215, 257, 364, 365]. In one study, 
CD8+ EM and EMRA increased three-fold following vigorous exercise (30 minute steady state 
cycling at 15% above blood lactate threshold) [257]. Another study found that CD8+ EMRA 
were the most sensitive to exercise induced mobilisation increasing following 20 minutes of 
both low (35% Wattmax) and vigorous (85% Wattmax) exercise. CD8+ EMRA showed the 




greatest percentage increase (450%) following vigorous exercise compared to naïve CD8+ T 
cells which increased by 84% [199]. Further studies showed that CD8+ EM and EMRA that 
exhibited the largest increase following exercise (60 minute treadmill running at 60% VO2 
max) were fully differentiated (CD27-CD28-). This effect was almost twice as large in antigen 
experienced CMV+CD8+ memory T cells [200]. Other studies have investigated markers of 
terminal differentiation and senescence such as CD57 and KLRG1+ on CD8+ T cells following 
acute exercise. Exhaustive exercise (80% VO2 max for 1 hour) resulted in an increase in the 
proportion of KLRG1+CD57+ (56%) and KLRG1+CD28- (61%) CD8+ T cells [215]. These 
findings were also shown following a maximal treadmill protocol [364]. A maximal bicycle 
exercise test resulted in an increase in CD8+CD28- memory T cells with shorter telomeres, 
another marker of senescence [365]. 
Following the dramatic increase in frequency after exercise, it is the exercise sensitive CD8+ 
EM and EMRA subsets which exhibit the largest egress from the peripheral blood during the 
recovery period [200, 215]. Multiple causes of exercise induced lymphopenia such as tissue 
redistribution and lymphocyte apoptosis have been explored, and are described next.  
Tissue redistribution of lymphocytes is one cause of exercise induced lymphopenia [191]. 
However, this mechanism has not been well studied because of difficulties in measuring 
lymphocyte relocation to tissues. Krüger et al. 2007 used fluorescent cell tracking in mice to 
examine T cell redistribution after exercise. This study showed that T cells were released from 
the spleen and accumulated in the lungs, bone marrow and Peyer's patches of the mice 
following acute exercise [214]. More depth regarding the homing propensity and function of 
the redeployed T cell populations is needed. CD69 is a marker of recent activation and tissue 
resident T cell subsets [423]. To date, only two studies have shown higher levels of CD69+ 
CD4+ and CD8+ T cells following endurance exercise [424, 425]. Measuring CD69 expression 




on specific subsets would identify activated T cell subsets that have migrated out from 
secondary lymphoid tissues during acute exercise. CD11b is an adhesion molecule involved in 
T cell migration, and potentially identifies activated T cell subsets migrating to secondary 
lymphoid tissues following mobilisation during exercise [426-429]. Increased CD11b+ 
lymphocytes following exercise has been shown previously; however CD11b+ T cell subsets 
specifically have not yet been examined [195, 351-353].  
Lymphopenia is also thought to partially occur from lymphocyte apoptosis [216-218]. Acute 
exercise, particularly of vigorous intensity (i.e. above 70% VO2 max), mobilises CD95+ 
memory T cells [216, 219]. It has been postulated that CD95 expression may indicate an 
apoptotic fate and create “immunological space” [220, 221]. This theory has been examined in 
multiple studies [216-220]. The percentage of apoptotic lymphocytes increased following 
exhaustive exercise (80% VO2 max) in healthy participants. This increase was accompanied 
by an increase in CD95hi lymphocytes [216]. A study including paediatric participants cycling 
at 70% VO2 max for 60 minutes found an increase in CD95hi T cells in females and CD95lo T 
cells in all groups with exercise [219]. Following a treadmill test to exhaustion, apoptosis 
measured by TUNEL was increased in 63% of lymphocytes immediately following exercise 
and in 86.2% of lymphocytes 24 hours later [218]. Furthermore, mice subjected to a strenuous 
90-minute treadmill running protocol showed a decrease in CD8+ T cells 24 hours following 
exercise. However, apoptosis of intestinal CD8+ T cells was higher 24 hours following exercise 
[217]. 
It is hypothesised that this vacant immune space following exercise can be taken up by newly 
generated immature cells, creating the opportunity to reprogram our immune memory. 
Vigorous acute exercise also increases hematopoietic stem and progenitor cells (HSPC) post 
exercise [212, 213]. Furthermore, acute exercise stimulates haematopoiesis [213]. HSPC 




proliferation in the bone marrow was increased by 40% in mice following an intense acute 
exercise bout [213].  
The mobilisation of T cells in a non-disease state is well reported. However, the effects of acute 
exercise on T cell subsets in T1D has not been studied. Given that acute exercise mobilises 
CD8+ T cells with a highly differentiated phenotype that express markers of tissue residency, 
and that CD8+ T cells with this phenotype are thought to sustain beta cell destruction in T1D, 
it is important to explore the impact of acute exercise on these T cell subsets in T1D. It may be 
that benefits observed in T1D are in part attributable to changes arising to the immune system 
during single, repeated bouts of exercise. This study aims to provide a comprehensive 
phenotypic characterisation of exercise induced T cell mobilisation in healthy and T1D cohorts.  





Acute exercise preferentially mobilises progressively differentiated T cell subsets in T1D 
participants.  
5.1.5 Aims 
To characterise progressively differentiated T cell subsets in the peripheral blood using multi-
parameter flow cytometry: 
1. In T1D and control participants at rest. 
2. In T1D and control participants following an acute bout of moderate intensity exercise. 
3. In T1D and control participants following an acute bout of vigorous intensity exercise. 
  





5.2.1 Experimental design 
Twelve controls and twelve T1D male participants were recruited into the study (as described 
in Chapter 3). Briefly, participants had one enrolment visit, where an incremental sub-maximal 
cycle ergometer test was performed to calculate their predicted VO2 max. This was used to 
calculate workload and heart rate for subsequent exercise visits adjusted to individual fitness 
[285]. These two visits consisted of a thirty-minute bout of cycling at either 40% VO2 max 
(moderate) or 80% VO2 max (vigorous). Blood was collected intravenously at baseline, 
immediately post exercise, and 1 hour post exercise in vacuette heparin tubes (95057-405, 
Greiner Bio-one GmbH, Frickenhausen, Germany).  
5.2.2 T cell subset analysis 
A twelve-colour flow cytometry panel was designed to phenotype T cells subsets using the 
following mAbs (see Table 3, Section 2.3.2 for mAb details); anti-CD3 PE-Cy7, anti-CD4 
APC-R700, anti-CD8 APC-H7, anti-CD11b PE-CF594, anti-CD27 BB515, anti-CD28 BV510, 
anti-CD45RA BV786, anti-CD69 BV650, anti-CD95 BV421, anti-CD127 AF647, anti-CCR7 
PE, anti-7-AAD PerCP-Cy5.5. Whole blood was stained as per Chapter 2 (Section 2.3.2). 
Whole blood counts were completed using a coulter haematology analyser (Section 2.2.2) to 
calculate relative cell frequency (cells/μl) of T cell subsets.  
5.2.3 Data analysis 
Flowjo v.10 (FlowJo LLC, Oregon) was used to analyse flow cytometry data. Doublets were 
removed using FSC-A versus FSH-H. Lymphocytes were gated based on size on SSC-A versus 
FSC-A dot plot (Figure 26.1), single cells were selected as the linear populations on FSC-H 
versus FSC-A dot plot (Figure 26.2), and dead cells positive for 7-AAD viability stain were 
removed (Figure 26.3). T cells were selected as CD3+ (Figure 26.4), and further selected as 
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separate CD4+ and CD8+ populations. Spider gates were used within CD4+ and CD8+ 
populations to define distinct progressively differentiated subsets as outlined in Figure 27; 
naïve (CD45RA+CCR7+), TSCM (CD45RA+CCR7+CD95+CD127+), central memory (CM: 
CD45RA-CCR7+), effector memory (EM: CD45RA-CCR7-), early differentiated (ED; 
CD45RA-CCR7-CD27+CD28+), early-like differentiated (ELD: CD45RA- CCR7- CD27-
CD28+) and intermediately differentiated (ID; CD45RA- CCR7-CD27+CD28-), and effector 
memory re-expressing CD45RA (EMRA: CD45RA+CCR7-). Single cell surface expression of 
CD69, CD11b, CD127, and CD95 was gated on CD4 and CD8 naïve, CM, EM, and EMRA T 
cell subsets. See Figure 27 displaying T cell gating strategy and Figure 28 displaying TSCM 
gating strategy.  
 
Figure 26 Selection of CD3+ lymphocytes shown by representative flow plots 
Representative flow cytometry plots showing (1) Lymphocyte selection based on size (SSC-A vs FSC-A) (2) 
Doublets exclusion (FSC-A vs FSC-H) (3) Dead cell removal based on positivity for viability stain (7-AAD 
PerCP-Cy5.5) (4) CD3+ lymphocytes gate. 
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Figure 27 CD4 and CD8 T cell sub populations gating strategy shown by representative flow plots. 
Representative flow cytometry plots showing following parent gate for CD3+ T cell populations (shown in figure 
2) (1) CD3+CD4+ T cells gate (2) CD3+CD8+ T cells gate (3) Quadrant gating for naïve (CD45RA+ CCR7+), 
central memory (CM: CD45RA- CCR7+), effector memory (EM: CD45RA- CCR7-), and EMRA (CD45RA- 
CCR7-) (4) CD45RA- CCR7- selected to gate on early differentiated (ED; CD45RA- CCR7- CD27+CD28+), 





Figure 28 TSCM gating strategy shown by representative flow plots 
Representative flow cytometry plots showing following parent gate for CD3+, CD4+ and CD8+ T cell populations 
(shown in figure 2 and 3) (1) CD45RA+ CCR7+ T cell gate (2) CD45RA+ CCR7+CD95+ T cell gate (3) TSCM 
selection (CD45RA+ CCR7+ CD95+ CD127+). 





5.3.1 Peripheral blood lymphocyte and T cell populations in T1D and 
control participants 
 
The proportion and frequency of peripheral blood lymphocytes, CD3+, CD4+ and CD8+ 
populations were measured at rest in T1D and control participants. There were no significant 
differences in the proportion (%) or frequency (cells/μl) of peripheral lymphocytes, CD3+, 
CD4+, and CD8+ populations between T1D and control groups at baseline (Table 26).  
 
  
Table 26 Lymphocyte and T cell populations at baseline in T1D and controls. 
Mean and standard deviation values for the proportion and frequency of lymphocytes, CD3+, CD4+, and CD8+ 
populations in controls and T1D subjects. 
1controls n=23, 2T1D n=15 
 
The effects of moderate (40% VO2 max) and vigorous (80% VO2 max) intensity exercise on 
the frequency of lymphocyte subpopulations (cells/μl) were investigated in T1D and control 
participants.  
Lymphocyte subpopulations were measured pre, post, and 1 hour post exercise. The change 
over time was analysed in groups combined under the heading “time (overall)” and in each 
group independently (time) displayed in all results tables. The interaction over time between 
mean SD mean SD
Lymphocyte (cells/μl) 1348 398 1375 262
CD3 (%) 58.73 18.98 49.86 28.06
CD3 (cells/μl) 805.6 381.7 695.0 340.1
CD4 (%) 53.52 6.70 57.03 9.24
CD4 (cells/μl) 610.0 253.5 580.9 316.8
CD8 (%) 35.18 5.32 35.92 7.35
CD8 (cells/μl) 386.8 166.0 348.9 192.6
1Controls 2T1D




groups was compared and results are displayed under the heading “time*group”. Post and 1 
hour post exercise measurements were compared to baseline levels as shown under the heading 
“contrasts” displayed in the results tables. The mean, standard deviation, and statistical 
analyses are displayed in Table 27.  
There was an overall change over time in lymphocytes during moderate intensity exercise 
(p=0.021), but this was not seen in either the T1D or control group independently. 
Lymphocytes were increased immediately post moderate intensity exercise in controls 
(p=0.046) but not in the T1D group (Figure 29a). Lymphocytes were significantly mobilised 
by vigorous intensity exercise overall (p<0.001), and in both T1D (p=0.002) and control 
(p<0.001) groups independently. They were significantly increased immediately post vigorous 
exercise in T1D (p=0.003) and controls (p<0.001), but significantly decreased below baseline 
in controls only 1 hour post vigorous exercise (p=0.032) (Figure 29b).  
There was an overall change over time in the frequency of CD3+ cells during moderate intensity 
exercise (p=0.029), but this was not seen in either group independently (Figure 29c). CD3+ 
cells were significantly mobilised by vigorous intensity exercise overall (p<0.001), and in T1D 
(p=0.008) and control (p=0.001) groups independently. CD3+ cells were significantly increased 
immediately post vigorous exercise in T1D (p=0.048) and controls (p=0.030), but significantly 





Figure 29 Lymphocyte and CD3+ cell frequencies during moderate and vigorous exercise in control and 
T1D groups 
Flow cytometry and whole blood cell counts were used to determine the frequency of lymphocytes and CD3+ 
populations in control and T1D participants during moderate and vigorous intensity exercise. (a) Frequency of 
lymphocytes during moderate intensity (b) Frequency of lymphocytes during vigorous intensity exercise (c) The 
frequency of CD3+ cells during low intensity (d) The frequency of CD3+ cells during vigorous intensity. Error 
bars represent SEM. Statistical significance represented by * p<0.05, ** p<0.01, ***p<0.001. 









Table 27 Lymphocytes and CD3+ populations mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation and statistical analysis of lymphocytes and CD3+ populations for control and T1D subjects during moderate and vigorous intensity exercise. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 




Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
Lymphocytes moderate 1290.91 350.58 1754.55 759.43 1340.00 435.12 F(1.2, 12.1)= 4.177, p=0.058 T2 F(1, 10)= 5.202, p=0.046 35.92 1400.00 310.91 1814.29 893.36 1350.00 216.79 F(1.05, 5.3)= 3.405, p=0.074 T2 F(1, 5)= 2.925, p=0.148 29.59 F(1.2, 15.8)= 6.209, p=0.021 F(1.2, 15.8)= 0.230, p=0.667
T3 F(1, 10)= 0.013, p=0.912 3.80 T3 F(1, 5)= 4.000, p=0.102 3.57
vigorous 1400.00 445.18 2400.00 475.39 1233.33 336.65 F(1.26, 13.9)= 46.127, p<0.001 T2 F(1, 11)= 55.113, p<0.001 71.43 1355.56 235.11 2088.89 658.49 1255.56 174.01 F(1.1, 8.8)= 319.030, p=0.002 T2 F(1, 8)= 18.615, p=0.003 54.10 F(1.24, 22.4)= 74.637, p<0.001 F(1.24, 22.4)= 1.867, p=0.185
T3 F(1, 11)= 6.044, p=0.032 11.90 T3 F(1, 8)= 4.500, p=0.067 7.38
CD3 moderate 687.29 286.59 938.15 514.82 733.70 403.06 F(2, 20)= 3.397, p=0.054 T2 F(1, 10)= 2.862, p=0.122 36.50 698.67 269.53 838.30 320.03 469.46 340.67 F(1.1, 5.5)= 2.315, p=0.184 T2 F(1, 5)= 1.923, p=0.224 19.98 F (2, 26)= 4.069, p=0.029 F (2, 26)= 0.483, p=0.572
T3 F(1, 10)= 0.417, p=0.533 6.75 T3 F(1, 5)= 2.41, p=0.181 32.81
vigorous 923.84 438.08 1259.75 494.55 614.76 222.14 F(2, 22)= 10.144, p=0.001 T2 F(1,11)= 6.217, p=0.030 36.36 692.14 402.88 942.91 522.38 581.22 373.82 F(2, 16)= 6.612, p=0.008 T2 F(1, 8)= 5.417, p=0.048 36.23 F(1.33, 22.6)= 14.429, p<0.001 F(1.33, 22.6)= 0.345, p=0.625
T3 F(1, 11)= 7.463, p=0.020 33.46 T3 F(1, 8)= 6.428, p=0.035 16.03
ccontrast
1Controls 2T1D
T1 T2 T3 ccontrast T1 T2 T3
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5.3.2 CD4+ T cells  
5.3.2.1 CD4+ T cells at baseline in T1D and control participants  
CD4+ T cells subsets were analysed in T1D and control participants at baseline, before 
proceeding to assessing the effect of exercise on the following populations: naïve 
(CD45RA+CCR7+), CM (CD45RA-CCR7+), EM (CD45RA-CCR7-) ED (CD45RA-CCR7-
CD27+CD28+), ELD (CD45RA-CCR7-CD27-CD28+), ID (CD45RA-CCR7-CD27+CD28-) and 
EMRA (CD45RA+CCR7-) [430]. 
The proportion and frequency of CD4+ EMRA cells were reduced in T1D compared to the 
control group (p=0.015, p=<0.0001 respectively) (Figure 30). However, there were no 
differences in the proportion or frequency of CD4+ CM, EM, ED, ELD or ID CD4+ T cells 
between groups. The mean and SD values for these subsets are displayed in Table 28.  
 
Figure 30 The proportion and frequency of CD4+ T cell subsets at baseline in T1D and control groups. 
Flow cytometry and whole blood cell counts were used to determine the frequency of CD4+ sub populations in 
control and T1D participants at baseline. (a) Proportion of CD4+ subpopulations in control and T1D groups (b) 
Frequency of CD4+ subpopulations in control and T1D groups. Error bars represent SEM. Statistical significance 
represented by * p<0.05, ** p<0.01, ***p<0.001. Note: broken line (----) represents time*group differences. 






Table 28 CD4+ T cell sub populations at baseline in T1D and controls. 
Mean and standard deviation values for the proportion and frequency of CD4+ subpopulations in control and 
T1D groups. 
1 controls n=23, 2 T1D n=15 
naïve CM EM ED ELD ID EMRA
mean SD mean SD mean SD mean SD mean SD mean SD mean SD
CD4 (%) 22.53 18.16 23.01 10.11 50.79 19.92 45.02 23.83 33.97 27.37 12.92 16.61 3.57 2.23
CD4 (cells/μl) 90.45 145.04 85.12 57.42 204.06 150.11 114.92 117.47 64.53 54.17 19.55 26.71 13.98 11.72
CD4 (%) 17.36 20.52 21.55 9.98 59.48 23.71 36.15 34.77 52.44 37.07 2.74 6.03 1.88 1.09
CD4 (cells/μl) 109.00 187.15 93.84 73.37 203.31 110.06 79.74 113.33 92.37 82.76 20.98 21.26 6.96 5.06
1Controls
2T1D




5.3.2.2 CD4+ T cell phenotype at baseline in T1D and control participants 
 
A number of cell surface markers were measured on CD4+ T cells to define the homing 
propensity and function of circulating CD4+ populations in T1D and control participants. These 
were examined on naïve, CM, EM, and EMRA CD4+ T cell subsets. CD69 was used as a 
marker of tissue-resident CD4+ T cells to understand where they had migrated from. This is in 
contrast to CCR7+ cells which migrate from lymph nodes rather than tissue [431, 432]. CD11b, 
is an adhesion molecule which identifies CD4+ T cells subsets with tissue homing propensity 
[433]. CD127, otherwise known as IL-7Ra, is necessary for memory CD4+ T cell maintenance 
[434]. Lastly, CD95 is highly expressed on memory populations. CD95 is also a marker for 
apoptosis and may underlie memory T cell lymphopenia during the recovery period post 
exercise [216, 218-220]. Baseline levels for the proportion and frequency of these markers on 
CD4+ subsets are shown in Table 29.  
5.3.2.2i CD69 
 
There were no significant differences between groups in CD69+ expression on CD4+ naïve, 
CM, EM or EMRA populations (Table 29). This indicates that both groups had an equal amount 




The proportion CD4+CD11b+ CM cells was significantly higher in T1D compared to control 
participants (p=0.027). There were no significant differences in CD11b+ expression on CD4+ 
naïve, EM or EMRA populations (Table 29). This suggests that CD4+ CM T cells have a higher 
homing propensity in T1D participants than controls.  
5.3.2.2iii CD127 
 




The proportion of CD4+CD127+ naïve and CD4+CD127+ EMRA cells were significantly higher 
in T1D compared to control participants (p=0.047, p=0.023 respectively). There were no 
significant differences in CD127+ expression on CD4+ CM or EM populations (Table 29). This 
suggests that CD4+ naïve and CD4+ EMRA cells expressing higher IL-7Rα (CD127) are 
preferentially maintained in T1D.  
5.3.2.2iv CD95 
 
There were no significant differences between groups in CD95+ expression on CD4+ naïve, 
CM, EM or EMRA populations (Table 29). This suggests that both groups had an equal amount 
of CD4+ T cells expressing CD95 on lineage subsets. 
5.3.2.2v EMRA differentiation (CD27/CD28) 
 
It has been assumed that EMRA are CD27-CD28- (fully differentiated) however recent studies 
have shown the presence of mixed differentiated subsets of CD4+ EMRA in healthy and ageing 
cohorts [409]. In this study herein, differentiated subsets of CD4+ EMRA were identified in 
T1D. There was a significant difference in the proportion and frequency of CD4+ CD27+CD28- 
EMRA (early-like differentiation stage) between groups (p=0.014, p=0.001 respectively) 
(Figure 31a and b). A significant difference in the frequency of CD4+CD27+CD28+ EMRA 
(early differentiation stage) was also found (p=0.031) (Figure 31b). Table 30 displays the mean 




Figure 31 The proportion and frequency of differentiated CD4+ EMRA T cell subsets at baseline in T1D 
and control groups.  
Flow cytometry and whole blood counts were used to determine the differentiation CD4+ EMRA populations using CD27 and 
CD28 in control and T1D subjects (a) The proportion of differentiated CD4+ EMRA subsets (b) The frequency of 
differentiated CD4+ EMRA subsets. Error bars represent SEM. Statistical significance represented by * p<0.05, ** 
p<0.01, ***p<0.001. Note: broken line (----) represents time*group differences. 






Table 29 Surface marker expression on CD4+ naïve, CM, EM, and EMRA populations at baseline in T1D 
and controls 
Mean and standard deviation values for the proportion and frequency of CD69+, CD11b+, CD127+, and CD95+ 
CD4+ naïve, CM, EM, and EMRA populations in controls and T1D subjects. 






Table 30 Differentiated CD4+ EMRA T cell subsets at baseline in T1D and control groups. 
Mean and standard deviation values for the proportion and frequency of differentiated CD4+ EMRA subsets in 
controls and T1D subjects. 
1controls n=22, 2T1D n=15 
 
5.3.2.3 CD4+ T cell subsets in response to acute exercise in T1D and control participants  
 
mean SD mean SD mean SD mean SD
CD4 naïve 2.67 2.60 2.31 3.41 89.31 9.62 7.19 21.72
CD4 CM 3.12 2.22 2.34 2.86 84.86 8.50 19.40 25.61
CD4 EM 3.32 2.06 2.17 1.99 84.89 6.00 23.25 26.17
CD4 EMRA 4.57 4.63 5.48 7.38 77.87 11.23 9.42 24.46
CD4 naïve 5.02 6.02 1.56 2.73 86.61 90.04 0.97 1.04
CD4 CM 2.45 2.24 2.17 2.40 76.14 52.01 0.25 0.29
CD4 EM 6.00 4.75 4.23 4.41 190.76 138.35 42.20 57.04
CD4 EMRA 0.56 0.46 0.73 1.01 10.78 9.20 1.46 2.63
CD4 naïve 2.06 3.04 0.94 1.94 95.01 4.04 13.61 25.84
CD4 CM 2.33 1.59 0.57 0.95 85.71 9.20 36.71 30.92
CD4 EM 3.44 1.95 9.03 23.19 87.04 6.21 35.63 34.26
CD4 EMRA 7.79 7.17 6.53 12.01 86.15 7.43 19.36 31.54
CD4 naïve 4.44 9.68 0.88 1.96 110.03 190.47 7.34 16.88
CD4 CM 2.01 1.87 0.94 1.40 82.97 71.19 0.62 1.32
CD4 EM 6.68 4.64 14.89 38.55 176.69 98.06 76.34 102.00









CD28-CD27- CD28-CD27+ CD28+CD27- CD28+CD27+
mean SD mean SD mean SD mean SD
CD4 (%) 10.69 10.38 27.33 27.93 18.08 24.21 44.07 29.10
CD4 (cells/μl) 7.57 11.53 5.55 9.32 2.25 4.50 6.06 6.33
CD4 (%) 8.64 19.65 5.31 8.66 39.37 37.18 47.01 37.39
CD4 (cells/μl) 22.02 57.34 0.10 0.18 2.66 4.37 2.13 3.15
1Controls
2T1D




The effects of moderate (40% VO2 max) and vigorous (80% VO2 max) intensity exercise on 
CD4+ subsets were examined (Table 31). The results are given in progressive order of 
differentiation in Table 31.  
CD4+ T cells were mobilised by vigorous intensity exercise in the control group (p=0.028) but 
not in the T1D group. Within the CD4+ population, three subsets showed significant 
mobilisation during moderate and/or vigorous intensity exercise; CM, ED, and EMRA.  
CD4+ CM significantly mobilised overall during moderate (p=0.029) and vigorous (p=0.040) 
intensity but this was not seen in either T1D or control groups independently. There were no 
significant changes seen immediately post or 1 hour post moderate or vigorous exercise (Table 
31).  
CD4+ ED significantly mobilised during moderate intensity exercise in the control group only 
(p=0.029). There was a significant decrease below baseline at 1 hour post moderate exercise in 
this subset (p=0.018). CD4+ ED changes over time were significantly different between groups 
(p=0.010) (time*group). Both groups showed a similar percentage increase post moderate 
exercise (T1D:14.87%, control: 12.53%). However, the fall below baseline 1 hour post 
moderate exercise was much larger in the T1D group compared to controls. There were fewer 
participants in the T1D group for this time-point which may contribute to a skewed difference 
in response. There were no significant changes in CD4+ ED during vigorous intensity exercise 
in either group (Table 31).  
CD4+ EMRA significantly mobilised (p=0.039) with moderate intensity exercise in the control 
group only. There was a trend to fall below baseline at 1 hour post moderate exercise in this 
subset (p=0.067). CD4+ EMRA did not show significant mobilisation during vigorous intensity 
exercise. However, CD4+ EMRA significantly fell below baseline at 1 hour post vigorous 
exercise in the control group following vigorous intensity exercise (p=0.029) (Table 31).  




There were no significant changes in CD4+ naïve, EM, ELD or ID during moderate or vigorous 
intensity in either group (Table 31).  






Table 31 CD4+ T cell sub populations mobilised by moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of CD4+ sub populations for control and T1D subjects during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1Controls n=11, 2T1D n =6-9 
dTime (overall) dTime*Group
Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
Total CD4 moderate 707.02 204.45 939.65 438.80 715.06 280.96 F(2, 20)= 2.617, p=0.098 T2 F(1, 10)= 1.467, p=0.254 32.90 815.54 220.42 1014.44 366.69 772.06 226.57 F(2, 10)= 2.472, p=0.134 T2 F(1, 5)= 3.230, p=0.132 24.39 F (2, 26)= 3.306, p=0.053 F (2, 26)= 0.252, p=0.779
T3 F(1, 10)= 1.142, p=0.310 1.14 T3 F(1, 5)= 1.703, p=0.249 5.33
vigorous 512.94 269.18 628.42 291.04 319.58 121.06 F(2, 22)= 4.290, p=0.028 T2 F(1, 10)= 2.087, p=0.179 22.51 398.44 257.07 511.93 302.77 356.99 251.93 F(1.1, 8.82)= 3.506, p=0.092 T2 F(1, 8)= 3.596, p=0.094 28.48 F(1.31, 20.9)= 5.859, p=0.018 F(1.31, 20.9)= 0.311, p=0.644
T3 F(1, 10)= 4.815, p=0.053 37.70 T3 F(1, 8)= 0.910, p=0.368 10.40
CD4 naïve moderate 93.73 119.16 112.04 131.14 84.75 100.64 F(2, 20)= 1.624, p=0.222 T2 F(1, 10)= 0.398, p=0.542 19.53 142.84 210.45 169.83 224.61 48.81 48.33 F(2,10)= 0.366, p=0.702 T2 F(1, 5)= 0.340, p=0.585 18.90 F(1.1, 13.2)= 2.398, p=0.144 F(1.1, 13.2)= 2.536, p=0.133
T3 F(1, 10)= 1.126, p=0.314 9.58 T3 F(1, 5)= 0.454, p=0.530 65.83
vigorous 107.02 86.43 122.49 130.99 74.07 42.46 F(1.25, 12.5)= 0.541, p=0.590 T2 F(1, 10)= 0.643, p=0.441 14.45 86.44 179.40 112.23 187.25 77.05 149.60 F(2,16)= 1.074, p=0.365 T2 F(1, 6)= 1.779, p=0.219 29.84 F (1.12, 17.9)= 0.092, p=0.793 F (1.12, 17.9)= 1.300, p=0.275
T3 F(1, 10)= 1.522, p=0.246 30.79 T3 F(1, 6)= 0.052, p=0.825 10.87
CD4 CM moderate 75.95 50.19 89.93 57.88 71.43 36.39 F(2, 20)= 2.185, p=0.139 T2 F(1, 10)= 1.009, p=0.339 18.41 139.08 70.99 171.38 114.70 99.26 65.61 F(2, 8)= 3.055, p=0.103 T2 F(1, 4)= 2.066, p=0.224 23.23 F (2, 24)=4.123, p=0.029 F (2, 24)= 1.252, p=0.126
T3 F(1, 10)= 0.964, p=0.349 5.94 T3 F(1, 4)= 2.634, p=0.180 28.63
vigorous 93.53 64.36 107.32 68.03 81.44 44.53 F(2, 20)= 2.125, p=0.146 T2 F(1, 10)= 0.709, p=0.419 14.75 63.69 60.94 102.84 90.52 60.25 60.93 F(1.06, 8.45)= 3.096, p=0.114 T2 F(1, 8)= 3.318, p=0.106 61.47 F (2, 32)=3.552, p=0.040 F (2, 32)=0.917, p=0.410
T3 F(1, 10)= 01.842, p=0.205 12.92 T3 F(1, 8)= 0.418, p=0.536 5.40
CD4 EM moderate 183.52 116.82 210.82 137.22 166.70 100.61 F(1.2, 12.4)= 1.249, p=0.297 T2 F(1, 10)= 0.069, p=0.799 14.88 276.04 87.90 313.00 105.71 284.55 137.07 F(2,10)= 0.738, p=0.503 T2 F(1, 5)= 0.094, p=0.771 13.39 F (2, 24)=  1.076, p=0.357 F (2, 24)= 0.240, p=0.789
T3 F(1, 10)= 1.214, p=0.296 9.17 T3 F(1, 5)= 1.170, p=0.329 3.08
vigorous 222.89 178.47 294.17 253.01 188.04 144.15 F(1.2, 12.3)= 2.051, p=0.177 T2 F(1, 10)= 0.261, p=0.620 31.98 154.82 98.78 221.62 134.35 145.01 111.24 F(1.18, 9.5)= 1.335, p=0.285 T2 F(1, 8)= 0.402, p=0.544 43.14 F(1.3, 19.9)= 2.262, p=0.145 F(1.3, 19.9)=  0.274, p=0.658
T3 F(1, 10)= 2.301, p=0.160 15.64 T3 F(1, 8)= 3.629, p=0.093 6.34
CD4 ED moderate 80.89 95.74 91.03 117.69 50.68 63.05 F(2, 18)= 4.341, p=0.029 T2 F(1, 9)= 0.233, p=0.640 12.53 116.47 181.71 133.79 192.19 22.27 0.00 F(2,8)= 0.478, p=0.636 T2 F(1, 4)= 0.569, p=0.493 14.87 F(2, 16)= 5.943, p=0.012 F(2, 16)= 6.308 p=0.010
T3 F(1, 9)= 8.289, p=0.018 37.35 T3 F(1, 4)= 0.572, p=0.491 80.88
vigorous 148.96 131.88 196.75 174.51 133.70 105.19 F(1.1, 9.7)= 0.758, p=0.415 T2 F(1, 9)= 0.847, p=0.381 32.09 64.00 85.42 82.53 85.71 58.79 85.44 F(1.1, 6.5)= 0.720, p=0.438 T2 F(1, 6)= 0.191, p=0.677 28.95 F(1.2, 15.5)= 3.739, p=0.066. F(1.2, 15.5)= 0.036, p=0.889
T3 F(1, 6)= 0.524, p=0.488 10.24 T3 F(1, 6)= 2.206, p=0.188 8.14
CD4 ELD moderate 53.10 43.78 69.22 61.57 48.29 47.86 F(2, 18)= 2.899, p=0.081 T2 F(1, 9)= 0.847, p=0.381 30.35 143.09 91.03 197.87 131.04 134.58 0.00 F(2,8)= 1.155, p=0.363 T2 F(1, 4)= 0.358, p=0.582 38.29 F(2, 16)= 2.506, p=0.113 F(2, 16)= 1.798, p=0.198
T3 F(1, 9)= 2.087, p=0.182 9.07 T3 F(1, 4)= 1.866, p=0.244 5.95
vigorous 75.96 63.15 117.72 85.08 67.49 48.91 F(1.2, 10.8)= 1.980, p=0.189 T2 F(1, 9)= 1.597, p=0.238 54.97 70.64 75.33 86.24 86.95 64.15 75.73 F(1.172, 7)= 0.909, p=0.390 T2 F(1, 6)= 0.089, p=0.775 22.09 F(1.1, 14.1)= 1.149, p=0.308 F(1.1, 14.1)= 0.283, p=0.622.
T3 F(1, 9)= 1.766, p=0.217 11.16 T3 F(1, 6)= 5.243, p=0.062 9.18
CD4 ID moderate 24.87 34.80 20.92 25.29 34.48 41.89 F(2, 18)= 0.313, p=0.735 T2 F(1, 9)= 0.886, p=0.371 15.89 1.16 2.01 0.99 1.71 0.00 0.00 F(2,8)= 0.106, p=0.901 T2 F(1, 4)= 0.026, p=0.880 14.89 F(1.2, 9.5)= 4.733, p=0.051 F(1.2, 9.5)= 1.484, p=0.260
T3 F(1, 9)= 0.000, p=0.991 38.64 T3 F(1, 4)= 0.434, p=0.546 100.00
vigorous 14.22 15.22 12.74 13.78 12.25 13.53 F(1, 9.4)= 0.524, p=0.494 T2 F(1, 9)= 0.210, p=0.658 10.45 25.93 20.99 35.35 26.47 19.22 11.57 F(1.1, 6.4)= 0.180, p=0.700 T2 F(1, 6)= 0.179, p=0.687 36.29 F(1.2, 15.3)= 1.696, p=0.215 F(1.2, 15.3)=  0.285, p=0.638.
T3 F(1, 9)= 2.684, p=0.136 13.87 T3 F(1, 6)= 0.143, p=0.719 25.90
CD4 EMRA moderate 14.59 14.52 16.01 13.44 12.73 13.30 F(2, 20)= 3.823, p=0.039 T2 F(1, 10)= 0.361, p=0.561 9.75 8.20 3.19 11.32 3.41 15.36 18.04 F(2,10)= 0.961, p=0.415 T2 F(1, 5)= 2.932, p=0.148 37.97 F (2, 24)= 0.126, p=0.853 F (2, 24)= 1.716, p=0.496
T3 F(1, 10)= 4.228, p=0.067 12.75 T3 F(1, 5)= 0.373, p=0.568 87.21
vigorous 13.42 9.07 16.54 14.76 9.46 7.71 F(1.2, 12)= 2.851, p=0.113 T2 F(1, 10)= 0.405, p=0.539 23.26 6.13 6.04 12.00 16.36 6.22 5.65 F(1.26, 10)= 2.032, p=0.185 T2 F(1, 8)= 2.161, p=0.180 95.70 F(1.4, 23.8)= 2.117, p=0.154 F(1.4, 23.8)=0.748, p=0.439
T3 F(1, 10)= 6.467, p=0.029 29.49 T3 F(1, 8)= 0.004, p=0.951 1.42
1Controls 2T1D
T1 T2 T3 ccontrast T1 T2 T3 ccontrast




5.3.2.4 CD4+ T cell subset phenotypes in response to acute exercise in T1D and control 
participants 
As shown for CD4+ T cell subsets at baseline, surfaces markers were used to examine the 
homing propensity and function of CD4+ T cell subsets mobilised during moderate (40% VO2 
max) and vigorous (80% VO2 max) intensity exercise. The mean, standard deviation, and 
statistical analyses are displayed in Table 32. 
5.3.2.4i CD69 
 
There were no significant changes in CD4+ CD69+ naïve subsets during moderate or vigorous 
exercise.  
The frequency of CD4+CD69+ CM cells were significantly mobilised by vigorous intensity in 
the control group (p=0.049). There was a significant increase post vigorous exercise in the 
control group (p=0.018). There was an overall significant change in CD4+CD69+ CM subsets 
during moderate intensity (p=0.044) but not seen in either T1D or control groups 
independently.  
The frequency of CD4+CD69+ EM cells were significantly mobilised during moderate intensity 
in T1D but not control groups (p=0.043). CD4+CD69+ EM subsets were significantly mobilised 
during vigorous intensity in the control group (p=0.007), but not in the T1D group, increasing 
significantly post vigorous exercise in controls only (p=0.012).  
The frequency of CD4+CD69+ EMRA T cells showed a trend to change over time during 
moderate intensity exercise (p=0.051). However, there was a significant change in frequency 
over time post vigorous intensity exercise overall (p=0.029) but this is not seen in either T1D 
or control groups separately (Table 32).  






There were no significant changes in the frequency of CD4+CD11b+ naïve cells during 
moderate or vigorous exercise.  
The frequency of CD4+CD11b+ CM cells significantly fell below baseline following vigorous 
intensity in T1D group only (p=0.038). There were no significant changes in this subset during 
moderate intensity exercise. 
The frequency of CD4+CD11b+ EM cells significantly mobilised during vigorous intensity in 
controls but not T1D (p=0.013), increasing significantly post vigorous exercise (p=0.020). 
There were no significant changes in this subset during moderate intensity exercise. 
The frequency of CD4+CD11b+ EMRA cells significantly changed during moderate intensity 
exercise in the control group only (p=0.028), decreasing below baseline at 1 hour post moderate 




There were no significant changes in CD4+ naïve, CM or EM CD127+ subsets during moderate 
or vigorous exercise.  
The frequency of CD4+CD127+ EMRA cells were significantly mobilised during moderate 
intensity exercise in controls only (p=0.035). CD4+CD127+ EMRA were significantly 
increased immediately post vigorous exercise in the control group only (p=0.028) (Table 32). 
  






There were no changes in CD4+ CM, EM or EMRA CD95+ subsets during moderate or 
vigorous exercise.  
The frequency CD4+CD95+ naïve cells significantly changed over time during vigorous 
intensity exercise overall but not in either T1D or control group independently (p=0.003). There 
were no significant changes in this subset during moderate intensity exercise (Table 32). 
5.3.2.4v EMRA differentiation (CD27/CD28) 
 
Data for vigorous intensity exercise only in T1D and both exercise intensities in control 
participants is shown (Table 32). There were no changes in CD4+ EMRA CD27+CD28+ (early 
differentiation stage), CD4+ EMRA CD27+CD28- (early-like differentiation stage) or CD4+ 
EMRA CD27-CD28- (fully differentiated) subsets during moderate or vigorous exercise.  
The frequency of CD4+CD27-CD28+ EMRA (intermediate differentiation stage) significantly 
mobilised during vigorous intensity exercise in controls only (p=0.025). There were no 
significant changes in this subset during moderate intensity exercise. 




Table 32 Surface marker expression on CD4+ naïve, CM, EM, and EMRA populations mobilised by moderate and vigorous intensity exercise in control and T1D 
groups 
Mean, standard deviation, and statistical analysis of CD69+, CD11b+, CD127+, and CD95+ CD4+ naïve, CM, EM, and EMRA populations for control and T1D subjects 
during moderate and vigorous intensity exercise. Significant results highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 






Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
CD4 Na CD69+ moderate 6.85 7.83 4.85 7.51 6.18 7.45 F(2, 20)= 0.678, p=0.519 T2 F(1, 10)= 0.554, p=0.074 29.20 9.08 14.74 9.11 11.46 11.71 13.33 F(2,10)= 0.099, p=0.907 T2 F(1, 5)= 0.068, p=0.804 0.28 F(1.1, 12.8)= 3.186 p=0.096 F(1.1, 12.8)=  2.485, p=0.105
T3 F(1, 10)= 0.119, p=0.737 9.76 T3 F(1, 5)= 0.123, p=0.740 28.94
vigorous 3.01 1.98 6.14 8.09 4.19 2.59 F(1.3, 11.75)= 42.393, p=0.12 T2 F(1, 9)= 4.185, p=0.071 103.82 3.59 6.77 3.48 7.05 4.17 5.71 F(2,16)= 0.716, p=0.504 T2 F(1, 8)= 1.851, p=0.211 3.19 F(1.1, 16.8)= 0.083, p=0.790 F(1.1, 16.8)=  1.671, p=0.215
T3 F(1, 9)= 3.966, p=0.078 39.07 T3 F(1, 8)= 0.001, p=0.971 16.28
CD4 CM CD69+ moderate 2.77 2.65 3.07 2.93 2.82 2.54 F(2, 20)= 0.343, p=0.714 T2 F(1, 10)= 0.054, p=0.821 10.73 3.12 2.07 3.94 2.29 2.19 2.12 F(2, 10)= 0.261, p=0.775 T2 F(1, 5)= 0.041, p=0.848 26.35 F (2, 26)=  3.529 p=0.044 F (2, 26)= 1.584, p=0.224
T3 F(1, 10)= 0.325, p=0.581 1.60 T3 F(1, 5)= 0.523, p=0.502 29.83
vigorous 2.08 1.76 4.69 3.74 2.58 2.40 F(2, 18)= 3.585, p=0.049 T2 F(1, 9)= 8.299, p=0.018 124.81 1.27 1.37 1.74 2.04 1.18 1.40 F(2, 16)=  1.317, p=0.296 T2 F(1, 8)= 0.962, p=0.355 36.57 F(1.1, 27.7)= 3.805 p=0.056 F(1.1, 27.7)= 1.192, p=0.302
T3 F(1, 9)= 0.462, p=0.514 13.21 T3 F(1, 8)= 0.954, p=0.357 7.41
CD4 EM CD69+ moderate 6.29 5.02 6.94 7.02 7.54 8.14 F(1.3, 12.9)= 0.525, p=0.526 T2 F(1, 10)= 0.017, p=0.899 10.35 7.78 2.94 8.01 3.10 6.91 2.45 F(2,10)= 4.376, p=0.043 T2 F(1, 5)= 1.555, p=0.268 2.90 F (2, 24)= 0.376, p=0.691 F (2, 24)= 0.125, p=0.883
T3 F(1, 10)= 0.526, p=0.485 19.89 T3 F(1, 5)= 1.978, p=0.219 11.29
vigorous 5.67 4.69 16.94 23.81 6.80 5.12 F(2, 20)= 6.647, p=0.007 T2 F(1, 9)= 9.924, p=0.012 198.59 5.94 5.54 9.78 9.92 5.85 6.42 F(2, 16)=  2.104, p=0.154 T2 F(1, 8)= 1.675, p=0.232 64.50 F(1.4, 20.8)= 6.303, p=0.013 F(1.4, 20.8)=  0.188, p=0.748
T3 F(1, 9)= 2.764, p=0.131 19.89 T3 F(1, 8)= 0.034, p=0.858 1.56
CD4 EMRA CD69+ moderate 0.64 0.51 0.73 0.61 0.62 0.51 F(2, 20)= 1.321, p=0.289 T2 F(1, 10)= 0.395, p=0.544 14.18 0.65 0.46 0.74 0.95 0.88 1.08 F(2, 12)= 0.965, p=0.409 T2 F(1, 6)= 1.761, p=0.233 12.43 F (2, 24)= 3.366 p=0.051 F (2, 24)= 0.452, p=0.641
T3 F(1, 10)= 1.281, p=0.284 3.32 T3 F(1, 6)= 0.095, p=0.769 34.84
vigorous 0.48 0.42 1.15 1.03 0.60 0.82 F(2, 22)= 0.918, p=0.414 T2 F(1, 11)= 0.037, p=0.851 139.75 0.33 0.25 0.43 0.47 0.24 0.21 F(2,20)= 2.965, p=0.075 T2 F(1, 10)= 0.686, p=0.427 28.65 F (2, 32)= 3.963, p=0.029 F (2, 32)= 1.463, p=0.247
T3 F(1, 11)= 0.852, p=0.376 25.21 T3 F(1, 10)= 3.083, p=0.110 28.47
ccontrast
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Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
CD4 Na CD11b+ moderate 2.78 3.49 2.44 2.84 1.85 1.77 F(2, 20)= 1.856, p=0.182 T2 F(1, 10)= 0.071, p=0.796 12.19 2.04 2.84 2.86 4.35 4.40 5.10 F(2,10)= 0.495, p=0.624 T2 F(1, 5)= 0.840, p=0.401 40.74 F (2, 24)=2.413 p=0.111 F (2, 24)= 0.262, p=0.772
T3 F(1, 10)= 2.208, p=0.168 33.51 T3 F(1, 5)= 2.208, p=0.168 116.26
vigorous 1.84 3.43 6.58 17.27 1.47 1.77 F(1.3, 13.2)= 0.919, p=0.384 T2 F(1, 10)= 2.732, p=0.129 257.97 0.21 0.28 0.43 0.66 0.22 0.25 F(2,16)= 1.673, p=0.219 T2 F(1, 8)= 2.887, p=0.128 99.25 F(1.3, 20.8)= 0.057, p=0.872. F(1.3, 20.8)= 1.462, p=0.248
T3 F(1, 10)= 0.376, p=0.553 20.03 T3 F(1, 8)= 0.074, p=0.793 5.03
CD4 CM CD11b+ moderate 2.35 2.84 2.18 2.66 1.58 1.77 F(2, 20)= 2.296, p=0.127 T2 F(1, 10)= 0.024, p=0.880 7.10 1.42 2.08 1.97 2.39 2.48 3.03 F(2, 10)= 1.460, p=0.278 T2 F(1, 5)= 0.126, p=0.737 39.08 F (2, 24)=1.553 p=0.232 F (2, 24)=1.553, p=0.446
T3 F(1, 10)= 3.124, p=0.108 32.71 T3 F(1, 5)= 3.543, p=0.119 75.34
vigorous 1.98 1.94 4.26 6.49 1.90 2.09 F(2, 18)= 1.288, p=0.300 T2 F(1, 9)= 53.697, p=0.087 114.75 0.61 0.65 0.61 0.53 0.39 0.42 F(1.16, 9.37)= 1.696, p=0.228 T2 F(1, 8)= 0.012, p=0.916 1.05 F(1.3, 22.2)= 1.646 p=0.218 F(1.3, 22.2)= 0.465, p=0.552
T3 F(1, 9)= 0.060, p=0.813 4.19 T3 F(1, 8)= 6.165, p=0.038 35.81
CD4 EM CD11b+ moderate 5.67 5.43 4.03 5.05 3.73 4.26 F(2, 20)= 0.259, p=0.774 T2 F(1, 10)= 2.937, p=0.117 28.99 6.36 8.52 5.89 7.89 5.74 6.47 F(2,10)= 3.201, p=0.084 T2 F(1, 5)= 0.043, p=0.844 7.36 F(1.16, 22)= 3.749 p=0.070 F(1.16, 22)= 0.063, p=0.841
T3 F(1, 10)= 5.916, p=0.035 34.16 T3 F(1, 5)= 2.668, p=0.163 9.75
vigorous 2.80 2.60 7.12 8.41 3.14 3.38 F(2, 20)= 5.498, p=0.013 T2 F(1, 10)= 7.649, p=0.020 154.34 20.01 48.57 4.15 5.31 2.12 3.38 F(1.2, 9.8)= 2.022, p=0.187 T2 F(1, 8)= 0.682, p=0.433 79.27 F(1.3, 21.5)= 2.012 p=0.169 F(1.3, 21.5)=  1.908, p=0.181
T3 F(1, 10)= 0.338, p=0.574 12.11 T3 F(1, 8)= 3.305, p=0.107 89.40
CD4 EMRA CD11b+ moderate 1.11 1.29 0.82 1.07 0.59 0.67 F(2, 20)= 4.315, p=0.028 T2 F(1, 10)= 1.801, p=0.209 26.08 0.72 1.07 1.04 1.51 1.26 1.57 F(1.1, 6.4)= 0.553, p=0.548 T2 F(1, 6)= 1.384, p=0.284 44.03 F (2, 24)= 4.080 p=0.030 F (2, 24)= 0.381, p=0.687
T3 F(1, 10)= 6.170, p=0.032 47.11 T3 F(1, 6)= 0.028, p=0.873 74.88
vigorous 0.34 0.40 1.13 2.63 0.37 0.60 F(2, 22)= 1.982, p=0.162 T2 F(1, 11)= 4.052, p=0.069 229.13 0.12 0.20 0.09 0.12 0.05 0.08 F(2,20)= 1.170, p=0.331 T2 F(1, 10)= 0.213, p=0.654 24.69 F(1.3,23.2)= 0.947 p=0.364 F(1.3,23.2)= 0.854, p=0.393
T3 F(1, 11)= 0.284, p=0.604 7.22 T3 F(1, 10)= 2.339, p=0.157 55.46
CD4 Na  CD127+ moderate 92.83 116.60 112.98 127.51 87.14 99.01 F(2, 18)= 1.370, p=0.279 T2 F(1, 9)= 0.531, p=0.485 21.71 139.79 208.63 166.55 222.33 58.79 44.98 F(2,10)= 0.523, p=0.608 T2 F(1, 5)= 0.271, p=0.625 19.15 F (2, 24)=2.413 0.588 p=0.561 F (2, 24)=2.4131.382, p=0.270
T3 F(1, 9)= 0.271, p=0.625 6.13 T3 F(1, 5)= 0.637, p=0.461 57.94
vigorous 80.38 59.53 115.80 124.97 64.80 39.53 F(1.2, 10.6)= 0.399, p=0.575 T2 F(1, 9)= 0.480, p=0.506 44.06 87.71 186.96 112.90 194.25 77.56 156.12 F(2,16)= 0.968, p=0.384 T2 F(1, 8)= 1.707, p=0.228 28.71 F (2, 36)= F 3.151, p=0.075 F (2, 36)= 0.487, p=0.556.
T3 F(1, 9)= 0.980, p=0.348 19.39 T3 F(1, 8)= 0.095, p=0.766 11.58
CD4 CM  CD127+ moderate 67.03 39.69 80.82 47.62 64.32 24.34 F(2, 18)= 0.259, p=0.774 T2 F(1, 9)= 0.080, p=0.784 20.58 126.75 69.04 156.74 110.70 113.73 34.22 F(2,10)= 0.308, p=0.742 T2 F(1, 5)= 0.75, p=0.796 23.66 F (2, 22)=1.010 p=0.380 F (2, 22)=1.010, p=0.661
T3 F(1, 9)= 0.400, p=0.543 4.04 T3 F(1, 5)= 0.395, p=0.557 10.27
vigorous 85.26 63.13 106.67 59.77 78.29 36.32 F(2, 16)= 0.147, p=0.865 T2 F(1, 8)= 0.361, p=0.564 25.11 50.14 55.97 84.39 84.34 46.33 53.74 F(1.1, 9.1)= 1.385, p=0.279 T2 F(1, 8)= 0.918, p=0.366 68.30 F(1.2, 16.6)= 0.823 p=0.397 F(1.2, 16.6)=  0.695, p=0.440.
T3 F(1, 8)= 0.337, p=0.578 8.17 T3 F(1, 8)= 2.057, p=0.189 7.61
CD4 EM  CD127+ moderate 164.92 99.48 191.89 120.46 141.94 62.14 F(1.3, 11.5)= 1.248, p=0.311 T2 F(1, 9)= 0.112, p=0.746 16.36 241.41 67.74 276.38 87.85 205.23 51.45 F(2,10)= 0.362, p=0.705 T2 F(1, 5)= 0.045, p=0.840 14.49 F (2, 22)=1.063 p=0.359 F (2, 22)=0.211, p=0.812
T3 F(1, 9)= 1.182, p=0.305 13.93 T3 F(1, 5)= 0.543, p=0.494 14.99
vigorous 216.60 171.10 311.57 238.44 194.39 131.40 F(1.25, 11.3)= 1.760, p=0.215 T2 F(1, 9)= 0.453, p=0.518 43.85 128.15 91.08 184.03 124.82 114.92 96.80 F(1.2, 9.67)= 1.172, p=0.319 T2 F(1, 8)= 0.506, p=0.497 43.60 F(1.2, 18.14)= 1.663, p=0.217 F(1.2, 18.14)= 0.267, p=0.656
T3 F(1, 9)= 2.142, p=0.177 10.25 T3 F(1, 8)= 2.398, p=0.160 10.32
CD4 EMRA CD127+ moderate 11.21 11.83 11.94 8.18 8.36 7.03 F(2, 20)= 3.988, p=0.035 T2 F(1, 10)= 0.853, p=0.377 6.57 7.24 2.79 9.93 3.15 6.68 4.85 F(2, 12)= 0.251, p=0.782 T2 F(1, 6)= 0.340, p=0.581 37.23 F (2, 24)= 3.837 p=0.036 F (2, 24)= 0.631, p=0.531
T3 F(1, 10)= 3.573, p=0.088 25.43 T3 F(1, 6)= 1.175, p=0.320 7.73
vigorous 10.36 6.31 13.46 10.82 9.29 4.86 F(1.1, 11.9)= 4.282, p=0.058 T2 F(1, 11)= 6.430, p=0.028 29.92 5.20 5.82 10.83 16.40 5.00 5.18 F(1.2, 12.3)= 1.905, p=0.194 T2 F(1, 10)= 1.946, p=0.193 108.22 F (2, 32)=5.414, p=0.009 F (2, 32)= 0.101, p=0.904
T3 F(1, 11)= 3.199, p=0.101 10.31 T3 F(1, 10)= 0.045, p=0.836 3.88
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mean SD mean SD mean SD mean SD mean SD mean SD
CD4 Na CD95+ moderate 1.05 0.92 1.52 1.61 1.14 1.42 F(1.1, 9.6)= 0.362, p=0.575 T2 F(1, 9)= 2.466, p=0.151 44.92 4.71 7.13 19.65 34.71 12.03 10.51 F(1, 4)= 0.855, p=0.461 T2 F(1, 4)= 0.848, p=0.409 317.54 F(1.2, 16)= 3.779, p=0.063 F(1.2, 16)=  0.618, p=0.476
T3 F(1, 9)= 0.519, p=0.490 8.77 T3 F(1, 4)= 0.887, p=0.400 155.58
vigorous 0.90 1.18 2.20 4.66 0.72 0.95 F(2, 18)= 0.518, p=0.603 T2 F(1, 10)= 0.986, p=0.344 144.96 9.32 21.96 2.30 6.02 18.25 48.82 F(1, 7)= 0.562, p=0.489 T2 F(1, 7)= 0.705, p=0.429 75.34 F(1.3, 23.2)= 9.840, p=0.003 F(1.3, 23.2)= 0.325, p=0.631
T3 F(1, 10)= 0.999, p=0.341 20.20 T3 F(1, 7)= 0.008, p=0.932 95.86
CD4 CM CD95+ moderate 0.33 0.35 0.40 0.48 0.28 0.40 F(1.02, 10.18)= 0.605, p=0.457 T2 F(1, 10)= 0.470, p=0.509 19.55 1.18 2.00 1.55 2.16 2.10 2.55 F(2,10)= 2.712, p=0.115 T2 F(1, 5)= 0.407, p=0.551 31.98 F (2, 24)= 3.281, p=0.055 F (2, 24)= 1.666, p=0.210.
T3 F(1, 10)= 0.670, p=0.432 14.88 T3 F(1, 5)= 4.429, p=0.089 78.10
vigorous 0.17 0.19 0.59 0.85 0.23 0.39 F(1.1, 10)= 1.056, p=0.368 T2 F(1, 9)= 4.454, p=0.064 238.13 0.25 0.43 0.18 0.23 0.13 0.22 F(1.2, 9.64)= 1.421, p=0.270 T2 F(1, 8)= 0.309, p=0.593 27.85 F (2, 34)= 2.112, p=0.137 F (2, 34)= 2.061, p=0.153
T3 F(1, 9)= 1.410, p=0.265 33.30 T3 F(1, 8)= 4.301, p=0.072 47.08
CD4 EM CD95+ moderate 51.72 75.11 63.20 88.81 58.19 84.12 F(1.3, 13.1)= 0.166, p=0.756 T2 F(1, 10)= 1.149, p=0.309 22.18 138.57 141.03 179.27 174.23 170.38 108.69 F(2,10)= 0.514, p=0.613 T2 F(1, 5)= 0.792, p=0.414 29.37 F (2, 24)=2.484, p=0.105 F (2, 24)= 0.994, p=0.385
T3 F(1, 10)= 0.080, p=0.782 12.51 T3 F(1, 5)= 0.956, p=0.373 22.96
vigorous 32.68 31.49 87.47 199.46 28.31 23.21 F(2, 20)= 0.093, p=0.912 T2 F(1, 10)= 0.107, p=0.750 167.70 34.86 30.61 61.88 95.04 43.94 37.24 F(2, 16)=  0.223, p=0.802 T2 F(1, 8)= 0.261, p=0.623 77.55 F (2, 32)= 0.712, p=0.499 F (2, 32)= 0.187, p=0.831
T3 F(1, 10)= 0.026, p=0.875 13.36 T3 F(1, 8)= 0.006, p=0.941 26.06
CD4 EMRA CD95+ moderate 1.15 1.96 1.23 1.95 0.89 1.31 F(2, 20)= 1.830, p=0.186 T2 F(1, 10)= 0.388, p=0.547 6.92 2.63 3.47 2.95 3.01 3.19 3.71 F(2,12)= 0.107, p=0.899 T2 F(1, 6)= 0.002, p=0.968 12.14 F (2, 24)= 0.650, p=0.531 F (2, 24)= 0.083, p=0.921
T3 F(1, 10)= 0.163, p=0.311 23.09 T3 F(1, 8)= 3.616, p=0.094 21.08
vigorous 0.63 0.37 1.32 2.16 0.61 0.89 F(1.32, 14.5)= 2.060, p=0.171 T2 F(1, 11)= 0.443, p=0.519 110.38 1.67 2.56 2.30 5.45 1.60 2.42 F(1.1, 11.1)= 0.061, p=0.833 T2 F(1, 10)= 0.087, p=0.774 37.75 F(1.3, 20.2)= 0.314, p=0.633 F(1.3, 20.2)=0.578, p=0.494





moderate 1.62 2.54 1.95 3.15 1.44 2.30 F(2, 18)= 0.591, p=0.564 T2 F(1, 9)= 0.568, p=0.470 20.13 T2 F(2, 16)= 12.080, p=0.001
T3 F(1, 9)= 0.154, p=0.704 11.06 T3
vigorous 1.52 2.00 2.92 3.82 0.85 0.81 F(2, 18)= 3.189, p=0.065 T2 F(1, 9)= 4.579, p=0.061 91.93 0.27 0.55 0.39 0.39 0.27 0.31 F(2,12)= 0.508, p=0.614 T2 F(1, 6)= 0.617, p=0.462 42.19 F(1.14, 15.9)= 0.269, p=0.641 F(1.14, 15.9)= 0.727, p=0.424





moderate 6.49 11.68 4.41 6.57 4.70 5.93 F(2, 16)= 1.024, p=0.381 T2 F(1, 8)= 1.875, p=0.208 32.05 T2 F(2, 24)= 2.124, p=0.142
T3 F(1, 9)= 1.160, p=0.313 27.56 T3
vigorous 4.70 7.13 3.39 4.38 3.96 6.99 F(1.2, 10.6)= 0.502, p=0.524 T2 F(1, 9)= 0.016, p=0.901 27.90 0.11 0.21 0.18 0.35 0.14 0.14 F(2,12)= 0.153, p=0.860 T2 F(1, 6)= 0.265, p=0.625 68.22 F(1.4, 21.9)= 0.105, p=0.826 F(1.4, 21.9)=1.527, p=0.237





moderate 2.84 6.36 4.48 8.79 3.08 6.30 F(2, 18)= 0.620, p=0.549 T2 F(1, 9)= 1.404, p=0.266 58.05 T2 F(2, 24)= 0.244, p=0.712
T3 F(1, 9)= 0.651, p=0.440 8.49 T3
vigorous 1.67 1.23 2.72 2.11 1.45 0.98 F(2, 18)= 4.557, p=0.025 T2 F(1, 9)= 4.925, p=0.054 62.64 2.51 4.98 3.42 6.72 2.24 3.80 F(2,12)= 1.406, p=0.283 T2 F(1, 6)= 2.182, p=0.190 36.62 F(1.2, 19.8)= 0.536, p=0.499 F(1.2, 19.8)= 1.051, p=0.330





moderate 4.92 7.19 6.12 9.54 4.46 8.13 F(2, 18)= 0.071, p=0.932 T2 F(1, 9)= 0.270, p=0.616 24.44 T2 F(2, 24)= 2.545, p=0.099
T3 F(1, 9)= 0.000, p=0.986 9.26 T3
vigorous 7.19 5.49 8.81 7.59 5.89 3.08 F(1.1, 10)= 0.456, p=0.535 T2 F(1, 9)= 1.852, p=0.207 22.45 1.36 1.81 2.33 2.65 1.44 1.68 F(1.1,6.7)= 0.816, p=0.412 T2 F(1, 6)= 1.036, p=0.348 70.80 F(1.2, 18.6)= 0.466, p=0.532 F(1.2, 18.6)= 0.655, p=0.451
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5.3.3 CD8+ T cells 
 
5.3.3.1 CD8+ T cells at baseline in T1D and control participants  
 
CD8+ T cells subset were analysed in T1D and control groups at baseline, before proceeding 
to assessing the effects of exercise on these populations. Naïve (CD45RA+CCR7+), CM 
(CD45RA-CCR7+), EM (CD45RA-CCR7-) ED (CD45RA-CCR7-CD27+CD28+), ELD 
(CD45RA-CCR7-CD27-CD28+), ID (CD45RA-CCR7-CD27+CD28-) and EMRA 
(CD45RA+CCR7-) were examined [430]. Table 33 displays the mean baseline values of the 
proportion (%) and frequency (cells/µl) CD8+ T cell populations in T1D and control groups.  
There was a significant difference in the proportion of early differentiated (ED: CD27+CD28+), 
early-like differentiated (ELD: CD27-CD28+) and intermediately differentiated (ID: 
CD27+CD28-) subsets between groups (Figure 32a). The proportion of CD8+ ED were 
significantly lower in T1D subjects (p=0.023) (Figure 32a) with a supporting trend in the 
relative cell frequency (p=0.062) (Figure 32b). The proportion of CD8+ ELD were significantly 
higher in T1D subjects (p=0.026) (Figure 32a). The proportion of CD8+ ID (p=0.019) (Figure 
32a) and frequency (p=0.005) (Figure 32b) were significantly reduced in T1D subjects.  
In contrast to CD4+ EMRA (Section 3.2.1), the proportion of CD8+EMRA were significantly 
higher in T1D subjects (p<0.0011) (Figure 32a), with no increase in relative cell frequencies 
found (Figure 32b). 
This data shows that the distribution of CD8+ ED, ELD, ID and EMRA T cells, i.e. manly later 
differentiated subsets, differs between T1D and control groups at baseline. There were no 




Figure 32 The proportion and frequency of CD8+ T cell subsets at baseline in T1D and control groups. 
Flow cytometry and whole blood cell counts were used to determine the frequency of CD8+ sub populations in 
control and T1D participants at baseline. (a) Proportion of CD8+ subpopulations in control and T1D groups (b) 
Frequency of CD8+ subpopulations in control and T1D groups. Error bars represent SEM. Statistical significance 
represented by * p<0.05, ** p<0.01, ***p<0.001. Note: broken line (----) represents time*group differences. 
  
Table 33 CD8+ T cell sub populations at baseline in T1D and controls. 
Mean and standard deviation values for the proportion and frequency of CD8+ subpopulations in controls and 
T1D groups. 
1 controls n=23, 2 T1D n=15 
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5.3.3.2 CD8+ T cell subset phenotypes at baseline in T1D and control participants 
 
A number of cell surface markers were measured on CD8+ T cell subsets to define the homing 
propensity and function of circulating CD8+ populations in T1D and control participants. These 
markers included CD69, CD11b, CD127, and CD95 (as described for CD4+ subsets in Section 
3.2.2) and were measured on naïve, CM, EM and EMRA CD8+ T cells (Table 34).  
5.3.3.2i CD69 
CD8+ T cell subsets that were activated and had migrated from tissues, defined by CD69 
expression, were measured in T1D and control groups. There were no differences between 
groups in CD69 expression on CD8+ naive and CM subsets.  
A higher proportion of CD8+CD69+ EM (p=0.025), with a trend to increase in frequencies 
(p=0.069), was found in T1D than controls (Table 34).  
The frequency, but not the proportion, of CD8+CD69+ EMRA were significantly increased in 
T1D subjects (p=0.037) (Figure 33c) (Table 34). 
This suggests that a higher frequency of CD8+ EM and EMRA in T1D were activated and had 
recently migrated from tissues into circulation compared to controls.  
5.3.3.2ii CD11b 
CD8+ T cell subsets with a migratory capacity, defined by CD11b expression, were measured 
in T1D and control groups. There were no differences between groups in CD11b expression 
on CD8+ naïve, CM or EM subsets. 
The frequency of CD8+CD11b+ EMRA were significantly elevated in the T1D group (p=0.038) 
(Figure 33c) (Table 34). This indicates that there was a higher frequency of CD8+ EMRA with 
a homing propensity in the T1D group compared to controls.  





CD127, necessary for T cell maintenance, expression across CD8+ T cell subsets was measured 
in T1D and control subjects. No significant differences are reported in CD127 expression on 
CD8+ T cell subsets (Table 34).  
5.3.3.2iv CD95  
CD95+, marker of apoptosis, expression on CD8+ T cell subsets was measured in both groups. 
No significant differences are reported in CD95 expression on CD8+ T cell subsets (Table 34). 
There was a trend to increase in the frequency CD8+CD95+ EMRA in T1D subject (Figure 
33c).  
5.3.3.2v EMRA Differentiation (CD27/CD28) 
 
As discussed in section CD4+ baseline, it has been assumed EMRA are CD27-CD28- i.e. fully 
differentiated, however recent studies have shown the presence of mixed differentiated subsets 
of EMRA in healthy and ageing populations [408, 409]. This has not been measured in T1D 
previously. 
Table 35 displays the mean baseline data for the proportion and frequency of differentiated 
EMRA subsets. CD8+ EMRA subsets showed a significant difference in the proportion of 
CD27+ CD28- subsets between groups (p=0.021) (Figure 33a), but this was not significant in 
frequencies (Figure 33b). There were no differences between groups in the other EMRA 
subsets (Table 35). This shows that there were less intermediately differentiated CD8+ EMRA 




Figure 33 The frequency of surface marker expression on CD8+ naïve, EM, CM, and EMRA. The 
proportion and frequency of differentiated CD8+ EMRA T cell subsets at baseline in T1D and control 
groups.  
Flow cytometry and whole blood counts were used to determine the phenotype CD8+ sub populations in control and T1D 
subjects (a) The proportion of differentiated CD8+ EMRA subsets (b) The frequency of differentiated CD8+ EMRA subsets 
(c) The frequency of CD69+, CD11b+, CD127+, and CD95+ CD8+ subsets. Error bars represent SEM. Statistical 
significance represented by * p<0.05, ** p<0.01, ***p<0.001. Note: broken line (----) represents time*group 
differences. 






Table 34 Surface marker expression on CD8+ naïve, CM, EM, and EMRA populations at baseline in T1D 
and controls 
Mean and standard deviation values for the proportion and frequency of CD69+, CD11b+, CD127+, and CD95+ 
CD8+ naïve, CM, EM, and EMRA populations in controls and T1D participants. 




Table 35 Differentiated CD8+ EMRA T cell subsets at baseline in T1D and control groups. 
Mean and standard deviation values for the proportion and frequency of differentiated CD8+ EMRA subsets in 
controls and T1D participants. 
1controls n=22, 2T1D n=15 
mean SD mean SD mean SD mean SD
CD8 naïve 4.57 3.89 10.25 23.93 75.59 20.26 6.67 18.88
CD8 CM 4.65 3.74 8.23 13.42 77.19 15.06 11.84 20.46
CD8 EM 4.83 2.04 10.33 17.18 64.80 15.58 12.15 23.33
CD8 EMRA 6.77 7.62 15.43 21.91 45.59 21.80 6.67 18.88
CD8 naïve 2.86 2.61 3.88 3.51 62.90 63.81 1.60 2.55
CD8 CM 1.14 1.20 13.22 34.96 18.42 10.48 2.39 4.03
CD8 EM 7.85 6.04 20.23 35.70 124.23 100.64 18.70 33.73
CD8 EMRA 1.56 1.16 2.37 2.20 10.37 9.65 1.57 2.61
CD8 naïve 5.59 4.09 18.40 35.32 86.72 24.50 15.07 24.85
CD8 CM 3.65 2.27 11.58 18.32 83.99 24.66 26.57 28.91
CD8 EM 6.91 3.39 20.25 24.12 70.35 18.14 25.99 32.05
CD8 EMRA 11.04 5.46 29.41 34.38 42.21 23.79 15.07 24.85
CD8 naïve 1.61 1.19 8.43 24.99 57.25 66.17 11.17 24.41
CD8 CM 0.74 0.59 28.31 66.10 16.54 10.85 10.21 21.53
CD8 EM 14.50 15.04 50.69 82.59 140.78 101.37 41.46 66.68
CD8 EMRA 5.47 8.41 26.71 54.64 14.53 16.29 17.82 41.52







CD28-CD27- CD28-CD27+ CD28+CD27- CD28+CD27+
mean SD mean SD mean SD mean SD
CD8 (%) 41.89 24.04 23.51 22.71 13.53 14.49 21.62 17.82
CD8 (cells/μl) 12.89 12.89 5.92 6.83 4.57 6.95 5.76 7.59
CD8 (%) 41.38 27.97 7.30 9.14 34.61 30.46 16.96 24.63
CD8 (cells/μl) 27.87 56.81 2.98 4.35 14.51 27.02 4.48 7.94
2T1D
1Controls




5.3.3.3 CD8+ T cell subsets in response to acute exercise in T1D and control participants  
 
The effects of moderate (40% VO2 max) and vigorous (80% VO2 max) intensity exercise on 
CD8+ T cell subsets were examined. The results are provided in progressive order of 
differentiation in Table 36. Table 36 displays the mean, standard deviation, and statistical 
values for CD8+ T cell subsets. 
CD8+ T cells were significantly mobilised by vigorous intensity exercise in T1D (p=0.016) and 
control groups (p=0.001). Both groups showed a significant increase immediately post 
vigorous exercise (p=0.40, p=0.033 respectively). The percentage increase post vigorous 
exercise between groups was similar. Within the CD8+ T cell population, significant changes 
were seen in CD8+ EM, ED, ELD, ID, EM, and EMRA during moderate and/or vigorous 
exercise. It is evident from this data that the increase in CD8+ T cells is driven by mobilisation 
of later differentiated CD8+ T cell subsets and these changes were most consistent between 
groups in the CD8+ EMRA subset. Naïve subsets do not significantly change with exercise in 
either group, however there was a marginal difference in the response between groups during 
moderate intensity exercise (p=0.048). There was no significant change in CD8+ CM T cells in 
either group independently (Table 36).  
CD8+ EM were significantly mobilised by moderate intensity exercise in the T1D only 
(p=0.018). CD8+ EM showed a trend to mobilise during vigorous exercise (p=0.067), with a 
fall below baseline at 1 hour post vigorous exercise (p=0.040) in the T1D group. No significant 
changes were seen in the control group (Table 36).  
CD8+ ED changed with vigorous intensity exercise overall only (p=0.040), but this is not seen 
in either T1D or control groups independently (Table 36).  




CD8+ ELD were significantly mobilised by moderate intensity exercise in T1D (p=0.025) and 
controls (p=0.029). This was supported by an overall change in this subset (p=0.001). There 
was an overall change in CD8+ ELD during vigorous intensity exercise (p<0.001), with a trend 
to change in the T1D group (p=0.054) but not the control group. There was a significant fall 
below baseline 1 hour post vigorous exercise in the T1D group only (p=0.029) (Table 36). 
There was a significant change during moderate intensity exercise in CD8+ ID in the T1D group 
(p=0.022) and overall (p=0.001), but not in the control group. CD8+ ID significantly increased 
immediately post moderate exercise in the T1D group (p=0.046). There was a significant 
overall change in CD8+ ID with vigorous exercise (p<0.001) but not in either T1D or control 
groups independently. CD8+ ID significantly fell below baseline 1 hour post vigorous exercise 
in the control group only (p=0.027) (Table 36). 
Figure 34 displays that both intensities resulted in a significant change in CD8+ EMRA cell 
frequencies overall (low: p=0.005, vigorous: p=0.001). CD8+ EMRA cells were significantly 
mobilised by moderate intensity exercise in T1D (p=0.002) and control groups (p=0.002). They 
were significantly increased immediately post moderate exercise in the T1D group only 
(p=0.013), but decreased significantly below baseline 1 hour post exercise in the control group 
only (p=0.022) (Figure 34a). CD8+ EMRA were significantly mobilised by vigorous intensity 
exercise in T1D (p=0.004) and control groups (p=0.010). There was a significant decrease 1 
hour post vigorous exercise in both T1D (p=0.019) and control groups (p=0.004) (Figure 34b). 
This concludes that CD8+ EMRA subsets are mobilised by both moderate and vigorous 
intensity exercise in both T1D and control groups. However, the percentage increase post 




Figure 34 The frequencies of CD8+ EMRA subsets mobilised during moderate and vigorous intensity 
exercise in control and T1D participants 
Flow cytometry and whole blood counts were used to determine the frequency of CD8+ EMRA populations in control and 
T1D subjects during moderate and vigorous intensity exercise. (a) The frequency of CD8+ EMRA during moderate intensity 
exercise (b) The frequency of CD8+ EMRA during vigorous intensity exercise. Error bars represent SEM. Statistical 
significance represented by * p<0.05, ** p<0.01, ***p<0.001.  






Table 36 CD8+ T cell sub populations mobilised by moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of CD8+ sub populations for control and T1D subjects during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 












mean SD mean SD mean SD mean SD mean SD mean SD
Total CD8 moderate 448.95 149.11 626.88 335.59 480.60 162.84 F(2, 20)= 3.224, p=0.061 T2 F(1, 10)= 3.357, p=0.097 39.63 478.30 157.11 677.33 430.18 491.82 80.48 F(2,10)= 2.186, p=0.163 T2 F(1, 5)= 1.317, p=0.303 41.61 F (1, 17.1)= 0.315, p=0.597 F (1, 17.1)= 0.474, p=0.513
T3 F(1, 10)= 0.352, p=0.566 7.05 T3 F(1, 5)= 3.020, p=0.143 2.83
vigorous 329.85 165.90 460.90 178.81 229.11 98.35 F(2, 22)= 10.326, p=0.001 T2 F(1, 11)= 5.961, p=0.033 39.73 248.34 158.17 354.41 225.31 192.54 122.80 F(1.2, 9.7)= 7.791, p=0.016 T2 F(1, 8)= 6.021, p=0.040 42.71 F (2, 42)= 3.295, p=0.047 F (2, 42)= 0.126, p=0.882
T3 F(1, 11)= 7.253, p=0.021 30.54 T3 F(1, 8)= 4.942, p=0.057 22.47
CD8 naïve moderate 74.25 82.28 79.03 76.02 64.54 64.17 F(2, 20)= 2.770, p=0.087 T2 F(1, 10)= 0.693, p=0.425 6.44 76.41 70.98 88.04 76.07 59.95 61.22 F(2, 10)= 0.185, p=0.834 T2 F(1, 5)= 0.261, p=0.631 15.22 F (2, 24)= 1.743, p=0.196 F (2, 24)= 3.465, p=0.048
T3 F(1, 10)= 2.095, p=0.178 13.08 T3 F(1, 5)= 0.217, p=0.661 21.55
vigorous 100.77 70.41 108.43 84.76 81.54 57.25 F(1.3, 14.5)= 0.751, p=0.436 T2 F(1, 10)= 0.368, p=0.556 7.60 48.16 62.31 61.36 66.97 48.68 53.50 F(2,16)= 1.159, p=0.339 T2 F(1, 8)= 1.654, p=0.234 27.41 F (2, 34)=1.834, p=0.175 F (2, 34)=0.797, p=0.459
T3 F(1, 10)= 2.051, p=0.180 19.08 T3 F(1, 8)= 0.156, p=0.704 1.07
CD8 CM moderate 19.94 9.38 25.15 16.89 26.73 16.75 F(2, 20)= 0.434, p=0.654 T2 F(1, 10)= 0.497, p=0.497 26.16 25.82 10.51 29.66 17.33 17.95 10.19 F(2,10)= 1.274, p=0.322 T2 F(1, 5)= 0.441, p=0.536 14.90 F (2, 24)= 2.374, p=0.115 F (2, 24)= 1.872, p=0.770
T3 F(1, 10)= 0.168, p=0.690 34.07 T3 F(1, 5)= 0.904, p=0.385 30.48
vigorous 27.09 13.66 27.70 16.48 25.42 13.49 F(2, 22)= 1.343, p=0.282 T2 F(1, 11)= 0.012. p=0.914 2.25 14.94 9.79 24.13 15.94 13.85 11.05 F(1.35, 4.9)= 2.209, p=0.173 T2 F(1, 8)= 2.048, p=0.190 61.51 F(1.3, 21.9)= 0.546, p=0.511 F(1.3, 21.9)= 0.255, p=0.678
T3 F(1, 8)= 2.059, p=0.179 6.15 T3 F(1, 8)= 1.961, p=0.199 7.30
CD8 EM moderate 153.96 97.90 210.92 145.86 162.59 108.94 F(2, 20)= 0.907, p=0.420 T2 F(1, 10)= 0.259, p=0.622 37.00 235.32 108.88 300.97 233.38 209.06 46.63 F(2,10)= 6.119, p=0.018 T2 F(1, 5)= 2.058, p=0.211 27.90 F (2, 24)= 1.031, p=0.130 F (2, 24)=  0.698, p=0.507
T3 F(1, 10)= 0.720, p=0.416 5.61 T3 F(1, 5)= 2.594, p=0.168 11.16
vigorous 213.22 129.35 314.69 218.55 179.30 102.03 F(2, 22)= 1.486, p=0.248 T2 F(1, 11)= 0.06, p=0.763 47.59 157.07 151.50 269.78 224.42 124.62 115.28 F(1.2, 9.8)= 4.060, p=0.067 T2 F(1, 8)= 2.124, p=0.183 71.76 F(1.257, 21.4)= 0.822, p=0.401 F(1.257, 21.4)=0.286, p=0.651
T3 F(1, 11)= 3.356, p=0.094 15.91 T3 F(1, 8)= 5.978, p=0.040 20.66
CD8 ED moderate 61.46 74.81 66.14 78.03 57.25 73.21 F(2, 20)= 1.656, p=0.216 T2 F(1, 10)= 0.041, p=0.844 7.61 25.14 61.10 31.14 74.81 0.28 0.56 F(1.07, 5.34)= 2.934, p=0.074 T2 F(1, 5)= 1.501, p=0.275 23.86 F(1.3, 16.3)= 1.103, p=0.326 F(1.3, 16.3)= 1.214, p=0.300
T3 F(1, 10)= 2.146, p=0.174 6.86 T3 F(1, 5)= 2.772, p=0.157 98.90
vigorous 102.30 97.85 123.23 116.89 65.15 52.83 F(2, 22)= 0.882, p=0.428 T2 F(1, 11)= 0.011, p=0.918 20.46 37.27 64.35 53.51 85.79 8.50 11.81 F(1.2, 9.3)= 3.599, p=0.085 T2 F(1, 8)= 1.289, p=0.289 43.55 F(1.2, 20.3)= 4.520, p=0.040 F(1.2, 20.3)= 0.051, p=0.864
T3 F(1, 11)= 1.498, p=0.247 36.32 T3 F(1, 8)= 4.830, p=0.059 77.20
CD8 ELD moderate 34.40 28.22 49.32 52.42 33.25 32.30 F(2, 20)= 4.266, p=0.029 T2 F(1, 10)= 0.517, p=0.489 43.37 85.10 96.31 108.69 114.59 78.54 82.81 F(2, 10)= 5.477, p=0.025 T2 F(1, 5)= 0.876, p=0.392 27.72 F(2, 24)= 9.012, p=0.001 F(2, 24)= 0.194, p=0.825
T3 F(1, 10)= 3.849, p=0.078 3.34 T3 F(1, 5)= 3.722, p=0.112 7.70
vigorous 38.91 39.00 63.49 62.18 33.49 30.31 F(1.1, 12.1)= 1.390, p=0.266 T2 F(1, 11)= 0.906, p=0.362 63.17 84.05 140.43 144.09 222.84 54.26 81.30 F(1.2, 9.9)= 4.492, p=0.054 T2 F(1, 8)= 2.044, p=0.191 71.44 F(1.4, 24.5)= 14.969, p<0.001 F(1.4, 24.5)= 1.501, p=0.240
T3 F(1, 11)= 2.436, p=0.147 13.94 T3 F(1, 8)= 7.006, p=0.029 35.44
CD8 ID moderate 27.03 25.04 36.94 45.26 43.66 50.73 F(2, 20)= 0.490, p=0.620 T2 F(1, 10)= 1.194, p=0.300 36.66 5.79 9.06 6.08 9.42 5.69 11.39 F(2, 10)= 5.765, p=0.022 T2 F(1, 5)= 6.933, p=0.046 5.05 F(2, 24)= 9.558, p=0.001 F(2, 24)= 0.151, p=0.860
T3 F(1, 10)= 0.002, p=0.961 61.54 T3 F(1, 5)= 0.534, p=0.498 1.63
vigorous 25.93 20.99 35.35 26.47 19.22 11.57 F(1.3, 13.9)= 3.252, p=0.086 T2 F(1, 11)= 1.143, p=0.308 36.29 9.18 12.76 14.78 22.44 8.52 13.08 F(1.1, 8.75)= 2.317, p=0.163 T2 F(1, 8)= 1.819, p=0.214 60.94 F(1.4, 24)= 15.543, p<0.001 F(1.4, 24)= 0.660, p=0.476
T3 F(1, 11)= 6.518, p=0.027 25.90 T3 F(1, 8)= 2.922, p=0.126 7.22
CD8 EMRA moderate 24.21 19.60 42.31 46.36 22.33 19.83 F(2, 20)= 9.075, p=0.002 T2 F(1, 10)= 0.517, p=0.489 74.79 62.28 64.68 97.35 122.66 68.15 63.20 F(2, 10)= 12.227, p=0.002 T2 F(1, 5)= 14.035, p=0.013 56.31 F (2, 24)= 6.582, p=0.005 F (2, 24)= 0.049, p=0.952
T3 F(1, 10)= 7.390, p=0.022 7.75 T3 F(1, 5)= 3.106, p=0.138 9.42
vigorous 30.29 26.28 50.32 49.30 21.67 16.27 F(1.37, 15.1)= 7.458, p=0.010 T2 F(1, 11)= 2.5052, p=0.180 66.13 39.00 61.60 49.31 32.36 20.75 24.74 F(2,16)= 8.053, p=0.004 T2 F(1, 8)= 3.981, p=0.081 26.45 F (1.5, 25)= 11.823, p=0.001 F (1.5, 25)= 0.472, p=0.571
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5.3.3.4 CD8+ T cell phenotype in response to acute exercise in T1D and control 
participants 
 
As shown for CD8+ T cell subsets at baseline, cell surface markers were used to examine the 
homing propensity and function of CD8+ T cell subsets mobilised during moderate and 
vigorous intensity exercise. Table 37 displays the frequency (cells/µl) of each marker on CD8+ 
subsets during moderate and vigorous intensity exercise.  
5.3.3.4i CD69 
CD8+CD69+ naïve T cells showed a significant change over time during moderate intensity 
exercise in controls only (p=0.029), falling below baseline 1 hour post moderate exercise 
(p=0.042). CD8+CD69+ naïve were significantly increased immediately post vigorous exercise 
in T1D (p=0.021) and control groups (p=0.029), with a significant change over time in the T1D 
group only (p=0.010). This percentage increase was marginally blunted in the T1D group 
(T1D: 43.69%, Control: 79.90%) (Table 37). 
CD8+CD69+ CM T cells were mobilised during moderate intensity exercise in the T1D group 
only (p=0.037). Vigorous intensity exercise mobilised this subset in T1D (p=0.020) and control 
groups (p=0.037), with a significant increase immediately post vigorous exercise in both 
groups (p=0.021, p=0.010 respectively). This percentage increase was marginally blunted in 
the T1D group (T1D: 59.98%, Control: 85.57%) (Table 37).  
CD8+CD69+ EM T cells changed during moderate intensity exercise overall (p=0.044), but not 
in either T1D or control groups separately. Vigorous intensity exercise resulted in the 
mobilisation of this subset in the T1D group (p=0.012), but not in controls (Table 37). 
CD8+CD69+ EMRA T cells significantly changed during moderate intensity exercise in T1D 
(p=0.003) and control groups (p=0.022), with a significant increase seen immediately post 




moderate exercise seen in the T1D only (p=0.012). Vigorous intensity exercise resulted in the 
mobilisation of this subset in T1D (p=0.002) and control groups (p=0.003), with a significant 
increase seen immediately post vigorous exercise observed in the control group only (p=0.010) 
(Figure 35a). The percentage increase was blunted in the T1D group following moderate (T1D: 
44.05%, Control: 92.33%) and considerably blunted following vigorous (T1D: 29.87%, 
Control: 161.43%) intensity exercise (Table 37). 
5.3.3.4ii CD11b 
CD8+CD11b+ EMRA subsets significantly changed during moderate intensity exercise in T1D 
(p=0.014) and control groups (p=0.001). They were further elevated 1 hour post moderate 
exercise in the T1D group (p=0.047), but were significantly below baseline at this time point 
in the control group (p=0.017). However, this difference in response was not significant. 
CD8+CD11b+ EMRA subsets were mobilised by vigorous intensity exercise in T1D (p=0.007) 
and control groups (p=0.001). There was a significant increase immediately post vigorous 
exercise in the control group only (p=0.010). In the T1D group only, this subset significantly 
fell below baseline 1 hour post vigorous exercise (p=0.006) (Figure 35b). The percentage 
increase was blunted in the T1D group following moderate (T1D: 14.82%, Control: 38.61%) 
and vigorous (T1D: 37.70% decrease, Control: 91.48%) intensity exercise (Table 37). 
There were no significant changes in CD8+CD11b+ naïve, CM or EM subsets with either 
exercise intensity (Table 37). 
5.3.3.4iii CD127 
CD8+CD127+ CM subsets significantly changed overall with moderate (p=0.040) and vigorous 
(p=0.038) intensity exercise but this is not seen in either T1D or control groups independently 
(Table 37). 




CD8+CD127+ EM significantly changed vigorous (p=0.035) intensity exercise overall but this 
was not seen in either T1D or control groups independently. There was a significant fall below 
baseline 1 hour post vigorous exercise in the T1D group (p=0.037) (Table 37). 
CD8+CD127+ EMRA significantly changed overall during moderate (p=0.026) and vigorous 
(p=0.037) exercise. This was observed in both T1D (p=0.038) and control groups (p=0.033) 
during moderate but not vigorous intensity exercise, with a significant increase immediately 
post moderate exercise (p=0.046) in the T1D group (Figure 35c). A blunted increase post 
moderate exercise in the T1D is not seen with CD8+CD127+ EMRA. Furthermore, the 
percentage increase post vigorous exercise was higher in the T1D group (T1D: 61.49%, 
Control: 36.16%) (Table 37). 
There were no significant changes in CD8+CD127+ naïve with either exercise intensity (Table 
37). 
5.3.3.4iv CD95 
CD8+CD95+ CM significantly changed overall with moderate (p=0.024) intensity exercise but 
this was not seen in either T1D or control groups independently. There were no significant 
changes during vigorous intensity exercise in this subset (Table 37). 
CD8+CD95+ EMRA were significantly mobilised by moderate (p=0.004) and vigorous 
(p=0.003) overall, but this was not seen in either T1D or control groups independently (Figure 
35d) (Table 37). 
There were no significant changes in CD8+ naïve and EM expressing CD95 with either exercise 
intensity (Table 37). 
The percentage increase post exercise of all CD8+CD95+ subsets was higher in the T1D group 
following moderate intensity exercise (Table 37). However, the percentage increase post 




exercise of all CD8+CD95+ subsets was blunted in the T1D group following vigorous intensity 
exercise (Table 37).  
5.3.3.4v Differentiation of EMRA (CD27/CD28) 
Using the same approach as in CD4+ subsets (Section 3.2.4), CD8+ EMRA subsets at the 4 
differentiation stages were assessed during exercise in T1D and control participants. Data for 
vigorous intensity exercise only in T1D and both exercise intensities in control participants is 
shown (Table 37). 
The frequency of CD8+CD27-CD28- EMRA significantly changed during vigorous intensity 
exercise overall (p=0.005) and was seen in both the T1D (p=0.050) and control group 
(p=0.037) independently. The percentage increase post vigorous exercise was considerably 
blunted in the T1D group (T1D: 7.02% decrease, control: 113.76%). There was a significant 
fall below baseline 1 hour post vigorous intensity exercise in the T1D group only (p=0.005) 
(Figure 35e) (Table 37). 
There were significant changes over time in the CD8+CD27-CD28+ EMRA (intermediately 




Figure 35 Expression of surface markers CD69, CD11b, CD127, CD95, CD27 and CD28 on CD8+ EMRA 
subsets during low and vigorous intensity exercise in control and T1D subjects 
Flow cytometry and whole blood counts were used to determine the frequency of CD8+ subsets expressing CD69, CD11b, 
CD127, and CD95 in control and T1D participants (a) The frequency of CD8+CD69+ EMRA (b) CD8+CD11b+ EMRA (c)
CD8+CD127+ EMRA and (d) CD8+CD95+ EMRA during low and vigorous intensity exercise (e) The frequency of 
CD8+CD27-CD28- EMRA during vigorous intensity exercise. Error bars represent SEM. Statistical significance 
represented by * p<0.05, ** p<0.01, ***p<0.001.  




Table 37 Surface marker expression on CD8+ naïve, CM, EM, and EMRA populations mobilised by moderate and vigorous intensity exercise in control and T1D 
groups 
Mean, standard deviation and statistical analysis of CD69+, CD11b+, CD127+, and CD95+ on CD8+ naïve, CM, EM, and EMRA populations for control and T1D subjects 
during moderate and vigorous intensity exercise. Significant results highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 




Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
CD8 Na CD69+ moderate 2.94 2.76 2.79 2.99 2.13 2.20 F(2, 20)= 4.230, p=0.029 T2 F(1, 10)= 0.266, p=0.617 5.17 2.02 1.36 2.33 0.24 2.31 1.21 F(2, 10)= 1.980, p=0.189 T2 F(1, 5)= 4.563, p=0.086 15.70 F (2, 24)= 1.962 p=0.163 F (2, 24)=  0.797, p=0.462
T3 F(1, 10)= 5.400, p=0.042 27.49 T3 F(1, 5)= 0.020, p=0.894 14.29
vigorous 2.78 2.58 5.00 5.82 3.52 3.41 F(1.2, 12.1)= 2.761, p=0.118 T2 F(1, 10)= 6.517, p=0.029 79.90 1.34 1.06 1.93 1.44 1.18 1.26 F(2,16)= 6.162, p=0.010 T2 F(1, 8)= 8.294, p=0.021 43.69 F(1.26, 22.8)= 0.907p=0.374 F(1.26, 22.8)=0.370, p=0.598
T3 F(1, 10)= 4.602, p=0.058 26.61 T3 F(1, 8)= 1.414, p=0.269 12.12
CD8 CM CD69+ moderate 1.24 1.10 1.46 1.16 1.21 0.87 F(2, 20)= 0.996, p=0.387 T2 F(1, 10)= 1.598, p=0.235 17.87 1.05 0.49 1.94 2.13 0.37 0.26 F(2,10)= 4.685, p=0.037 T2 F(1, 5)= 3.865, p=0.106 84.49 F (2, 24)=  1.384 p=0.270 F (2, 24)= 0.624, p=0.545
T3 F(1, 10)= 0.006, p=0.941 1.88 T3 F(1, 5)= 4.453, p=0.089 64.79
vigorous 1.04 1.33 1.92 2.17 1.32 1.41 F(1.33, 13.25= 4.884, p=0.037 T2 F(1, 10)= 10.016, p=0.010 85.57 0.53 0.59 0.85 1.11 0.38 0.40 F(1.2, 9.7)= 7.190, p=0.020 T2 F(1, 8)= 8.133, p=0.021 59.98 F(1.11, 20)= 2.978, p=0.362 F(1.11, 20)= 1.905, p=0.163.
T3 F(1, 10)= 1.160, p=0.307 27.61 T3 F(1, 8)= 3.895, p=0.084 28.86
CD8 EM CD69+ moderate 7.79 6.72 10.01 9.20 11.01 10.02 F(1.3, 13)= 0.510, p=0.535 T2 F(1, 10)= 0.382, p=0.551 28.44 15.02 9.75 16.04 10.76 7.11 2.99 F(2, 10)= 2.886, p=0.102 T2 F(1, 5)= 4.134, p=0.098 6.80 F (2, 24)= 3.582 p=0.044 F (2, 24)= 1.403, p=0.265.
T3 F(1, 10)= 0.834, p=0.383 41.28 T3 F(1, 5)= 1.143, p=0.334 52.67
vigorous 7.91 5.60 21.44 25.80 9.28 8.97 F(2, 20)= 2.070, p=0.152 T2 F(1, 10)= 3.141, p=0.107 170.99 14.15 18.34 28.62 42.23 19.90 43.81 F(2,16)= 5.970, p=0.012 T2 F(1, 8)= 5.052, p=0.055 102.26 F (2, 34)= 1.046 p=0.362 F (2, 34)= 0.527, p=0.595
T3 F(1, 10)= 0.095, p=0.764 17.25 T3 F(1, 8)= 2.708, p=0.138 40.62
CD8 EMRA CD69+ moderate 1.50 1.12 2.89 2.76 1.52 1.43 F(2, 20)= 4.678, p=0.022 T2 F(1, 10)= 4.267, p=0.066 92.33 6.39 10.26 9.21 14.43 6.50 7.24 F(2, 10)= 10.886, p=0.003 T2 F(1, 5)= 14.783, p=0.012 44.05 F (2, 24)= 6.517 p=0.005 F (2, 24)= 0.234, p=0.793
T3 F(1, 10)= 0.730, p=0.413 1.10 T3 F(1, 5)= 0.852, p=0.398 1.64
vigorous 1.62 1.25 4.24 4.34 1.96 1.70 F(2, 20)= 8.049, p=0.003 T2 F(1, 10)= 10.152, p=0.010 161.43 4.86 7.55 6.31 5.23 2.96 4.56 F(2,16)= 9.665, p=0.002 T2 F(1, 8)= 4.554, p=0.065 29.87 F(1.2, 21.2)= 1.884 p=0.184 F(1.2, 21.2)= 1.638, p=0.217
T3 F(1, 10)= 0.087, p=0.774 21.13 T3 F(1, 8)= 3.616, p=0.094 39.21
ccontrast
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Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
CD8 Na CD11b+ moderate 4.96 4.33 6.42 8.78 4.83 7.37 F(2, 20)= 2.873, p=0.080 T2 F(1, 10)=0.289, p=0.602 29.64 18.86 39.01 23.88 46.58 41.47 58.91 F(2, 10)= 0.191, p=0.829 T2 F(1, 5)= 0.625, p=0.465 26.64 F (2, 24)=2.983 p=0.070. F (2, 24)= 3.079, p=0.065.
T3 F(1, 10)= 2.442, p=0.149 2.45 T3 F(1, 5)= 0.015, p=0.906 119.93
vigorous 2.90 2.31 4.74 6.16 3.20 2.72 F(2, 22)= 0.418, p=0.663 T2 F(1, 11)= 0.977, p=0.344 63.15 1.48 2.39 1.56 1.73 1.15 1.48 F(2,16)= 1.274, p=0.307 T2 F(1, 8)= 1.196, p=0.306 5.80 F(1.1,18.7)= 0.086 p=0.797 F(1.1,18.7)= 1.378, p=0.259
T3 F(1, 11)= 0.067, p=0.801 10.30 T3 F(1, 8)= 0.285, p=0.608 22.46
CD8 CM CD11b+ moderate 2.43 3.72 3.95 8.09 5.83 11.38 F(1.3, 13.06)= 0.783, p=0.470 T2 F(1, 10)= 1.563, p=0.240 62.86 4.28 5.96 4.19 5.41 5.67 6.35 F(1.05, 5.3)= 0.230, p=0.798 T2 F(1, 5)= 0.127, p=0.736 2.23 F (2, 24)= 0.665 p=0.523 F (2, 24)=1.201, p=0.318
T3 F(1, 10)= 0.778, p=0.398 140.03 T3 F(1, 5)= 0.321, p=0.596 32.51
vigorous 1.10 1.32 1.52 1.42 0.96 0.99 F(2, 22)= 2.455, p=0.109 T2 F(1, 11)= 2.497, p=0.114 37.25 0.61 0.60 0.62 0.67 0.50 0.67 F(2,16)= 1.225, p=0.313 T2 F(1, 8)= 0.013, p=0.911 1.09 F(1.22, 20.7)= 1.404, p=0.252 F(1.22, 20.7)= 1.055, p=0.319
T3 F(1, 11)= 0.111, p=0.745 12.81 T3 F(1, 8)= 1.825, p=0.214 18.59
CD8 EM CD11b+ moderate 26.43 48.16 39.54 76.72 29.01 57.67 F(1.2, 11.8)= 1.830, p=0.204 T2 F(1, 10)= 2.233, p=0.166 49.60 69.86 93.70 68.61 88.75 82.18 78.01 F(2, 10)= 0.321, p=0.733 T2 F(1, 5)= 1.925, p=0.224 1.79 F (2, 24)=1.077 p=0.357 F (2, 24)= 0.192, p=0.826
T3 F(1, 10)= 1.129, p=0.313 9.76 T3 F(1, 5)= 0.033, p=0.862 17.64
vigorous 14.55 19.17 32.14 46.56 14.35 16.81 F(2, 22)= 1.186, p=0.324 T2 F(1, 11)= 3.799, p=0.077 120.96 37.91 77.40 58.88 120.62 13.86 18.71 F(2,16)= 1.858, p=0.188 T2 F(1, 8)= 2.295, p=0.168 55.33 F(1.1, 18.6)= 2.040, p=0.169 F(1.1, 18.6)= 0.742, p=0.412
T3 F(1, 11)= 0.168, p=0.689 1.37 T3 F(1, 8)= 0.692, p=0.430 63.44
CD8 EMRA CD11b+ moderate 3.07 2.84 4.26 4.74 1.99 2.01 F(2, 20)= 10.454, p=0.001 T2 F(1, 10)= 2.000, p=0.188 38.61 33.63 56.42 38.62 58.86 48.70 76.74 F(2, 10)= 6.752, p=0.014 T2 F(1, 5)= 4.405, p=0.090 14.82 F (2, 24)=3.134 p=0.062 F (2, 24)=1.514, p=0.240
T3 F(1, 10)= 8.225, p=0.017 35.28 T3 F(1, 5)= 6.881, p=0.047 44.81
vigorous 1.72 1.17 3.30 3.05 1.29 1.39 F(2, 22)= 10.424, p=0.001 T2 F(1, 11)= 9.678, p=0.010 91.48 22.09 56.35 13.76 20.34 7.86 18.66 F(1, 16)= 6.807, p=0.007 T2 F(1, 8)= 2.296, p=0.168 37.70 F(1.34, 22.8)= 1.483 p=0.243 F(1.34, 22.8)=1.428, p=0.254
T3 F(1, 11)= 3.828, p=0.076 24.82 T3 F(1, 8)= 14.156, p=0.006 64.43
CD8 Na  CD127+ moderate 57.31 75.58 60.46 62.52 48.90 54.33 F(2, 18)= 2.262, p=0.133 T2 F(1, 9)= 0.585, p=0.464 5.50 71.89 69.24 82.69 74.09 66.03 52.29 F(2, 10)= 0.218, p=0.808 T2 F(1, 5)= 0.170, p=0.697 15.01 F(1.3, 19.5)= 3.216 p=0.087 F(1.3, 19.5)= 3.126, p=0.092
T3 F(1, 9)= 1.782, p=0.215 14.66 T3 F(1, 5)= 0.243, p=0.643 8.16
vigorous 67.94 54.84 84.76 66.64 58.84 43.04 F(1.4, 11.17)= 0.498, p=0.530 T2 F(1, 10)= 0.076, p=0.788 24.76 46.26 66.22 58.96 70.71 46.59 56.68 F(2,16)= 0.895, p=0.428 T2 F(1, 8)= 1.642, p=0.236 27.45 F(1.24, 19.8)= 0.162 p=0.744 F(1.24, 19.8)= 0.832, p=0.397.
T3 F(1, 10)= 1.140, p=0.311 13.39 T3 F(1, 8)= 0.012, p=0.915 0.70
CD8 CM  CD127+ moderate 15.29 2.68 19.87 13.56 20.21 10.65 F(2, 20)= 1.131, p=0.345 T2 F(1, 9)= 0.287, p=0.605 29.93 22.53 10.47 26.09 18.04 19.02 4.38 F(2,10)= 0.819, p=0.468 T2 F(1, 5)= 0.011, p=0.922 15.79 F (2, 24)= 3.681 p=0.040 F (2, 24)= 2.809, p=0.080
T3 F(1, 9)= 1.542, p=0.246 32.14 T3 F(1, 5)= 1.098, p=0.343 15.58
vigorous 21.24 13.95 23.70 14.20 20.85 10.42 F(2, 20)= 0.288, p=0.753 T2 F(1, 10)= 0.256, p=0.624 11.61 12.04 9.30 19.84 15.56 10.64 10.10 F(1.1, 8.78)= 1.437, p=0.267 T2 F(1, 8)= 1.292, p=0.289 64.86 F (2, 36)= 3.583, p=0.038 F (2, 36)= 0.810, p=0.453.
T3 F(1, 10)= 0.468, p=0.510 1.83 T3 F(1, 8)= 1.330, p=0.282 11.62
CD8 EM  CD127+ moderate 92.83 42.12 120.96 65.88 98.29 46.14 F(2, 18)= 0.893, p=0.427 T2 F(1, 9)= 0.197, p=0.668 30.30 167.63 82.21 190.21 98.76 144.76 50.20 F(2, 10)= 3.125, p=0.088 T2 F(1, 5)= 0.193, p=0.679 13.48 F (2, 24)= 2.620 p=0.100 F (2, 24)= 0.13, p=0.987
T3 F(1, 9)= 0.193, p=0.679 5.89 T3 F(1, 5)= 3.796, p=0.109 13.64
vigorous 152.49 129.64 223.97 166.96 136.06 90.49 F(1.2, 12.1)= 0.470, p=0.632 T2 F(1, 10)= 0.094, p=0.766 46.87 120.65 114.79 195.35 168.84 97.52 97.81 F(1.1, 9.1)= 2.603, p=0.105 T2 F(1, 8)= 1.068, p=0.332 61.91 F(1.2, 19.9)= 1.274 p=0.035 F(1.2, 19.9)= 0.855, p=0.385.
T3 F(1, 10)= 1.319, p=0.277 10.78 T3 F(1, 8)= 6.288, p=0.037 19.17
CD8 EMRA CD127+ moderate 8.41 3.51 11.04 9.16 7.18 3.93 F(2, 18)= 4.143, p=0.033 T2 F(1, 10)= 0.328, p=0.581 31.26 20.57 23.13 25.43 23.96 22.08 27.10 F(2, 10)= 4.625, p=0.038 T2 F(1, 5)= 7.008, p=0.046 23.61 F (2, 24)= 4.271 p=0.026 F (2, 24)= 0.044, p=0.957.
T3 F(1, 10)= 4.719, p=0.058 14.59 T3 F(1, 5)= 1.544, p=0.269 7.34
vigorous 13.15 12.71 17.90 16.17 11.41 9.04 F(1.3, 12.5)= 1.793, p=0.192 T2 F(1, 10)= 1.541, p=0.243 36.16 10.00 7.50 16.15 11.51 8.70 10.00 F(1.2, 9.7)= 3.852, p=0.074 T2 F(1, 8)= 2.333, p=0.165 61.49 F(1.24, 21)= 4.606 p=0.037 F(1.24, 21)=0.200, p=0.711
T3 F(1, 10)= 1.398, p=0.264 13.24 T3 F(1, 8)= 5.058, p=0.055 12.98
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Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
CD8 Na CD95+ moderate 2.24 3.55 3.12 5.37 1.28 2.48 F(1.06, 9.58)= 0.089, p=0.787 T2 F(1, 9)= 2.619, p=0.140 39.13 10.12 20.35 15.40 22.21 23.95 32.94 F(1, 4)= 0.885, p=0.400 T2 F(1, 4)= 6.447, p=0.064 52.20 F(1.3, 13.9)= 3.126, p=0.087 F(1.3, 13.9)=3.126, p=0.092
T3 F(1, 9)= 0.017, p=0.900 42.78 T3 F(1, 4)=  0.961, p=382 136.66
vigorous 1.06 1.20 11.50 36.36 0.71 1.45 F(2, 22)= 0.218, p=0.806 T2 F(1, 11)= 0.460, p=0.512 983.77 11.97 28.45 1.69 2.88 14.88 38.89 F(1.5, 7.3)= 0.642, p=0.454 T2 F(1, 7)= 0.201, p=0.667 85.84 F(1, 16.5)= 0.009, p=0.991 F(1, 16.5)=1.588, p=0.220
T3 F(1, 11)= 0.193, p=0.669 33.41 T3 F(1, 7)= 0.536, p=0.488 24.35
CD8 CM CD95+ moderate 3.84 5.45 5.44 8.01 4.22 7.42 F(1.07, 10.71)= 0.210, p=0.673 T2 F(1, 10)= 3.810, p=0.079 41.58 7.87 7.78 15.12 23.28 9.99 9.12 F(2,10)= 0.448, p=0.651 T2 F(1, 5)= 0.557, p=0.489 92.00 F (2, 26)= 4.316, p=0.024 F (2, 26)=1.800, p=0.185
T3 F(1, 10)= 0.080, p=0.783 9.81 T3 F(1, 5)= 0.025, p=0.880 26.84
vigorous 1.42 1.17 3.94 9.92 1.54 1.98 F(2, 22)= 0.196, p=0.823 T2 F(1, 11)= 0.434, p=0.523 176.70 2.68 3.26 2.33 2.93 2.35 3.38 F(1.14, 9.1)= 0.056, p=0.847 T2 F(1, 8)= 0.004, p=0.950 12.77 F(1.5, 25.2)= 2.081, p=0.155 F(1.5, 25.2)= 0.585 p=0.515
T3 F(1, 11)= 0.117, p=0.739 8.09 T3 F(1, 8)= 0.704, p=0.426 12.23
CD8 EM CD95+ moderate 26.53 47.35 38.74 66.38 28.97 51.70 F(1.17, 11.65)= 0.332, p=0.609 T2 F(1, 10)= 2.445, p=0.149 46.03 73.02 97.65 179.36 288.58 126.12 86.95 F(1.1, 5.5)= 0.458, p=0.544 T2 F(1, 5)= 0.521, p=0.503 145.65 F(1.1, 13.7)= 0.063, p=0.818 F(1.1, 13.7)= 0.036, p=0.863
T3 F(1, 10)= 0.016, p=0.903 9.21 T3 F(1, 5)= 0.192, p=0.679 72.72
vigorous 11.53 10.99 58.31 170.75 8.27 9.83 F(2, 22)= 0.104, p=0.901 T2 F(1, 11)= 0.006, p=0.941 405.65 20.42 24.03 23.64 44.90 16.44 18.71 F(1.1, 8.7)= 0.103, p=0.777 T2 F(1, 8)= 0.051, p=0.827 15.79 F(1.4, 23)= 2.993, p=0.087 F(1.4, 23)= 0.383, p=0.605
T3 F(1, 11)= 0.258, p=0.622 28.27 T3 F(1, 8)= 2.424, p=0.158 19.50
CD8 EMRA CD95+ moderate 2.30 3.58 4.56 7.06 0.96 1.64 F(1.48, 12.93)= 2.026, p=0.158 T2 F(1, 10)= 3.880, p=0.077 98.49 16.03 25.78 67.45 126.20 42.96 42.21 F(2, 10)= 0.489, p=0.627 T2 F(1, 5)= 0.443, p=0.535 320.67 F (2, 24)= 7.135, p=0.004 F (2, 24)= 0.762, p=0.478
T3 F(1, 10)= 0.622, p=0.448 58.46 T3 F(1, 5)= 0.007, p=0.938 167.92
vigorous 0.91 0.98 3.91 9.85 0.44 0.74 F(1.35, 14.8)= 0.909, p=0.386 T2 F(1, 11)= 1.003, p=0.338 330.92 19.02 50.96 7.65 17.02 6.85 15.61 F(1.4, 11.143)= 0.289, p=0.753 T2 F(1, 8)= 0.292, p=0.604 59.76 F(1.24, 21)= 10.025, p=0.003 F(1.24, 21)= 1.106, p=0.320
T3 F(1, 11)= 0.380, p=0.550 51.84 T3 F(1, 8)= 1.016, p=0.343 63.96
CD8 EMRA CD28-CD27- moderate 12.78 12.47 28.41 35.96 12.42 11.96 F(2, 18)= 10.310, p=0.001 T2 F(1, 9)= 5.977, p=0.037 122.33 T2 F(2, 16)= 18.722, p<0.001
T3 F(1, 9)= 4.485, p=0.063 2.79 T3
vigorous 12.98 13.87 27.76 30.42 9.24 7.78 F(2, 20)= 3.912, p=0.037 T2 F(1, 10)= 3.426, p=0.094 113.76 31.36 67.78 29.13 29.74 11.94 22.78 F(1.13, 6.8)= 5.464, p=0.050 T2 F(1, 6)= 2.061, p=0.201 7.12 F(1.4, 20.5)= 8.955, p=0.004 F(1.4, 20.5)= 1.967, p=0.174
T3 F(1, 10)= 1.074, p=0.324 28.82 T3 F(1, 6)= 19.107, p=0.005 61.91
CD8 EMRA CD28-CD27+ moderate 4.79 4.85 4.87 6.20 4.39 5.66 F(2, 18)= 2.543, p=0.106 T2 F(1, 9)= 0.039, p=0.849 1.66 T2 F(2, 16)= 0.132, p=0.877
T3 F(1, 9)= 3.517, p=0.093 8.36 T3
vigorous 6.94 8.34 9.46 12.59 5.70 7.68 F(1.3, 13.1)= 3.765, p=0.066 T2 F(1, 10)= 3.041, p=0.112 36.30 3.16 4.73 4.34 5.09 2.52 3.73 F(2,12)= 1.174, p=0.342 T2 F(1, 6)= 0.829, p=0.398 37.12 F(1.35, 18.9)= 2.559, p=0.119. F(1.35, 18.9)= 0.808, p=0.456
T3 F(1, 10)= 2.860, p=0.122 17.94 T3 F(1, 6)= 1.295, p=0.298 20.45
CD8 EMRA CD28+CD27- moderate 3.21 4.14 6.63 12.85 2.83 3.78 F(2, 18)= 2.870, p=0.083 T2 F(1, 9)= 2.841, p=0.126 106.79 T2 F(2, 24)= 1.583, p=0.226
T3 F(1, 9)= 1.026, p=0.338 11.79 T3
vigorous 5.81 8.82 10.34 19.88 4.43 8.52 F(2, 20)= 3.214, p=0.062 T2 F(1, 10)= 1.430, p=0.259 78.06 7.68 9.94 12.83 17.45 3.32 4.43 F(2,12)= 5.293, p=0.022 T2 F(1, 6)= 1.951, p=0.212 67.07 F(1.4, 23)= 0.409, p=0.590. F(1.4, 23)= 1.092, p=0.328
T3 F(1, 10)= 2.133, p=0.175 23.74 T3 F(1, 6)= 6.245, p=0.047 56.78
CD8 EMRA CD28+CD27+ moderate 4.89 7.84 4.96 8.34 4.38 8.09 F(2, 18)= 0.037, p=0.964 T2 F(1, 9)= 0.393, p=0.547 1.39 T2 F(2, 24)= 0.890, p=0.424
T3 F(1, 9)= 0.000, p=0.986 10.52 T3
vigorous 6.55 7.64 6.41 7.14 3.84 3.74 F(1.1, 10.1)= 0.114, p=0.757 T2 F(1, 10)= 0.009, p=0.926 2.26 4.41 8.14 7.25 13.92 6.01 12.95 F(2,12)= 1.185, p=0.339 T2 F(1, 6)= 1.989, p=0.208 64.38 F(1.3, 22.7)= 1.132, p=0.314 F(1.3, 22.7)= 0.083, p=0.831
T3 F(1, 10)= 0.097, p=0.761 41.33 T3 F(1, 6)= 0.339, p=0.582 36.47
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5.3.4 Stem cell like memory (T SCM) T cell subsets 
CD4+ and CD8+ TSCM (CD45RA+CCR7+CD95+CD127+) populations were measured in T1D 
and control participants at baseline, and following moderate and vigorous intensity exercise. 
Table 38 displays the mean data for CD4+ and CD8+ TSCM subsets during exercise in control 
and T1D groups. 
5.3.4.1 CD4+ TSCM in T1D and control participants 
CD4+ TSCM (CD4+CD45RA+CCR7+CD95+CD127+) populations were measured in T1D and 
control participants at rest (Table 38). There was a trend to increase in the frequency of CD4+ 
TSCM populations in the T1D group (Figure 36a).  
There were no significant changes overtime in CD4+ TSCM during moderate or vigorous 
intensity exercise in either group. Although not significant, increases in CD4+ TSCM frequency 
immediately post exercise are evident in the control group. The percentage increase following 
moderate exercise is 364.39% in the T1D group and 48.34% in the control group (Figure 36c). 
However, during vigorous intensity exercise a blunted response is noted in the T1D group. 
CD4+ TSCM decrease following vigorous exercise by 76.44% in the T1D group but increase by 
331.06% in the control group (Figure 36d). 
5.3.4.2 CD8+ TSCM in T1D and control participants 
CD8+ TSCM (CD8+CD45RA+CCR7+CD95+CD127+) populations were measured in T1D and 
control participants at rest (Table 38). There was a trend to increase in the frequency of CD8+ 
TSCM populations in the T1D group (Figure 36b).  
CD8+ TSCM significantly changed overtime during moderate intensity exercise in control 
participants only. There were significant no change overtime in CD8+ TSCM during vigorous 
intensity exercise in either group. Although not significant, increases in CD8+ TSCM frequency 




immediately post exercise are evident. The percentage increase following moderate exercise is 
57.27% in the T1D group and 49.09% in the control group (Figure 36e). However, during 
vigorous intensity exercise a blunted response is noted in the T1D group. CD8+ TSCM decrease 
following vigorous exercise by 90.97% in the T1D group but increase dramatically by 







Figure 36 T cells with beta cell specific phenotype during low and vigorous intensity exercise in control and 
T1D subjects 
Flow cytometry and whole blood counts were used to determine the TSCM populations in control and T1D subjects. 
(a) The frequency of CD4+ and (b) CD8+ TSCM (CD45RA+ CCR7+ CD95+ CD127+) at baseline (c) The 
frequency of CD4+ TSCM during low and (d) vigorous intensity exercise (e) The frequency of CD8+ TSCM during 
moderate and (f) vigorous intensity exercise. Error bars represent SEM. No statistical significance observed.







Table 38 TSCM populations mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of TSCM populations for control and T1D subjects at baseline, during moderate and vigorous intensity exercise. Significant 
results highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2) or 1 hour post exercise (T3). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 














mean SD mean SD mean SD mean SD mean SD mean SD
CD4 TSCM moderate 0.77 0.83 1.14 1.53 0.91 1.31 F(1, 9)= 0.993, p=0.345 T2 F(1, 9)= 1.217, p=0.299 48.34 4.10 6.63 19.06 34.39 7.57 9.74 F(1, 4)= 1.017, p=0.370 T2 F(1, 4)= 0.992, p=0.376 364.39 F(1.35, 17.54)= 0.029, p=0.924 F(1.35, 17.54)= 2.172, p=0.134
T3 F(1, 9)= 0.997, p=0.344 17.54 T3 F(1, 4)= 1.005, p=0.373 84.37
vigorous 0.41 0.69 1.78 4.38 0.42 0.76 F(1, 10)= 0.991, p=0.343 T2 F(1, 10)= 1.833, p=0.206 331.06 7.97 20.13 1.88 5.47 17.79 47.77 F(1, 7)= 1.008, p=0.349 T2 F(1, 7)= 0.816, p=0.396 76.44 F(1.5, 25.5)= 2.061, p=0.157 F(1.5, 25.5)= 0.647, p=0.489
T3 F(1, 10)= 1.007, p=0.339 0.42 T3 F(1, 7)= 1.001, p=0.350 123.31
CD8 TSCM moderate 1.35 2.50 2.01 4.39 0.93 2.10 F(2, 14)= 4.419, p=0.033 T2 F(1, 7)= 1.802, p=0.221 49.09 8.73 17.59 13.73 19.52 16.53 25.92 F(1, 4)= 0.875, p=0.403 T2 F(1, 4)= 0.797, p=0.423 57.27 F(1.27, 12.7)= 2.853, p=0.110 F(1.27, 12.7)= 2.740, p=0.117
T3 F(1, 7)= 2.344, p=0.170 31.21 T3 F(1, 4)= 4.118, p=0.112 89.43
vigorous 0.53 0.69 10.65 34.51 0.47 1.01 F(1.1, 9.6)= 1.036, p=0.340 T2 F(1, 9)= 1.084, p=0.325 1898.68 9.71 26.74 0.88 2.19 12.62 36.22 F(1.02, 7.12)= 0.701, p=0.432 T2 F(1, 7)= 0.730, p=0.421 90.97 F(1.04, 16.6)= 0.052, p=0.832 F(1.04, 16.6)= 1.140, p=0.304












5.4 Discussion  
The first aim of this study was to measure progressively differentiated T cell subsets at baseline 
in T1D and control participants. A shift in EMRA proportions at baseline was found in T1D 
compared to the control group; CD4+ EMRA were reduced whereas CD8+ EMRA were 
elevated in the T1D group. The elevated CD8+ EMRA population in T1D comprised of subsets 
with tissue residency and homing propensity i.e. CD69+ and CD11b+.  
This study also aimed to investigate the effects of moderate and vigorous intensity exercise on 
the mobilisation of T cell subsets in T1D and control participants. As expected, vigorous 
intensity exercise induced a significant mobilisation of CD3+ T cells in both T1D and control 
participants, with no significant mobilisation during moderate intensity exercise. CD4+ T cells 
mobilised during vigorous exercise in the control group, but not the T1D group. This had a 
downstream effect on CD4+ T cell subsets in T1D participants because no significant 
mobilisation of differentiated CD4+ T cell subsets was seen during either exercise intensity in 
the T1D group. The changes seen during exercise within the CD4+ compartment were minimal 
compared to changes seen within the CD8+ compartment. Vigorous intensity exercise 
significantly mobilised CD8+ T cells in both T1D and control participants. CD8+ T cells 
increased to the same extent after vigorous intensity exercise in both the T1D and control 
group. Within CD8+ T cells, CD8+ EMRA cells were the most responsive to exercise. CD8+ 
EMRA mobilised during both moderate and vigorous intensity exercise in the T1D and control 
groups. However, the percentage increase of CD8+ EMRA in the T1D group following 
vigorous intensity exercise was blunted.  
Further phenotyping of CD8+ EMRA populations revealed that the mobilised subsets were 
mainly comprised of fully differentiated (CD27-CD28-), recently activated tissue-resident 





above EMRA subsets following vigorous exercise was blunted in the T1D group. Additionally, 
CD8+CD127+ EMRA and CD8+CD95+ EMRA significantly changed overall during vigorous 
intensity exercise, but this was not seen in either T1D or control groups independently.  
This study also identified that the rise in peripheral blood lymphocytes during exercise is a 
result of recently activated CD8+ T cell egress from tissues as shown by CD69 expression. 
Naïve, CM, and EMRA CD8+ T cell subsets that increased immediately following vigorous 
exercise were CD69+.  
The strengths of this study are that it is the first study of steady state acute exercise and T cell 
subset mobilisation in T1D. This study gives an in-depth analysis of T cell subsets mobilised 
by two different exercise intensities, in two cohorts. The use of surface markers to define T cell 
function and fate improves understanding of the specific subsets mobilised. Increases in both 
CD69 and CD11b on CD4+ and CD8+ lymphocytes have been reported following exercise 
previously, but not on specific T cell subsets as demonstrated in this study herein [195, 351-
353, 424-429]. The effects of exercise have not been looked at previously on CD127+ T cells 
and TSCM subsets. This is the first time this has been shown in T1D and healthy cohorts. 
Furthermore, the differentiation status of EMRA based on differential expression of CD27 and 
CD28 is reported here in T1D participants at rest and following exercise. 
However, the limitations of the study are that the number of recruited participants were low 
therefore comparisons between groups are difficult. Secondly, the majority of the experimental 
group were long-standing T1D. However, baseline differences highlighted in this study support 
findings from recently diagnosed and long standing T1D [339, 370, 371]. Long-standing T1D 
also show persistence of islet autoimmunity and CD8+ T cell infiltration [28, 129, 372]. 
Nonetheless, a large proportion of the autoimmune destruction and immune alterations occur 





who have been recently diagnosed may provide more insight into early disease prevention. 
Additionally, with a larger cohort, data could be adjusted for T1D duration.  
Previously, studies have demonstrated that vigorous exercise causes a significant rise in 
peripheral blood lymphocytes, followed by lymphopenia, in healthy cohorts [191-195]. This is 
also the case in this study and the first time this has been shown in T1D. The data shown agrees 
with previous studies because only minor exercise induced mobilisation of CD4+ T cells has 
been reported [199, 257]. The majority of redeployed lymphocytes are late differentiated CD8+ 
T cell subsets, with a decrease in naïve and CM populations [191, 200, 215, 257, 364, 365]. 
CD8+ EMRA are the most sensitive to mobilisation, and are shown to mobilise by both 
moderate and vigorous exercise in this study herein and others [199, 200, 257]. However, it 
has not been previously reported that CD8+ EMRA subsets that express adhesion and activation 
markers are mobilised by exercise [199, 200, 215]. CD95+ subsets were mobilised by exercise, 
yet not to the same extent as seen in previous studies [216, 218, 220]. This is possibly due to 
the limitations of a small study cohort. 
This is the first study of T cell subset mobilisation in T1D and the blunted T cell egress during 
vigorous intensity exercise has not been demonstrated before. It is possible that the blunting is 
due to sequestration of T cell subsets in the pancreas of people with T1D. T cell subsets 
exhibiting a blunted response share similarities with those seen in the pancreas of T1D models 
(NOD mice) [126, 127, 134, 435]. The proportion of CD8+CD69+ T cells was higher in the 
pancreas than salivary glands taken from NOD mice [126]. CD8+CD11b+ T cells have also 
been found within NOD islets [127, 134] and found to be higher in the islets of NOD mice 
compared to peripheral blood [435]. Furthermore, antigen-experienced islet reactive CD8+ T 
cells were found sequestered in the pancreas of T1D donors [131]. Islet reactive CD8+ T cells 





analogous to the CD8+ EMRA T cell phenotype. More recently, autoreactive CD8+ T cells 
were shown to display a TSCM phenotype [421]. In this study herein, there is an evident blunted 
percentage increase of CD8+ EMRA that express CD69, CD11b, and were highly 
differentiated, immediately following vigorous exercise in the T1D group. Both CD4+ and 
CD8+ TSCM also displayed a blunted egress following vigorous exercise compared to the control 
group. It therefore is possible to postulate that the blunted increase following exercise in these 
CD8+ T cell subsets is due to their sequestration in the pancreas in T1D.  
However, the mechanisms for this blunted T cell egress in T1D warrants further investigation. 
The down regulation of S1PR, necessary for T cell exit from tissue into the blood stream, is 
one potential mechanism. Islet reactive T cells accumulate in the pancreas during T1D onset 
[436] and are found to be enriched within the pancreas of T1D donors [131]. Yet, the 
mechanisms by which islet reactive T cells are retained in the pancreas are unknown. It is 
however known that tissue resident memory T cells down-regulate S1PR [437]. Pancreatic 
resident T cells exhibit a tissue resident memory phenotype; therefore the lack of S1PR 
expression may inhibit their egress from the pancreas during acute exercise. 
This study provides insight into the implications of acute exercise in T1D. Access to the 
pancreas is limited and therefore human research on pancreatic T cell infiltration is challenging. 
However, peripheral blood is to some extent a representative source of diabetogenic T cells 
[438, 439]. Identical beta cell specific CD8+ T cell subsets were found in the pancreas and 
peripheral blood in NOD mice [438, 439]. Exercise induced lymphocytosis in T1D participants 
may improve accessibility to diabetogenic T cells in peripheral blood. 
On the contrary to the observed blunted increase, lymphocytosis followed by lymphopenia is 
still evident in T1D. However, a major limitation of this study is that the cause of lymphopenia 





pancreas to cause further beta cell destruction. As discussed in Chapter 4, measuring 
diabetogenic T cell migration specifically would offer insight into their redeployment patterns 
during vigorous exercise. If the migrated lymphocytes had been collected at the end of the 
TEM assay and characterised by flow cytometry, quantification of diabetogenic T cells during 
and following exercise would clarify whether migration of diabetogenic T cells is impaired by 
vigorous exercise, thereby preserving beta cell health. In addition to including this in future 
studies, tracking of T cells in NOD mice during and following vigorous exercise could be done 
using bioluminescent tagging of the T cells, live imaging of T cell location before and after 
acute exercise, as well as harvesting organs to measure T cell infiltration into multiple organs 
including the pancreas. Although the impact of exercise-induced lymphopenia in T1D is not 
defined, the potential benefits of lymphopenia following exercise is discuss below. 
The mobilisation of terminally differentiated memory subsets by acute exercise has been 
hypothesised to create immune space in healthy participants [220, 221]. Lymphocytes isolated 
from healthy participants following vigorous exercise were more susceptible to apoptosis 
induction and expressed higher levels of CD95 [216, 218, 219]. Total CD8+ T cells positive 
for annexin V, a marker for apoptosis, were increased in the gut 24 hours after the cessation of 
treadmill running in mice [217]. There is a strong link between the gut and the pancreas, leading 
to the premise that this organ specific deletion of memory T cells could occur in T1D [440, 
441]. Given that a comparable response to acute exercise is seen in T1D participants, immune 
space could also be created in T1D. Vigorous acute exercise increases the frequency of 
hematopoietic stem and progenitor cells (HSPC) in the peripheral blood and haematopoiesis in 
the bone marrow [212, 213]. This would allow for more naïve and newly differentiated subsets 
with a less aggressive autoimmune phenotype to take up the vacant immune space thereby 





Current immunotherapies target pathogenic T cells to reduce autoreactive subsets in T1D 
[442]. One such immunotherapy, teplizumab, a nonactivating anti-CD3 monoclonal antibody, 
aims to reduce effector memory subsets, and increase naïve and early memory subsets; 
comparable to an acute exercise bout. Anti-CD3 mAbs, that are non-Fc receptor (FcR) binding, 
selectively induce apoptosis of antigen-activated T cell phenotypes such as those with 
memory/pathogenic phenotypes but not naïve T cells [153]. Teplizumab treatment resulted in 
maintained or improved beta cell function for at least 2 years post treatment in recent-onset 
T1D patients [149-152]. Evidence for beta cell preservation was also reported in long standing 
T1D patients up to 1 year post clinical diagnosis [154]. One study identified a group of 
responders who had higher activated CD8+ terminally differentiated effector and CD8+ EM in 
T cells at baseline [155]. This is consistent with increased CD8+ terminally differentiated EM 
T cells following acute exercise, therefore exercise could improve access to target T cell 
populations. Pairing an acute exercise bout with treatment administration could potentially 
increase response to treatment. Responders also had different metabolic features such as lower 
levels of HbA1c and insulin use, features observed with frequent exercise in T2D [182, 443, 
444]. Therefore, frequent bouts of acute exercise could create an environment in which T1D 
participants respond better to treatment. 
Preliminary data from this study herein provides a basis for a future chronic exercise trial, 
leading to the hypothesis that current findings in healthy participants can be implemented in 
T1D, as reported here with acute exercise. Chronic exercise reduces senescent T cells in the 
blood [445]. In an ageing study, physically fit age matched controls had a lower proportion of 
peripheral blood memory T cells (KLRG1+CD57+, KLRG1+CD28-) compared to those with a 
lower VO2 max [221, 446]. Naïve-memory T cell balance is disrupted in the ageing population 
and a similar observation has been found in T1D [419]. Therefore, reduced senescent memory 





The mechanisms by which exercise training could preserve beta cells in T1D have yet to be 
explored. Exercise training modulates immunity in other T cell mediated autoimmune disorders 
[447]. Mice with EAE, a routinely used model for multiple sclerosis (MS), completed 6 weeks 
exercise training. T cells taken from lymph nodes had an inhibited immune response to 
autoantigen whilst sustaining an increased immune response to non-specific stimulus such as 
concanavalin A [447]. This suggests the generation of new naïve and early memory T cells 
with exercise training as the recall response to autoantigen is reduced. Another study showed 
improved immune modulation by exercise in EAE models resulting in delayed onset of disease 
and increased T cells with a regulatory phenotype [448]. However, other autoimmune disorders 
such as rheumatoid arthritis (RA) and systemic lupus (SLE) have different responses to 
exercise, where CD8+ T cells are reduced following exercise and CD4+ T cells are reduced at 
peak exercise but increased after cessation [238]. It is unclear if exercise training would result 
in the same improvements in these disorders such as those seen in MS and T1D, where 
responses to exercise are comparable to healthy controls i.e. lymphocytosis occurs in a similar 
pattern.  
In conclusion, acute exercise preferentially mobilised differentiated and antigen experienced 
CD8+ T cells in T1D, but to a lesser extent than healthy individuals. A contributing factor to 
the relatively reduced mobilisation pattern in T1D was attributable to a blunted response 
amongst highly differentiated CD8+ T cells, which may indicate sequestering of CD8+ T cells 
in the pancreas. Further evaluation of the immunomodulatory effects of acute exercise on 
autoreactive memory T cells in T1D is warranted to ascertain impact on disease prognosis. 












CHAPTER 6.THE EFFECTS OF 
ACUTE EXERCISE ON 
PERIPHERAL BLOOD T-HELPER 
AND T-REGULATORY CELL 








6.1.1 CD4+ T cell differentiation  
 
The effects of exercise on CD4+ and CD8+ T cells at different stages of their respective 
differentiation have been described in Chapter 5. In addition to the analytical approach adopted 
in Chapter 5, CD4+ T cells can also be subdivided into T-helper (Th) and T-Regulatory (TReg) 
subsets [291, 449]. There is strong evidence to suggest that the balance between T-helper and 
TRegs is disrupted by T1D. CD4+ Th differentiation is skewed towards increased pro-
inflammatory Th1 and Th17 cells in T1D [450, 451]. Whereas CD4+ TReg function, and 
potentially TReg frequency, are compromised in T1D [452]. It is proposed that regular exercise 
may facilitate a shift in this balance back towards homeostasis [453-457]. Accordingly, this 
study explored the effects of acute exercise on T-helper and TReg populations in T1D.  
6.1.1.1 CD4+ T-helper cells 
 
The T-helper arm of CD4+ T cells are defined by CD45RO+CD127hiCD25low cell surface 
expression. Subsets are further distinguished by chemokine receptor expression and cytokine 
secretion patterns [291, 458-460].  
Type 1 helper (Th1) cells are identified by CXCR3 expression. They are critical for cell-
mediated immunity and secrete large amounts of IFN-g [291, 461, 462]. Type 2 helper (Th2) 
cells are CXCR3-CCR4+ and can also co-express the chemokines CCR3, CCR6, CCR8, and 
CCR10. They support activation of other leukocytes through production of cytokines IL-4, IL-
5, and IL-13 to do so [291, 461]. Th1 and Th2 were initially thought to work in the classical 
biphasic model. Additional subsets Th9, Th17, and Th22 cells have also been discovered, and 
are characterised by IL-9, IL-17 and IL-22 secretion respectively [463]. Type 17 helper (Th17) 
cells are CXCR3-CCR4-CCR6+ and are known for their potent IL-17 secretion [291, 464-466]. 





CCR6, is expressed on Th17 cells. This specifically mediates Th17 cell recruitment via CCR6, 
but not Th1 or Th2 cells [467].  
6.1.1.2 CD4+ T-Regulatory cells 
 
CD4+ T- Regulatory cells (TRegs) play a critical role in the maintenance of self-tolerance and 
protection against autoimmunity [468-472]. CD4+ TRegs are generated in the thymus (tTReg) 
or in the periphery (pTReg) in the presence of TGF-β [473, 474]. TRegs make up 2-4% of total 
CD4+ T cells [475]. They are conventionally defined by surface marker expression of 
CD4+CD127lowCD25+ and their transcription factor expression of forkhead winged helix 
transcription factor (FoxP3) [378, 476, 477]. Additionally, HELIOS is a transcription factor 
which can distinguish tTReg (HELIOS+) from pTReg (HELIOS-) [478, 479]. Ubiquitous 
expression of FoxP3 is required for CD4+ TReg maintenance and function [477]. IL-2 secreted 
from effector T cells is critical for CD4+ TReg maintenance as it regulates FoxP3 expression 
[480-482]. CD4+ TRegs are immunomodulatory and conduct their suppressive function via 
cell-cell (e.g. CTLA-4, granzyme B) and soluble factor (e.g. TGF-β, IL-10, IL-35) mediated 
mechanisms [483, 484]. 
CD4+ TRegs are routinely identified by flow cytometry using their surface marker expression 
alone (CD4+CD127lowCD25+) [378]. Co- expression of T cell immunoreceptor with Ig and 
ITIM domains (TIGIT) and Fgl2 (FCRL3) on CD4+ TReg cell surface can identify HELIOS+ 
TRegs (i.e. tTReg) [485]. TIGIT is a coinhibitory molecule expressed by activated CD4+ TRegs 
[486]. TIGIT was shown to supress Th1 and Th17 cell differentiation and responses, but 
promoted Th2 cell responses [486] . Upon TIGIT engagement, IL-10 and Fibrinogen-like 
protein 2 (Fgl2) are secreted which may supress IL-12 secretion by Th1 cells [486]. CD4+ 






CD4+ TReg subsets consist of naïve (naTRegs) and memory TRegs (mTRegs). As described 
for progressive differentiation of T cells in Chapter 5, naTRegs express CD45RA whereas 
mTRegs lose CD45RA and acquire CD45RO upon antigen exposure [378, 487]. mTRegs are 
an activated antigen primed subset of CD4+ TRegs and make up the larger proportion of CD4+ 
TRegs [488, 489]. CTLA-4, a coinhibitory molecule, is preferentially expressed by mTRegs to 
exert their suppressive functions [490]. Nonetheless, naTRegs and mTRegs have equal 
suppressive capacity, but carry out their regulatory functions at different sites. mTRegs are 
predominantly tissue resident whereas naTRegs home to the bone marrow [487]. Turnover of 
existing TRegs maintains the CD4+ TReg pool as indicated by the highly proliferative capacity 
of mTRegs [487]. mTRegs show similar gene expression patterns to effector T cells and are 
highly differentiated. This is characterized by short telomeres, inability to upregulate 
telomerase, and susceptibility to apoptosis [487, 491].  
A phenotypically distinct CD4+ TReg subset with increased suppressive, tissue-infiltrating 
capacity was identified recently [492]. They are TIGIT-IL-6Rhi mTReg cells that lack HELIOS 
expression (i.e. formed in the periphery). They also exhibit a Th17 signature 
(RORγt+CD161+CCR6+). Increased expression of CTLA-4 and CCR4 indicate that they are 
highly suppressive, tissue-infiltrating, effector TRegs. TIGIT-IL-6Rhi mTReg cells are also 
highly sensitive to IL-2, increasing dramatically with a single dose [492].  
6.1.2 CD4+ T-helper and T-Regulatory cells in T1D 
 
Th1/Th2 imbalance has been reported in autoimmunity [493] and in T1D [494]. This is 
evidenced by diabetogenic T cells isolated from NOD mice shown to differentiate into Th1, 
not Th2, subsets [450, 494]. In support of this, a Th1 signature has been described in T1D, 
indicated by elevated soluble IFN-γ [495, 496]. Moreover, disease progression can be 





polarization demonstrate beneficial effects in T1D models. IL-4 is a Th2 polarising cytokine. 
When IL-4 was administered to NOD mice, diabetes was inhibited [498]. Furthermore, a Th2 
response (as seen with helminth infection) protected NOD mice from diabetes [499].  
Th17 cells are another subset of CD4+ T-helper cells involved in the pathogenesis of T1D [78, 
451, 500-503]. Studies have shown up-regulated Th17 immunity in T1D [78, 503]. Circulating 
IL-17+ islet reactive CD4+ T cells have been found at diagnosis of T1D, and are a potential 
biomarker of the disease [502]. Th17 cells are potent secretors of IFN-γ [504, 505]. Increased 
IFN-γ mRNA [506] and ratio of IFN-γ/IL-17 expression [451] in Th17 cells has also been 
shown in T1D. IFN-γ secreting, islet reactive Th17 cells were shown to drive T1D in NOD 
mice [501]. Furthermore, Th17 cells were highly plastic in T1D and had the potential to acquire 
an IFN-γ secreting Th1 like profile [507]. In addition to Th17 cells, it has been shown that islet-
reactive T cells share characteristics with follicular helper T cells, such as expressing high 
levels of CXCR5 and IL-21 [508].  
Peripheral blood frequencies of CD4+ TRegs in T1D have been examined, yielding mixed 
results. Some studies have reported lower peripheral blood CD4+ TRegs frequencies in young 
patients with T1D [509]. Others have reported higher activated CD4+ TReg frequencies in T1D 
[77]. Other studies have shown no difference in peripheral blood frequencies of CD4+ TReg 
between T1D and control groups [75, 76, 510].  
There has however been consistency in studies of CD4+ TReg function in T1D. Here, defects 
in CD4+ TReg suppressive capacity/function have been described in T1D [75-78]. Co-culture 
of TRegs from people with T1D with effector T cells failed to suppress the proliferation 
capacity of the effector T cells in a number of studies [75, 77, 79]. Furthermore, IFN-γ 
production was increased from these co-cultures, whiles IL-10 was decreased [75]. These 





2RA correlates with reduced IL-2R (CD25) expression and therefore decreased TReg IL-2 
sensitivity [452, 480, 511]. Secondly, HELIOS deficiency results in an unstable CD4+ TReg 
phenotype and is associated with developing autoimmunity. HELIOS may be important for IL-
2 signalling, therefore FoxP3 maintenance and CD4+ TReg function [512]. Due to their 
plasticity, CD4+ TRegs lose FoxP3 in chronic inflammatory conditions [513]. This may also 
occur in T1D. Lastly, CTLA-4 polymorphisms are associated with T1D due to decreased CD4+ 
TReg suppressive capacity [80, 81]. Treatment with anti CTLA-4 (abatacept) suppresses 
effector T cell activity thereby delaying progression of T1D [514].  
A population of IL-17 secreting regulatory T-helper type 17 (TReg17) cells have been 
previously described to have a preventative role in T1D. Adoptive transfer of TReg17 cells in 
NOD mice delayed disease onset [515-517]. This population shares similarities to the TIGIT-
IL-6Rhi TReg suppressive subset identified by Ferreira, R.C., et al. as they also are IL-17 
secreting TReg cells [492].  
6.1.3 CD4+ T cells during acute exercise  
 
Exercise evokes a shift from Th1 to Th2 polarisation [453, 454, 518-520] . Gene expression of 
PBMCs isolated following a marathon displayed upregulation of Th2 related genes, and down 
regulation of Th1 related genes, persisting for up to 1 week [518]. Other studies have shown 
that vigorous exercise reduces Th1 cells, with no change in Th2 cells, and thus the Th1/Th2 
ratio declined [453, 454]. A shift in the Th1/Th2 ratio following exercise is also supported 
through studies measuring the IFN-γ/IL-4 ratio [519, 520].  
There is a clear lack of evidence of the effects of acute exercise on Th17 cells. One study 
demonstrated an increase in the percentage of Th17 cells following endurance exercise 
(marathon and half-ironman triathlon) [521]. However, IL-17 following acute exercise has 





One study reported an increase in IL-17 following strenuous exercise in trained rats [522]. 
Another study showed no changes in IL-17 following an acute exercise bout in a group of male 
athletes [523].  
Acute exercise increases the frequency and proportion of peripheral blood CD4+ TRegs in 
healthy participants [455-457]. Increased absolute CD4+ TReg frequencies following an 
intense acute exercise bout in trained and untrained participants has been reported [455, 456]. 
An increase in the percentage of peripheral CD4+ TReg following moderate exercise has also 
been demonstrated [457]. Within CD4+ TReg subsets, increases in naïve TReg frequencies, and 
not memory TReg frequencies, following low intensity endurance exercise was shown in one 
study [524]. Further characterisation of TReg mobilisation following acute exercise is needed.  
No studies have measured the effects of acute exercise on CD4+ T-helper and TReg populations 
in T1D. As seen previously (Chapter 5), fully differentiated effector memory T cells are 
preferentially redeployed during exercise. Therefore, it can be speculated that mTReg subsets 
will be responsive to exercise as they also exhibit a highly differentiated phenotype [491]. 
Furthermore, no studies have measured the effect of acute exercise on IL-6Rhi TReg subsets in 
either T1D or control participants. Given that IL-6 is increased dramatically during exercise it 
could be postulated that suppressive IL-6Rhi subsets will mobilise during exercise also [367].  
CD4+ TReg insufficiency drives T1D therefore expansion of TRegs with suppressive function 
via exercise mobilisation could overcome this deficiency. Cell based therapies increasing CD4+ 
TRegs in NOD mice and children have been demonstrated to delay the onset of T1D [525, 
526]. Indeed, increased C-peptide (measure of beta-cell function) and reduced insulin use 1-2 
years post-trial was reported [526-528]. Accordingly, this study herein explored the effects of 






Acute exercise will shift the CD4+ T-helper balance towards Th2 immunity and will mobilise 
memory TReg subsets in T1D participants. 
6.1.5 Aims 
To characterise peripheral blood T-helper and T-Regulatory cell subsets using multi-parameter 
flow cytometry; 
1. In T1D and control participants at rest. 
2. In T1D and control participants following an acute bout of moderate intensity exercise. 








6.2.1 Experimental design 
Twelve controls and twelve T1D male participants were recruited into the study (as described 
in Chapter 3). Briefly, participants had one enrolment visit, where an incremental sub-maximal 
cycle ergometer test was performed to calculate their predicted VO2 max. This was used to 
calculate workload and heart rate for subsequent exercise visits adjusted to individual fitness 
[285]. These two visits consisted of a thirty-minute bout of cycling at either 40% VO2 max 
(moderate) or 80% VO2 max (vigorous). Blood was collected intravenously at baseline, 
immediately post exercise, and 1 hour post exercise in vacuette heparin tubes (95057-405, 
Greiner Bio-one GmbH, Frickenhausen, Germany).  
6.2.2 T-helper and T-Regulatory cell subset analysis 
A twelve-colour flow cytometry panel was designed to phenotype T-Regulatory and T-helper 
cell subsets using the following mAbs (see Table 3, Section 2.3.2 for mAb details); anti-CD3 
PE-Cy7, anti-CD4 APC-R700, anti-CD25 PE, anti-CD45RO BV786, anti-CD127 AF647, anti-
CXCR3 PE-CF594, anti-CCR4 BV421, anti-CCR6 BV711, anti-TIGIT PerCP-Cy5.5, anti-IL-
6R FITC, and Live/Dead-Fixable Viability Stain 780. Whole blood was stained as per Chapter 
2 (Section 2.3.2). Whole blood counts were done using a coulter haematology analyser (Section 
2.2.2) to calculate relative cell frequency (cells/µl) of T-helper and T-regulatory cell subsets.  
6.2.3 Data analysis 
Flowjo v.10 (FlowJo LLC, Oregon) was used to analyse flow cytometry data. Doublets were 
removed using FSC-A versus FSH-H. Lymphocytes were gated based on size on SSC-A versus 
FSC-A dot plot (Figure 37.1), singlets were detected as the linear population on FSC-H versus 
FSC-A dot plot (Figure 37.2), and dead cells positive for 7-AAD viability stain were removed 
(Figure 37.3). T cells were selected as CD3+ (Figure 37.4), and further gated on CD4+ 
 
250 
populations (Figure 37.5). Spider gates were used within these populations to define non-
overlapping subsets; CD4+ T-Regulatory (T-Reg:CD127lo CD25hi), naïve T-Reg (CD45RO-
CD127loCD25hi), memory T-Reg (CD45RO-CD127lo CD25hi), non-TReg (CD127+CD25-), T-
helper (Th: CD127+CD25-CD45RO+), Th1 (CXCR3+CCR6+CCR4-), Th2 (CXCR3-CCR6-
CCR4+), and Th17 (CXCR3-CCR6+CCR4+). TIGIT and IL-6R were analysed on TReg and 
non-TReg populations. Figure 37 displays gating strategy for CD3+CD4+ T cells. See Figure 
38 and 39 for T-helper and TReg gating strategy following definition of CD4+ T cells. Figure 
40 displays gating strategy for IL-6Rhi subsets as defined by Ricardo et al (2017) [492].  
 
Figure 37 Selection of CD3+ lymphocytes shown by representative flow plots 
Representative flow cytometry plots showing (1) Lymphocyte selection based on size (SSC-A vs FSC-A) (2)
Doublets exclusion (FSC-A vs FSC-H) (3) Dead cell removal based on positivity for viability stain (7-AAD 




Figure 38 CD4 T-helper cell gating strategy shown by representative flow plots. 
Representative flow cytometry plots showing following parent gate for CD3+CD4+ T-helper populations (shown 
in figure 1) (1) CD127+CD25- non-TReg gate (2) CD45RO+ T-helper cell gate (3) CXCR3+ gate for Th1 subsets, 
CXCR3- gate for Th2/Th17 subsets (4) CXCR3+CCR6- Th1 cells (5) Quadrant gate used to define CXCR3-




Figure 39 T-Regulatory cell gating strategy shown by representative flow plots 
Representative flow cytometry plots showing following parent gate for CD3+CD4+ T-Regulatory cell populations 
(1) CD3+CD4+ TReg cells gate (2) CD127lowCD25hi TReg cell gate (3) nTReg (CD45RO-) and mTReg 




Figure 40 IL-6Rhi subsets gating strategy shown by representative flow plots. 
Representative flow cytometry plots showing following parent gate for CD3+CD4+ T-helper populations (shown 
in figure 1) (1) CD127lowCD25hi TReg cell gate (2) IL-6Rhi defined as top 20th percentile on TReg subsets (3)







6.3.1 Peripheral blood lymphocyte and T cell populations in T1D and 
control participants 
	
The proportion (%) and frequency (cells/μl) of peripheral blood lymphocytes, CD3+, and CD4+ 
cells were measured at rest in T1D and control participants. There were no significant 
differences in peripheral lymphocytes, CD3+, and CD4+ populations between groups at 
baseline (Table 39).  
 
  
Table 39 Lymphocyte and T cell populations at baseline in T1D and controls. 
Mean and standard deviation values for the proportion and frequency of lymphocytes, CD3+, and CD4+ 
populations in controls and T1D subjects. 
1controls n=21, 2T1D n=14 
 
The effect of moderate (40% VO2 max) and vigorous (80% VO2 max) intensity exercise on 
lymphocytes was investigated in T1D and control participants. Lymphocyte subpopulations 
were measured pre, post, and 1 hour post exercise. The change over time was analysed in 
groups combined under the heading “time (overall)” and in each group independently (time) 
displayed in all results tables. The interaction over time between groups was compared and 
results are displayed under the heading “time*group” in all results tables. Post and 1 hour post 
exercise measurements were compared to baseline levels as shown under the heading 
“contrasts” displayed in the results tables. The mean, standard deviation, and statistical 
analyses are displayed in Table 40. 
mean SD mean SD
Lymphocytes  (cells/μl) 1357 391 1407 249
CD3                (%) 57.20 20.85 46.84 25.17
                        (cells/μl) 750.2 417.6 678.4 317.8
CD4                (%) 51.51 9.29 53.76 7.70







There was an overall change over time in lymphocytes during moderate intensity exercise 
(p=0.025), this was seen in controls (p=0.046) but not in T1D (Figure 41a). Lymphocytes 
significantly mobilised during vigorous intensity exercise overall (p<0.001), and in T1D 
(p=0.004) and control (p<0.001) groups independently. Lymphocytes were significantly 
increased immediately post vigorous exercise in T1D (p=0.006) and controls (p<0.001), 
followed by a significant fall below baseline in T1D (p=0.028) and controls (p=0.026) 1 hour 
post vigorous exercise (Figure 41b) (Table 40).  
CD3+ T cells were significantly mobilised by vigorous intensity exercise overall (p=0.001) and 
in controls (p=0.002), but not in the T1D group. CD3+ T cells were significantly increased 
immediately post vigorous exercise in controls (p=0.004), and significantly fell below baseline 
1 hour post vigorous exercise in control participants only (p=0.041) (Figure 5d). There was no 
change over time in CD3+ populations during moderate intensity exercise (Figure 41c) (Table 
40). 
CD4+ T cells were significantly mobilised by vigorous intensity exercise overall (p=0.017) and 
in controls (p=0.009), but not in the T1D group. CD4+ T cells were significantly increased 
immediately post vigorous exercise in control participants only (p=0.039) (Figure 41f). 
However, the percentage increase immediately post vigorous exercise was similar in the T1D 
compared to the control group (T1D: 39.71%, control: 43.94%). There was no change over 
time in CD4+ populations during moderate intensity exercise (Figure 41e) (Table 40). 
Figure 42 displays raw data for CD3+ and CD4+ T cells during vigorous intensity exercise in 
T1D and controls. It is evident from this that one T1D participant responded negatively to 





Figure 41 Lymphocyte, CD3+ and CD4+ populations during moderate and vigorous exercise in control and 
T1D groups 
Flow cytometry and whole blood cell counts were used to determine the frequency of lymphocytes, CD3+, and 
CD4+ populations in control and T1D participants during moderate and vigorous intensity exercise. (a) Frequency
of lymphocytes during moderate intensity (b) Frequency of lymphocytes during vigorous intensity exercise (c) 
The frequency of CD3+ cells during moderate intensity (d) The frequency of CD3+ cells during vigorous intensity
(e) The frequency of CD4+ cells during low intensity (f) The frequency of CD4+ cells during vigorous intensity. 







Table 40 Lymphocytes, CD3+ and CD4+ populations mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of lymphocytes, CD3+ and CD4+ populations for control and T1D subjects during moderate and vigorous intensity exercise. 
Significant results highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1Controls n=9-11, 2T1D n =6-8 
dTime (overall) dTime*Group
Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
Lymphocytes moderate 1322.22 269.89 1944.44 787.56 1325.00 386.49 F(2, 14)= 3.865, p=0.046 T2 F(1, 7 )= 4.743, p=0.066 47.06 1416.67 307.77 1883.33 874.48 1400.00 178.89 F(2, 8)= 2.983, p=0.108 T2 F(1, 4)= 2.815, p=0.169 32.94 F(1.2, 12.4)= 6.233, p=0.025 F(1.2, 12.4)= 0.049, p=0.855
T3 F(1, 7)= 0.000, p=0.100 0.21 T3 F(1, 4)= 2.250, p=0.208 1.18
vigorous 1383.33 459.77 2245.46 539.97 1233.33 344.80 F(1.22, 12.2)= 36.572, p<0.001 T2 F(1, 10)= 40.810, p<0.001 62.32 1400.00 193.65 2137.50 642.14 1275.00 163.94 F(1.1, 7.5)= 15.8904, p=0.004 T2 F(1, 7)= 14.652, p=0.006 52.68 F(1.2, 19.7)= 48.515, p<0.001 F(1.2, 19.7)= 0.268, p=0.766
T3 F(1, 10)= 6.811, p=0.026 10.84 T3 F(1, 7)= 7.609, p=0.028 8.93
CD3 moderate 721.07 250.34 1037.12 539.31 742.42 256.25 F(2, 14)= 2.086, p=0.161 T2 F(1, 7 )= 3.051, p=0.124 43.83 670.25 230.66 1082.79 532.05 653.44 274.55 F(2, 14)= 2.086, p=0.161 T2 F(1, 3)= 1.777, p=0.275 61.55 F(1.2, 12.3)= 4.039, p=0.061 F(1.2, 12.3)= 0.293, p=0.644
T3 F(1, 7)= 0.016, p=0.903 2.96 T3 F(1, 3)= 0.369, p=0.587 2.51
vigorous 838.18 503.21 1256.01 456.25 654.31 444.43 F(1.34, 13.4)= 12.486, p=0.002 T2 F(1, 10 )= 13.473, p=0.004 49.85 684.52 369.74 1068.35 349.45 703.77 268.37 F(1.05, 6.3)= 3.440, p=0.110 T2 F(1, 6)= 2.492, p=0.165 56.07 F(1.3, 21.929)= 13.250, p=0.001 F(1.3, 21.929)= 0.550, p=0.582
T2 F(1, 10)= 5.502, p=0.041 21.94 T3 F(1, 6)= 2.469, p=0.167 2.81
CD4 moderate 392.72 149.33 470.47 292.14 392.96 184.67 F(2, 12)= 0.319, p=0.733 T2 F(1, 6)= 0.636, p=0.456 19.80 387.12 66.34 450.90 104.44 396.48 158.19 F(2, 4)= 0.558, p=0.611 T2 F(1, 2)= 1.169, p=0.393 16.48 F(1.3, 9.9)= 0.580, p=0.501 F(1.3, 9.9)= 0.008, p=0.960
T3 F(1, 6)= 0.004, p=0.951 0.06 T3 F(1, 2)= 0.005, p=0.952 2.42
vigorous 445.68 275.15 641.52 261.10 346.20 251.58 F(2, 18)= 6.100, p=0.009 T2 F(1, 9)= 5.809, p=0.039 43.94 362.32 225.10 506.20 221.66 402.52 179.59 F(1.4, 6.9)= 1.210, p=0.318 T2 F(1, 6)= 1.119, p=0.331 39.71 F(1.4, 21)= 5.785, p=0.017 F(1.4, 21)= 1.402, p=0.261
T3 F(1, 9)= 3.426, p=0.097 22.32 T3 F(1, 6)= 0.032, p=0.864 11.10
1Controls 2T1D




Figure 42 Raw data for CD3+ and CD4+ populations mobilised during moderate and vigorous intensity 
exercise in control and T1D groups 
Flow cytometry and whole blood cell counts were used to determine the frequency of CD3+ and CD4+ 
populations in control and T1D participants during moderate and vigorous intensity exercise. (a) The frequency
of CD3+ cells during vigorous intensity (b) The frequency of CD4+ cells during moderate intensity. Statistical 
significance represented by * p<0.05, ** p<0.01, ***p<0.001. 
6.3.2 CD4+ T-helper subsets 
6.3.2.1 CD4+ T-helper subsets at baseline in T1D and control participants 
The proportion (%) and frequency of peripheral CD4+ T-helper cells (cells/µl) was measured 
at rest in T1D and control participants. There were no significant differences in T helper subsets 
(Th1, Th2, and Th17) between groups at baseline (Figure 43). The mean and standard deviation 




Figure 43 The proportion and frequency of CD4+ T-helper cell subsets at baseline in T1D and control 
groups. 
Flow cytometry and whole blood cell counts were used to determine the frequency of T-helper populations Th1, 
Th2, and Th17 in control and T1D participants at baseline. (a) Proportion of Th1, Th2, and Th17 in control and 
T1D groups (b) Frequency of Th1, Th2, and Th17 in control and T1D groups. Error bars represent SEM. No 
statistical significance observed. 
  
Table 41 CD4+ T-helper subsets at baseline in T1D and controls. 
Mean and standard deviation values for the proportion and frequency of CD4+ T-helper subsets in controls and 
T1D groups. 
1 controls n=14, 2 T1D n=8 
6.3.2.2 CD4+ T-helper subsets in response to acute exercise in T1D and control 
participants  
The effect of moderate (40% VO2 max) and vigorous (80% VO2 max) intensity exercise on 
CD4+ T-helper subsets was examined. Data for moderate intensity exercise is shown for the 
control group only due to missing data for the T1D group. Vigorous intensity exercise data for 
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both T1D and controls is displayed in Table 43. Figure 44 displays Th1, Th2, and Th17 cells 
during vigorous exercise in T1D and control groups.  
Total non-TReg CD4+ T cells significantly mobilised with vigorous intensity exercise overall 
(p=0.014), but this was only seen in control (p=0.008) and not T1D participants. There was a 
significant increase immediately post vigorous exercise overall (p=0.027) and in the control 
group (p=0.033) (Table 43).  
Total CD4+ T-helper populations significantly mobilised with vigorous intensity exercise 
overall (p=0.003), but this was only seen in control (p=0.017) and not T1D participants. There 
was an overall significant increase immediately post vigorous exercise (p=0.048), but this was 
not seen in either T1D or control group independently (Table 43). 
Th1 subsets are significantly mobilised by vigorous intensity exercise overall (p=0.035), with 
a trend seen in control (p=0.061) but not T1D participants. There was a significant difference 
between groups at 1 hour post vigorous exercise (p=0.044). This is because a larger decrease 
below baseline was shown in controls. Th1 subsets did not significantly mobilise with moderate 
intensity exercise in control participants (Table 43). 
Th2 subsets significantly mobilised during vigorous intensity exercise in control (p=0.042) but 
not T1D participants, with a significant increase post vigorous exercise in the control group 
(p=0.039). Th2 subsets did not significantly change during moderate intensity exercise in the 
control group, however there was a significant drop below baseline 1 hour post moderate 
exercise (p=0.019). The Th1/Th2 ratio was reduced post vigorous exercise in the control, but 
not the T1D group, indicating that Th2 cells increased in comparison to Th1 cells (Table 42).  
There was a significant change in Th17 cells over time during vigorous intensity exercise 
overall (p=0.006), but this was not seen in either T1D or control group independently. There 
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was a significant increase post vigorous exercise overall (p=0.040), but this was not seen in 
either T1D or control group independently. Th17 did not mobilise with moderate intensity 
exercise in T1D or control participants (Table 43). 
 
Figure 44 The frequencies of CD4+ Th1, Th2, and Th17 subsets mobilised during vigorous intensity 
exercise in control and T1D participants 
Flow cytometry and whole blood counts were used to determine the frequency of CD4+ Th1, Th2, and Th17 subsets in control 
and T1D subjects during vigorous intensity exercise. (a) The frequency of CD4+ Th1 cells during vigorous intensity exercise 
(b) The frequency of CD4+ Th2 cells during vigorous intensity exercise (c) The frequency of CD4+ Th17 cells during vigorous
intensity exercise. Error bars represent SEM. Statistical significance represented by * p<0.05, ** p<0.01, ***p<0.001.  
  
Table 42 Th1/Th2 ratio post vigorous exercise in T1D and controls.  
Th1/Th2 ratio in controls and T1D groups. 
1 controls n=7-8, 2 T1D n=8-9 
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Table 43 T-helper populations mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of T-helper populations for control and T1D subjects during moderate and vigorous intensity exercise. Significant results 
highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 





Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
non-TReg (CD127+CD25-) moderate 355.53 128.56 423.97 266.99 354.00 164.78 F(2, 12)= 0.288, p=0.755 T2 F(1, 6)= 0.571, p=0.479 19.25 322.66 103.68 389.27 80.98 325.72 205.29 F(2, 2)= 0.792, p=0.558 20.64 T2 F(1, 1)= 3.377, p=0.317 F(2, 14)= 0.501, p=0.617 F(2, 14)= 0.031, p=0.969
T3 F(1, 6)= 0.005, p=0.945 0.43 0.95 T3 F(1, 1)= 0.000, p=0.989
vigorous 406.35 245.97 578.27 223.63 319.57 230.11 F(2, 18)= 6.322, p=0.008 T2 F(1, 9)= 6.308, p=0.033 42.31 321.62 201.91 456.01 198.40 360.77 162.32 F(1.2, 6.9)= 1.252, p=0.311 41.79 T2 F(1, 6)= 1.218, p=0.312 F(1.5, 21.8)= 5.968, p=0.014 F(1.5, 21.8)= 1.381, p=0.266
T3 F(1, 9)= 3.244, p=0.105 21.36 12.17 T3 F(1, 6)= 0.001, p=0.975
Thelper (CD127+CD25-CD45RO+) moderate 182.25 104.84 227.25 178.44 130.97 95.93 F(1.04, 5.2)= 1.070, p=0.351 T2 F(1, 5)= 0.400, p=0.555 24.70 T2 F(1.04, 5.2)= 1.070, p=0.351
T3 F(1, 5)= 5.785, p=0.061 28.13 T3
vigorous 245.37 216.53 319.73 183.60 194.80 160.39 F(2, 12)= 5.890, p=0.017 T2 F(1, 6)= 2.736, p=0.149 30.31 173.48 93.79 277.47 128.04 192.20 94.74 F(1.1, 6.4)= 2.626, p=0.153 59.94 T2 F(1, 6)= 2.437, p=0.169 F(2, 24)= 7.316, p=0.003 F(2, 24)= 0.805, p=0.459
T3 F(1, 6)= 3.300, p=0.119 20.61 10.79 T3 F(1, 6)= 0.015, p=0.907
      └ Th1 (CXCR3+CCR6+CCR4-) moderate 94.80 58.98 107.10 66.11 69.90 62.26 F(1.04, 4.2)= 0.734, p=0.444 T2 F(1, 4)= 0.044, p=0.844 12.98 T2 F(1.04, 4.2)= 0.734, p=0.444
T3 F(1, 4)= 5.203, p=0.085 26.27 T3
vigorous 80.36 71.03 103.28 66.30 62.93 51.74 F(2, 12)= 3.533, p=0.062 T2 F(1, 6)= 1.122, p=0.330 28.51 47.51 54.36 65.08 56.56 58.42 61.04 F(2, 12)= 1.232, p=0.326 36.97 T2 F(1, 6)= 1.485 p=0.269 F(2, 24)= 3.865, p=0.035 F(2, 24)= 1.482, p=0.246
T3 F(1, 6)= 4.053, p=0.091 21.69 22.95 T3 F(1, 6)= 1.027, p=0.350
      └ Th2 (CXCR3-CCR6-CCR4+) moderate 27.51 20.20 33.08 23.35 21.91 21.71 F(2, 8)= 3.320, p=0.089 T2 F(1, 4)= 0.325, p=0.599 20.28 T2 F(2, 8)= 3.320, p=0.089
T3 F(1, 4)= 14.648, p=0.019 20.33 T3
vigorous 27.54 45.57 34.90 46.26 19.23 28.38 F(2, 12)= 4.192, p=0.042 T2 F(1, 6)= 6.964, p=0.039 26.72 18.19 14.33 25.20 14.77 18.96 12.83 F(1.1, 6.7)= 0.836, p=0.406 38.52 T2 F(1, 6)= 0.467, p=0.520 F(2, 24)= 3.634, p=0.042 F(2, 24)= 0.156, p=0.857
T3 F(1, 6)= 0.575, p=0.477 30.18 4.21 T3 F(1, 6)= 1.341, p=0.291
      └ Th17 (CXCR3-CCR6+CCR4+) moderate 7.57 4.98 11.68 13.09 5.78 3.77 F(2, 8)= 1.588, p=0.263 T2 F(1, 4)= 0.257, p=0.639 54.20 T2 F(2, 8)= 1.588, p=0.263
T3 F(1, 4)= 5.001, p=0.089 23.73 T3
vigorous 19.44 18.61 25.02 14.28 13.89 12.85 F(2, 12)= 3.075, p=0.084 T2 F(1, 6)= 3.561, p=0.108 28.72 11.63 9.66 21.71 18.75 10.75 7.80 F(1.1, 6.8)= 3.475, p=0.104 86.68 T2 F(1, 6)= 1.916, p=0.216 F(2, 24)= 6.363, p=0.006 F(2, 24)= 0.077, p=0.926
T3 F(1, 6)= 0.548, p=0.487 28.55 7.58 T3 F(1, 6)= 8.154, p=0.029
      └ CXCR3-CCR6-CCR4- moderate 38.92 23.44 48.39 29.00 30.43 13.06 F(2, 8)= 1.133, p=0.369 T2 F(1, 4)= 0.299, p=0.613 24.32 T2 F(2, 8)= 1.133, p=0.369
T3 F(1, 4)= 1.186, p=0.337 21.82 T3
vigorous 36.90 34.34 49.32 40.44 31.45 25.29 F(1.2, 6.9)= 3.927 p=0.085 T2 F(1, 6)= 7.080, p=0.037 33.67 45.64 46.78 70.70 68.32 51.45 49.66 F(1, 6.3)= 0.374, p=0.571 54.90 T2 F(1, 6)= 0.397, p=0.552 F(1.4, 16.2)= 1.617, p=0.219 F(1.4, 16.2)= 0.221, p=0.803
T3 F(1, 6)= 1.191, p=0.317 14.77 12.73 T3 F(1, 6)= 0.179, p=0.687
      └ CXCR3-CCR6+CCR4- moderate 10.17 7.85 15.22 19.96 6.61 6.40 F(2, 8)= 0.641, p=0.552 T2 F(1, 4)= 0.103, p=0.765 49.72 T2 F(2, 8)= 0.641, p=0.552
T3 F(1, 4)= 1.248, p=0.326 35.02 T3
vigorous 23.96 13.40 31.35 11.98 21.05 14.42 F(1.1, 6.8)= 2.971 p=0.129 T2 F(1, 6)= 6.022, p=0.050 30.83 42.49 65.50 57.39 72.46 45.45 68.52 F(1.1, 6.6)= 0.741, p=0.432 35.05 T2 F(1, 6)= 0.622, p=0.460 F(2, 24)= 2.471, p=0.106 F(2, 24)= 0.220, p=0.804










6.3.3 CD4+ T-Regulatory subsets 
6.3.3.1 CD4+ T-Regulatory subsets at baseline in T1D and control participants 
The proportion (%) and frequency of peripheral CD4+ T-Regulatory subsets (cells/µl) were
measured at rest in T1D and control participants. The proportion of TReg cells were 
significantly higher in T1D compared to controls at baseline (p=0.002). Within the TReg 
population, T1D had significantly higher memory TReg subsets (p=0.003) and significantly 
lower naïve TReg subsets (p=0.003) (Figure 45). No significant differences in TIGIT+ or 
TIGIT- mTRegs between groups was found. The proportion of mTReg TIGIT+ was higher in 
T1D (72%) than control participants (60%) but it did not reach significance. The mean and 
standard deviation are displayed in Table 44.  
 
Figure 45 The proportion and frequency of CD4+ T-Regulatory cell subsets at baseline in T1D and control 
groups. 
Flow cytometry and whole blood cell counts were used to determine the frequency of T-Regulatory populations 
in control and T1D participants at baseline. (a) Proportion of TRegs (b) Frequency of TRegs (c) Proportion of 
mTRegs and naTRegs (d) Frequency of mTRegs and nTRegs. Error bars represent SEM. Statistical significance 








Table 44 CD4+ T-Regulatory cell subsets at baseline in T1D and control groups 
Mean and standard deviation values for the proportion and frequency of CD4+ T-Regulatory subsets in controls 
and T1D groups. 
1 controls n=19, 2 T1D n=11 
 
6.3.3.2 CD4+ T-Regulatory subsets in response to acute exercise in T1D and control 
participants 
 
The effect of moderate (40% VO2 max) and vigorous (80% VO2 max) intensity exercise on 
CD4+ TReg subsets was investigated in T1D and control participants. The mean, standard 
deviation, and statistical analyses are displayed in Table 45.  
CD4+ TReg subsets were significantly mobilised by vigorous intensity exercise overall 
(p=0.010) and in control (p=0.009) but not T1D participants. There was a significant fall below 
baseline 1 hour post vigorous exercise overall (p=0.038), but this was not seen in either T1D 
or control group independently (Figure 46). The percentage change following vigorous 
exercise was much lower in the T1D compared to the control group (T1D: 23.74%, Control: 
47.65%). CD4+ TReg subsets did not significantly mobilise with moderate intensity exercise 
in either group (Table 45). 
 
mean SD mean SD
TReg                   (%) 5.94 1.85 8.53 2.48
                             (cells/μl) 27.12 22.15 29.97 15.71
naTReg               (%) 45.60 19.81 23.38 18.57
                             (cells/μl) 12.43 10.94 8.31 8.96
mTReg                (%) 52.99 20.21 75.98 17.85
                             (cells/μl) 14.69 13.22 21.65 9.85
mTReg TIGIT+    (%) 59.98 30.03 72.15 23.73
                             (cells/μl) 12.72 12.23 16.98 8.09
mTReg TIGIT-     (%) 40.03 30.04 27.85 23.73







Further delineation of CD4+ TRegs revealed that mTReg subsets were significantly mobilised 
by vigorous intensity exercise overall (p=0.004) and in the control group (p=0.006). There was 
a significant fall below baseline overall 1 hour post vigorous exercise (p=0.042), but this was 
not seen in either T1D or control group independently. Naïve TReg subsets did not significantly 
mobilise with either exercise intensity (Figure 46) (Table 45). 
TIGIT+ mTReg subsets were significantly mobilised by vigorous exercise overall (p=0.030) 
and in the control group (p=0.017). There was a significant drop below baseline 1 hour post 
vigorous exercise overall (p=0.003) and in the control group (p=0.032). There was a significant 
difference between T1D and controls 1 hour post vigorous exercise (p=0.023) because TIGIT+ 
mTReg fell below baseline in controls, but not in T1D participants. (Table 45). No statistically 
significant mobilisation of TIGIT+ mTReg subsets was observed following moderate intensity 
exercise in either group. 
TIGIT- mTReg subsets were significantly mobilised by vigorous exercise in the control 
(p=0.049) but not T1D group. There was a significant drop below baseline 1 hour post vigorous 
exercise overall (p=0.005) and in the control group (p=0.048). There was a significant 
difference between T1D and controls 1 hour post vigorous exercise (p=0.044) as TIGIT- 
mTReg fell below baseline in controls, but not in T1D participants (Table 45). No statistically 
significant mobilisation of TIGIT- mTReg subsets was observed following moderate intensity 





Figure 46 The frequencies of CD4+ TReg, mTReg, and nTReg subsets mobilised during vigorous 
intensity exercise in control and T1D participants 
Flow cytometry and whole blood counts were used to determine the frequency of CD4+ TReg, mTReg, and naTReg subsets 
in control and T1D subjects during vigorous intensity exercise. (a) The frequency of CD4+ TReg cells during vigorous
intensity exercise (b) The frequency of CD4+ mTReg cells during vigorous intensity exercise (c) The frequency of CD4+
naTReg cells during vigorous intensity exercise. Error bars represent SEM. Statistical significance represented by * 







Table 45 T-Regulatory populations mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of T-Regulatory populations for control and T1D subjects during moderate and vigorous intensity exercise. Significant 
results highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1Controls n=10-11, 2T1D n =8 
Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
TReg (CD127loCD25hi) moderate 25.08 14.85 30.62 22.21 23.43 15.03 F(1.14, 6.8)= 0.851, p=0.403 T2 F(1, 6)= 0.938, p=0.370 22.07 29.53 4.65 40.23 17.67 28.38 6.50 F(2, 2)= 1.371, p=0.422 T2 F(1, 1)= 2.091, p=0.385 36.23 F(1.1, 7.8)= 2.551, p=0.149 F(1.1, 7.8)= 0.569, p=0.491
T3 F(1, 6)= 0.434, p=0.534 6.59 T3 F(1, 1)= 0.344, p=0.662 3.90
vigorous 28.60 25.24 42.23 30.07 21.56 18.79 F(2, 16)= 6.376, p=0.009 T2 F(1, 8)= 2.324, p=0.166 47.65 30.13 17.33 37.28 18.85 30.75 14.09 F(1.1, 6.5)= 0.948, p=0.374 T2 F(1, 6)= 0.418, p=0.542 23.74 F(2, 28)= 5.401, p=0.010 F(2, 28)= 0.519, p=0.600
T3 F(1, 8)= 3.658, p=0.092 24.60 T3 F(1, 6)= 4.203, p=0.086 2.05
naïve TReg (CD45RO-) moderate 12.21 7.82 13.53 8.55 13.99 10.12 F(2, 12)= 0.260, p=0.775 T2 F(1, 6)= 1.140, p=0.327 10.79 3.61 4.66 7.88 10.71 5.07 5.00 F(2, 2)= 0.981, p=0.505 T2 F(1, 1)= 0.981, p=0.503 118.45 F(2, 14)= 1.860, p=0.192 F(2, 14)= 0.932, p=0.402
T3 F(1, 6)= 0.098, p=0.765 14.53 T3 F(1, 1)= 0.833, p=0.529 40.43
vigorous 12.59 12.30 19.98 22.39 7.72 8.25 F(1.1, 9.6)= 2.182, p=0.172 T2 F(1, 9)= 1.692, p=0.226 58.69 10.08 8.99 10.59 8.63 10.03 7.60 F(2, 12)= 0.382, p=0.690 T2 F(1, 6)= 0.124, p=0.737 5.06 F(1.1, 16.1)= 1.631, p=0.221 F(1.1, 16.1)= 1.299, p=0.275
T3 F(1, 9)= 2.712, p=0.134 38.68 T3 F(1, 6)= 4.382, p=0.081 0.48
memory TReg(CD45RO+) moderate 12.87 9.47 17.09 17.71 9.44 7.10 F(1.04, 6.3)= 1.221, p=0.313 T2 F(1, 6)= 0.798, p=0.409 32.77 25.92 4.13 32.36 9.05 23.31 11.50 F(2, 2)= 1.474, p=0.404 T2 F(1, 1)= 3.880, p=0.299 24.82 F(1.1, 7.5)= 2.647, p=0.145 F(1.1, 7.5)= 0.370, p=0.574
T3 F(1, 6)= 2.815, p=0.144 26.63 T3 F(1, 1)= 0.341, p=0.664 10.06
vigorous 16.01 14.72 22.25 11.69 13.07 11.16 F(2, 16)= 7.222, p=0.006 T2 F(1, 8)= 2.785, p=0.134 38.98 20.05 10.27 26.70 13.15 20.72 8.76 F(1.1, 6.6)= 1.606, p=0.252 T2 F(1, 6)= 1.232, p=0.310 33.12 F(2, 28)= 6.632, p=0.004 F(2, 28)= 0.291, p=0.750
T3 F(1, 8)= 4.198, p=0.075 18.34 T3 F(1, 6)= 1.8974, p=0.220 3.30
           └ TIGIT- moderate 5.24 4.27 6.30 4.28 4.87 4.53 F(2, 6)= 0.780, p=0.500 T2 F(1, 3)= 0.345, p=0.598 20.34 4.26 2.56 5.54 4.53 3.32 0.57 F(2, 2)= 1.141, p=0.467 T2 F(1, 1)= 1.374, p=0.450 30.06 F(2, 8)= 2.040, p=0.223 F(2, 8)= 0.186, p=0.833
T3 F(1, 3)= 5.587, p=0.099 7.01 T3 F(1, 1)= 0.945, p=0.509 22.23
vigorous 5.14 4.55 5.44 3.62 3.86 3.59 F(2, 8)= 4.503, p=0.049 T2 F(1, 4)= 0.146, p=0.722 5.83 4.83 2.94 6.54 4.13 5.05 2.60 F(1.9, 6.4)= 1.376, p=0.286 T2 F(1, 6)= 1.022, p=0.351 35.50 F(1.2, 12)= 2.717, p=0.121 F(1.2, 12)= 0.778, p=0.418
T3 F(1, 4)= 7.930, p=0.048 24.85 T3 F(1, 6)= 2.060 p=0.201 4.51
           └ TIGIT+ moderate 9.93 8.34 15.36 17.56 6.39 5.28 F(1, 3)= 0.934, p=0.405 T2 F(1, 3)= 0.859, p=0.422 54.69 21.66 5.54 26.81 6.70 20.00 12.07 F(2, 2)= 1.661, p=0.376 T2 F(1, 1)= 5.606, p=0.254 23.80 F(1, 4.2)= 1.915, p=0.238 F(1, 4.2)= 0.044, p=0.851
T3 F(1, 3)= 1.180 p=0.357 35.69 T3 F(1, 1)= 0.192 p=0.737 7.68
vigorous 15.04 13.39 18.49 10.48 10.63 10.30 F(2, 8)= 7.107, p=0.017 T2 F(1, 4)= 0.082, p=0.788 22.96 15.22 7.69 20.15 9.51 15.67 6.76 F(1.9, 6.7)= 1.641, p=0.247 T2 F(1, 6)= 1.280, p=0.301 32.37 F(1.3, 13.3)= 5.340, p=0.030 F(1.3, 13.3)= 1.069, p=0.342
T3 F(1, 4)= 10.520, p=0.032 29.32 T3 F(1, 6)= 1.605p=0.252 2.92
T1 T2 T3 ccontrast T1 T2 T3 ccontrast
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6.3.4 IL-6Rhi subsets 
A phenotypically distinct TReg subset with increased suppressive, tissue-infiltrating capacity 
was identified recently. They are identified as TIGIT-IL-6Rhi mTReg cells that exhibit a Th17 
signature (ROR!t+CD161+CCR6+) [492]. Here, IL-6Rhi expression, defined as the top 20th
percentile of IL-6R expression, is measured on naïve and memory TReg subsets in T1D and 
control participants.  
6.3.4.1 IL-6Rhi subsets at baseline in T1D and control participants 
IL-6Rhi expression on naïve and memory TReg subsets was measured at rest in T1D and control 
participants. There were no significant differences in IL-6Rhi naTReg or mTReg subsets
between groups at baseline (Figure 47). However, TIGIT-IL-6Rhi mTRegs showed a trend to 
be lower in T1D. The mean and standard deviation are displayed in Table 46.  
 
Figure 47 The proportion and frequency of CD4+ IL-6Rhi T-Regulatory cell subsets at baseline in T1D and 
control groups.
Flow cytometry and whole blood cell counts were used to determine the frequency of CD4+ IL-6Rhi T-Regulatory 
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Table 46 CD4+ IL-6Rhi T-Regulatory cell subsets at baseline in T1D and control groups 
Mean and standard deviation values for the proportion and frequency of CD4+ IL-6Rhi T-Regulatory subsets in 
controls and T1D groups. 
1 controls n=10, 2 T1D n=11 
 
6.3.4.2 IL-6Rhi subsets in response to acute exercise in T1D and control participants 
 
IL-6Rhi expression on naïve and memory TReg subsets was measured during moderate (40% 
VO2 max) and vigorous (80% VO2 max) intensity exercise in T1D and control participants. 
The mean, standard deviation, and statistical analyses are displayed in Table 47.  
There was a significant difference between groups 1 hour post vigorous intensity exercise in 
IL-6Rhi non-TReg and T-helper subsets (p=0.049, p=0.043 respectively). This is because IL-
6Rhi non-TReg and T-helper subsets fell below baseline in control, but not T1D participants. 
However, no overall significant mobilisation of these subsets was found following moderate 
of vigorous intensity exercise (Table 47).  
mean SD mean SD
IL-6Rhi TReg                 (%) 20.34 0.94 21.03 1.07
                                        (cells/μl) 1.11 1.16 0.68 0.72
IL-6Rhi mTReg              (%) 28.16 5.79 25.89 4.95
                                        (cells/μl) 5.54 5.11 5.65 2.77
IL-6Rhi naTReg             (%) 8.05 6.09 6.14 3.94
                                        (cells/μl) 1.11 1.16 0.68 0.72
TIGIT+IL-6Rhi                (%) 22.97 4.42 22.80 4.04
                                        (cells/μl) 3.58 3.26 3.83 1.77
TIGIT-IL-6Rhi                 (%) 39.40 7.19 38.55 8.85
                                        (cells/μl) 2.23 2.19 1.81 1.23
TIGIT-IL-6Rhi CCR6+    (%) 34.85 20.09 41.59 24.64
                                        (cells/μl) 0.87 1.07 0.84 0.83
TIGIT-IL-6Rhi CCR6-    (%) 65.16 20.10 58.41 24.65







Whilst not significant, IL-6Rhi TReg subsets showed a trend to increase immediately post 
moderate intensity exercise in the T1D (p=0.060), but not the control group (Table 47). A small 
but statistically insignificant increase in median fluorescent intensity (MFI) was found post 
moderate exercise in the T1D group (T1D; 1478 to 1547 MFI, controls; 1197 to 1238 MFI). 
Vigorous exercise exhibited no significant mobilisation or change in IL-6Rhi TReg MFI.  
TIGIT-IL-6Rhi mTReg significantly fell below baseline 1 hour post vigorous exercise in the 
control group only (p=0.033). However, no change over time during vigorous intensity exercise 
in T1D or control groups was found (Table 47). A small but statistically insignificant change 
in TIGIT-IL-6Rhi MFI post vigorous exercise in both groups was noted (T1D; 1348 to 1414 
MFI, controls; 1502 to 1596 MFI). TIGIT-IL-6Rhi mTReg subsets did not significantly mobilise 
with moderate intensity exercise in either group. 
TIGIT-IL-6RhiCCR6- cells were significantly different 1 hour post vigorous exercise between 
groups (p=0.012) because TIGIT-IL-6RhiCCR6- cells fell below baseline in control, and not 
T1D participants. However, when change over time during the exercise bout was analysed, 
TIGIT-IL-6RhiCCR6+ and TIGIT-IL-6Rhi CCR6- cells did not change significantly over time 
during moderate or vigorous intensity exercise in either group (Table 47). 
There were no significant changes over time during moderate or vigorous intensity exercise in 






Table 47 CD4+ IL-6Rhi T-Regulatory subsets mobilised during moderate and vigorous intensity exercise in control and T1D groups 
Mean, standard deviation, and statistical analysis of CD4+ IL-6Rhi T-Regulatory for control and T1D subjects during moderate and vigorous intensity exercise. Significant 
results highlighted in bold where p values <0.05 were considered significant. 
a Δ% Percentage change from baseline (T1) to immediately post exercise (T2). 
b Results were analysed using multiple regression analysis in control and T1D groups independently. 
c Contrast displays changes from baseline (T1) to immediately post exercise (T2) and 1 hour post exercise (T3). 
d Results were analysed using multiple regression analysis in control and T1D groups combined. 
1Controls n=5-6, 2T1D n =3-8 
dTime (overall) dTime*Group
Subset (cells/μl) Intensity bTime aΔ% bTime aΔ%
mean SD mean SD mean SD mean SD mean SD mean SD
non-TReg IL-6Rhi moderate 101.73 32.35 137.63 76.84 92.18 62.16 F(2, 4)= 0.387, p=0.702 T2 F(1, 2)= 0.329, p=0.624 35.29 72.45 25.27 102.63 33.45 92.44 64.74 F(2, 2)= 0.968, p=0.508 41.65 T2 F(1, 1)= 30.037, p=0.115 F(2, 6)= 0.553, p=0.602 F(2, 6)= 0.104, p=0.903
T3 F(1, 2)= 0.489, p=0.557 9.39 27.58 T3 F(1, 1)= 0.194, p=0.736
vigorous 128.33 105.00 129.61 69.65 94.88 83.69 F(2, 8)= 2.021, p=0.195 T2 F(1, 4)= 0.003, p=0.961 1.00 79.26 57.03 126.51 81.85 93.07 49.14 F(2, 12)= 1.984, p=0.180 59.61 T2 F(1, 6)= 2.272, p=0.182 F(2, 20)= 2.701, p=0.092 F(2, 20)= 1.020, p=0.379
T3 F(1, 4)= 6.853, p=0.059 26.07 17.43 T3 F(1, 6)= 0.111, p=0.750
Thelper IL-6Rhi moderate 66.18 25.78 93.12 58.20 54.48 36.78 F(2, 4)= 0.427, p=0.679 T2 F(1, 2)= 0.355, p=0.612 40.70 43.64 15.95 58.54 15.24 14.66 0.00 34.12 T2 F(2, 4)= 0.427, p=0.679
T3 F(1, 2)= 0.821, p=0.461 17.68 66.40 T3
vigorous 95.44 94.76 93.63 65.45 70.05 72.44 F(2, 8)= 1.638, p=0.253 T2 F(1, 4)= 0.009, p=0.931 1.89 53.30 31.73 89.44 54.53 63.94 30.81 F(2, 12)= 1.976, p=0.181 67.81 T2 F(1, 6)= 2.169, p=0.191 F(1.3, 13.2)= 2.283, p=0.151 F(1.3, 13.2)= 1.179, p=0.315
T3 F(1, 4)= 4.349, p=0.105 26.60 19.97 T3 F(1, 6)= 0.378, p=0.561
TReg IL-6Rhi moderate 5.93 3.38 7.77 5.60 6.38 5.18 F(1, 3.1)= 0.260, p=0.650 T2 F(1, 3)= 0.444, p=0.553 31.18 6.41 0.76 8.85 2.67 7.42 3.18 F(2, 2)= 1.098, p=0.477 38.00 T2 F(1, 1)= 113.438, p=0.060 F(2, 8)= 0.849, p=0.463 F(2, 8)= 0.088, p=0.917
T3 F(1, 3)= 0.002, p=0.971 7.60 15.76 T3 F(1, 1)= 0.022 p=0.906
vigorous 6.31 6.45 7.20 3.57 4.84 5.13 F(2, 8)= 1.086, p=0.383 T2 F(1, 4)= 0.009, p=0.930 14.15 6.22 3.58 9.16 5.81 7.39 3.98 F(2, 12)= 1.531, p=0.256 47.40 T2 F(1, 6)= 1.677, p=0.243 F(1.3, 12.6)= 1.504, p=0.250 F(1.3, 12.6)= 0.929, p=0.377
T3 F(1, 4)= 5.358, p=0.082 23.34 18.79 T3 F(1, 6)= 0.359, p=0.571
naïve TReg IL-6Rhi moderate 1.58 1.26 1.61 1.03 2.58 2.34 F(1, 3)= 0.544, p=0.515 T2 F(1, 3)= 0.054, p=0.831 2.37 0.43 0.41 0.76 0.76 0.96 0.00 78.00 T2 F(1, 3)= 0.159, p=0.718
T3 F(1, 3)= 0.807, p=0.435 64.12 124.98 T3
vigorous 0.64 0.65 0.63 0.54 0.55 0.62 F(1.1, 4.3)= 0.130, p=0.751 T2 F(1, 4)= 0.004, p=0.955 2.26 0.75 0.72 0.91 0.84 0.79 0.58 F(2, 12)= 0.849, p=0.452 22.15 T2 F(1, 6)= 0.716, p=0.430 F(2, 20)= 0.640, p=0.538 F(2, 20)= 0.266, p=0.706
T3 F(1, 4)= 2.978, p=0.159 14.18 6.08 T3 F(1, 6)= 0.185, p=0.682
memory TReg IL-6Rhi moderate 4.35 2.88 6.17 5.78 3.79 3.17 F(1, 3)= 0.513, p=0.526 T2 F(1, 3)= 0.487, p=0.536 41.65 6.12 0.48 8.35 2.38 6.93 3.65 F(2, 2)= 0.963, p=0.509 36.37 T2 F(1, 1)= 24.788, p=0.126 F(2, 8)= 1.119, p=0.358 F(2, 8)= 0.086, p=0.830
T3 F(1, 3)= 0.608, p=0.492 12.83 13.30 T3 F(1, 1)= 0.017, p=0.918
vigorous 6.72 6.00 6.57 3.37 5.01 4.78 F(2, 8)= 1.297, p=0.325 T2 F(1, 4)= 0.009, p=0.931 2.27 5.47 3.06 8.26 5.21 6.60 3.52 F(2, 12)= 1.504, p=0.261 50.89 T2 F(1, 6)= 2.169, p=0.191 F(2, 20)= 1.524, p=0.242 F(2, 20)= 1.024, p=0.377
T3 F(1, 4)= 4.349, p=0.105 25.44 20.53 T3 F(1, 6)= 0.378, p=0.561
           └ TIGIT+IL-6Rhi moderate 2.72 1.96 4.63 4.60 1.94 1.32 F(1, 2)= 0.764, p=0.474 T2 F(1, 2)= 0.745, p=0.479 69.88 4.48 0.78 6.46 2.24 5.53 3.64 F(2, 2)=  1.231, p=0.467 44.16 T2 F(1, 1)= 7.116, p=0.228 F(2, 6)= 1.421, p=0.312 F(2, 6)= 0.140, p=0.797
T3 F(1, 2)= 0.830, p=0.458 28.65 23.36 T3 F(1, 1)= 0.128 p=0.781
vigorous 4.26 3.59 4.43 1.92 3.27 2.81 F(2, 8)= 1.195 p=0.351 T2 F(1, 4)= 0.026, p=0.879 3.91 3.59 1.86 5.49 3.27 4.37 2.32 F(2, 12)= 1.555, p=0.251 52.98 T2 F(1, 6)= 1.941, p=0.213 F(2, 20)= 1.724, p=0.204 F(2, 20)= 0.835, p=0.448
T3 F(1, 4)= 3.681, p=0.127 23.29 21.76 T3 F(1, 6)= 0.642, p=0.454
           └ TIGIT-IL-6Rhi moderate 2.00 1.63 2.36 1.64 2.23 2.22 F(1.01, 3.04)= 0.145, p=0.732 T2 F(1, 3)= 0.217, p=0.673 18.20 1.63 0.87 1.88 1.39 1.41 0.02 F(2, 2)= 0.551, p=0.645 14.97 T2 F(1, 1)= 2.020, p=0.390 F(2, 8)= 0.525, p=0.611 F(2, 8)= 0.105, p=0.902
T3 F(1, 3)= 0.000, p=0.995 11.44 13.76 T3 F(1, 1)= 0.242, p=0.709
vigorous 2.45 2.43 2.15 1.56 1.74 2.02 F(2, 8)= 1.922, p=0.208 T2 F(1, 4)= 0.394, p=0.564 12.32 1.88 1.26 2.77 2.00 2.23 1.39 F(2, 12)= 1.378, p=0.289 47.06 T2 F(1, 6)= 1.492, p=0.268 F(2, 20)= 1.263, p=0.304 F(2, 20)= 1.418, p=0.266
T3 F(1, 4)= 10.282, p=0.033 28.95 18.37 T3 F(1, 6)= 0.130, p=0.731
                    └TIGIT-IL-6Rhi CCR6+ moderate 0.67 0.41 0.80 0.47 0.83 0.78 F(2, 6)= 0.087, p=0.917 T2 F(1, 3)= 0.130, p=0.742 20.11 0.55 0.58 0.43 0.30 0.50 0.03 F(2, 2)= 0.323, p=0.756 21.40 T2 F(1, 1)= 0.194, p=0.736 F(2, 8)= 0.035, p=0.965 F(2, 8)= 0.288, p=0.757
T3 F(1, 3)= 0.521, p=0.523 24.18 7.97 T3 F(1, 1)= 0.360, p=0.656
vigorous 1.13 1.39 0.85 0.95 0.87 1.28 F(2, 6)= 1.078, p=0.398 T2 F(1, 3)= 1.052, p=0.380 24.34 0.96 0.83 1.51 1.63 1.17 1.14 F(2, 12)= 1.731, p=0.218 56.81 T2 F(1, 6)= 2.032, p=0.204 F(1.3, 11.2)= 0.326, p=0.628 F(1.3, 11.2)= 1.841, p=0.204
T3 F(1, 3)= 5.336, p=0.104 22.77 21.50 T3 F(1, 6)= 1.502, p=0.266
                   └ TIGIT-IL-6Rhi CCR6- moderate 1.33 1.28 1.56 1.30 1.40 1.47 F(1, 3)= 0.362, p=0.590 T2 F(1, 3)= 0.281, p=0.633 17.23 1.08 0.34 1.45 1.15 0.90 0.05 F(2, 2)= 0.577, p=0.634 33.36 T2 F(1, 1)= 0.852, p=0.525 F(1, 4)= 1.096, p=0.355 F(1, 4)= 0.166, p=0.707
T3 F(1, 3)= 0.829, p=0.430 5.03 16.70 T3 F(1, 1)= 0.138 p=0.773
vigorous 1.59 1.26 1.60 0.69 1.06 0.95 F(2, 6)= 2.714, p=0.145 T2 F(1, 3)= 0.000, p=0.996 0.13 0.84 0.82 1.27 0.90 1.04 0.77 F(1.9, 5.3)= 0.893, p=0.393 51.85 T2 F(1, 5)= 0.943, p=0.376 F(1.1, 8.8)= 2.219, p=0.172 F(1.1, 8.8)= 1.539, p=0.251
T3 F(1, 3)= 8.159, p=0.065 33.55 24.68 T3 F(1, 5)= 0.844 p=0.400
ccontrast
1Controls 2T1D






The first aim of this study was to measure peripheral blood CD4+ T-helper (Th) and T-
Regulatory (TReg) subsets at rest in T1D and control cohorts. The proportion of CD4+ TRegs 
was elevated in T1D compared to control participants. This is driven by an increase in mTREG 
subsets. The naïve-memory TReg ratio was shifted in T1D, with higher proportions of memory 
TRegs and lower proportions of naïve TRegs compared to control participants. A significant 
increase in TIGIT+ mTRegs in T1D would support these findings because TIGIT is highly 
expressed by mTRegs [486]. However, only a non-statistical significant increase in TIGIT+ 
mTRegs was found in this study herein. Additionally, TIGIT-IL-6Rhi mTRegs showed a trend 
to be lower in T1D. This agrees with reduced TReg suppressive capacity reported in T1D in 
other studies. No differences between groups in CD4+ T-helper subsets were found. 
This study also aimed to investigate the effects of moderate and vigorous intensity exercise on 
the mobilisation of CD4+ T-helper and TReg subsets in T1D and control participants. As per 
the previous findings of this study (Chapter 4 and 5), vigorous intensity exercise caused a 
significant mobilisation of lymphocytes in both T1D and control participants, with minimal 
mobilisation during moderate intensity exercise. CD3+ and CD4+ T cells mobilised during 
vigorous intensity exercise only in the control group. There was no mobilisation of CD4+ T 
cells or individual CD4+ T cell subsets vigorous intensity exercise in T1D participants. 
Vigorous intensity exercise mobilised Th2 subsets, without changes in Th1 subsets, and this 
resulted in a shift in the Th1/Th2 ratio following vigorous exercise in the control group. No 
significant mobilisation of Th17 cells was found in T1D or control groups independently. 
However, there was significant mobilisation overall (i.e. groups combined) following vigorous 
exercise. There was a larger percentage increase in the frequency of Th17 cells following 




intensity exercise mobilised CD4+ TReg subsets in control participants, and these comprised 
of mainly memory TRegs, including both TIGIT+ and TIGIT- mTReg subsets. Neither 
moderate or vigorous intensity exercise significantly mobilised any IL-6Rhi CD4+ subsets in 
T1D or control groups. 
The strengths of this study are that it is the first study of acute exercise and CD4+ T cell subset 
mobilisation in T1D. This study gives a comprehensive analysis of CD4+ T-helper and TReg 
cell subsets mobilised by two different exercise intensities, in two cohorts. However, the 
limitations of this study were that the numbers of recruited participants were low therefore 
comparisons between groups are difficult. In Chapter 4 and 5, CD3+ T cell mobilisation is 
shown in both T1D and control groups. However, in this analysis CD3+ T cells were mobilised 
by vigorous exercise in the control group only. One T1D participant in particular responded 
negatively to vigorous exercise indicated by a decrease in CD3+ and CD4+ T cells immediately 
following exercise. This participant was not excluded because normal lymphocytosis occurred 
post-exercise and the CD3/CD4 whole blood staining appeared normal in this sample. This 
participant exhibits the same response in the data shown in Chapter 5; however there is less 
data for CD4+ T-helper/TRegs subsets due to missing stains for this analysis and so statistical 
significance is affected greatly by this variation. Excluding this participant from analysis shows 
that CD3+ T cells mobilised significantly during vigorous exercise in T1D, whereas CD4+ T 
cells remained insignificant, agreeing with data shown in Chapter 5. This demonstrates the 
issues with small sample size affecting significance levels. It is likely that this decrease in CD3+ 
T cells is due to a significant increase in the frequency of CD3- NK cells [198, 199]. Further 
analysis of subsets clarified that this is the case for this participant.  
IL-6Rhi CD4+ TRegs showed a trend towards an increase during vigorous exercise in T1D but 




TReg subsets mobilised significantly following vigorous intensity exercise in control but not 
T1D participants. However, the difference in mobilisation was not significant between groups. 
The percentage increase of CD4+ T cells following vigorous exercise was similar in T1D 
compared to the control group. It is possible with a larger cohort that exercise would have 
induced CD4+ T cell mobilisation in T1D participants as shown for control participants. On the 
other hand, the difference in mobilisation may be significant between groups in a larger cohort 
leading to further questions about why CD4+ T cells mobilisation is hindered in T1D.  
Previously, studies have demonstrated that vigorous endurance exercise causes a significant 
increase in the frequency of peripheral blood lymphocytes, followed by lymphopenia, in 
healthy cohorts [191-195]. These findings are supported by this study herein and observed for 
the first time in T1D. The data shown also agrees with previous studies because only minor 
exercise-induced mobilisation of CD4+ T cells in control cohorts has been reported [199, 257]. 
As discussed in Chapter 5, a blunted antigen-experienced CD8+ T cell egress in T1D may be 
indicative of sequestration in the pancreas during vigorous exercise. This may also be true for 
CD4+ T cells which show no significant mobilisation following vigorous exercise in T1D 
participants. As well as antigen-experienced CD8+ T cells, CD4+ T cells are also involved in 
the pathogenesis of T1D and therefore a proportion of the CD4+ T cells, which would be 
expected to mobilise in healthy participants, may be withheld in the pancreas during vigorous 
exercise in T1D [122, 123].  
A shift in the Th1/Th2 ratio indicated by increased Th2 cytokine levels has been demonstrated 
following an acute exercise bout in healthy cohorts. This is typically a result of lower Th1 T 
cells and Th1 cytokines, paired with an increase in Th2 cytokines only, not Th2 T cells [453, 
454, 518, 519]. In this study herein, the Th1/Th2 ratio is also shifted towards Th2. However, 




this study herein. Mobilisation of Th2 cells however is shown in this study. This resulted in a 
shift in the Th1/Th2 ratio. Plasma samples from this study have been cryo-preserved to measure 
T-helper cytokine patterns following moderate and vigorous exercise. This would provide 
insight into the Th1/Th2 shift following exercise in T1D. 
Few studies have measured Th17 cell mobilisation during acute exercise. Evidence of the 
effects of acute exercise on Th17 immunity has centred around IL-17 measurement [522, 523]. 
One study measuring Th17 cells reported a decrease in the percentage of Th17 after endurance 
exercise [521]. However, endurance exercise involving marathon running and triathlons as 
shown in the aforementioned study has to some extent different effects on lymphocytosis 
compared to a short acute vigorous exercise bout due to differences in adrenaline responses 
[521]. Th17 cell frequencies significantly changed overall during vigorous exercise in this 
study, but not in either T1D or control groups independently. The cryopreserved plasma 
samples from this study can also be used to measure Th17 related cytokines, including IL-17, 
following moderate and vigorous exercise. This would provide further evidence of the effects 
of acute exercise on Th17 immunity in both healthy and T1D cohorts. 
Previous studies report conflicting results on the effects of exercise on CD4+ TReg subsets in 
control cohorts [455-457, 521, 524]. Some suggest that the percentage of CD4+ TRegs decrease 
after endurance exercise [521]. As discussed, endurance exercise and short acute vigorous 
exercise bouts can cause different levels of lymphocytosis dependent on intensity and duration. 
However, acute exercise increased absolute CD4+ TReg frequencies post exercise in trained 
athletes and control participants [455-457]. In this study herein, CD4+ TRegs mobilised in 
control but not T1D participants, and these were mainly comprised of memory TRegs. One 
study previously reported increases in naïve TReg frequencies, but not memory TReg 




taken 12-36 hours before exercise began and the exercise consisted of 30km walking per day 
for 4 consecutive days. This would not be considered an acute exercise bout or comparable to 
the exercise protocol used in this study herein [524]. 
The effects of acute exercise on IL-6Rhi TReg subsets have not previously been examined. In 
this study herein, exercise did not significantly mobilise IL-6Rhi subsets in either T1D or 
control cohorts. As IL-6R is highly expressed on mTReg, which mobilised with vigorous 
exercise, mobilisation of IL-6Rhi subsets may be expected. However, IL-6R is shed by 
activated CD4+ T cells during shear stress; therefore CD4+ mTRegs may shed IL-6R during 
vigorous exercise. This is supported by elevated sIL-6R levels found following exercise [529, 
530]. Elevated IL-6 levels previously shown during exercise could potentially interact with 
sIL-6R rather than IL-6Rhi subsets. This may explain why hypothesised changes in IL-6Rhi 
subsets are not detected during exercise [530, 531].  
The implications of acute exercise on CD4+ T-helper and TReg subsets in T1D are not clear 
from this study because no significant mobilisation of CD4+ subsets was observed. However, 
evidence of elevated memory TRegs, and a subsequent decrease in naïve TRegs, reinforces 
TReg dysfunction/imbalance in T1D. Naïve-memory T cell balance is also disrupted in the 
ageing population and a similar observation has been found in T1D [419]. The baseline 
differences shown in this study herein support these findings. The proportion of naTRegs 
(CD45RA+) decrease, whereas mTRegs (CD45RO+) increase significantly with age [487]. 
Elevated mTRegs have a reduced proliferative capacity in the ageing group, indicating limited 
turnover of the TReg pool [487]. Assuming similarities, boosting naïve TRegs in T1D could 
restore naïve/memory TReg balance and improve turnover of the TReg pool. One such therapy, 
aldesleukin (Proleukin; recombinant human IL-2), increases suppressive TReg populations in 




from development of diabetes [533, 534]. The effect of IL-2 on TReg frequencies is likely due 
to increased conversion of effector T cells into TRegs [535]. Todd et al demonstrated that 
aldesleukin boosts TReg proportions by up to 20% in T1D cohorts. In the aforementioned 
study, they showed that mTRegs with efficient suppressive capacity (CTLA-4+ FoxP3+) were 
more responsive to IL-2 treatment due to higher CD25 expression than naTRegs [536]. 
Aldesleukin also upregulates CXCR3 and CCR6 on regulatory T cells, necessary for 
recruitment into inflammatory sites to exert their immunomodulatory effects [536].  
The data presented here supports a case for exploration of CD4+ T-helper and TReg subsets 
following exercise training in T1D. Clarification of the effects of exercise on CD4+ T cell 
subsets in a larger T1D cohort is necessary. In this study, no significant mobilisation of CD4+ 
T cells subsets during vigorous intensity exercise is shown in T1D participants. Regular 
exercise may however have a different effect. Additionally, TReg suppressive function should 
be assessed following regular exercise as a marker of change in immunomodulatory capacity 
of TReg subsets which would have positive implications in T1D. Increased TReg suppressive 
capacity in T1D would regulate effector diabetogenic T cell responses and therefore reduce 
beta cell destruction. TReg suppression can be measured in vitro by co-culturing autologous 
TRegs with effector T cells stained with CFSE. TReg suppression is defined as a reduction in 
the growth of T effector cells and therefore CFSE staining remains high. 
Exercise training promotes Th2 polarization and increases in CD4+ TReg frequencies [448, 
456, 537, 538]. Elevated CD4+ TReg frequencies have been found in trained humans and mice 
[456, 537]. A decrease in Th1 polarization indicated by lower IFN-γ	levels was also found in 
one study [537]. An increase in the frequency of TRegs in the lungs and LN, but not the spleen, 
with improved suppressive function was reported in mice following 4 weeks of moderate 




Another study showed improved immune modulation by exercise in a mouse model of multiple 
sclerosis (MS), EAE, resulting in delayed onset of disease and increased T cell proportions 
with a regulatory phenotype [448]. These studies demonstrate that exercise training has the 
potential to modulate CD4+ T cell immunity and increase tolerance in T1D.  
In conclusion, T1D exhibits a skewed memory TReg phenotype i.e. elevated memory TReg 
and decreased naïve TReg subsets. Acute exercise does not mobilise CD4+ T-helper or TReg 
subsets in T1D, but does so in control participants. A regular exercise study with a larger study 
cohort may provide insight into the reason for differential mobilisation of these subsets in T1D 
























This study was undertaken to explore the effects of acute exercise on immunity in people with 
T1D. In particular, this study aimed to phenotype and characterise the effects of acute exercise 
on lymphocyte trafficking and lymphocyte subset mobilisation in T1D. 
The most significant results were that acute exercise caused an intensity-dependent 
lymphocytosis in people with T1D. This is the first time this has been demonstrated in T1D. 
The subsets most sensitive to exercise-induced lymphocytosis in T1D were fully differentiated 
CD8+ EMRA T cells and CD56dimCD16bright NK cells. These subsets have been previously 
shown to preferentially mobilise in healthy cohorts. However, the percentage increase of these 
subsets was blunted in the T1D group compared to the control group following vigorous 
intensity exercise. There are a number of potential reasons for this blunted lymphocytosis 
response and are discussed below.  
Firstly, blood glucose levels are elevated in people with T1D. High glucose conditions affect 
the mobilisation of several cell types and therefore may affect lymphocytosis. Elevated plasma 
glucose in T1D and T2D mouse models has been reported to impair CD34+ hematopoietic stem 
progenitor cell (HSPC) and CD45+ cell migration [539]. Fibroblast migration is also reduced 
in high glucose conditions resulting in impaired wound healing in diabetic rats [540]. 
Furthermore, fewer lymphocytes were found in the wound site of streptozotocin-induced 
diabetic mice compared to control mice, indicating lower migration of lymphocytes in T1D 
[541]. Therefore, high glucose levels in T1D may have an effect on lymphocyte migration 
during exercise. In contrast, however, similar lymphocytosis following exercise has been 
described to be similar in people with T2D compared to a control cohort following HIIT 
exercise [542]. In this study, baseline glycaemic control and HbA1c could be compared to the 
percentage increase of lymphocyte subpopulations following exercise. Correlations between 




of glucose levels and glycaemic control of lymphocytosis. However, this is difficult as the 
sample size is small and dividing the T1D cohort into groups would reduce the power greatly.  
Secondly, the immune cell subsets which exhibit blunted lymphocytosis during vigorous 
exercise in T1D are those which typically exhibit a high level of beta-adrenergic receptor 
expression and thus a profound sensitivity to exercise-induced perturbations to catecholamines. 
Therefore, it is possible that the adrenaline response is blunted in T1D. NK cells and cytotoxic 
T cells express much higher levels of beta-adrenergic receptors than other mononuclear cells, 
causing their dramatic mobilisation during exercise [202-205]. Alterations in these receptors 
in T1D would alter the stress response to exercise. Reduced beta-adrenergic sensitivity of 
lymphocytes in T1D has been reported, resulting in a dampened adrenaline response during 
hypoglycaemic events [543-545]. During acute exercise, increased beta-adrenoceptor density 
and sensitivity of lymphocytes is noted in healthy participants. However, patients with 
congestive heart failure (CHF) exhibited a blunted increase in beta-adrenoceptor density and 
no increase in sensitivity [546]. A similar effect may be seen in T1D and may impact exercise-
induced lymphocytosis. However, platelets increase during moderate and vigorous exercise in 
both control and T1D groups. Platelets also respond to adrenaline but are not blunted in this 
study herein [283, 284]. Therefore, the reduced adrenaline response may be specific to reduced 
beta-adrenoceptors on lymphocytes. In this study, beta-adrenoreceptor density on lymphocytes 
could be measured on cryo-preserved PBMC samples and systemic adrenaline could be 
measured in cryo-preserved plasma samples to address this mechanism. 
Lastly, and most interestingly, the cell subsets exhibiting blunted lymphocytosis during 
vigorous exercise share characteristics with those sequestered in the pancreas during T1D [126, 
127, 134, 435]. These include CD8+CD69+ T cells [85, 126], CD8+CD11b+ T cells [127, 134], 




In this study herein, lymphocytosis of highly differentiated CD8+ EMRA that express CD69 
and CD11b was blunted immediately following vigorous exercise in T1D. NK cells, 
particularly CD56dim NK cell subsets, were also blunted immediately following vigorous 
exercise in T1D. Normally, tissue resident cells down-regulate S1PR which is necessary for 
egress from tissue into the blood stream [437]. It is therefore possible to postulate that the 
blunted increase following exercise in these subsets is due to their sequestration in the pancreas 
via down-regulation of S1PR. However, in humans this is difficult to measure. Diabetogenic T 
cells can be measured using tetramer staining by flow cytometry. This could be carried out on 
cryo-preserved PBMC samples to address this mechanism and assess the effect of acute 
exercise on the number of diabetogenic T cells in the peripheral blood. Furthermore, this could 
be studied using NOD mice. Diabetogenic T cells can be fluorescently tagged and tracked 
during acute vigorous exercise in NOD mice. In particular, the number of diabetogenic T cells 
in the pancreas of NOD mice before and after acute exercise could be quantified and therefore 
highlight whether they are sequestered in the pancreas during the acute exercise bout.  
In addition to the mobilisation of NK cells and CD8+ EMRA T cells, acute exercise also 
affected other immune parameters. Although CD4+ T cell subset mobilisation was blunted in 
T1D, vigorous intensity exercise mobilised CD4+ TReg subsets in control participants. 
Mobilised CD4+ TRegs comprised mainly of memory TRegs. In addition to changes in 
lymphocytes, an increase in monocytes, granulocytes, and platelets was also found following 
vigorous exercise in both T1D and control groups. However, lymphocyte mobilisation during 
exercise exhibited the most pronounced response. Lastly, TEM and total adherence of 
lymphocytes to endothelium was affected by vigorous intensity exercise in T1D. Specifically, 
TEM was significantly suppressed during the recovery period following vigorous exercise in 
T1D. This is likely due to changes in the composition of the T cell repertoire and a reduction 




The strengths of this study are that it is the first comprehensive immunophenotyping analysis 
of lymphocyte mobilisation during acute exercise and provides imperative evidence of the 
effects of acute exercise on immunity in people with T1D. This study provides evidence of the 
immune response in T1D during two exercise intensities. Furthermore, measuring TEM of 
lymphocytes provides functional evidence of immunomodulation by exercise in T1D. This is 
complimented by quantifying lymphocyte trafficking signals such as chemokine receptors and 
adhesion molecules to identify the mechanisms by which transmigration of lymphocytes is 
modulated in T1D. Importantly, this provides a platform for future investigations of exercise 
in T1D, allowing for new avenues to be explored to increase the initial honeymoon phase 
following diagnosis [236], reduce disease severity, and ultimately for the treatment of T1D. 
The limitations of this study are that the study groups were small, and low participant numbers 
increased the error of the data. Populations reported to be significantly mobilised overall, but 
not in either group independently, suggests that with a larger study group, significant 
mobilisation may be observed for these subsets in both groups individually. Moreover, due to 
the large number of parameters measured in a small study cohort, multiple testing may increase 
the chance of statistically significant changes. Therefore, to address this in future, significant 
changes should be defined by a lower p value (e.g. p<0.001). Another limitation due to the 
small sample size is the lack of adjustment for baseline values. Due to higher baseline values 
evident in T1D, this may impact the lower percentage change observed following exercise 
(referred to as regression to the mean). This could be due to disease duration or glycaemic 
control. In future this can be corrected for using analysis of covariance (ANCOVA), which 





Furthermore, the analysis was limited by the number of parameters measurable by flow 
cytometry. Day to day variation of flow cytometry increases error and reduces sensitivity of 
detecting small subsets. However, in order to process fresh patient samples over the course of 
the study, this variation was inevitable. This variation made it difficult to compare data from 
moderate and vigorous intensity visits as they were conducted on separate days. New platforms, 
such as CyTOF, allow for a much larger scale single cell analysis of immune populations [547]. 
CyTOF is not limited by fluorophore-based detection; for this reason, there is increased 
sensitivity and reduced variability in longitudinal sample acquisition. Therefore, 
cryopreservation of samples may be more stable with CyTOF analysis, leading to the option of 
bulk sample analysis following the trial’s cessation [548].  
Another potential limitation of this study is that C-peptide was not measured. C-peptide is a 
measure of beta cell function and therefore indicates the degree of function in the remaining 
beta cells in T1D. If beta cell function is low in T1D, then improvements following exercise 
may not be evident. This may also increase variation in responses due to non-responders within 
the T1D group. 
Mechanisms through which islet immunity can be modulated in people with T1D have been 
explored in this study. These mechanisms include mobilisation of highly differentiated T cells 
and reduced lymphocyte TEM. As previously discussed, lymphocyte trafficking and tissue 
redistribution is essential for immunosurveillance and regulation [191, 214]. Furthermore, the 
deletion of exercise sensitive EM and EMRA CD8+ T cells following acute exercise has the 
potential to create “immune space” in people with T1D [216-221]. This immune space 
following exercise can be taken up by newly generated HSPC and reprogram immune memory 
in T1D [212, 213], reducing aggressive memory T cell phenotypes and therefore preserving 




potential to modulate egress of islet reactive T cells out of the circulation and into the islet 
[315].  
Mechanisms through which acute exercise could be used in combination with current trial 
immunotherapies have also been explored. Some immunotherapeutic approaches to preserve 
beta cell function in T1D aim to reduce aggressive memory phenotypes, and promote the 
generation of new naïve cells in T1D. This has been achieved with acute exercise and exercise 
training in healthy cohorts. Therefore, exercise in T1D may be used as an adjunct for other 
immunotherapeutic agents. As discussed, agents that target CD8+ T cells may be more effective 
if administered following a bout of vigorous intensity exercise when CD8+ T cells are mobilised 
[149-153]. Furthermore, exercise also increases regulatory cytokines such as IL-1RA. The 
increases in IL-1RA reported following acute exercise are comparable, and may be higher, than 
those seen in trials of immunomodulation in T1D with synthetic IL-1RA therapy [167, 227]. 
This study provides for the first time a clear and detailed analysis of the effects of an acute bout 
of exercise at two different intensities in people with T1D. The findings support the potential 
for exercise to modulate the autoimmune response against the islet in T1D. However, a number 
of important questions remain. Chief amongst these questions is clarifying the effects of 
exercise on T cells specific to the beta cell, because these cells have a direct bearing on islet 
immunity. Other questions include those relating to the mechanisms underlying the blunted 
lymphocytosis following vigorous intensity exercise in T1D. Lastly, the question of the effects 
of regular exercise on immunity and beta cell health in people with T1D needs to be explored. 
These questions can be addressed in the future work listed below. 
Identify mechanisms of blunted lymphocytosis in T1D: 
• Is the blunted lymphocytosis in T1D glucose or immune dependent? This can be 




• Is the blunted lymphocytosis in T1D due to a blunted adrenaline response? Plans 
to measure soluble catecholamines were in original experimental design. Plasma and 
PBMC samples were taken for the measurement of cortisol and adrenaline. For future 
work, this can be done by measuring systemic adrenaline (plasma catecholamine 
measurement by ELISA or Luminex) and beta-adrenergic receptor density 
measurement on lymphocytes (flow cytometry) using the stored plasma and PBMC 
samples. 
• Is the blunted lymphocytosis in T1D due to sequestration for islet specific T cells 
in the pancreas in T1D? This could be explored by measuring islet specific T cells 
following acute exercise using tetramer staining on stored frozen PBMC samples (flow 
cytometry). This may highlight whether islet specific T cells increase following 
exercise in T1D, and if not this may indicate that islet specific T cells are sequestered 
in the pancreas during acute exercise in the T1D cohort. Furthermore, this could 
specifically be examined in murine T1D models using fluorescent dyes to track cell 
mobilisation. In future work, diabetogenic T cells from NOD mice could be tagged with 
a bioluminescent dye. Live imaging could be used to identify diabetogenic T cell within 
the pancreas before and after acute exercise. At the end of the experiment, organs 
should be harvested to quantify diabetogenic T cell within the pancreas and measure T 
cell infiltration into multiple organs including the pancreas.  
Identify immunomodulatory mechanisms to preserve beta cell health in T1D: 
• Does acute exercise modulate systemic inflammatory responses in T1D? Plans to 
measure inflammatory markers and hormones were in the original experimental design. 
Plasma samples were taken for the measurement of IL-6, IL-6R, GLP1, FGF21, 




IL-1Rα, IL-10, TNFα, Leptin, IL7, Cortisol, Glucagon, Resistin, Visfatin, Growth 
Hormone, IGF, IL-4, IL-13, and IL-17. The above soluble cytokines, adipokines, 
myokines, and hormones can be measured in the stored plasma samples by Luminex. 
This would provide more depth to the anti-inflammatory and immunomodulatory 
changes acute during exercise that may affect beta cell health in T1D.  
Furthermore, serum samples were taken and stored to assess the impact of exercise on 
beta cell models in vitro. Beta cell models such as MIN6 and INS-1E cell lines can be 
grown in rest or exercise-conditioned media. Beta cell health outcome measures such 
as insulin secretion, viability, and proliferation can be assessed and then compared 
based on culture conditions to elucidate mechanisms by which exercise can improve 
beta cell health. This data could be used to plan future experiments to block specific 
cytokines or hormones identified by Luminex to elucidate mechanisms by which 
exercise could improve beta cell health.  
• Can acute exercise be used as an adjunct for T1D immunotherapy? This could be 
explored through a trial combining vigorous acute exercise with immunotherapies 
targeting CD8+ T cells, providing useful implications for advances in immunotherapy 
in T1D.  
Identify mechanisms of immunomodulation and beta cell preservation by regular exercise 
training in T1D: 
• Can regular exercise training modulate immunity and preserve residual beta cell 
function in T1D? This could be explored in NOD mice and T1D cohorts. These studies 
should include characterisation of changes to immune cell subsets and systemic 
inflammation, paired with C-peptide (beta cell function) measurements. Functional 




These include lymphocyte trafficking and TEM, apoptosis of memory T cells following 
exercise, stem cell generation, and changes in islet specific T cell frequencies. This 
would follow up immunomodulation and immune space theories in T1D models and 
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Dear   
 
Study title: Exploring the effect of exercise on immune function and 
beta cell health in patients with type 1 diabetes mellitus 
REC reference: 16/NW/0051 
IRAS project ID: 189283 
 
Thank you for your letter of 14 March 2016, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this opinion letter.  Should you wish to provide a substitute contact point, require 
further information, or wish to make a request to postpone publication, please contact the REC 
Manager, ,   
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
 
A Research Ethics Committee established by the Health Research Authority 
 
 
Management permission should be sought from all NHS organisations involved in the study in 
accordance with NHS research governance arrangements. Each NHS organisation must confirm 
through the signing of agreements and/or other documents that it has given permission for the 
research to proceed (except where explicitly specified otherwise).  
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System, www.hra.nhs.uk or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of management permissions from host 
organisations 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database within 6 weeks of recruitment of the first participant (for 
medical device studies, within the timeline determined by the current registration and publication 
trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact  
, the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS.  
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 




The final list of documents reviewed and approved by the Committee is as follows: 
Document   Version   Date   
Covering letter on headed paper [Cover letter for ethics re-
submission]  
1  26 February 2016  
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [insurance confirmation]  
  07 January 2016  
 
A Research Ethics Committee established by the Health Research Authority 
 
GP/consultant information sheets or letters [GP letter]  1  01 December 2015  
IRAS Checklist XML [Checklist_04032016]    04 March 2016  
Letter from sponsor [sponsorship letter]    07 January 2016  
Other [clarification on recruitment]      
Participant consent form [Consent Form]  2  16 February 2016  
Participant information sheet (PIS)  3  11 March 2016  
Participant information sheet (PIS) [Healthy Subjects]  1  16 February 2016  
REC Application Form [REC_Form_08012016]    08 January 2016  
Research protocol or project proposal [Protocol]  3  16 February 2016  
Summary CV for Chief Investigator (CI) [CV CI]  1  19 January 2015  
Summary CV for student [CV student researcher]  1  01 December 2015  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
x Notifying substantial amendments 
x Adding new sites and investigators 
x Notification of serious breaches of the protocol 
x Progress and safety reports 
x Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 





The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-




We are pleased to welcome researchers and R&D staff at our training days – see details at 






A Research Ethics Committee established by the Health Research Authority 
 
16/NW/0051                          Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 




Email:   
 
Enclosures:  “After ethical review – guidance for researchers” 
 
Copy to:  
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Location(s): Wellcome Trust Clinical Research Facility, University Hospital Birmingham. 
Investigators: Michelle Curran, Dr. Parth Narendran, Dr. John Campbell, Professor Mark 
Drayson.  
Study aims: This study aims to investigate how exercise can improve the health of the 
insulin producing beta-cells in healthy people and people with type 1 diabetes (T1D). This 
may help improve their diabetes control and reduce the risk of long-term complications.  
 
 
Study Background:  
There are two types of diabetes mellitus; type 1 diabetes (T1D) and type 2 diabetes (T2D). 
Both types of diabetes have different causes but similar symptoms. 
The pancreas contains cells, known as beta-cells, which ensure blood glucose levels are 
maintained at a normal level through the secretion of insulin. Insulin transports glucose out 
from the bloodstream into tissues. If glucose is not removed from the bloodstream, it 
becomes toxic, a state referred to as hyperglycaemia. Hyperglycaemia results in the hallmark 
symptoms of diabetes including increased thirst, fatigue, and frequent urination. Chronic 
hyperglycaemia causes complications such as death, eye, kidney, and nerve damage.  
T1D solely results from a lack of insulin. It is an autoimmune disorder, meaning that it is 
caused by our immune system destroying native tissue, in this case, beta cells. Consequently, 
there is no insulin production.  
 
Exercise has marked improvements in fitness, insulin requirements, mortality and well-being 
as well as a reduction in fat, insulin resistance, and cardiovascular disease in T1D. Whilst 
there is some understanding that exercise improves the health of beta cells in patients with 
type 2 diabetes, little is known of the benefits in T1D. We would like to explore how exercise 
improves beta cell health in patients with T1D and healthy people.  
 
At the time of diagnosis, a T1D patient will have some of their beta cells intact, but these 
remaining beta cells will also be destroyed gradually in the years that follow the diagnosis of 
T1D being make. Uptake of exercise early after diagnosis with T1D could therefore help 
preserve these beta cells, and we know that preserving beta cell function will help the 
management of diabetes.  
 
During exercise a variety of substances and hormones are produced by the liver, muscles, and 
fat, which signal to beta cells to produce insulin and stop the autoimmune process. In this 
study we would like to identify these substances to better understand the mechanisms through 
which exercise could benefit patients with T1D. We will be undertaking this research in 
patients with new as well as long standing diabetes, as well as in patients without diabetes as 







A free fitness test is included in the first visit. We all also measure general health, for 
example blood pressure and heart rate. Once the study has finished, we will provide advice 
on options to continue to exercise and advised quantity of exercise to benefit your health and 
T1D.  
Participating in the study will only cost you some of your time, all travel costs upto the 
value of £10 for each visit will be compensated for at the end of the visit.  
Study design: 
If you agree to take part in the study and meet the inclusion criteria, you will be required to 
attend the study centre on three separate occasions. All health and fitness assessments will be 
performed at the Wellcome Trust Clinical Research Facility at University Hospital 
Birmingham. 
 
Visit 1: Enrolment & Baseline visit 
In this visit we will collect your informed consent to participate in the study. For patients 
with T1D, HbA1C will be checked if not done within the previous 6 weeks. We will also ask 
you to wear an activity meter to measure how much activity you are doing.  
We will provide food diaries for you to record your meals and also as a reference to the meal 
you had before exercise study visits. We would like you to have the same meal each of the 
exercise visits to control for any dietary influences. This means the same quantity of the meal 
also. 
Blood glucose diaries will also be provided. You will be asked to measure your glucose at 
least 4 times a day during the study (before each meal, before bed, and any time when you are 
feeling unwell or it is appropriate to do so).  
You will undergo a fitness test on a stationary exercise bike in the exercise rooms of the 
NIHR/WT CRF at The Queen Elizabeth Hospital in Birmingham. This will be used as a 
guide for the required exercise intensity for the subsequent exercise study visits where you 
will partake in light and high exercise intensities. 
 
Visit 2-3: Exercise Study Visits 
These visits will lasts approximately 6 hours. You will be involved in three exercise study 
visits, each separated by between 7-21 days. During these visits we will take a small amount 
of blood at four different times (out-lined in the time plan). The exercise visits will consist of 
 
 
30 minutes of either light or heavy exercise. The order of these visits will be randomised so 
you will only know what intervention you are doing on the day of the visit.  
For all visits, you must be fasted (without having consumed food (water allowed) since 
midnight the night before). The meals consumed within the previous 24 hours (recorded in 
your food diary) should be repeated for the 24 hours preceding each of the other two study 
visits. You will be encouraged to undertake your usual levels of physical activity between 
study visits (measured by the actigraph), but you must refrain from exercise for a 24-hour 
period before an exercise study visit. For patients with T1D, basal insulin (with either pens or 
insulin pump) is encouraged to be taken as usual. ‘’ 
After the intervention glucose will be monitored post-exercise every 20 minutes until the 
hour blood sample. If your blood sugar drops to 5mM before the 60 minutes post exercise 
time-point, a blood sample will be and the subject will be fed.  
  
 
Example time-plan of the day of exercise study visit: 
8.00am – Arrive at WT CRF Reception 
8.15am - Insert cannulae to take blood samples, wait 30 mins while you relax. 
8.45am - Take resting blood sample. 
9.05am - Take blood sample and start 30 min exercise intervention (light exercise or heavy 
exercise). 
9.35am - Take blood sample at end of exercise.
10.35am - Take blood sample 60 minutes after end of exercise. 
10.45am - Provide breakfast/lunch. For patients with T1D, we will check your blood glucose 
is stable. We also will advise you to test blood glucose 6-8 hours post exercise and consume 
carbohydrates to avoid post-exercise hypoglycaemia. Arrange next visit and pay for travel. 
Total amount of blood taken per visit: 100ml. 100ml is about 6-7 tablespoons. 
 
 
For your information: 
Do I have to take part in the study? 
No. Taking part in this study is entirely voluntary. If you would like to participate, you will 
be given this information sheet to keep and be asked to sign a consent form. You are still free 
to withdraw at any time and without giving a reason.  
May I be excluded from the study? 
Yes. You can be excluded from the study at any time point if something happens that affects 
your eligibility for the study or you are unable to complete the study.  
 
Confidentiality: 
All data and samples will be labeled with a code, not with your name. Only the research team 
which is in contact with you has access to the link between code and name of the subject. 
The results of this study are expected to be published in a scientific journal, but names of 
participants will never be published. 
 
Rights: 
It is your choice whether or not you wish to take part in this study. If you wish to take part in 
this study, you will be given this information sheet to read and be asked to sign a consent 
form. You are reminded that if you decide to take part in the study, you are still free to 
withdraw from the study at any time without giving a reason. If you withdraw from the 
study, the data and blood samples already collected will be retained, unless you request for 
them to be removed within 12 weeks of the first visit. 
 
What happens if something goes wrong on the day of the trials? 
All procedures have been included within University Hospital Birmingham Liability 
insurances and if you are harmed in any way by taking part in this research project your 
normal rights apply and you may have ground for legal action. 
 
Complaints 
If you have any problems or complaints during the study procedure, you are welcome to 
contact either the investigator, or independently the hospital PALS (patient advice and liaison 





What happens now? 
You will be asked to complete an informed consent form to confirm that you are happy to 
participate in this study. You will be asked to keep a copy of this information sheet and the 
signed consent forms. We will then inform your GP that you have decided to take part in this 
study. 
 
Thank you for your time, and if you want to participate in the study or have any further 
questions, please feel free to contact any of the investigators listed below. If you wish to 














                                             
                          
Exploring the effect of exercise on immune function 
and beta cell health in patients with type 1 diabetes 
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Location(s): Wellcome Trust Clinical Research Facility, University Hospital Birmingham. 
Investigators: Michelle Curran, Dr. Parth Narendran, Dr. John Campbell, Professor Mark 
Drayson.  
Study aims: This study aims to investigate how exercise can improve the health of the 
insulin producing beta-cells in healthy people and people with type 1 diabetes (T1D). This 
may help improve their diabetes control and reduce the risk of long-term complications.  
 
 
Study Background:  
There are two types of diabetes mellitus; type 1 diabetes (T1D) and type 2 diabetes (T2D). 
Both types of diabetes have different pathogenesis but similar symptoms. 
The pancreas contains cells, known as beta-cells, which ensure blood glucose levels are 
maintained at a normal level through the secretion of insulin. Insulin transports glucose out 
from the bloodstream into tissues. If glucose is not removed from the bloodstream, it 
becomes toxic, a state referred to as hyperglycaemia. Hyperglycaemia results in the hallmark 
symptoms of diabetes including increased thirst, fatigue, and frequent urination. Chronic 
hyperglycaemia causes complications such as death, eye, kidney, and nerve damage.  
T1D solely results from a lack of insulin. It is an autoimmune disorder, meaning that it is 
caused by our immune system destroying native tissue, in this case, beta cells. Consequently, 
there is no insulin production.  
 
Exercise has marked improvements in fitness, insulin requirements, mortality and well-being 
as well as a reduction in fat, insulin resistance, and cardiovascular disease in T1D. Whilst 
there is some understanding that exercise improves the health of beta cells in patients with 
type 2 diabetes, little is known of the benefits in T1D. We would like to explore how exercise 
improves beta cell health in patients with T1D and healthy people.  
 
At the time of diagnosis, a T1D patient will have some of their beta cells intact, but these 
remaining beta cells will also be destroyed gradually in the years that follow the diagnosis of 
T1D being make. Uptake of exercise early after diagnosis with T1D could therefore help 
preserve these beta cells, and we know that preserving beta cell function will help the 
management of diabetes.  
 
During exercise a variety of substances and hormones are produced by the liver, muscles, and 
fat, which signal to beta cells to produce insulin and stop the autoimmune process. In this 
study we would like to identify these substances to better understand the mechanisms through 
which exercise could benefit patients with T1D. We will be undertaking this research in 
patients with new as well as long standing diabetes, as well as in patients without diabetes as 







A free fitness test is included in the first visit. After following your routine of activity 
through a device called actigraph, we will be able to advise you on changes you can make to 
increase your participation in exercise as part of your daily life. We all also measure general 
health, for example blood pressure and heart rate. 
Once the study has finished, we will provide advice on options to continue to exercise and 
advised quantity of exercise to benefit your health and T1D.  
Participating in the study will only cost you some of your time, all travel costs for each visit 
will be compensated for at the end of the visit.  
 
Study design: 
If you agree to take part in the study and meet the inclusion criteria, you will be required to 
attend the study centre on four separate occasions. All health and fitness assessments will be 
performed at the Wellcome Trust Clinical Research Facility at University Hospital 
Birmingham. 
Visit 1: Enrolment & Baseline visit 
In this visit we will collect your informed consent to participate in the study. HbA1C will be 
checked in all participants, healthy and T1D. This is to exclude any underlying T2D that may 
not have been diagnosed.  
We will provide food diaries for you to record your meals and also as a reference to the meal 
you had before exercise study visits. We would like you to have the same meal each of the 
exercise visits to control for any dietary influences. 
You will undergo a fitness test on a stationary exercise bike in the exercise rooms of the 
NIHR/WT CRF. This will be used as a guide for the required exercise intensity for the 
subsequent exercise study visits where you will partake in light and high exercise intensities. 
 
Visit 2 + 3: Exercise Study Visits 
These visits will lasts approximately 6 hours. You will be involved in three exercise study 
visits, each separated by between 7-21 days. During these visits we will take a small amount 
of blood at five different times (out-lined in the time plan). The exercise visits will consist of 
30 minutes of either light or heavy exercise. The order of these visits will be randomised so 
you will only know what intervention you are doing on the day of the visit.  
For all visits, you must be fasted (without having consumed food (water allowed) since 
midnight the night before). The meals consumed within the previous 24 hours (recorded in 
 
 
your food diary) should be repeated for the 24 hours preceding each of the other two study 
visits. This means same quantity of this meal. You will be encouraged to undertake your 
usual levels of physical activity between study visits (measured by the actigraph), but you 




Example time-plan of the day of exercise study visit: 
8.30am - Arrive at WT CRF Reception 
8.45am - Insert cannulae to take blood samples, wait 30 mins while you relax. 
9.00am - Take resting blood sample. 
9.20am - Following 20minute rest, take blood sample and start 5 min warm up and 30 min 
exercise intervention (light exercise or heavy exercise). 
9.55am - Take blood sample at end of exercise. 
10.55am - Take blood sample 60 minutes after end of exercise. 
13.55pm - Take blood sample 240 minutes post exercise.  
14.00pm - Provide breakfast/lunch. Arrange next visit and pay for travel. 
Total Blood Volume per visit: 110mls, about 6-7 tablespoons.  
 
 
For your information: 
Do I have to take part in the study? 
No. Taking part in this study is entirely voluntary. If you would like to participate, you will 
be given this information sheet to keep and be asked to sign a consent form. You are still free 
to withdraw at any time and without giving a reason.  
 
May I be excluded from the study? 
Yes. You can be excluded from the study at any time point if something happens that affects 
your eligibility for the study or you are unable to complete the study.  
 
Confidentiality: 
All data and samples will be labeled with a code, not with your name. Only the research team 
which is in contact with you has access to the link between code and name of the subject. 
The results of this study are expected to be published in a scientific journal, but names of 
participants will never be published. 
Rights: 
It is your choice whether or not you wish to take part in this study. If you wish to take part in 
this study, you will be given this information sheet to read and be asked to sign a consent 
form. You are reminded that if you decide to take part in the study, you are still free to 
withdraw from the study at any time without giving a reason. If you withdraw from the 
study, the data and blood samples already collected will be retained, unless you request for 
them to be removed within 12 weeks of the first visit. 
 
What happens if something goes wrong on the day of the trials? 
All procedures have been included within University Hospital Birmingham Liability 
insurances and if you are harmed in any way by taking part in this research project your 
normal rights apply and you may have ground for legal action. 
 
Complaints 
If you have any problems or complaints during the study procedure, you are welcome to 






What happens now? 
You will be asked to complete an informed consent form to confirm that you are happy to 
participate in this study. You will be asked to keep a copy of this information sheet and the 
signed consent forms. We will then inform your GP that you have decided to take part in this 
study. 
 
Thank you for your time, and if you want to participate in the study or have any further 
questions, please feel free to contact any of the investigators listed below. If you wish to 




















Title of Project: Exploring the effect of exercise on immune function and beta cell health in patients 
with type 1 diabetes mellitus 
 
The EXTOD Mechanisms study 
	
	
Name of Researcher: Dr Parth Narendran 
	
Please initial box  
 
 
1. I confirm that I have read and understand the information sheet for the above study. I have 
had the opportunity to consider the information, ask questions and have had these answered 
satisfactorily. Version: ____ Date: ___________ Healthy Volunteer/ Type 1 diabetes (delete 
as appropriate) 
 
2.  I understand that my participation is voluntary and that I am free to withdraw at any time  
 without giving any reason, without my medical care or legal rights being affected.  
 
3.  I understand that individuals may look at relevant sections of my medical notes and data 
collected during the study, from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these individuals to have 
access to my records. 
 
4.  I agree to the taking and storage of blood samples for the purposes of this study  
 
5.  I agree to the taking and storage of DNA for the purposes of this and future studies  
 




_______________   ________________    _________________  




_________________   ________________    ___________________  
Name of Person   Date      Signature  
taking consent  
 
 





Dear (insert doctor’s name) 
I am writing to advise you that (insert patient name) has agreed to participate in our EXTOD 
mechanisms exercise study. Please find attached the patient information sheet for details on 
the procedure. If you have any concerns for the health or wellbeing of your patient, please do 






Clinical Senior Lecturer and Consultant in Medicine 
Email:  






Case Report Form (Baseline) 
 





Tick the box to indicate YES this does apply 
6. 16-65 years of age  
7. Male  
8. ≤150mins moderate intensity exercise plus 2 days of strengthening exercise per week. 
9. Safe to exercise 
10. In addition if subjects are in the T1D group, they will  
1. have been given a clinical diagnosis of T1D 
2. be on basal bolus insulin regime or insulin pump therapy 
3. be able to estimate carbohydrate content of meals 
4. be willing to test glucose through capillary testing and adjust insulin and 
carbohydrate doses accordingly 




Tick the box to indicate NO this does not apply. 
 
6. Unable to provide fully informed consent. 
7. History of cardiac disease. 
8. Significant illness or condition that prevents attendance at a study site clinical centre. 
9. PI feels that participation in the study would not be in the individual’s best 
interest. 
10. In addition, if subjects are in the T1D group: 
1. active proliferative diabetic retinopathy 
2. autonomic neuropathy 




Received signed Consent 
Has the participant had caffeine in the last 12 hours?   Yes/No 
Has the participant had alcohol in the last 12 hours?  Yes/No 
Has the participant had breakfast this morning?  Yes/No 
 
Record participants anthropometric assessment: 
 
Height: ___________cm   
Weight: _____________kg 
BMI:________________kg/m2 
Waist: ___________cm   
Hip: ____________________cm  
Chest: ____________________cm 
Waist-to-hip ratio: (waist cm/hip cm) ____________________  
Body Fat %: ________________ 
 
Test for HbA1c in all participants:   3ml EDTA (purple top)  
 
Fitness Test- Sub-maximal VO2 assessment 
 
- Put polar watch and strap on participant 
- Adjust seat and handle bar height (record for future visits) 
Seat: ____________cm   Handle bars: ______________cm 
 
Target HR: (220-age) x 0.85=_________________________    _____________bpm 
 
- Begin fitness test:   
Part 1: 
- Set the workload at 50 – 100W (based on activity levels). Participant cycling @ 
50rpm. 
WL ______________________ watts  



































































- Target HR achieved: Yes/No 
- Cool Down- 5 minutes cycling at a low resistance 
 
 
- Give Participant questionnaire pack.  Completed: __________________  
 
- Give Participant 2 food diaries + explain same evening dinner 24hours before next 
visit 
 






































Case Report Form (visit 1/2) 
 
Participant ID: ______________  Visit no.______________  Date: ______________ 
  
Safety checks: 
- Hypoglycaemia kit in the room 
- Bed available in the room 
- Polar watches working 
- Bucket of ice ready for samples 
- Glucose monitor 
- Blood pressure monitor 
 
Participant arrives @ WT CRF reception- check in at reception and bring to exercise room. 
- collect informed consent 
- check participant is fasted       Yes/No 
- Has the participant had alcohol or coffee in the last 24 hours? Yes/No 
- Has the participant had any hypos?     Yes/No 
 
- check blood glucose: _______mmol/L 
- Record time of waking-up: ___________am 
 
- Put HR monitor on participant 
- Participant resting- insert cannulae (blue)- 
- HR: ________bpm 
- BP:_________mmHg 
 
Wait upto 20mins 
 
- Give them questionnaires and some light reading 
First resting blood sample 
- 5ml clotted (red top)  
- 5ml EDTA (purple top) Put straight onto ice 
 
*Aliquot 1ml blood from plasma EDTA tubes into EDTA tube (for whole blood cell 
counts) and leave on roller  
- Check glucose: ___________mmol/L 
 
Wait upto 20 mins 
 






Pre-exercise blood sample (person is seated on the bike) 
"! 20mls Lithium Heparin (green top) Put onto roller 
"! 5mls EDTA (purple top) Put straight onto ice 
"! 5mls clotted (red top)  
"! 2mls DDP4 inhibitor (red top) Put straight onto ice 
*Aliquot 1ml blood from plasma EDTA tubes into EDTA tube (for whole blood cell 
counts) and leave on roller. 
"! Record HR 
HR ___________bpm 
BP ___________mmHg 
Warm-up: 5 minutes building up pace, and then start 30 minutes intervention. 
Exercise intervention: 40% / 80%  
40% Intervention protocol: Desired HR 
"! 30mins @ 40% _______________
80% Intervention protocol:     Desired HR  
"! 0-10mins Get up 70%  _______________ 
"! 10-20mins: maintain 75% _______________
"! 20-30mins: maintain 80% _______________
"! Record HR after 5 minute warm-up. 
HR ___________bpm 
"! Record glucose and flush @ 0,10,20, 30minutes 




"! Record Borg scale @ 0,10,15,25,30minutes 








Post-exercise blood sample (immediately -while participant is sitting on the bike) 
"! 20mls Lithium Heparin (green top) Put onto roller 
"! 5mls EDTA (purple top) Put straight onto ice 
"! 5mls clotted (red top)  
"! 2mls DDP4 inhibitor (red top) Put straight onto ice 
*Aliquot 1ml blood from plasma EDTA tube into EDTA tube (for whole blood cell counts) 
and leave on roller.  
"! Record blood pressure and HR 
HR ___________bpm 
BP ___________mmHg 
Cool down: 5 minutes post-blood sample. 
Then have them seated for 60 minutes 
T1D participants-check blood glucose levels every 30mins. 
Must be above 5mM!! (If it drops below this, take blood sample and feed) 
Sample taken @ _______minutes post-exercise.  
1 hour post-exercise blood sample 
"! 20mls Lithium Heparin (green top) Put onto roller 
"! 5mls EDTA (purple top) Put straight onto ice 
"! 5mls clotted (red top)  
"! 2mls DDP4 inhibitor (red top) Put straight onto ice 
*Aliquot 1ml blood from plasma EDTA into EDTA tube (for whole blood cell counts) and 
leave on roller. 
Check glucose___________________ mmol 
"! Record BP every 15minutes in the 1hour recovery.  
0mins  BP ___________mmHg  HR_______________ bpm 
15mins BP___________ mmHg HR_______________ bpm 
30mins BP___________ mmHg  HR_______________ bpm 
45mins BP ___________mmHg  HR_______________ bpm 
60mins BP ___________mmHg  HR_______________ bpm 
**Cannulae can be taken out at 1hour post-exercise. Healthy participants will then be asked 
to remain resting until 4hours post-exercise. 
Heparin tubes brought to the IBR by Michelle 
4 hour post-exercise blood sample 
(Sample taken with butterfly needle)  
"! 5mls EDTA (purple top) Put straight onto ice 
"! 5mls clotted (red top)  











- 1ml EDTA (purple top) - leave on roller  
Record blood pressure and HR 




Remaining EDTA and Serum tubes taken to IBR for serum and plasma isolation 
(Anmol or Michelle) 
 
*Pay for travel and arrange next visit 




































Signed: _______________________    Date:________________ 
 
Name: ________________________  
 
 
Psychological Stress Questionnaires 
 
Has this event happened to you in the TWO WEEKS? If yes, please indicate how stressful 










1 Death (family member or friend) Yes No 0 1 2 3 
2 Had a lot of tests Yes No 0 1 2 3 
3 It’s finals week Yes No 0 1 2 3 
4 Applying to postgraduate education Yes No 0 1 2 3 
5 Victim of a crime Yes No 0 1 2 3 
6 Coursework in all modules/courses due 
the same day 
Yes No 0 1 2 3 
7 Breaking up with boy-/girlfriend Yes No 0 1 2 3 
8 Found out boy-/girlfriend cheated on 
you 
Yes No 0 1 2 3 
9 Lots of deadlines to meet Yes No 0 1 2 3 
10 Property stolen Yes No 0 1 2 3 
11 You have a hard upcoming week Yes No 0 1 2 3 
12 Went into a test/exam unprepared Yes No 0 1 2 3 
13 Lost something (especially wallet) Yes No 0 1 2 3 
14 Death of a pet Yes No 0 1 2 3 
15 Did worse than expected on test/exam Yes No 0 1 2 3 
16 Had an interview Yes No 0 1 2 3 
17 Had projects, essays due Yes No 0 1 2 3 
18 Did badly on a test/exam Yes No 0 1 2 3 
19 Parents getting divorce Yes No 0 1 2 3 
20 Dependent on other people Yes No 0 1 2 3 
21 Having housemate conflicts Yes No 0 1 2 3 
22 Car/bike broke down, flat tyre, etc. Yes No 0 1 2 3 
23 Got a traffic ticket Yes No 0 1 2 3 
24 Missed your period and waiting Yes No 0 1 2 3 
25 Coping with addictions Yes No 0 1 2 3 
26 Thoughts about future Yes No 0 1 2 3 
27 Lack of money Yes No 0 1 2 3 
28 Dealt with incompetence in university 
administration 
Yes No 0 1 2 3 
29 Thought about unfinished work Yes No 0 1 2 3 
30 No sleep Yes No 0 1 2 3 
31 Sick, injury Yes No 0 1 2 3 
32 Had a class presentation Yes No 0 1 2 3 
33 Applying for a job Yes No 0 1 2 3 
34 Fought with boy-/girlfriend Yes No 0 1 2 3 
35 Working (e.g. part-time job) while at 
university 
Yes No 0 1 2 3 
36 Arguments, conflict of values with 
friends 
Yes No 0 1 2 3 
 
 
37 Bothered by having no social support of 
family 
Yes No 0 1 2 3 
38 Performed poorly at a task Yes No 0 1 2 3 
39 Can’t finish everything you needed to 
do 
Yes No 0 1 2 3 
 
In the two weeks, has this event happened to you? If yes, please indicate how stressful 










40 Heard bad news Yes No 0 1 2 3 
41 Had confrontation with an authority 
figure 
Yes No 0 1 2 3 
42 Maintaining a long-distance boy-
/girlfriend 
Yes No 0 1 2 3 
43 Crammed for a test/exam Yes No 0 1 2 3 
44 Feel unorganized Yes No 0 1 2 3 
45 Trying to decide on module choices Yes No 0 1 2 3 
46 Feel isolated Yes No 0 1 2 3 
47 Parents controlling with money Yes No 0 1 2 3 
48 Couldn’t find a parking space Yes No 0 1 2 3 
49 Noise disturbed you while trying to 
study 
Yes No 0 1 2 3 
50 Someone borrowed something without 
permission 
Yes No 0 1 2 3 
51 Had to ask for money Yes No 0 1 2 3 
52 Ran out of printer ink for computer Yes No 0 1 2 3 
53 Erratic schedule Yes No 0 1 2 3 
54 Can’t understand your lecturer Yes No 0 1 2 3 
55 Trying to get onto a specific 
course/module 
Yes No 0 1 2 3 
56 Problems applying for student loan Yes No 0 1 2 3 
57 Stayed up late writing an essay Yes No 0 1 2 3 
58 Someone you expected to call did not Yes No 0 1 2 3 
59  Someone broke a promise Yes No 0 1 2 3 
60  Can’t concentrate Yes No 0 1 2 3 
61 Someone did something that annoyed 
you 
Yes No 0 1 2 3 
62  Living with boy-/girlfriend Yes No 0 1 2 3 
63  Felt need for own car Yes No 0 1 2 3 
64  Bad haircut today Yes No 0 1 2 3 
65  Job requirements changed Yes No 0 1 2 3 
66 No time to eat Yes No 0 1 2 3 
67 Felt some peer pressure Yes No 0 1 2 3 
68 You have a hangover Yes No 0 1 2 3 
69 Problems with your computer Yes No 0 1 2 3 
70 Problems getting home from bar when 
drunk  
Yes No 0 1 2 3 
 
 
71 Stopped from entering nightclub Yes No 0 1 2 3 
72 No sex in a while Yes No 0 1 2 3 
73 Someone pushed ahead of you in a 
queue 
Yes No 0 1 2 3 
74 Chequebook didn’t balance Yes No 0 1 2 3 
75 Visit from a relative and entertaining 
them 
Yes No 0 1 2 3 
76 Worrying about whether to have sex 
with someone 
Yes No 0 1 2 3 
77 Talked with a tutor/lecturer Yes No 0 1 2 3 
78 Change of environment (new doctor, 
dentist, etc.) 




In the two weeks, has this event happened to you? If yes, please indicate how stressful 










79 Exposed to upsetting TV programme, 
book, or film 
Yes No 0 1 2 3 
80 Got to lecture/seminar late Yes No 0 1 2 3 
81 Holiday Yes No 0 1 2 3 
82 Sat through a boring lecture/seminar Yes No 0 1 2 3 






The questions in this scale ask you about your feelings and thoughts during THE TWO 
WEEKS. In each case, you will be asked to indicate how often you felt or thought a certain 
way. Indicate the alternative that seems like a reasonable estimate. 
 
In the last month, how often have you been upset 










In the last month, how often have you felt that you 




















In the last month, how often have you dealt with 









In the last month, how often have you felt that you 
were effectively coping with important changes 









In the last month, how often have you felt 










In the last month, how often have you felt that 









In the last month, how often have you found that 










In the last month, how often have you been able to 









In the last month, how often have you felt that you 









In the last month, how often have you been 
angered because of things that happened that were 









In the last month, how often have you found 










In the last month, how often have you been able to 









In the last month, how often have you felt 
difficulties were piling up so high that you could 












 LONG LAST 7 DAYS SELF-ADMINISTERED version of the IPAQ. Revised October 2002. 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
(October 2002) 
 
LONG LAST 7 DAYS SELF-ADMINISTERED FORMAT 
 
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. 
Long (5 activity domains asked independently) and short (4 generic items) versions for use by 
either telephone or self-administered methods are available. The purpose of the questionnaires 
is to provide common instruments that can be used to obtain internationally comparable data on 
health–related physical activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in Geneva in 
1998 and was followed by extensive reliability and validity testing undertaken across 12 
countries (14 sites) during 2000. The final results suggest that these measures have acceptable 
measurement properties for use in many settings and in different languages, and are suitable 
for national population-based prevalence studies of participation in physical activity. 
 
Using IPAQ  
Use of the IPAQ instruments for monitoring and research purposes is encouraged. It is 
recommended that no changes be made to the order or wording of the questions as this will 
affect the psychometric properties of the instruments.  
 
Translation from English and Cultural Adaptation 
Translation from English is encouraged to facilitate worldwide use of IPAQ. Information on the 
availability of IPAQ in different languages can be obtained at www.ipaq.ki.se. If a new 
translation is undertaken we highly recommend using the prescribed back translation methods 
available on the IPAQ website. If possible please consider making your translated version of 
IPAQ available to others by contributing it to the IPAQ website. Further details on translation 
and cultural adaptation can be downloaded from the website. 
 
Further Developments of IPAQ  
International collaboration on IPAQ is on-going and an International Physical Activity 
Prevalence Study is in progress. For further information see the IPAQ website.  
 
More Information 
More detailed information on the IPAQ process and the research methods used in the 
development of IPAQ instruments is available at www.ipaq.ki.se and Booth, M.L. (2000). 
Assessment of Physical Activity: An International Perspective. Research Quarterly for Exercise 
and Sport, 71 (2): s114-20. Other scientific publications and presentations on the use of IPAQ 
are summarized on the website. 
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as part of 
their everyday lives. The questions will ask you about the time you spent being physically active 
in the last 7 days. Please answer each question even if you do not consider yourself to be an 
active person. Please think about the activities you do at work, as part of your house and yard 
work, to get from place to place, and in your spare time for recreation, exercise or sport. 
 
Think about all the vigorous and moderate activities that you did in the last 7 days. Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe much 
harder than normal. Moderate activities refer to activities that take moderate physical effort and 
make you breathe somewhat harder than normal. 
 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
 
The first section is about your work. This includes paid jobs, farming, volunteer work, course 
work, and any other unpaid work that you did outside your home. Do not include unpaid work 
you might do around your home, like housework, yard work, general maintenance, and caring 
for your family. These are asked in Part 3. 
 




 No Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you did in the last 7 days as part of your 
paid or unpaid work. This does not include traveling to and from work. 
 
2.  During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, digging, heavy construction, or climbing up stairs as part of your work? 
Think about only those physical activities that you did for at least 10 minutes at a time. 
 
_____ days per week 
 
 No vigorous job-related physical activity Skip to question 4 
 
3. How much time did you usually spend on one of those days doing vigorous physical 
activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
4. Again, think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads as part of your work? Please do not include walking. 
 
_____ days per week 
 
 No moderate job-related physical activity Skip to question 6 
 LONG LAST 7 DAYS SELF-ADMINISTERED version of the IPAQ. Revised October 2002. 
5. How much time did you usually spend on one of those days doing moderate physical 
activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
6. During the last 7 days, on how many days did you walk for at least 10 minutes at a time 
as part of your work? Please do not count any walking you did to travel to or from 
work. 
 
_____ days per week 
 
 No job-related walking Skip to PART 2: TRANSPORTATION 
 
7. How much time did you usually spend on one of those days walking as part of your 
work? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
 
These questions are about how you traveled from place to place, including to places like work, 
stores, movies, and so on. 
 
8. During the last 7 days, on how many days did you travel in a motor vehicle like a train, 
bus, car, or tram? 
 
_____ days per week 
 
 No traveling in a motor vehicle Skip to question 10 
 
9. How much time did you usually spend on one of those days traveling in a train, bus, 
car, tram, or other kind of motor vehicle? 
 
_____ hours per day 
_____ minutes per day 
 
Now think only about the bicycling and walking you might have done to travel to and from 
work, to do errands, or to go from place to place. 
 
10. During the last 7 days, on how many days did you bicycle for at least 10 minutes at a 
time to go from place to place? 
 
_____ days per week 
 
 No bicycling from place to place Skip to question 12 
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11. How much time did you usually spend on one of those days to bicycle from place to 
place? 
 
_____ hours per day 
_____ minutes per day 
 
12. During the last 7 days, on how many days did you walk for at least 10 minutes at a time 
to go from place to place? 
 
_____ days per week 
 
 No walking from place to place Skip to PART 3: HOUSEWORK, 
HOUSE MAINTENANCE, AND 
CARING FOR FAMILY 
 
13. How much time did you usually spend on one of those days walking from place to 
place? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
This section is about some of the physical activities you might have done in the last 7 days in 
and around your home, like housework, gardening, yard work, general maintenance work, and 
caring for your family. 
 
14. Think about only those physical activities that you did for at least 10 minutes at a time. 
During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard? 
 
_____ days per week 
 
 No vigorous activity in garden or yard Skip to question 16 
 
 
15. How much time did you usually spend on one of those days doing vigorous physical 
activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
16. Again, think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do moderate activities like 
carrying light loads, sweeping, washing windows, and raking in the garden or yard? 
 
_____ days per week 
 
 No moderate activity in garden or yard Skip to question 18 
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17. How much time did you usually spend on one of those days doing moderate physical 
activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
18. Once again, think about only those physical activities that you did for at least 10 minutes 
at a time. During the last 7 days, on how many days did you do moderate activities like 
carrying light loads, washing windows, scrubbing floors and sweeping inside your 
home? 
 
_____ days per week 
 
 No moderate activity inside home Skip to PART 4: RECREATION, 
SPORT AND LEISURE-TIME 
PHYSICAL ACTIVITY 
 
19. How much time did you usually spend on one of those days doing moderate physical 
activities inside your home? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you did in the last 7 days solely for 
recreation, sport, exercise or leisure. Please do not include any activities you have already 
mentioned. 
 
20. Not counting any walking you have already mentioned, during the last 7 days, on how 
many days did you walk for at least 10 minutes at a time in your leisure time? 
 
_____ days per week 
 
 No walking in leisure time Skip to question 22 
 
21. How much time did you usually spend on one of those days walking in your leisure 
time? 
 
_____ hours per day 
_____ minutes per day 
 
22. Think about only those physical activities that you did for at least 10 minutes at a time. 
During the last 7 days, on how many days did you do vigorous physical activities like 
aerobics, running, fast bicycling, or fast swimming in your leisure time? 
 
_____ days per week 
 
 No vigorous activity in leisure time Skip to question 24 
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23. How much time did you usually spend on one of those days doing vigorous physical 
activities in your leisure time? 
 
_____ hours per day 
_____ minutes per day 
 
24. Again, think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do moderate physical activities 
like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your 
leisure time? 
 
_____ days per week 
 
 No moderate activity in leisure time Skip to PART 5: TIME SPENT 
SITTING 
 
25. How much time did you usually spend on one of those days doing moderate physical 
activities in your leisure time? 
_____ hours per day 
_____ minutes per day 
 
 
PART 5: TIME SPENT SITTING 
 
The last questions are about the time you spend sitting while at work, at home, while doing 
course work and during leisure time. This may include time spent sitting at a desk, visiting 
friends, reading or sitting or lying down to watch television. Do not include any time spent sitting 
in a motor vehicle that you have already told me about. 
 
26. During the last 7 days, how much time did you usually spend sitting on a weekday? 
 
_____ hours per day 
_____ minutes per day 
 
27. During the last 7 days, how much time did you usually spend sitting on a weekend 
day? 
 
_____ hours per day 
_____ minutes per day 
 
 
This is the end of the questionnaire, thank you for participating. 
